assay_id,assay_subcellular_fraction,assay_test_type,bao_format,tissue_id,cell_id,doc_id,description,assay_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue
1,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,
2,,,BAO_0000219,,,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,
3,,,BAO_0000019,,,15453,,B,,,,,
4,,,BAO_0000249,,,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,Bos taurus,9913.0,,
5,,,BAO_0000219,,163.0,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,Homo sapiens,9606.0,,
6,,,BAO_0000219,,163.0,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,Homo sapiens,9606.0,,
7,,,BAO_0000219,,163.0,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,Mus musculus,10090.0,,
8,,,BAO_0000219,,163.0,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,Homo sapiens,9606.0,,
9,,,BAO_0000219,,163.0,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,Homo sapiens,9606.0,,
10,,,BAO_0000219,,163.0,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,Homo sapiens,9606.0,,
11,,,BAO_0000219,,163.0,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,Homo sapiens,9606.0,,
12,,,BAO_0000219,,163.0,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,Homo sapiens,9606.0,,
13,,,BAO_0000218,,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,1280.0,,
14,,,BAO_0000218,,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,1280.0,,
15,,,BAO_0000218,,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,1280.0,,
16,,,BAO_0000218,,,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,Staphylococcus aureus,1280.0,,
17,,,BAO_0000357,,,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,Rattus norvegicus,10116.0,,
18,,,BAO_0000357,,,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
19,,,BAO_0000019,,,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,
20,,,BAO_0000357,,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
21,,,BAO_0000357,,,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
22,,,BAO_0000357,,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,
23,,,BAO_0000357,,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,
24,,,BAO_0000357,,,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,
25,,,BAO_0000219,,,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,
26,,,BAO_0000357,,,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,Oryctolagus cuniculus,9986.0,,
27,,,BAO_0000357,,,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,Oryctolagus cuniculus,9986.0,,
28,,,BAO_0000219,,,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,
29,,,BAO_0000357,,,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,soya bean,3847.0,,
30,,,BAO_0000357,,,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,Glycine max,3847.0,,
31,,,BAO_0000357,,,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,Glycine max,3847.0,,
32,,,BAO_0000357,,,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,Glycine max,3847.0,,
33,,,BAO_0000357,,,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,Glycine max,3847.0,,
34,,,BAO_0000357,,,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,Glycine max,3847.0,,
35,,,BAO_0000357,,,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,Glycine max,3847.0,,
36,,,BAO_0000019,,,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,Rattus norvegicus,10116.0,,
37,,,BAO_0000019,,,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,Escherichia coli,562.0,,
38,,,BAO_0000019,,,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,
39,,,BAO_0000225,,,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,
40,,,BAO_0000225,,,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,
41,,,BAO_0000225,,,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,Escherichia coli,562.0,,
42,,,BAO_0000225,,,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,Escherichia coli,562.0,,
43,,,BAO_0000019,,,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,
44,,,BAO_0000019,,,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,
45,,,BAO_0000019,,,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,Homo sapiens,9606.0,,
46,,,BAO_0000019,,,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,Homo sapiens,9606.0,,
47,,,BAO_0000019,,,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,Rattus norvegicus,10116.0,,
48,,,BAO_0000019,,,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,Rattus norvegicus,10116.0,,
49,,,BAO_0000019,,,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,Rattus norvegicus,10116.0,,
50,,,BAO_0000019,,,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,Rattus norvegicus,10116.0,,
51,,,BAO_0000019,,,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,
52,,,BAO_0000357,,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,
53,,,BAO_0000357,,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,
54,,,BAO_0000357,,,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,
55,Membranes,,BAO_0000249,,,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,Rattus norvegicus,10116.0,,
56,,,BAO_0000219,,506.0,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,Homo sapiens,9606.0,,
57,,,BAO_0000219,,,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,Rattus norvegicus,10116.0,,
58,,,BAO_0000219,,,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,Rattus norvegicus,10116.0,,
59,,,BAO_0000219,,,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,Rattus norvegicus,10116.0,,
60,,,BAO_0000219,,506.0,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,Homo sapiens,9606.0,,
61,,,BAO_0000219,,506.0,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,Homo sapiens,9606.0,,
62,,,BAO_0000219,,506.0,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,Homo sapiens,9606.0,,
63,,,BAO_0000219,,506.0,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,Homo sapiens,9606.0,,
64,,,BAO_0000219,,506.0,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,Homo sapiens,9606.0,,
65,,,BAO_0000219,,506.0,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,Homo sapiens,9606.0,,
66,,,BAO_0000219,,506.0,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,Homo sapiens,9606.0,,
67,,,BAO_0000219,,506.0,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,Homo sapiens,9606.0,,
68,,,BAO_0000219,,506.0,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,Homo sapiens,9606.0,,
69,,,BAO_0000219,,506.0,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,Homo sapiens,9606.0,,
70,,,BAO_0000219,,506.0,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,Homo sapiens,9606.0,,
71,,,BAO_0000219,,506.0,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,Homo sapiens,9606.0,,
72,,,BAO_0000219,,506.0,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,Homo sapiens,9606.0,,
73,,,BAO_0000219,,506.0,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,Homo sapiens,9606.0,,
74,,,BAO_0000219,,506.0,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,Homo sapiens,9606.0,,
75,,,BAO_0000219,,506.0,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,Homo sapiens,9606.0,,
76,,,BAO_0000219,,503.0,17721,Inhibitory concentration against Jurkat cells,F,,Homo sapiens,9606.0,,
77,,,BAO_0000019,,,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,
78,,,BAO_0000357,,,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,Rattus norvegicus,10116.0,,
79,,,BAO_0000357,,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,
80,,,BAO_0000357,,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,
81,,,BAO_0000357,,,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,
82,Microsomes,,BAO_0000251,,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,Candida albicans,5476.0,,
83,Microsomes,,BAO_0000251,,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,Candida albicans,5476.0,,
84,Microsomes,,BAO_0000251,,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,Saccharomyces cerevisiae,4932.0,,
85,Microsomes,,BAO_0000251,,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,Saccharomyces cerevisiae,4932.0,,
86,Microsomes,,BAO_0000251,2107.0,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,Sus scrofa,9823.0,,Liver
87,,,BAO_0000019,,,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,Rattus norvegicus,10116.0,,
88,,,BAO_0000019,,,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,Rattus norvegicus,10116.0,,
89,,,BAO_0000019,,,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,Rattus norvegicus,10116.0,,
90,Microsomes,,BAO_0000251,2107.0,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,Rattus norvegicus,10116.0,,Liver
91,Microsomes,,BAO_0000251,2107.0,,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,Rattus norvegicus,10116.0,,Liver
92,Microsomes,,BAO_0000251,2107.0,,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,Rattus norvegicus,10116.0,,Liver
93,,,BAO_0000357,,,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,
94,,,BAO_0000357,,,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,
95,,,BAO_0000219,,726.0,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,Homo sapiens,9606.0,,
96,,,BAO_0000219,,726.0,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,Homo sapiens,9606.0,,
97,,,BAO_0000219,,726.0,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,Homo sapiens,9606.0,,
98,,,BAO_0000219,,726.0,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,Homo sapiens,9606.0,,
99,,,BAO_0000219,,726.0,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,Homo sapiens,9606.0,,
100,,,BAO_0000218,,,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,Hepatitis B virus,10407.0,,
101,,,BAO_0000219,,726.0,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,Homo sapiens,9606.0,,
102,,,BAO_0000219,,726.0,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,Homo sapiens,9606.0,,
103,,,BAO_0000219,,726.0,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,Homo sapiens,9606.0,,
104,,,BAO_0000218,,,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,Homo sapiens,9606.0,,
105,,,BAO_0000218,,,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,Homo sapiens,9606.0,,
106,,,BAO_0000218,,,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,Hepatitis B virus,10407.0,,
107,,,BAO_0000218,,,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,Homo sapiens,9606.0,,
108,,,BAO_0000218,,,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,Homo sapiens,9606.0,,
109,,,BAO_0000218,,,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,Homo sapiens,9606.0,,
110,,,BAO_0000218,,,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,Homo sapiens,9606.0,,
111,,,BAO_0000218,,,1593,Cytotoxicity in 2.2.15 cells,F,,Homo sapiens,9606.0,,
112,,,BAO_0000218,,,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,Homo sapiens,9606.0,,
113,,,BAO_0000218,,,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,Homo sapiens,9606.0,,
114,,,BAO_0000218,,,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,Homo sapiens,9606.0,,
115,,,BAO_0000218,,,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,Homo sapiens,9606.0,,
116,,,BAO_0000219,,726.0,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,Homo sapiens,9606.0,,
117,Microsomes,,BAO_0000251,,,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,Homo sapiens,9606.0,,
118,,,BAO_0000019,,,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,
119,,,BAO_0000219,,388.0,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,Homo sapiens,9606.0,,
120,,,BAO_0000219,,388.0,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,Homo sapiens,9606.0,,
121,,,BAO_0000219,,388.0,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,Homo sapiens,9606.0,,
122,,,BAO_0000219,,388.0,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,Homo sapiens,9606.0,,
123,,,BAO_0000219,,388.0,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,Homo sapiens,9606.0,,
124,,,BAO_0000219,,561.0,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,Homo sapiens,9606.0,,
125,,,BAO_0000219,,561.0,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,Homo sapiens,9606.0,,
126,,,BAO_0000219,,389.0,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,Homo sapiens,9606.0,,
127,,,BAO_0000219,,389.0,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,Homo sapiens,9606.0,,
128,,,BAO_0000220,,,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,Homo sapiens,9606.0,,
129,,,BAO_0000220,,,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,Homo sapiens,9606.0,,
130,,,BAO_0000220,,,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,
131,,,BAO_0000220,,,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,
132,,,BAO_0000220,,,3260,Inhibitory activity against 20S proteosome,B,,,,,
133,,,BAO_0000019,,,3451,Compound was tested for inhibitory activity against tryptase,B,,Homo sapiens,9606.0,,
134,,,BAO_0000219,,726.0,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,Homo sapiens,9606.0,,
135,,,BAO_0000219,,726.0,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,Homo sapiens,9606.0,,
136,,,BAO_0000019,,,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,
137,,,BAO_0000357,,,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,
138,,,BAO_0000218,948.0,,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,Rattus norvegicus,10116.0,,Heart
139,,,BAO_0000019,,,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,
140,,,BAO_0000019,,,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,
141,,,BAO_0000357,,,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,
142,,,BAO_0000019,,,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,
143,,,BAO_0000219,,524.0,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,Mus musculus,10090.0,,
144,,,BAO_0000219,,524.0,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,Mus musculus,10090.0,,
145,,,BAO_0000219,,554.0,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,Homo sapiens,9606.0,,
146,,,BAO_0000019,,,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,Ovis aries,9940.0,,
147,,,BAO_0000019,,,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,Ovis aries,9940.0,,
148,,,BAO_0000357,,,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,
149,,,BAO_0000019,,,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,Homo sapiens,9606.0,,
150,,,BAO_0000019,,,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,Homo sapiens,9606.0,,
151,,,BAO_0000219,,635.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,Homo sapiens,9606.0,,
152,,,BAO_0000219,,635.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,Homo sapiens,9606.0,,
153,,,BAO_0000219,,635.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,Homo sapiens,9606.0,,
154,,,BAO_0000219,,635.0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,Homo sapiens,9606.0,,
155,,,BAO_0000019,,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,Homo sapiens,9606.0,,
156,,,BAO_0000019,,,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,Homo sapiens,9606.0,,
157,,,BAO_0000249,,,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,
158,,,BAO_0000218,,,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,Streptococcus pyogenes,1314.0,,
159,,,BAO_0000218,,,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,Human herpesvirus 3,10335.0,,
160,,,BAO_0000218,,468.0,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,vericilla zoster virus,10335.0,,
161,,,BAO_0000218,,,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,vericilla zoster virus,10335.0,,
162,,,BAO_0000218,,,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,vericilla zoster virus,10335.0,,
163,,,BAO_0000218,,,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,escherichia cloac,561.0,,
164,,,BAO_0000019,,,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,
165,,,BAO_0000249,,,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,Candida albicans,5476.0,,
166,,,BAO_0000357,,,2205,"Inhibition of 1,3-beta-glucan synthase",B,,Candida glabrata CBS 138,284593.0,,
167,,,BAO_0000219,,832.0,11900,Inhibition of growth of 1-87 human tumor cell line,F,,Homo sapiens,9606.0,,
168,,,BAO_0000219,,,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,Rattus norvegicus,10116.0,,
169,,,BAO_0000357,,,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,Glycine max,3847.0,,
170,,,BAO_0000357,,,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,Glycine max,3847.0,,
171,,,BAO_0000357,,,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,Glycine max,3847.0,,
172,,,BAO_0000357,,,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,Glycine max,3847.0,,
173,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,Glycine max,3847.0,,
174,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,Glycine max,3847.0,,
175,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,Glycine max,3847.0,,
176,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,Glycine max,3847.0,,
177,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,Glycine max,3847.0,,
178,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,Glycine max,3847.0,,
179,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,Glycine max,3847.0,,
180,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,Glycine max,3847.0,,
181,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,Glycine max,3847.0,,
182,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,Glycine max,3847.0,,
183,,,BAO_0000357,,,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,Glycine max,3847.0,,
184,,,BAO_0000019,,,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,Mus musculus,10090.0,,
185,,,BAO_0000219,,294.0,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,Mus musculus,10090.0,,
186,,,BAO_0000019,,,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,
187,,,BAO_0000357,,,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,
188,,,BAO_0000357,,,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,
189,,,BAO_0000357,,,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,
190,,,BAO_0000357,,,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,
191,,,BAO_0000357,,,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,
192,,,BAO_0000019,,,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,Bos taurus,9913.0,,
193,,,BAO_0000357,,,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,Rattus norvegicus,10116.0,,
194,,,BAO_0000357,2369.0,,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,Rattus norvegicus,10116.0,,Adrenal gland
195,,,BAO_0000357,,,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,Rattus norvegicus,10116.0,,
196,,,BAO_0000357,,,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,Rattus norvegicus,10116.0,,
197,,,BAO_0000357,,,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,Rattus norvegicus,10116.0,,
198,,,BAO_0000019,,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,
199,,,BAO_0000357,,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,
200,,,BAO_0000357,,,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,
201,,,BAO_0000019,,,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,
202,,,BAO_0000019,,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,
203,,,BAO_0000019,,,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,
204,,,BAO_0000019,,,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,
205,,,BAO_0000019,,,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,
206,,,BAO_0000019,,,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,Homo sapiens,9606.0,,
207,,,BAO_0000019,,,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,
208,,,BAO_0000357,,,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,
209,,,BAO_0000019,,,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,
210,,,BAO_0000019,,,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,
211,,,BAO_0000019,,,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,
212,,,BAO_0000019,,,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,
213,,,BAO_0000019,,,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,
214,,,BAO_0000019,,,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,
215,,,BAO_0000357,,,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,
216,,,BAO_0000357,,,11966,Tested for inhibition against porcine 12-LO,B,,,,,
217,,,BAO_0000019,,,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,
218,,,BAO_0000019,,,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,
219,,,BAO_0000019,,,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,
220,,,BAO_0000019,,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,
221,,,BAO_0000019,,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,
222,,,BAO_0000019,,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,
223,,,BAO_0000019,,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,
224,,,BAO_0000019,,,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,
225,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,
226,,,BAO_0000219,,621.0,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,Homo sapiens,9606.0,,
227,,,BAO_0000219,,621.0,12989,In vitro antitumor activity against 41M cell line.,F,,Homo sapiens,9606.0,,
228,,,BAO_0000219,,621.0,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,Homo sapiens,9606.0,,
229,,,BAO_0000219,,621.0,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,Homo sapiens,9606.0,,
230,,,BAO_0000219,,621.0,12989,In vitro antitumor activity against 41McisR cell line.,F,,Homo sapiens,9606.0,,
231,,,BAO_0000219,,621.0,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,Homo sapiens,9606.0,,
232,,,BAO_0000219,,621.0,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,Homo sapiens,9606.0,,
233,,,BAO_0000357,,,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,Homo sapiens,9606.0,,
234,,,BAO_0000357,,,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,Homo sapiens,9606.0,,
235,,,BAO_0000357,,,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,
236,,,BAO_0000357,,,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,
237,,,BAO_0000357,,,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,
238,,,BAO_0000357,,,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,
239,,,BAO_0000357,,,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,
240,,,BAO_0000357,,,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,Escherichia coli,562.0,,
241,,,BAO_0000357,,,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,Escherichia coli,562.0,,
242,,,BAO_0000357,,,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,Escherichia coli,562.0,,
243,,,BAO_0000357,,,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,
244,,,BAO_0000357,,,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,
245,,,BAO_0000357,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,9823.0,,
246,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,Sus scrofa,9823.0,,
247,,,BAO_0000357,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,9823.0,,
248,,,BAO_0000357,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,Sus scrofa,9823.0,,
249,,,BAO_0000357,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,9823.0,,
250,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,9823.0,,
251,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,Sus scrofa,9823.0,,
252,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,9823.0,,
253,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,Sus scrofa,9823.0,,
254,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,Sus scrofa,9823.0,,
255,,,BAO_0000357,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,Sus scrofa,9823.0,,
256,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,9823.0,,
257,,,BAO_0000357,,,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,
258,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,Sus scrofa,9823.0,,
259,,,BAO_0000019,,,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,Sus scrofa,9823.0,,
260,,,BAO_0000357,,,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,Saccharomyces cerevisiae,4932.0,,
261,,,BAO_0000019,,,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,Rattus norvegicus,10116.0,,
262,,,BAO_0000019,,,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,Rattus norvegicus,10116.0,,
263,,,BAO_0000019,,,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,Rattus norvegicus,10116.0,,
264,,,BAO_0000019,,,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,
265,,,BAO_0000019,,,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,
266,,,BAO_0000221,2116.0,,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,Cavia porcellus,10141.0,,Ileum
267,,,BAO_0000019,,,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,
268,,,BAO_0000357,,,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,
269,,,BAO_0000218,,,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,Rattus norvegicus,10116.0,,
270,,,BAO_0000019,,,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,
271,,,BAO_0000357,,,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,Homo sapiens,9606.0,,
272,,,BAO_0000357,,,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,Homo sapiens,9606.0,,
273,,,BAO_0000019,,,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,
274,,,BAO_0000357,,,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,
275,,,BAO_0000019,,,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,
276,,,BAO_0000019,,,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,
277,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,
278,,,BAO_0000019,,,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,
279,,,BAO_0000357,,,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,Bos taurus,9913.0,,
280,,,BAO_0000224,,,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,Rattus norvegicus,10116.0,,
281,,,BAO_0000224,,,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,
282,Membranes,,BAO_0000249,,,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,
283,Membranes,,BAO_0000249,,,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,
284,,,BAO_0000019,,,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
285,,,BAO_0000019,,,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,
286,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
287,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
288,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
289,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,,,,,
290,,,BAO_0000019,,,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,Cavia porcellus,10141.0,,
291,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
292,,,BAO_0000357,,,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,
293,,,BAO_0000019,,,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,Rattus norvegicus,10116.0,,
294,,,BAO_0000019,,,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,
295,,,BAO_0000019,,,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,
296,,,BAO_0000019,,,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,
297,,,BAO_0000019,,,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,
298,,,BAO_0000019,,,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,
299,,,BAO_0000019,,,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,
300,,,BAO_0000221,2116.0,,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,10141.0,,Ileum
301,,,BAO_0000221,2116.0,,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,Cavia porcellus,10141.0,,Ileum
302,,,BAO_0000221,2116.0,,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,10141.0,,Ileum
303,,,BAO_0000357,,,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,
304,,,BAO_0000019,,,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,Rattus norvegicus,10116.0,,
305,,,BAO_0000357,,,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
306,,,BAO_0000019,,,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,Gallus gallus,9031.0,,
307,,,BAO_0000019,,,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,Homo sapiens,9606.0,,
308,,,BAO_0000019,,,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,Homo sapiens,9606.0,,
309,,,BAO_0000219,,649.0,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,Homo sapiens,9606.0,,
310,,,BAO_0000019,,,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,Homo sapiens,9606.0,,
311,,,BAO_0000019,,,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,Homo sapiens,9606.0,,
312,,,BAO_0000219,,,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,Homo sapiens,9606.0,,
313,,,BAO_0000220,,,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,
314,,,BAO_0000220,,,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,
315,,,BAO_0000219,,478.0,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,Homo sapiens,9606.0,,
316,,,BAO_0000219,,478.0,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,Homo sapiens,9606.0,,
317,,,BAO_0000019,,,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,Homo sapiens,9606.0,,
318,,,BAO_0000225,,,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,
319,,,BAO_0000225,,,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,
320,,,BAO_0000225,,,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,
321,,,BAO_0000225,,,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,
322,,,BAO_0000019,,,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,Homo sapiens,9606.0,,
323,,,BAO_0000019,,,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,Homo sapiens,9606.0,,
324,,,BAO_0000019,,,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,Homo sapiens,9606.0,,
325,,,BAO_0000019,,,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,Cricetulus griseus,10029.0,,
326,,,BAO_0000019,,,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,Cricetulus griseus,10029.0,,
327,,,BAO_0000019,,,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,Cricetulus griseus,10029.0,,
328,,,BAO_0000357,,,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,
329,,,BAO_0000357,,,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,Homo sapiens,9606.0,,
330,,,BAO_0000019,,,9964,Selectivity ratio of ID50 in liver and heart,B,,Rattus norvegicus,10116.0,,
331,,,BAO_0000019,,,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,
332,,,BAO_0000019,,,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,
333,,,BAO_0000218,,,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
334,,,BAO_0000218,,,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
335,,In vivo,BAO_0000218,,,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
336,,In vivo,BAO_0000218,,,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,,,,,
337,,,BAO_0000019,,,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,
338,,,BAO_0000019,,,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,
339,,,BAO_0000019,,,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,Homo sapiens,9606.0,,
340,,,BAO_0000019,,,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,
341,,,BAO_0000019,,,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,
342,,,BAO_0000019,,,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,
343,,,BAO_0000218,,,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,Rattus norvegicus,10116.0,,
344,,In vivo,BAO_0000218,,,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,,,,,
345,,,BAO_0000218,,,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,
346,,,BAO_0000218,,,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,Rattus norvegicus,10116.0,,
347,,,BAO_0000019,,,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,
348,,,BAO_0000019,,,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,
349,,,BAO_0000019,,,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,Rattus norvegicus,10116.0,,
350,,,BAO_0000357,,,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,Escherichia coli,562.0,,
351,,,BAO_0000357,,,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,Escherichia coli,562.0,,
352,,,BAO_0000357,,,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,Escherichia coli,562.0,,
353,,,BAO_0000357,,,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,Escherichia coli,562.0,,
354,,,BAO_0000357,,,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,
355,,,BAO_0000357,,,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,
356,,,BAO_0000357,,,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,
357,,,BAO_0000357,,,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,
358,,,BAO_0000357,,,166,Rate constant against 3-dehydroquinate synthase,B,,,,,
359,,,BAO_0000019,,,3548,Inhibitory activity against fuc-TVII,B,,,,,
360,Microsomes,,BAO_0000251,2107.0,,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,10116.0,,Liver
361,Microsomes,,BAO_0000251,2107.0,,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,10116.0,,Liver
362,Microsomes,,BAO_0000251,2107.0,,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,10116.0,,Liver
363,Microsomes,,BAO_0000251,2107.0,,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,10116.0,,Liver
364,Microsomes,,BAO_0000251,2107.0,,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,Rattus norvegicus,10116.0,,Liver
365,Microsomes,,BAO_0000251,2107.0,,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,Rattus norvegicus,10116.0,,Liver
366,Microsomes,,BAO_0000251,2107.0,,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,Rattus norvegicus,10116.0,,Liver
367,Microsomes,,BAO_0000251,2107.0,,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,Rattus norvegicus,10116.0,,Liver
368,Microsomes,,BAO_0000251,2107.0,,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,Rattus norvegicus,10116.0,,Liver
369,Microsomes,,BAO_0000251,2107.0,,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,Rattus norvegicus,10116.0,,Liver
370,Microsomes,,BAO_0000251,2107.0,,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,Rattus norvegicus,10116.0,,Liver
371,,,BAO_0000224,,,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,
372,,,BAO_0000224,,,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,
373,,,BAO_0000224,,,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,
374,,,BAO_0000357,,,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,Homo sapiens,9606.0,,
375,,,BAO_0000219,,844.0,6072,Cytotoxicity on 3677 melanoma cells,F,,Homo sapiens,9606.0,,
376,,,BAO_0000219,,844.0,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,Homo sapiens,9606.0,,
377,,,BAO_0000219,,700.0,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,Mus musculus,10090.0,,
378,,,BAO_0000019,,,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,Homo sapiens,9606.0,,
379,,,BAO_0000218,,798.0,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,
380,,,BAO_0000218,,798.0,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,
381,,,BAO_0000019,,,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,Human rhinovirus 14,12131.0,,
382,,,BAO_0000218,,,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,Human rhinovirus sp.,169066.0,,
383,,,BAO_0000218,,,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,human rhinovirus type 14,169066.0,,
384,,,BAO_0000218,,,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,human rhinovirus type 14,169066.0,,
385,,,BAO_0000019,,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,Human rhinovirus 14,12131.0,,
386,,,BAO_0000019,,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,Human rhinovirus 14,12131.0,,
387,,,BAO_0000019,,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,Human rhinovirus 14,12131.0,,
388,,,BAO_0000019,,,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,Human rhinovirus 14,12131.0,,
389,,,BAO_0000218,,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,Enterovirus,12059.0,,
390,,,BAO_0000218,,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,Enterovirus,12059.0,,
391,,,BAO_0000218,,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,Enterovirus,12059.0,,
392,,,BAO_0000218,,,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,Enterovirus,12059.0,,
393,,,BAO_0000357,,,13748,Inhibition of human rhinovirus 3C protease,B,,Human rhinovirus B,147712.0,,
394,,,BAO_0000019,,,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,Homo sapiens,9606.0,,
395,,,BAO_0000218,,833.0,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,Mus musculus,10090.0,,
396,,,BAO_0000218,,833.0,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,Mus musculus,10090.0,,
397,,,BAO_0000218,,833.0,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,Mus musculus,10090.0,,
398,,,BAO_0000218,,833.0,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,Mus musculus,10090.0,,
399,,,BAO_0000218,,833.0,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,Mus musculus,10090.0,,
400,,,BAO_0000218,,833.0,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,Mus musculus,10090.0,,
401,,,BAO_0000218,,847.0,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,Mus musculus,10090.0,,
402,,,BAO_0000218,,847.0,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,Mus musculus,10090.0,,
403,,,BAO_0000218,,847.0,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,Mus musculus,10090.0,,
404,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,Mus musculus,10090.0,,
405,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,Mus musculus,10090.0,,
406,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,Mus musculus,10090.0,,
407,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,Mus musculus,10090.0,,
408,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,Mus musculus,10090.0,,
409,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,Mus musculus,10090.0,,
410,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,Mus musculus,10090.0,,
411,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,Mus musculus,10090.0,,
412,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,Mus musculus,10090.0,,
413,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,Mus musculus,10090.0,,
414,,,BAO_0000219,,847.0,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,Mus musculus,10090.0,,
415,,,BAO_0000219,,847.0,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,Mus musculus,10090.0,,
416,,,BAO_0000219,,847.0,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,Mus musculus,10090.0,,
417,,,BAO_0000219,,847.0,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,Mus musculus,10090.0,,
418,,,BAO_0000219,,847.0,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,Mus musculus,10090.0,,
419,,,BAO_0000219,,847.0,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,Mus musculus,10090.0,,
420,,,BAO_0000219,,847.0,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,Mus musculus,10090.0,,
421,,,BAO_0000219,,847.0,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,Mus musculus,10090.0,,
422,,,BAO_0000219,,847.0,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,Mus musculus,10090.0,,
423,,,BAO_0000219,,847.0,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,Mus musculus,10090.0,,
424,,,BAO_0000219,,847.0,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,Mus musculus,10090.0,,
425,,,BAO_0000219,,847.0,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,Mus musculus,10090.0,,
426,,,BAO_0000219,,847.0,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,Mus musculus,10090.0,,
427,,,BAO_0000219,,847.0,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,Mus musculus,10090.0,,
428,,,BAO_0000219,,847.0,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,Mus musculus,10090.0,,
429,,,BAO_0000219,,847.0,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,Mus musculus,10090.0,,
430,,,BAO_0000219,,971.0,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,Homo sapiens,9606.0,,
431,,,BAO_0000218,,,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,
432,,,BAO_0000218,,,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,
433,,,BAO_0000218,,,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,
434,,,BAO_0000218,,,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,
435,,,BAO_0000219,,723.0,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,Mus musculus,10090.0,,
436,,,BAO_0000219,,723.0,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,Mus musculus,10090.0,,
437,,,BAO_0000219,,723.0,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,
438,,,BAO_0000219,,723.0,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,Mus musculus,10090.0,,
439,,,BAO_0000219,,723.0,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,Mus musculus,10090.0,,
440,,,BAO_0000219,,723.0,17642,Effective dose against murine 3T3 fibroblasts cells,F,,Mus musculus,10090.0,,
441,,,BAO_0000219,,723.0,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,Mus musculus,10090.0,,
442,,,BAO_0000219,,723.0,12340,Cytotoxic effect on 3T3 cells,F,,Mus musculus,10090.0,,
443,,,BAO_0000219,,723.0,12340,Cytotoxic effect on 3T3 cells,F,,Mus musculus,10090.0,,
444,,,BAO_0000219,,723.0,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,Mus musculus,10090.0,,
445,,,BAO_0000219,,723.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,Mus musculus,10090.0,,
446,,,BAO_0000219,,723.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,Mus musculus,10090.0,,
447,,,BAO_0000219,,723.0,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,Mus musculus,10090.0,,
448,,,BAO_0000219,,723.0,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,Mus musculus,10090.0,,
449,,,BAO_0000219,,723.0,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,Mus musculus,10090.0,,
450,,,BAO_0000219,,723.0,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,Mus musculus,10090.0,,
451,,,BAO_0000219,,723.0,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,Mus musculus,10090.0,,
452,,,BAO_0000219,,723.0,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,Mus musculus,10090.0,,
453,,,BAO_0000218,,723.0,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,Mus musculus,10090.0,,
454,,,BAO_0000219,,,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,Mus musculus,10090.0,,
455,,,BAO_0000219,,723.0,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,Mus musculus,10090.0,,
456,,,BAO_0000219,,723.0,14892,Inhibitory activity against 3T3 cell line,F,,Mus musculus,10090.0,,
457,,,BAO_0000219,,723.0,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,Mus musculus,10090.0,,
458,,,BAO_0000019,,,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,
459,,,BAO_0000219,,723.0,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,Mus musculus,10090.0,,
460,,,BAO_0000219,,723.0,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,Mus musculus,10090.0,,
461,,,BAO_0000019,,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,
462,,,BAO_0000019,,,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,
463,,,BAO_0000219,,723.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,Mus musculus,10090.0,,
464,,,BAO_0000219,,723.0,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,Mus musculus,10090.0,,
465,,,BAO_0000219,,723.0,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,Homo sapiens,9606.0,,
466,,,BAO_0000219,,723.0,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,Homo sapiens,9606.0,,
467,,,BAO_0000219,,723.0,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,Homo sapiens,9606.0,,
468,,,BAO_0000219,,723.0,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,Homo sapiens,9606.0,,
469,,,BAO_0000219,,723.0,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,Mus musculus,10090.0,,
470,,,BAO_0000219,,723.0,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,Mus musculus,10090.0,,
471,,,BAO_0000219,,723.0,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,Mus musculus,10090.0,,
472,,,BAO_0000219,,723.0,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,Mus musculus,10090.0,,
473,,,BAO_0000219,,723.0,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,Mus musculus,10090.0,,
474,,,BAO_0000219,,723.0,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,Mus musculus,10090.0,,
475,,,BAO_0000219,,723.0,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,Mus musculus,10090.0,,
476,,,BAO_0000219,,723.0,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,Mus musculus,10090.0,,
477,,,BAO_0000219,,723.0,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,Mus musculus,10090.0,,
478,,,BAO_0000219,,723.0,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,10090.0,,
479,,,BAO_0000219,,723.0,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,10090.0,,
480,,,BAO_0000219,,723.0,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,10090.0,,
481,,,BAO_0000219,,723.0,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,10090.0,,
482,,,BAO_0000219,,723.0,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,Mus musculus,10090.0,,
483,,,BAO_0000219,,723.0,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,Mus musculus,10090.0,,
484,,,BAO_0000219,,723.0,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,Mus musculus,10090.0,,
485,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,
486,,,BAO_0000219,,620.0,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,Mus musculus,10090.0,,
487,,,BAO_0000219,,620.0,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,Mus musculus,10090.0,,
488,,,BAO_0000219,,620.0,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,Mus musculus,10090.0,,
489,,,BAO_0000219,,620.0,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,Mus musculus,10090.0,,
490,,,BAO_0000218,,620.0,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,Mus musculus,10090.0,,
491,,,BAO_0000218,,620.0,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,Mus musculus,10090.0,,
492,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,
493,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,
494,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,
495,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,
496,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,
497,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,
498,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,
499,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,
500,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,
501,,,BAO_0000218,,620.0,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,
502,,,BAO_0000218,,620.0,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,
503,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,
504,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,
505,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,
506,,,BAO_0000218,,620.0,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,
507,,,BAO_0000218,,620.0,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,
508,,,BAO_0000218,,620.0,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,
509,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,
510,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,
511,,,BAO_0000219,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,
512,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,
513,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,
514,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,
515,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,
516,,,BAO_0000218,,620.0,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,
517,,,BAO_0000219,,620.0,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,
518,,,BAO_0000219,,620.0,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,Mus musculus,10090.0,,
519,,,BAO_0000219,,620.0,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,
520,,,BAO_0000219,,620.0,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,Mus musculus,10090.0,,
521,,,BAO_0000219,,620.0,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,Mus musculus,10090.0,,
522,,,BAO_0000219,,620.0,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,Mus musculus,10090.0,,
523,,,BAO_0000219,,620.0,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,Mus musculus,10090.0,,
524,,,BAO_0000219,,620.0,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,Mus musculus,10090.0,,
525,,,BAO_0000219,,620.0,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,Mus musculus,10090.0,,
526,,,BAO_0000219,,620.0,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,Mus musculus,10090.0,,
527,,,BAO_0000219,,620.0,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,Mus musculus,10090.0,,
528,,,BAO_0000219,,620.0,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,Mus musculus,10090.0,,
529,,,BAO_0000219,,1118.0,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,Rattus norvegicus,10116.0,,
530,,,BAO_0000219,,1118.0,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,Rattus norvegicus,10116.0,,
531,,,BAO_0000219,,1118.0,15899,Cytotoxicity in 3Y1 cells.,F,,Rattus norvegicus,10116.0,,
532,,,BAO_0000219,,1118.0,15899,Cytostatic effect in 3Y1 cells.,F,,Rattus norvegicus,10116.0,,
533,,,BAO_0000219,,1118.0,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,Rattus norvegicus,10116.0,,
534,,,BAO_0000219,,1118.0,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,Rattus norvegicus,10116.0,,
535,,,BAO_0000019,,,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,
536,,,BAO_0000019,,,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,
537,,,BAO_0000019,,,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,
538,,,BAO_0000019,,,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,Sus scrofa,9823.0,,
539,,,BAO_0000019,,,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,
540,,,BAO_0000019,,,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,
541,,,BAO_0000019,,,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,
542,,,BAO_0000019,,,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,
543,,,BAO_0000019,,,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,
544,,,BAO_0000357,,,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,
545,,,BAO_0000019,,,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,
546,,,BAO_0000019,,,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,
547,,,BAO_0000019,,,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,Sus scrofa,9823.0,,
548,,,BAO_0000019,,,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,
549,,,BAO_0000357,,,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,
550,,,BAO_0000019,,,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,
551,,,BAO_0000019,,,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,
552,,,BAO_0000224,,,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,
553,,,BAO_0000019,,,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,
554,,,BAO_0000019,,,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,
555,,,BAO_0000019,,,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,
556,,,BAO_0000357,,,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,
557,,,BAO_0000357,,,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,
558,,,BAO_0000221,10000000.0,,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,Hippocampus
559,,,BAO_0000357,,,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,
560,,,BAO_0000357,,,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,
561,,,BAO_0000019,,,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,
562,,,BAO_0000221,10000000.0,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,Hippocampus
563,,,BAO_0000221,10000000.0,,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,Hippocampus
564,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
565,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
566,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
567,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
568,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
569,,,BAO_0000221,10000000.0,,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,Hippocampus
570,,,BAO_0000221,10000000.0,,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,Hippocampus
571,Membranes,,BAO_0000249,,,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,Rattus norvegicus,10116.0,,
572,,,BAO_0000221,10000000.0,,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,Bos taurus,9913.0,,Hippocampus
573,,,BAO_0000221,10000000.0,,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,Hippocampus
574,,,BAO_0000221,10000000.0,,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,Hippocampus
575,,,BAO_0000221,10000000.0,,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,Hippocampus
576,,,BAO_0000221,10000000.0,,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,Hippocampus
577,,,BAO_0000219,,449.0,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,
578,,,BAO_0000221,10000000.0,,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,Hippocampus
579,,,BAO_0000221,10000000.0,,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,Hippocampus
580,,,BAO_0000219,,449.0,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
581,,,BAO_0000221,10000000.0,,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,Hippocampus
582,,,BAO_0000357,,,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,
583,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
584,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
585,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
586,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
587,,,BAO_0000221,10000000.0,,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,Hippocampus
588,,,BAO_0000218,10000000.0,,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,Hippocampus
589,,,BAO_0000221,10000000.0,,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
590,,,BAO_0000219,,449.0,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,Homo sapiens,9606.0,,
591,,,BAO_0000019,,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,Cavia porcellus,10141.0,,
592,,,BAO_0000019,,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,Cavia porcellus,10141.0,,
593,,,BAO_0000221,10000000.0,,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,Cavia porcellus,10141.0,,Hippocampus
594,,,BAO_0000221,2116.0,,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,Cavia porcellus,10141.0,,Ileum
595,,,BAO_0000221,2116.0,,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,Cavia porcellus,10141.0,,Ileum
596,,,BAO_0000221,2116.0,,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,Cavia porcellus,10141.0,,Ileum
597,,,BAO_0000221,2116.0,,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,Cavia porcellus,10141.0,,Ileum
598,,,BAO_0000221,2116.0,,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,Cavia porcellus,10141.0,,Ileum
599,,,BAO_0000221,2116.0,,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,Cavia porcellus,10141.0,,Ileum
600,,,BAO_0000357,,,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,Cavia porcellus,10141.0,,
601,,,BAO_0000357,,,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,Cavia porcellus,10141.0,,
602,,,BAO_0000357,,,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,Cavia porcellus,10141.0,,
603,,,BAO_0000221,10000000.0,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,Cavia porcellus,10141.0,,Hippocampus
604,,,BAO_0000221,10000000.0,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,Cavia porcellus,10141.0,,Hippocampus
605,,,BAO_0000218,,449.0,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,Cricetulus griseus,10029.0,,
606,,,BAO_0000357,,,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,
607,,,BAO_0000219,,308.0,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,
608,,,BAO_0000219,,308.0,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,
609,,,BAO_0000019,,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,
610,,,BAO_0000219,,449.0,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,
611,,,BAO_0000219,,449.0,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,
612,,,BAO_0000219,,449.0,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,
613,,,BAO_0000219,,449.0,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,
614,,,BAO_0000219,,449.0,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
615,,,BAO_0000219,,449.0,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
616,,,BAO_0000219,,449.0,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,
617,,,BAO_0000219,,,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,
618,,,BAO_0000219,,308.0,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,Homo sapiens,9606.0,,
619,,,BAO_0000219,,308.0,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,Homo sapiens,9606.0,,
620,,,BAO_0000219,,449.0,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
621,,,BAO_0000219,,449.0,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,Homo sapiens,9606.0,,
622,,,BAO_0000019,,,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,
623,,,BAO_0000019,,,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,
624,,,BAO_0000019,,,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,
625,,,BAO_0000219,,449.0,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,
626,,,BAO_0000219,,449.0,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,Homo sapiens,9606.0,,
627,,,BAO_0000219,,449.0,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,
628,,,BAO_0000219,,449.0,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,Homo sapiens,9606.0,,
629,,,BAO_0000219,,449.0,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,
630,,,BAO_0000219,,449.0,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,
631,,,BAO_0000219,,449.0,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,Homo sapiens,9606.0,,
632,,,BAO_0000219,,449.0,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,
633,,,BAO_0000219,,449.0,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,Homo sapiens,9606.0,,
634,,,BAO_0000019,,,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,Homo sapiens,9606.0,,
635,,,BAO_0000019,,,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,9606.0,,
636,,,BAO_0000019,,,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,Homo sapiens,9606.0,,
637,,,BAO_0000019,,,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,9606.0,,
638,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,
639,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,
640,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,
641,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,
642,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,
643,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,
644,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,
645,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,
646,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,
647,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,
648,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,
649,,,BAO_0000219,,449.0,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,
650,,,BAO_0000019,,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
651,,,BAO_0000019,,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
652,,,BAO_0000019,,,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,
653,,,BAO_0000219,,722.0,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
654,,,BAO_0000019,,,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,Homo sapiens,9606.0,,
655,,,BAO_0000019,,,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,
656,,,BAO_0000019,,,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,Homo sapiens,9606.0,,
657,,,BAO_0000019,,,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,Homo sapiens,9606.0,,
658,,,BAO_0000019,,,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,
659,,,BAO_0000019,,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,
660,,,BAO_0000019,,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,
661,,,BAO_0000019,,,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,
662,,,BAO_0000019,,,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,
663,,,BAO_0000019,,,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,Homo sapiens,9606.0,,
664,,,BAO_0000019,,,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,Homo sapiens,9606.0,,
665,,,BAO_0000019,,,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,
666,,,BAO_0000019,,,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,
667,,,BAO_0000019,,,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,
668,,,BAO_0000219,,449.0,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,
669,,,BAO_0000219,,449.0,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,
670,,,BAO_0000357,,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,
671,,,BAO_0000357,,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,
672,,,BAO_0000019,,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
673,,,BAO_0000019,,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,
674,,,BAO_0000019,,,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,
675,,,BAO_0000019,,,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,Homo sapiens,9606.0,,
676,,,BAO_0000019,,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
677,,,BAO_0000019,,,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,Homo sapiens,9606.0,,
678,,,BAO_0000019,,,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,9606.0,,
679,,,BAO_0000019,,,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,Homo sapiens,9606.0,,
680,,,BAO_0000019,,,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,Homo sapiens,9606.0,,
681,,,BAO_0000019,,,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,Homo sapiens,9606.0,,
682,,,BAO_0000019,,,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,Homo sapiens,9606.0,,
683,,,BAO_0000019,,,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,Homo sapiens,9606.0,,
684,,,BAO_0000019,,,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,Homo sapiens,9606.0,,
685,,,BAO_0000357,,,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
686,,,BAO_0000219,,449.0,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
687,,,BAO_0000219,,722.0,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,
688,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,
689,,,BAO_0000219,,449.0,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,
690,,,BAO_0000357,,,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,
691,,,BAO_0000357,,,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
692,,,BAO_0000219,,449.0,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
693,,,BAO_0000219,,449.0,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
694,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,,Rattus norvegicus,10116.0,,
695,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,,Rattus norvegicus,10116.0,,
696,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,,Rattus norvegicus,10116.0,,
697,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,,Rattus norvegicus,10116.0,,
698,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,,Rattus norvegicus,10116.0,,
699,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,,Rattus norvegicus,10116.0,,
700,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,,Rattus norvegicus,10116.0,,
701,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,,Rattus norvegicus,10116.0,,
702,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,,Rattus norvegicus,10116.0,,
703,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,,Rattus norvegicus,10116.0,,
704,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,,Rattus norvegicus,10116.0,,
705,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,,Rattus norvegicus,10116.0,,
706,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,,Rattus norvegicus,10116.0,,
707,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,,Rattus norvegicus,10116.0,,
708,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,,Rattus norvegicus,10116.0,,
709,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,,Rattus norvegicus,10116.0,,
710,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,,Rattus norvegicus,10116.0,,
711,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,,Rattus norvegicus,10116.0,,
712,,In vivo,BAO_0000218,,,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,,Rattus norvegicus,10116.0,,
713,,,BAO_0000019,,,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,
714,,,BAO_0000249,1898.0,,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,Hypothalamus
715,,,BAO_0000019,,,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,
716,,,BAO_0000019,,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,
717,,,BAO_0000019,,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,
718,,,BAO_0000357,,,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,
719,,,BAO_0000357,,,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,
720,,,BAO_0000019,,,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,
721,,,BAO_0000019,,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,
722,,,BAO_0000019,,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,
723,,,BAO_0000019,,,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,
724,,,BAO_0000019,,,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,Cavia porcellus,10141.0,,
725,,,BAO_0000019,,,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,Cavia porcellus,10141.0,,
726,,,BAO_0000019,,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,Cavia porcellus,10141.0,,
727,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,Cavia porcellus,10141.0,,
728,,,BAO_0000357,,,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,Homo sapiens,9606.0,,
729,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,
730,,,BAO_0000218,,,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,
731,,,BAO_0000357,,,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,
732,,,BAO_0000218,,,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,
733,,,BAO_0000019,,,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,Sus scrofa,9823.0,,
734,,,BAO_0000357,,,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,
735,,,BAO_0000357,,,11481,Inhibitory activity against 5-Lipoxygenase,B,,Rattus norvegicus,10116.0,,
736,,,BAO_0000219,,702.0,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,
737,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,
738,,,BAO_0000219,,702.0,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,
739,,,BAO_0000019,,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,
740,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,
741,,,BAO_0000357,,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,
742,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,
743,,,BAO_0000357,,,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,
744,,,BAO_0000019,,,11481,Ratio of IC50 against 5-LO and COX,B,,Rattus norvegicus,10116.0,,
745,,,BAO_0000357,,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,
746,,,BAO_0000357,,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,
747,,,BAO_0000219,,,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,
748,,,BAO_0000019,,,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,
749,,,BAO_0000357,2367.0,,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,Prostate gland
750,,,BAO_0000019,,,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,Columba livia,8932.0,,
751,,,BAO_0000019,,,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,Columba livia,8932.0,,
752,,,BAO_0000019,,,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,Columba livia,8932.0,,
753,,,BAO_0000357,,,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,
754,,,BAO_0000019,,,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,Rattus norvegicus,10116.0,,
755,,,BAO_0000019,,,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,Rattus norvegicus,10116.0,,
756,,,BAO_0000019,,,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,Rattus norvegicus,10116.0,,
757,,,BAO_0000221,10000000.0,,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,Hippocampus
758,,,BAO_0000357,,,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,
759,,,BAO_0000019,,,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
760,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
761,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
762,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
763,,,BAO_0000221,10000000.0,,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,Hippocampus
764,,,BAO_0000221,10000000.0,,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,Hippocampus
765,,,BAO_0000221,10000000.0,,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,Hippocampus
766,Membranes,,BAO_0000249,,,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,
767,,,BAO_0000249,,,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,Rattus norvegicus,10116.0,,
768,,,BAO_0000019,,,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,Rattus norvegicus,10116.0,,
769,,,BAO_0000019,,,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,Rattus norvegicus,10116.0,,
770,,,BAO_0000224,,,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,
771,,,BAO_0000221,10000000.0,,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,Hippocampus
772,,,BAO_0000221,10000000.0,,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,Hippocampus
773,,,BAO_0000224,,,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,
774,,,BAO_0000019,,,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,
775,,,BAO_0000249,,,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,Rattus norvegicus,10116.0,,
776,,,BAO_0000019,,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
777,,,BAO_0000019,,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
778,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,Brain
779,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,Brain
780,,,BAO_0000019,,,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,
781,,,BAO_0000224,,,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,Rattus norvegicus,10116.0,,
782,,,BAO_0000224,,,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,
783,,,BAO_0000224,,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,
784,,,BAO_0000224,,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,
785,,,BAO_0000224,,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,
786,,,BAO_0000019,,,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,
787,,,BAO_0000019,,,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,
788,,,BAO_0000224,,,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,
789,,,BAO_0000019,,,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,Rattus norvegicus,10116.0,,
790,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,Brain
791,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,Brain
792,,,BAO_0000224,,,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,
793,,,BAO_0000221,955.0,,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,Brain
794,,,BAO_0000019,,,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,
795,,,BAO_0000019,,,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,Rattus norvegicus,10116.0,,
796,,,BAO_0000019,,,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,
797,,,BAO_0000019,,,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,Rattus norvegicus,10116.0,,
798,,,BAO_0000019,,,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,Rattus norvegicus,10116.0,,
799,,,BAO_0000019,,,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,
800,,,BAO_0000221,955.0,,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,Brain
801,,,BAO_0000019,,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,
802,,,BAO_0000220,955.0,,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,Brain
803,,,BAO_0000221,955.0,,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,Brain
804,,,BAO_0000019,,,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,
805,,,BAO_0000019,,,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,
806,,,BAO_0000357,,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,
807,,,BAO_0000249,,,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,
808,,In vivo,BAO_0000218,,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,,,,,
809,,In vivo,BAO_0000218,,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,,,,,
810,,,BAO_0000019,,,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,
811,,In vivo,BAO_0000218,,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,,,,,
812,,In vivo,BAO_0000218,,,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,,,,,
813,,,BAO_0000019,,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,
814,,,BAO_0000219,,,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,
815,,,BAO_0000219,,,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,
816,,,BAO_0000219,,,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,
817,,,BAO_0000249,,,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,
818,,,BAO_0000221,10000000.0,,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,Hippocampus
819,,,BAO_0000221,10000000.0,,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,Hippocampus
820,Membranes,,BAO_0000249,,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,
821,,,BAO_0000221,10000000.0,,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,Hippocampus
822,,,BAO_0000221,10000000.0,,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,Rattus norvegicus,10116.0,,Hippocampus
823,,,BAO_0000221,10000000.0,,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
824,,,BAO_0000221,10000000.0,,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,Rattus norvegicus,10116.0,,Hippocampus
825,,,BAO_0000221,10000000.0,,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,Rattus norvegicus,10116.0,,Hippocampus
826,,,BAO_0000357,,,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,
827,,,BAO_0000249,,,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,
828,,,BAO_0000249,10000000.0,,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
829,,,BAO_0000221,10000000.0,,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
830,,,BAO_0000221,10000000.0,,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
831,,,BAO_0000221,10000000.0,,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,Hippocampus
832,,,BAO_0000357,,,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,
833,,,BAO_0000019,,,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,
834,,,BAO_0000221,10000000.0,,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,Hippocampus
835,,,BAO_0000249,,,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,
836,,,BAO_0000249,10000000.0,,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,Hippocampus
837,,,BAO_0000019,,,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,Rattus norvegicus,10116.0,,
838,,,BAO_0000019,,,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,Rattus norvegicus,10116.0,,
839,,,BAO_0000249,,,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,
840,,,BAO_0000019,,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,
841,,,BAO_0000249,,,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,
842,,,BAO_0000221,10000000.0,,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
843,,,BAO_0000019,,,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,
844,,,BAO_0000221,10000000.0,,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,Hippocampus
845,,,BAO_0000221,10000000.0,,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,Hippocampus
846,,,BAO_0000357,,,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,
847,,,BAO_0000221,10000000.0,,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,Hippocampus
848,,,BAO_0000357,,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,
849,,,BAO_0000357,,,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,
850,,,BAO_0000019,,,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,
851,,,BAO_0000019,,,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,
852,,,BAO_0000019,,,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,
853,,,BAO_0000221,10000000.0,,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,Hippocampus
854,,,BAO_0000019,,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,
855,,,BAO_0000019,,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,
856,,,BAO_0000019,,,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,
857,,,BAO_0000019,,,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,
858,,,BAO_0000357,,,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,
859,,,BAO_0000221,10000000.0,,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,Hippocampus
860,,,BAO_0000357,,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,
861,,,BAO_0000357,,,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,
862,,,BAO_0000357,,,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,
863,,,BAO_0000249,10000000.0,,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,Hippocampus
864,,,BAO_0000221,10000000.0,,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,Rattus norvegicus,10116.0,,Hippocampus
865,,,BAO_0000357,,,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,
866,,,BAO_0000357,,,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,
867,,,BAO_0000249,,,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,Rattus norvegicus,10116.0,,
868,,,BAO_0000221,10000000.0,,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,Hippocampus
869,,,BAO_0000221,10000000.0,,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,Hippocampus
870,,,BAO_0000221,10000000.0,,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,Hippocampus
871,,,BAO_0000357,,,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
872,,,BAO_0000019,,,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
873,,,BAO_0000221,10000000.0,,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,Hippocampus
874,,,BAO_0000357,,,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,Rattus norvegicus,10116.0,,
875,,,BAO_0000221,10000000.0,,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,Hippocampus
876,,,BAO_0000219,,449.0,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,
877,,,BAO_0000219,,449.0,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,
878,,,BAO_0000219,,449.0,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,
879,,,BAO_0000357,,,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,
880,,,BAO_0000357,,,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,
881,,,BAO_0000019,,,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,
882,,,BAO_0000219,,449.0,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,
883,,,BAO_0000357,,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,
884,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,
885,,,BAO_0000357,,,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
886,,,BAO_0000357,,,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,
887,,,BAO_0000357,,,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,
888,,,BAO_0000357,,,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
889,,,BAO_0000219,,722.0,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
890,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,
891,,,BAO_0000357,,,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,
892,,,BAO_0000019,,,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,
893,,,BAO_0000019,,,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,
894,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,
895,,,BAO_0000219,,449.0,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,
896,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,Homo sapiens,9606.0,,
897,,,BAO_0000357,,,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,
898,,,BAO_0000357,,,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
899,,,BAO_0000219,,308.0,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,
900,,,BAO_0000357,,,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
901,,,BAO_0000219,,449.0,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,
902,,,BAO_0000219,,449.0,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
903,,,BAO_0000357,,,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,
904,,,BAO_0000219,,449.0,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,
905,,,BAO_0000219,,449.0,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,
906,,,BAO_0000357,,,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,
907,,,BAO_0000219,,449.0,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
908,,,BAO_0000019,,,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,
909,,,BAO_0000357,,,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,
910,,,BAO_0000357,,,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,
911,,,BAO_0000357,,,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,
912,,,BAO_0000219,,308.0,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,
913,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,
914,,,BAO_0000357,,,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
915,,,BAO_0000357,,,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
916,,,BAO_0000357,,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,
917,,,BAO_0000219,,1167.0,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,
918,,,BAO_0000019,,,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,
919,,,BAO_0000357,,,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
920,,,BAO_0000357,,,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
921,,,BAO_0000357,,,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
922,,,BAO_0000357,,,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,
923,,,BAO_0000357,,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
924,,,BAO_0000357,,,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,
925,,,BAO_0000357,,,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
926,,,BAO_0000357,,,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,
927,,,BAO_0000357,,,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
928,,,BAO_0000357,,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,
929,,,BAO_0000357,,,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
930,,,BAO_0000219,,,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,
931,,,BAO_0000357,,,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,Homo sapiens,9606.0,,
932,,,BAO_0000357,,,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,
933,,,BAO_0000357,,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,
934,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,
935,,,BAO_0000219,,485.0,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,
936,,,BAO_0000219,,485.0,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,
937,,,BAO_0000019,,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,
938,,,BAO_0000019,,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,
939,,,BAO_0000019,,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,
940,,,BAO_0000019,,,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,
941,,,BAO_0000219,,308.0,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,Homo sapiens,9606.0,,
942,,,BAO_0000357,,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,
943,,,BAO_0000357,,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,
944,,,BAO_0000357,,,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,
945,,,BAO_0000357,,,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
946,,,BAO_0000357,,,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,
947,,,BAO_0000357,,,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,
948,,,BAO_0000219,,449.0,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,
949,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,
950,,,BAO_0000357,,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,
951,,,BAO_0000357,,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,
952,,,BAO_0000357,,,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,
953,,,BAO_0000219,,308.0,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,
954,,,BAO_0000219,,308.0,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,Homo sapiens,9606.0,,
955,,,BAO_0000357,,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
956,,,BAO_0000357,,,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,
957,,,BAO_0000357,,,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,Homo sapiens,9606.0,,
958,,,BAO_0000019,,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,
959,,,BAO_0000019,,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,
960,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,
961,,,BAO_0000357,,,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
962,,,BAO_0000019,,,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,
963,,,BAO_0000019,,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,
964,,,BAO_0000357,,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
965,,,BAO_0000357,,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,
966,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,
967,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,
968,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,
969,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,
970,,,BAO_0000019,,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,
971,,,BAO_0000019,,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,
972,,,BAO_0000019,,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,
973,,In vivo,BAO_0000218,,,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,,,,,
974,,,BAO_0000019,,,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,
975,,,BAO_0000019,,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,
976,,,BAO_0000019,,,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,
977,,,BAO_0000357,,,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,
978,,,BAO_0000219,,722.0,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
979,,,BAO_0000019,,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,
980,,,BAO_0000019,,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,
981,,,BAO_0000019,,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,
982,,,BAO_0000019,,,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,
983,,,BAO_0000219,,449.0,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,
984,,,BAO_0000019,,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,
985,,,BAO_0000019,,,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,Homo sapiens,9606.0,,
986,,,BAO_0000019,,,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,Homo sapiens,9606.0,,
987,,,BAO_0000219,,449.0,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,
988,,,BAO_0000019,,,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,
989,,,BAO_0000019,,,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,Homo sapiens,9606.0,,
990,,,BAO_0000019,,,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,Homo sapiens,9606.0,,
991,,,BAO_0000019,,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
992,,,BAO_0000019,,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
993,,,BAO_0000019,,,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,
994,,,BAO_0000019,,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
995,,,BAO_0000019,,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
996,,,BAO_0000019,,,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,
997,,,BAO_0000019,,,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,
998,,,BAO_0000219,,308.0,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,Homo sapiens,9606.0,,
999,,,BAO_0000219,,308.0,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,Homo sapiens,9606.0,,
1000,,,BAO_0000219,,308.0,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,Homo sapiens,9606.0,,
1001,,,BAO_0000019,,,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,
1002,,,BAO_0000019,,,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,
1003,,,BAO_0000219,,722.0,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,
1004,,,BAO_0000219,,449.0,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,
1005,,,BAO_0000219,,449.0,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,
1006,,,BAO_0000219,,449.0,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,Homo sapiens,9606.0,,
1007,,,BAO_0000219,,449.0,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,
1008,,,BAO_0000219,,,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,
1009,,,BAO_0000219,,,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,
1010,,,BAO_0000019,,,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,
1011,,In vitro,BAO_0000219,,,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,,,,,
1012,,In vitro,BAO_0000219,,,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,,,,,
1013,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
1014,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
1015,,,BAO_0000357,,,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,
1016,,,BAO_0000357,,,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,
1017,,,BAO_0000357,,,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,
1018,,,BAO_0000357,,,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
1019,,,BAO_0000357,,,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,
1020,,,BAO_0000219,,449.0,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,Homo sapiens,9606.0,,
1021,,,BAO_0000019,,,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,
1022,,,BAO_0000019,,,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,
1023,,,BAO_0000019,,,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,
1024,,,BAO_0000219,,722.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,Homo sapiens,9606.0,,
1025,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,
1026,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,
1027,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,
1028,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,
1029,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,
1030,,,BAO_0000357,,,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,
1031,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,
1032,,,BAO_0000219,,722.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,
1033,,,BAO_0000219,,,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,
1034,,,BAO_0000357,,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,
1035,,,BAO_0000219,,308.0,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,
1036,,,BAO_0000019,,,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,
1037,,,BAO_0000219,,722.0,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,
1038,,,BAO_0000219,,722.0,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,
1039,,,BAO_0000219,,,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,
1040,,,BAO_0000219,,308.0,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,Homo sapiens,9606.0,,
1041,,,BAO_0000219,,722.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,
1042,,,BAO_0000219,,722.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,
1043,,,BAO_0000357,,,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,
1044,,,BAO_0000357,,,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,Homo sapiens,9606.0,,
1045,,,BAO_0000357,,,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,
1046,,,BAO_0000357,,,5254,Binding affinity against 5-HT1D receptor,B,,,,,
1047,,,BAO_0000357,,,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1048,,,BAO_0000357,,,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,
1049,,,BAO_0000357,,,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,Homo sapiens,9606.0,,
1050,,,BAO_0000357,,,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,
1051,,In vivo,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,,,,,
1052,,In vivo,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,,,,,
1053,,In vivo,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,,,,,
1054,,,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,Mus musculus,10090.0,,
1055,,,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,Mus musculus,10090.0,,
1056,,,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,Mus musculus,10090.0,,
1057,,,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,Mus musculus,10090.0,,
1058,,,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,Mus musculus,10090.0,,
1059,,,BAO_0000218,,,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,Mus musculus,10090.0,,
1060,,,BAO_0000221,10000000.0,,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,Hippocampus
1061,,,BAO_0000357,,,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,
1062,,,BAO_0000221,10000000.0,,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,Mus musculus,10090.0,,Hippocampus
1063,,,BAO_0000221,10000000.0,,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,Hippocampus
1064,,,BAO_0000221,10000000.0,,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,Mus musculus,10090.0,,Hippocampus
1065,,,BAO_0000221,10000000.0,,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,Hippocampus
1066,,,BAO_0000357,,,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,
1067,,,BAO_0000221,10000000.0,,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,Mus musculus,10090.0,,Hippocampus
1068,,,BAO_0000357,,,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,Sus scrofa,9823.0,,
1069,,,BAO_0000357,,,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,Sus scrofa,9823.0,,
1070,,,BAO_0000019,,,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,Sus scrofa,9823.0,,
1071,,,BAO_0000357,,,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,Sus scrofa,9823.0,,
1072,,,BAO_0000019,,,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,Sus scrofa,9823.0,,
1073,,,BAO_0000019,,,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,Sus scrofa,9823.0,,
1074,,,BAO_0000019,,,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,Sus scrofa,9823.0,,
1075,,,BAO_0000357,,,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,Sus scrofa,9823.0,,
1076,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,Sus scrofa,9823.0,,
1077,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,Sus scrofa,9823.0,,
1078,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,Sus scrofa,9823.0,,
1079,,,BAO_0000019,,,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,
1080,,,BAO_0000019,,,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,Sus scrofa,9823.0,,
1081,,,BAO_0000221,10000000.0,,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,Sus scrofa,9823.0,,Hippocampus
1082,,,BAO_0000249,,,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,Sus scrofa,9823.0,,
1083,,,BAO_0000019,,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,Sus scrofa,9823.0,,
1084,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,Sus scrofa,9823.0,,
1085,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,Oryctolagus cuniculus,9986.0,,
1086,,,BAO_0000249,,,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,Rattus norvegicus,10116.0,,
1087,,,BAO_0000221,10000000.0,,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,Rattus norvegicus,10116.0,,Hippocampus
1088,,,BAO_0000357,,,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,
1089,Membranes,,BAO_0000249,,,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,Rattus norvegicus,10116.0,,
1090,Membranes,,BAO_0000249,10000000.0,,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,Rattus norvegicus,10116.0,,Hippocampus
1091,,,BAO_0000221,10000000.0,,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,Hippocampus
1092,,,BAO_0000221,10000000.0,,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,Rattus norvegicus,10116.0,,Hippocampus
1093,,,BAO_0000019,,,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,
1094,,,BAO_0000357,,,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,
1095,,,BAO_0000357,,,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,
1096,,In vitro,BAO_0000219,,,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,
1097,,,BAO_0000357,,,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,
1098,Membranes,,BAO_0000249,,,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,
1099,Membranes,,BAO_0000249,,,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,
1100,Membranes,,BAO_0000249,,,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,
1101,,,BAO_0000357,,,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,Rattus norvegicus,10116.0,,
1102,,,BAO_0000357,,,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,
1103,,,BAO_0000357,,,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,
1104,,,BAO_0000221,10000000.0,,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,Hippocampus
1105,,,BAO_0000221,10000000.0,,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,Hippocampus
1106,,,BAO_0000221,10000000.0,,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1107,,,BAO_0000357,,,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
1108,,,BAO_0000357,,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,
1109,,,BAO_0000249,,,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,
1110,,,BAO_0000357,,,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1111,,,BAO_0000357,,,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,
1112,,,BAO_0000019,,,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,
1113,,,BAO_0000221,955.0,,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,Rattus norvegicus,10116.0,,Brain
1114,,,BAO_0000221,955.0,,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,Brain
1115,,,BAO_0000249,,,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,
1116,,,BAO_0000221,10000000.0,,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,Hippocampus
1117,,,BAO_0000221,10000000.0,,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,Hippocampus
1118,,,BAO_0000249,,,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,
1119,,,BAO_0000249,2435.0,,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,Striatum
1120,Membranes,,BAO_0000249,,,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,Rattus norvegicus,10116.0,,
1121,Membranes,,BAO_0000249,,,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,Rattus norvegicus,10116.0,,
1122,,,BAO_0000221,10000000.0,,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1123,,,BAO_0000221,10000000.0,,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,Hippocampus
1124,,,BAO_0000221,10000000.0,,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1125,,,BAO_0000249,,,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,
1126,,,BAO_0000221,10000000.0,,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1127,,,BAO_0000221,10000000.0,,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,Hippocampus
1128,,,BAO_0000221,10000000.0,,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,Hippocampus
1129,,,BAO_0000221,10000000.0,,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,Hippocampus
1130,,,BAO_0000019,,,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,
1131,,,BAO_0000357,,,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,
1132,,,BAO_0000019,,,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,Rattus norvegicus,10116.0,,
1133,,,BAO_0000019,,,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,Rattus norvegicus,10116.0,,
1134,,,BAO_0000019,,,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,Rattus norvegicus,10116.0,,
1135,,,BAO_0000219,,485.0,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,10116.0,,
1136,,,BAO_0000357,,,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1137,,,BAO_0000221,10000000.0,,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,Rattus norvegicus,10116.0,,Hippocampus
1138,,,BAO_0000221,10000000.0,,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,Hippocampus
1139,,,BAO_0000019,,,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,
1140,,,BAO_0000019,,,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,
1141,,,BAO_0000019,,,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,
1142,,,BAO_0000221,10000000.0,,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,Hippocampus
1143,,,BAO_0000357,,,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,
1144,,,BAO_0000019,,,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,
1145,,,BAO_0000357,,,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,Rattus norvegicus,10116.0,,
1146,,,BAO_0000357,,,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,
1147,Membranes,,BAO_0000249,2435.0,,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,Striatum
1148,,,BAO_0000357,,,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,
1149,,In vivo,BAO_0000218,,,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,,,,,
1150,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,Brain
1151,,,BAO_0000357,,,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
1152,,,BAO_0000249,,,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,
1153,Membranes,,BAO_0000249,,,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,Rattus norvegicus,10116.0,,
1154,,,BAO_0000221,10000000.0,,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1155,,,BAO_0000221,10000000.0,,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1156,,,BAO_0000357,,,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,
1157,,,BAO_0000249,,,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,
1158,,,BAO_0000357,,,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,
1159,,,BAO_0000019,,,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,
1160,,,BAO_0000019,,,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,
1161,,,BAO_0000019,,,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
1162,,,BAO_0000019,,,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,
1163,,,BAO_0000357,,,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,
1164,,,BAO_0000221,10000000.0,,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,Hippocampus
1165,,,BAO_0000357,,,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,
1166,,,BAO_0000219,,449.0,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,
1167,,,BAO_0000019,,,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,
1168,,,BAO_0000221,10000000.0,,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,Hippocampus
1169,,,BAO_0000019,,,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,
1170,,,BAO_0000019,,,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,
1171,,,BAO_0000357,,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,
1172,,,BAO_0000221,955.0,,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,Brain
1173,,,BAO_0000221,10000000.0,,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,Hippocampus
1174,,,BAO_0000019,,,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,
1175,,,BAO_0000221,10000000.0,,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,Hippocampus
1176,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,Hippocampus
1177,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,Hippocampus
1178,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,Hippocampus
1179,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,Hippocampus
1180,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,Hippocampus
1181,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,Hippocampus
1182,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,Hippocampus
1183,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,Hippocampus
1184,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,Hippocampus
1185,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,Hippocampus
1186,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,Hippocampus
1187,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,Hippocampus
1188,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,Hippocampus
1189,,,BAO_0000221,10000000.0,,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,Rattus norvegicus,10116.0,,Hippocampus
1190,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,Hippocampus
1191,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,Hippocampus
1192,,,BAO_0000019,,,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,
1193,,,BAO_0000019,,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,
1194,,,BAO_0000019,,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,
1195,,,BAO_0000019,,,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,
1196,,,BAO_0000221,955.0,,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,Brain
1197,,,BAO_0000019,,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,
1198,,,BAO_0000019,,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,
1199,,,BAO_0000019,,,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,
1200,,,BAO_0000219,,449.0,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,
1201,,,BAO_0000249,,,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,
1202,,,BAO_0000019,,,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,
1203,,,BAO_0000218,,449.0,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,
1204,,,BAO_0000218,,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,
1205,,,BAO_0000357,,,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,
1206,Membranes,,BAO_0000249,,,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,
1207,,,BAO_0000249,,,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,
1208,,,BAO_0000249,,,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,
1209,,,BAO_0000219,,449.0,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
1210,,,BAO_0000249,,,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,
1211,,,BAO_0000221,10000000.0,,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,Rattus norvegicus,10116.0,,Hippocampus
1212,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
1213,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,
1214,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,
1215,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,
1216,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,
1217,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,
1218,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,
1219,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,
1220,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,
1221,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,
1222,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,
1223,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,
1224,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,
1225,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,
1226,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,
1227,,,BAO_0000019,,,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,
1228,,,BAO_0000357,,,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,
1229,,,BAO_0000357,,,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,
1230,,,BAO_0000019,,,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,
1231,,,BAO_0000221,10000000.0,,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,Hippocampus
1232,,,BAO_0000019,,,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,
1233,,,BAO_0000219,,485.0,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,10116.0,,
1234,,,BAO_0000019,,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,
1235,,,BAO_0000019,,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,
1236,,,BAO_0000357,,,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,
1237,,,BAO_0000357,,,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,
1238,,,BAO_0000357,,,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,
1239,,,BAO_0000019,,,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,
1240,,,BAO_0000019,,,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,Rattus norvegicus,10116.0,,
1241,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,,,,,
1242,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,,,,,
1243,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,,,,,
1244,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,,,,,
1245,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,,,,,
1246,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,,,,,
1247,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,,,,,
1248,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,,,,,
1249,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,,,,,
1250,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,,,,,
1251,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,,,,,
1252,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,,,,,
1253,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,,,,,
1254,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,,,,,
1255,,In vivo,BAO_0000218,,,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,,,,,
1256,Membranes,,BAO_0000249,,,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,Rattus norvegicus,10116.0,,
1257,,,BAO_0000019,,,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,
1258,,,BAO_0000019,,,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,
1259,,,BAO_0000357,,,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,
1260,,,BAO_0000249,,,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,
1261,,,BAO_0000221,10000000.0,,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1262,,,BAO_0000249,10000000.0,,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,Hippocampus
1263,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,Brain
1264,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,
1265,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,
1266,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,
1267,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,
1268,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,
1269,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,
1270,,,BAO_0000019,,,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,Rattus norvegicus,10116.0,,
1271,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,
1272,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,
1273,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,
1274,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,
1275,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,
1276,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,
1277,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,
1278,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,
1279,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,
1280,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,
1281,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,
1282,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,
1283,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,
1284,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,
1285,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,
1286,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,
1287,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,
1288,,,BAO_0000221,10000000.0,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,Hippocampus
1289,,,BAO_0000221,10000000.0,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,Hippocampus
1290,Membranes,,BAO_0000249,,,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,Rattus norvegicus,10116.0,,
1291,,,BAO_0000221,10000000.0,,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,Hippocampus
1292,,,BAO_0000221,10000000.0,,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,Hippocampus
1293,,,BAO_0000221,10000000.0,,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,Hippocampus
1294,,,BAO_0000249,,,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,Rattus norvegicus,10116.0,,
1295,,,BAO_0000357,,,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,
1296,,,BAO_0000019,,,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,
1297,,,BAO_0000019,,,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,
1298,,,BAO_0000357,,,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,
1299,,,BAO_0000221,10000000.0,,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,Hippocampus
1300,,,BAO_0000221,10000000.0,,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,Hippocampus
1301,,,BAO_0000221,10000000.0,,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,Hippocampus
1302,,,BAO_0000357,,,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
1303,,,BAO_0000221,10000000.0,,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,Hippocampus
1304,,,BAO_0000221,10000000.0,,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1305,,,BAO_0000221,10000000.0,,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1306,,,BAO_0000221,10000000.0,,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,Hippocampus
1307,,,BAO_0000221,10000000.0,,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,Hippocampus
1308,,,BAO_0000221,10000000.0,,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,Hippocampus
1309,,,BAO_0000221,955.0,,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,Brain
1310,,,BAO_0000357,,,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,
1311,,,BAO_0000357,,,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,
1312,,,BAO_0000221,10000000.0,,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,Hippocampus
1313,,,BAO_0000357,,,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,
1314,,,BAO_0000357,,,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,
1315,,,BAO_0000221,10000000.0,,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,Rattus norvegicus,10116.0,,Hippocampus
1316,,,BAO_0000249,,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,
1317,,,BAO_0000019,,,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,Rattus norvegicus,10116.0,,
1318,,,BAO_0000221,10000000.0,,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,Hippocampus
1319,,,BAO_0000357,,,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,
1320,,,BAO_0000357,,,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,
1321,,,BAO_0000357,,,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,
1322,,,BAO_0000019,,,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
1323,,,BAO_0000221,10000000.0,,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,Hippocampus
1324,,,BAO_0000357,,,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,
1325,,,BAO_0000221,955.0,,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,Brain
1326,,,BAO_0000221,955.0,,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,Brain
1327,,,BAO_0000357,,,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,
1328,,,BAO_0000357,,,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,
1329,,,BAO_0000357,,,14875,GTPgammaS radioligand binding assay,B,,,,,
1330,,,BAO_0000357,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,
1331,,,BAO_0000019,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,
1332,,,BAO_0000019,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,
1333,,,BAO_0000357,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,
1334,,,BAO_0000357,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,
1335,,,BAO_0000019,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,
1336,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,
1337,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,
1338,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,Homo sapiens,9606.0,,
1339,,,BAO_0000219,,449.0,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,
1340,,,BAO_0000019,,,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,
1341,,,BAO_0000019,,,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,
1342,,,BAO_0000357,,,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1343,,,BAO_0000219,,,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,
1344,,,BAO_0000357,,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,
1345,,,BAO_0000357,,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,
1346,,,BAO_0000357,,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1347,,,BAO_0000357,,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1348,,,BAO_0000357,,,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,
1349,,,BAO_0000357,,,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1350,,,BAO_0000357,,,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,
1351,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,
1352,,,BAO_0000357,,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,
1353,,,BAO_0000219,,485.0,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,
1354,,,BAO_0000019,,,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,
1355,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,
1356,,,BAO_0000357,,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,
1357,,,BAO_0000357,,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,
1358,,,BAO_0000219,,,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,Homo sapiens,9606.0,,
1359,,,BAO_0000357,,,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1360,,,BAO_0000357,,,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,Homo sapiens,9606.0,,
1361,,,BAO_0000357,,,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1362,,,BAO_0000219,,449.0,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,
1363,,,BAO_0000019,,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,
1364,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,
1365,,,BAO_0000219,,308.0,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,
1366,,,BAO_0000219,,308.0,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,
1367,,,BAO_0000357,,,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,Homo sapiens,9606.0,,
1368,,,BAO_0000219,,485.0,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,
1369,,,BAO_0000357,,,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,
1370,,,BAO_0000357,,,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,
1371,,,BAO_0000219,,485.0,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,
1372,,,BAO_0000357,,,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1373,,,BAO_0000357,,,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1374,,,BAO_0000219,,449.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,Homo sapiens,9606.0,,
1375,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,
1376,,,BAO_0000219,,449.0,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,
1377,,,BAO_0000219,,449.0,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,
1378,,,BAO_0000219,,449.0,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,
1379,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,
1380,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,
1381,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,
1382,,,BAO_0000219,,449.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,
1383,,,BAO_0000357,,,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1384,,,BAO_0000219,,449.0,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,
1385,,,BAO_0000357,,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
1386,,,BAO_0000219,,449.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,
1387,,,BAO_0000219,,449.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
1388,,,BAO_0000019,,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,
1389,,,BAO_0000019,,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,
1390,,,BAO_0000219,,449.0,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,
1391,,,BAO_0000219,,449.0,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,
1392,,,BAO_0000019,,,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,
1393,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,
1394,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,
1395,,,BAO_0000019,,,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,Oryctolagus cuniculus,9986.0,,
1396,,,BAO_0000019,,,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,Oryctolagus cuniculus,9986.0,,
1397,,,BAO_0000019,,,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,Oryctolagus cuniculus,9986.0,,
1398,,,BAO_0000019,,,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,Oryctolagus cuniculus,9986.0,,
1399,,,BAO_0000357,,,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,
1400,,,BAO_0000357,,,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,
1401,,,BAO_0000019,2435.0,,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,Rattus norvegicus,10116.0,,Striatum
1402,,,BAO_0000357,,,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,
1403,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,
1404,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,
1405,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,
1406,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,
1407,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,
1408,,,BAO_0000357,,,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,
1409,,,BAO_0000249,10000000.0,,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,Hippocampus
1410,,,BAO_0000019,,,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,
1411,,,BAO_0000221,10000000.0,,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,Hippocampus
1412,,,BAO_0000221,10000000.0,,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,Hippocampus
1413,,,BAO_0000221,10000000.0,,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1414,,,BAO_0000221,10000000.0,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,Hippocampus
1415,,,BAO_0000221,10000000.0,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,Hippocampus
1416,,,BAO_0000221,10000000.0,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,Hippocampus
1417,,,BAO_0000221,10000000.0,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,Hippocampus
1418,,,BAO_0000221,10000000.0,,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,Hippocampus
1419,,,BAO_0000249,,,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,
1420,,,BAO_0000249,,,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,
1421,,,BAO_0000249,,,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,
1422,,,BAO_0000357,,,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,
1423,,,BAO_0000221,10000000.0,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,Hippocampus
1424,,,BAO_0000221,10000000.0,,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,Hippocampus
1425,,,BAO_0000221,10000000.0,,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,Hippocampus
1426,,,BAO_0000019,,,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,
1427,,,BAO_0000221,10000000.0,,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,Hippocampus
1428,,,BAO_0000221,10000000.0,,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,Rattus norvegicus,10116.0,,Hippocampus
1429,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,
1430,,,BAO_0000221,10000000.0,,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,Hippocampus
1431,,,BAO_0000221,10000000.0,,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,Hippocampus
1432,,,BAO_0000221,10000000.0,,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,Hippocampus
1433,,,BAO_0000357,,,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,
1434,,,BAO_0000221,10000000.0,,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,Rattus norvegicus,10116.0,,Hippocampus
1435,,,BAO_0000357,,,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,
1436,,,BAO_0000019,,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,
1437,,,BAO_0000019,,,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,
1438,,,BAO_0000219,,449.0,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,
1439,,,BAO_0000357,,,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,
1440,,,BAO_0000357,,,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,
1441,,,BAO_0000221,10000000.0,,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,Hippocampus
1442,,,BAO_0000221,10000000.0,,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1443,,,BAO_0000221,10000000.0,,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,Hippocampus
1444,,,BAO_0000221,10000000.0,,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,Hippocampus
1445,,,BAO_0000019,,,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,
1446,,,BAO_0000357,,,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,
1447,,,BAO_0000357,,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,
1448,,,BAO_0000221,10000000.0,,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,Hippocampus
1449,,,BAO_0000249,,,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,
1450,,,BAO_0000357,,,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,
1451,,,BAO_0000221,10000000.0,,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,Hippocampus
1452,,,BAO_0000221,10000000.0,,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,Hippocampus
1453,,,BAO_0000357,,,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,
1454,,,BAO_0000249,,,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,
1455,,,BAO_0000249,,,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,
1456,,,BAO_0000357,,,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,
1457,,,BAO_0000019,,,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,Rattus norvegicus,10116.0,,
1458,,,BAO_0000019,,,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,
1459,,,BAO_0000221,10000000.0,,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1460,,,BAO_0000221,10000000.0,,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,Hippocampus
1461,,,BAO_0000221,10000000.0,,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,Hippocampus
1462,,,BAO_0000357,,,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1463,,,BAO_0000221,10000000.0,,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,Rattus norvegicus,10116.0,,Hippocampus
1464,,,BAO_0000221,10000000.0,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,Hippocampus
1465,,,BAO_0000221,10000000.0,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,Hippocampus
1466,,,BAO_0000221,10000000.0,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,Hippocampus
1467,,,BAO_0000221,10000000.0,,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,Hippocampus
1468,,,BAO_0000219,,449.0,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,
1469,,,BAO_0000357,,,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,
1470,,,BAO_0000357,,,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,
1471,,,BAO_0000219,,485.0,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,
1472,,,BAO_0000249,,,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,
1473,,,BAO_0000357,,,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,
1474,,,BAO_0000221,10000000.0,,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,Hippocampus
1475,,,BAO_0000221,10000000.0,,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,Hippocampus
1476,Membranes,,BAO_0000249,,,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,Rattus norvegicus,10116.0,,
1477,Membranes,,BAO_0000249,10000000.0,,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,Rattus norvegicus,10116.0,,Hippocampus
1478,,,BAO_0000019,,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,
1479,,,BAO_0000019,,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,
1480,,,BAO_0000019,,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,
1481,,,BAO_0000019,,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,
1482,,,BAO_0000249,,,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,
1483,,,BAO_0000249,,,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,
1484,,,BAO_0000019,,,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,Rattus norvegicus,10116.0,,
1485,,,BAO_0000221,10000000.0,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,Hippocampus
1486,,,BAO_0000221,10000000.0,,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,Hippocampus
1487,,,BAO_0000221,10000000.0,,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,Rattus norvegicus,10116.0,,Hippocampus
1488,,,BAO_0000019,,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,
1489,,,BAO_0000019,,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,
1490,,,BAO_0000357,,,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,
1491,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,Hippocampus
1492,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,Hippocampus
1493,,,BAO_0000221,10000000.0,,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,Hippocampus
1494,,,BAO_0000357,,,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,
1495,,,BAO_0000249,,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,
1496,,,BAO_0000249,,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,
1497,,,BAO_0000249,,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,
1498,,,BAO_0000249,,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,
1499,,,BAO_0000249,,,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,
1500,,,BAO_0000249,955.0,,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,Brain
1501,,,BAO_0000019,,,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,
1502,,,BAO_0000019,,,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,
1503,,,BAO_0000221,10000000.0,,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,Hippocampus
1504,,,BAO_0000019,,,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,
1505,,,BAO_0000249,,,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,
1506,,,BAO_0000019,,,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,
1507,,,BAO_0000221,10000000.0,,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,Hippocampus
1508,,,BAO_0000221,10000000.0,,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,Hippocampus
1509,,,BAO_0000357,,,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1510,,,BAO_0000357,,,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,Rattus norvegicus,10116.0,,
1511,,,BAO_0000019,,,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,Rattus norvegicus,10116.0,,
1512,,,BAO_0000019,,,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,
1513,,,BAO_0000357,,,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,
1514,,,BAO_0000019,,,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,
1515,,,BAO_0000221,10000000.0,,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,Hippocampus
1516,,,BAO_0000019,,,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,
1517,,,BAO_0000357,,,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,
1518,Membranes,,BAO_0000249,,,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,Rattus norvegicus,10116.0,,
1519,,,BAO_0000249,,,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,
1520,,,BAO_0000019,,,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,
1521,,,BAO_0000019,,,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,
1522,,,BAO_0000221,10000000.0,,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,Hippocampus
1523,,,BAO_0000221,10000000.0,,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,Rattus norvegicus,10116.0,,Hippocampus
1524,,,BAO_0000221,10000000.0,,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,Hippocampus
1525,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,
1526,,,BAO_0000357,,,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,
1527,,,BAO_0000019,,,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,
1528,,,BAO_0000019,,,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,
1529,,,BAO_0000357,,,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,Rattus norvegicus,10116.0,,
1530,Membranes,,BAO_0000249,,,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,
1531,,,BAO_0000221,955.0,,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,Brain
1532,,,BAO_0000019,,,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,Rattus norvegicus,10116.0,,
1533,,,BAO_0000019,,,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,
1534,,,BAO_0000221,955.0,,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,Brain
1535,,,BAO_0000019,,,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,
1536,,,BAO_0000357,,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1537,,,BAO_0000357,,,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,
1538,,,BAO_0000357,,,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1539,,,BAO_0000357,,,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,
1540,Brain membranes,,BAO_0000249,,,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,
1541,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,
1542,,,BAO_0000357,,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,
1543,,,BAO_0000357,,,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,
1544,,,BAO_0000357,,,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,
1545,,,BAO_0000357,,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,
1546,,,BAO_0000357,,,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1547,,,BAO_0000357,,,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1548,,,BAO_0000357,,,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,Homo sapiens,9606.0,,
1549,,,BAO_0000357,,,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,Homo sapiens,9606.0,,
1550,,,BAO_0000219,,449.0,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
1551,,,BAO_0000219,,,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,
1552,,In vivo,BAO_0000218,,,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,
1553,,,BAO_0000221,10000000.0,,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,Hippocampus
1554,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1555,,,BAO_0000357,,,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,
1556,,,BAO_0000357,,,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1557,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,
1558,,,BAO_0000357,,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,
1559,,,BAO_0000357,,,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,
1560,,,BAO_0000357,,,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,
1561,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,
1562,,,BAO_0000357,,,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,
1563,,,BAO_0000219,,449.0,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,Mus musculus,10090.0,,
1564,,,BAO_0000357,,,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,
1565,,,BAO_0000357,,,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,
1566,,,BAO_0000357,,,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1567,,,BAO_0000357,,,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,
1568,,,BAO_0000357,,,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,
1569,,,BAO_0000357,,,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,Mus musculus,10090.0,,
1570,,,BAO_0000357,,,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,
1571,,,BAO_0000357,,,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,
1572,,,BAO_0000219,,449.0,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
1573,,,BAO_0000219,,449.0,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,
1574,,,BAO_0000357,,,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,
1575,,,BAO_0000357,,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,
1576,,,BAO_0000218,,,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,
1577,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,
1578,,,BAO_0000357,,,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,
1579,,,BAO_0000357,,,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,Mus musculus,10090.0,,
1580,,,BAO_0000357,,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,
1581,,,BAO_0000357,,,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,
1582,,,BAO_0000357,,,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
1583,,,BAO_0000019,,,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,Oryctolagus cuniculus,9986.0,,
1584,,,BAO_0000019,,,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,Oryctolagus cuniculus,9986.0,,
1585,,,BAO_0000219,,722.0,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,Gorilla gorilla,9593.0,,
1586,,In vivo,BAO_0000218,,,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,,Cavia porcellus,10141.0,,
1587,,In vivo,BAO_0000218,,,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,,Cavia porcellus,10141.0,,
1588,,,BAO_0000019,,,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,Cavia porcellus,10141.0,,
1589,,,BAO_0000019,,,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,Cavia porcellus,10141.0,,
1590,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,Cavia porcellus,10141.0,,
1591,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,Cavia porcellus,10141.0,,
1592,,,BAO_0000019,,,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,
1593,,,BAO_0000019,,,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,
1594,,,BAO_0000019,,,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,
1595,,,BAO_0000019,,,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,Homo sapiens,9606.0,,
1596,,,BAO_0000219,,485.0,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,Homo sapiens,9606.0,,
1597,,,BAO_0000219,,449.0,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,
1598,,,BAO_0000357,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,
1599,,,BAO_0000019,,,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,
1600,,,BAO_0000219,,449.0,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,
1601,,,BAO_0000219,,449.0,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,
1602,,,BAO_0000219,,449.0,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,
1603,,,BAO_0000219,,449.0,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,
1604,,,BAO_0000219,,449.0,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,
1605,,,BAO_0000019,,,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,
1606,,,BAO_0000019,,,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,
1607,,,BAO_0000357,,,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1608,,,BAO_0000219,,449.0,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,
1609,,,BAO_0000357,,,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,
1610,,,BAO_0000357,,,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,Homo sapiens,9606.0,,
1611,,,BAO_0000219,,449.0,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
1612,,,BAO_0000219,,449.0,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,
1613,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,
1614,,,BAO_0000219,,449.0,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,
1615,,,BAO_0000219,,449.0,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,
1616,,,BAO_0000219,,449.0,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,
1617,,,BAO_0000219,,449.0,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,
1618,,,BAO_0000219,,449.0,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,
1619,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,
1620,,,BAO_0000357,,,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,
1621,,,BAO_0000019,,,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,Oryctolagus cuniculus,9986.0,,
1622,,,BAO_0000019,,,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,Oryctolagus cuniculus,9986.0,,
1623,,,BAO_0000357,,,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,
1624,,,BAO_0000357,,,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,
1625,,,BAO_0000357,,,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,
1626,,,BAO_0000357,,,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,Bos taurus,9913.0,,
1627,,,BAO_0000357,,,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,Bos taurus,9913.0,,
1628,,,BAO_0000019,2435.0,,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,Bos taurus,9913.0,,Striatum
1629,,,BAO_0000357,,,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,Bos taurus,9913.0,,
1630,,,BAO_0000019,,,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,Bos taurus,9913.0,,
1631,,,BAO_0000357,,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,Bos taurus,9913.0,,
1632,,,BAO_0000357,,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,Bos taurus,9913.0,,
1633,,,BAO_0000357,,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,Bos taurus,9913.0,,
1634,,,BAO_0000357,,,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,Bos taurus,9913.0,,
1635,,,BAO_0000357,,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,Bos taurus,9913.0,,
1636,,,BAO_0000357,,,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,Bos taurus,9913.0,,
1637,,,BAO_0000357,,,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,Bos taurus,9913.0,,
1638,,,BAO_0000357,,,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,Bos taurus,9913.0,,
1639,,,BAO_0000019,2435.0,,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,Bos taurus,9913.0,,Striatum
1640,,,BAO_0000019,,,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,Bos taurus,9913.0,,
1641,,,BAO_0000357,,,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,Bos taurus,9913.0,,
1642,,,BAO_0000357,,,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,Bos taurus,9913.0,,
1643,,,BAO_0000249,,,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,Bos taurus,9913.0,,
1644,,,BAO_0000249,,,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,Bos taurus,9913.0,,
1645,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,9913.0,,
1646,,,BAO_0000019,,,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,Bos taurus,9913.0,,
1647,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,9913.0,,
1648,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,9913.0,,
1649,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,Bos taurus,9913.0,,
1650,,,BAO_0000219,,722.0,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,Gorilla gorilla,9593.0,,
1651,,,BAO_0000019,,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,Cavia porcellus,10141.0,,
1652,,,BAO_0000019,,,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,Cavia porcellus,10141.0,,
1653,,,BAO_0000019,,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,Cavia porcellus,10141.0,,
1654,,,BAO_0000019,,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,10141.0,,
1655,,,BAO_0000019,,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,Cavia porcellus,10141.0,,
1656,,,BAO_0000019,,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,Cavia porcellus,10141.0,,
1657,,,BAO_0000019,,,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,Cavia porcellus,10141.0,,
1658,,,BAO_0000357,,,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,Cavia porcellus,10141.0,,
1659,,,BAO_0000357,,,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,Cavia porcellus,10141.0,,
1660,,,BAO_0000218,,,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,10141.0,,
1661,,,BAO_0000218,,,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,10141.0,,
1662,,,BAO_0000218,,,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,Cavia porcellus,10141.0,,
1663,,,BAO_0000218,,,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,Cavia porcellus,10141.0,,
1664,,,BAO_0000019,,,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,Cavia porcellus,10141.0,,
1665,,,BAO_0000357,,,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,Cavia porcellus,10141.0,,
1666,,,BAO_0000019,,,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,Cavia porcellus,10141.0,,
1667,,,BAO_0000357,2435.0,,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,Cavia porcellus,10141.0,,Striatum
1668,,,BAO_0000357,,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,Cavia porcellus,10141.0,,
1669,,,BAO_0000357,,,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1670,,,BAO_0000357,,,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,
1671,,,BAO_0000019,,,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,
1672,,,BAO_0000019,,,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,
1673,,,BAO_0000019,,,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,
1674,,,BAO_0000219,,449.0,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,Homo sapiens,9606.0,,
1675,,,BAO_0000219,,449.0,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,
1676,,,BAO_0000219,,449.0,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,
1677,,,BAO_0000219,,449.0,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,
1678,,,BAO_0000219,,449.0,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,
1679,,,BAO_0000219,,449.0,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,Homo sapiens,9606.0,,
1680,,,BAO_0000219,,449.0,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,
1681,,,BAO_0000219,,449.0,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,
1682,,,BAO_0000219,,449.0,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,
1683,,,BAO_0000219,,449.0,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,
1684,,,BAO_0000019,,,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,
1685,,,BAO_0000219,,449.0,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,
1686,,,BAO_0000219,,449.0,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,Homo sapiens,9606.0,,
1687,,,BAO_0000219,,449.0,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,Homo sapiens,9606.0,,
1688,,,BAO_0000019,,,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,
1689,,,BAO_0000019,,,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,
1690,,,BAO_0000019,,,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,Homo sapiens,9606.0,,
1691,,,BAO_0000219,,449.0,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,Homo sapiens,9606.0,,
1692,,,BAO_0000019,,,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,
1693,,In vitro,BAO_0000219,,,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,,,,,
1694,,,BAO_0000219,,449.0,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,
1695,,,BAO_0000357,,,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,
1696,,,BAO_0000219,,449.0,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
1697,,,BAO_0000219,,449.0,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,
1698,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,
1699,,,BAO_0000219,,449.0,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,
1700,,,BAO_0000219,,449.0,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,
1701,,,BAO_0000219,,449.0,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,
1702,,,BAO_0000219,,449.0,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
1703,,,BAO_0000219,,449.0,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
1704,,,BAO_0000219,,449.0,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,
1705,,,BAO_0000219,,449.0,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,
1706,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,
1707,,,BAO_0000219,,449.0,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,Homo sapiens,9606.0,,
1708,,,BAO_0000219,,449.0,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,
1709,,,BAO_0000019,,,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,
1710,,,BAO_0000357,,,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1711,,,BAO_0000357,,,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,
1712,,,BAO_0000219,,,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,
1713,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,
1714,,,BAO_0000357,,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,
1715,,,BAO_0000357,,,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,
1716,,,BAO_0000357,,,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1717,,,BAO_0000357,,,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,
1718,,,BAO_0000357,,,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1719,,,BAO_0000357,,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,
1720,,,BAO_0000357,,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,
1721,,,BAO_0000357,,,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,
1722,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,
1723,,,BAO_0000219,,485.0,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,
1724,,In vitro,BAO_0000219,,,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,,Homo sapiens,9606.0,,
1725,,,BAO_0000357,,,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1726,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,
1727,,,BAO_0000357,,,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,
1728,,,BAO_0000357,,,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1729,,,BAO_0000219,,,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,Homo sapiens,9606.0,,
1730,,,BAO_0000357,,,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1731,,,BAO_0000357,,,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,
1732,,,BAO_0000357,,,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,Homo sapiens,9606.0,,
1733,,,BAO_0000357,,,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1734,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,
1735,,,BAO_0000019,,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,
1736,,,BAO_0000357,,,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,Homo sapiens,9606.0,,
1737,,,BAO_0000219,,485.0,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,
1738,,,BAO_0000219,,485.0,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,
1739,,,BAO_0000219,,449.0,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,
1740,,,BAO_0000019,,,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,
1741,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
1742,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
1743,,,BAO_0000219,,485.0,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,
1744,,,BAO_0000357,,,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,
1745,,,BAO_0000357,,,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,
1746,,,BAO_0000357,,,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,
1747,,,BAO_0000357,,,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1748,,,BAO_0000219,,449.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,Homo sapiens,9606.0,,
1749,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,
1750,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
1751,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,
1752,,,BAO_0000219,,449.0,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,
1753,,,BAO_0000219,,449.0,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,
1754,,,BAO_0000219,,722.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,
1755,,,BAO_0000219,,722.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,
1756,,,BAO_0000219,,722.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,
1757,,,BAO_0000219,,449.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,
1758,,,BAO_0000357,,,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1759,,,BAO_0000219,,449.0,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,
1760,,,BAO_0000357,,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
1761,,,BAO_0000219,,449.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,
1762,,,BAO_0000219,,449.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
1763,,,BAO_0000019,,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,
1764,,,BAO_0000019,,,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,
1765,,,BAO_0000357,,,5254,Binding affinity against 5-HT2C receptor,B,,,,,
1766,,,BAO_0000357,,,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1767,,,BAO_0000357,,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,
1768,,,BAO_0000019,,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,
1769,,,BAO_0000019,,,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,
1770,,,BAO_0000357,,,9098,Binding affinity towards 5-HT1B was determined,B,,,,,
1771,,,BAO_0000019,,,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,
1772,,,BAO_0000019,,,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,
1773,,,BAO_0000019,,,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,
1774,,,BAO_0000019,,,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,
1775,,,BAO_0000019,,,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,Rattus norvegicus,10116.0,,
1776,,,BAO_0000357,,,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,
1777,,,BAO_0000357,,,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,
1778,,,BAO_0000249,,,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,
1779,,,BAO_0000019,2435.0,,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,Striatum
1780,,,BAO_0000357,,,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,Rattus norvegicus,10116.0,,
1781,,,BAO_0000019,,,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,
1782,,,BAO_0000019,2435.0,,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,Striatum
1783,,,BAO_0000019,2435.0,,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,Striatum
1784,,,BAO_0000357,2435.0,,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,Striatum
1785,,,BAO_0000249,,,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,
1786,,,BAO_0000357,,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,
1787,,,BAO_0000019,2435.0,,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,Striatum
1788,,,BAO_0000019,2435.0,,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,Striatum
1789,,,BAO_0000019,,,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,
1790,,,BAO_0000357,,,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,
1791,,,BAO_0000357,,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,
1792,,,BAO_0000357,,,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,Rattus norvegicus,10116.0,,
1793,,,BAO_0000357,2435.0,,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,Striatum
1794,,,BAO_0000357,2435.0,,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,Striatum
1795,,,BAO_0000357,,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,
1796,,,BAO_0000357,,,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,
1797,,,BAO_0000019,,,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,
1798,,,BAO_0000019,,,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,
1799,,,BAO_0000019,2435.0,,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,Striatum
1800,,,BAO_0000019,,,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,
1801,,,BAO_0000019,,,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,
1802,,,BAO_0000357,,,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,
1803,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,
1804,,,BAO_0000357,,,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,
1805,,,BAO_0000357,,,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,
1806,,,BAO_0000249,,,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,Rattus norvegicus,10116.0,,
1807,,,BAO_0000357,,,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,Rattus norvegicus,10116.0,,
1808,,,BAO_0000019,,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,
1809,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,
1810,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,
1811,,,BAO_0000019,2435.0,,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,Striatum
1812,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,
1813,,,BAO_0000249,955.0,,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,Brain
1814,,,BAO_0000019,,,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,
1815,,,BAO_0000249,955.0,,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,Brain
1816,,,BAO_0000357,,,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,
1817,,,BAO_0000357,,,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,
1818,,,BAO_0000019,,,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,Rattus norvegicus,10116.0,,
1819,,,BAO_0000357,,,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,
1820,,,BAO_0000019,,,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,
1821,,,BAO_0000249,,,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,Rattus norvegicus,10116.0,,
1822,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,
1823,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,
1824,,,BAO_0000019,,,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,
1825,,,BAO_0000357,,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,
1826,Brain membranes,,BAO_0000249,,,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,
1827,,,BAO_0000357,,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,
1828,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,
1829,,,BAO_0000357,,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,
1830,,,BAO_0000357,,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,
1831,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,
1832,,,BAO_0000357,,,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,
1833,,,BAO_0000357,,,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,
1834,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,
1835,,,BAO_0000357,,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,
1836,,,BAO_0000357,,,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,
1837,,,BAO_0000357,,,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,
1838,,,BAO_0000357,,,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,
1839,,,BAO_0000357,,,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,
1840,,,BAO_0000224,,,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,
1841,,,BAO_0000357,,,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,Bos taurus,9913.0,,
1842,,,BAO_0000357,,,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,Sus scrofa,9823.0,,
1843,,,BAO_0000357,,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,Sus scrofa,9823.0,,
1844,,,BAO_0000357,,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,Sus scrofa,9823.0,,
1845,,,BAO_0000357,,,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,Sus scrofa,9823.0,,
1846,,,BAO_0000357,,,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,Sus scrofa,9823.0,,
1847,,,BAO_0000357,,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,Sus scrofa,9823.0,,
1848,,,BAO_0000357,,,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,Sus scrofa,9823.0,,
1849,,,BAO_0000357,,,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,Sus scrofa,9823.0,,
1850,,,BAO_0000019,,,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,Sus scrofa,9823.0,,
1851,,,BAO_0000357,,,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,Sus scrofa,9823.0,,
1852,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
1853,,,BAO_0000357,,,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,Rattus norvegicus,10116.0,,
1854,,,BAO_0000357,,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,Rattus norvegicus,10116.0,,
1855,,,BAO_0000357,,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,Rattus norvegicus,10116.0,,
1856,,,BAO_0000019,,,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,Rattus norvegicus,10116.0,,
1857,,,BAO_0000357,,,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,Rattus norvegicus,10116.0,,
1858,,,BAO_0000357,,,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,Rattus norvegicus,10116.0,,
1859,,,BAO_0000019,,,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,Rattus norvegicus,10116.0,,
1860,,,BAO_0000357,,,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,Rattus norvegicus,10116.0,,
1861,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,10116.0,,
1862,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,10116.0,,
1863,,,BAO_0000019,,,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,10116.0,,
1864,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,Rattus norvegicus,10116.0,,
1865,,,BAO_0000357,,,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,Rattus norvegicus,10116.0,,
1866,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,Rattus norvegicus,10116.0,,
1867,,,BAO_0000357,,,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,
1868,,,BAO_0000357,,,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,Rattus norvegicus,10116.0,,
1869,,,BAO_0000019,,,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,Rattus norvegicus,10116.0,,
1870,,,BAO_0000219,,722.0,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,Rattus norvegicus,10116.0,,
1871,,,BAO_0000357,,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,
1872,,,BAO_0000357,,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,
1873,,,BAO_0000357,,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,
1874,,,BAO_0000357,,,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,
1875,,,BAO_0000357,,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,
1876,,,BAO_0000357,,,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,
1877,,,BAO_0000357,,,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,
1878,,,BAO_0000357,,,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,
1879,,,BAO_0000357,,,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,
1880,,,BAO_0000019,,,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,Oryctolagus cuniculus,9986.0,,
1881,,,BAO_0000224,,,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,
1882,,,BAO_0000224,,,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,
1883,,,BAO_0000019,,,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,
1884,,,BAO_0000019,,,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,Rattus norvegicus,10116.0,,
1885,,,BAO_0000249,,,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,Rattus norvegicus,10116.0,,
1886,,,BAO_0000221,955.0,,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,Rattus norvegicus,10116.0,,Brain
1887,,,BAO_0000224,,,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,
1888,,,BAO_0000224,,,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,
1889,,,BAO_0000019,,,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,
1890,,,BAO_0000224,,,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,
1891,,,BAO_0000224,,,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,
1892,,,BAO_0000224,,,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,
1893,,,BAO_0000019,,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1894,,,BAO_0000019,,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1895,,,BAO_0000019,,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,
1896,,,BAO_0000019,,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,
1897,,,BAO_0000019,,,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1898,,,BAO_0000019,,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,
1899,,,BAO_0000019,,,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,
1900,,,BAO_0000019,,,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,
1901,,,BAO_0000019,,,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1902,,,BAO_0000019,,,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,
1903,,,BAO_0000019,,,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,
1904,,,BAO_0000019,,,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,
1905,,,BAO_0000221,955.0,,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,Rattus norvegicus,10116.0,,Brain
1906,,,BAO_0000221,955.0,,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,Brain
1907,Membranes,,BAO_0000249,,,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,
1908,Membranes,,BAO_0000249,,,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,
1909,,,BAO_0000224,,,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,
1910,Membranes,,BAO_0000249,,,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,
1911,,,BAO_0000224,,,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,
1912,,,BAO_0000224,,,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,
1913,,,BAO_0000224,,,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
1914,,,BAO_0000224,,,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,
1915,,,BAO_0000019,,,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,
1916,,,BAO_0000224,,,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,
1917,,,BAO_0000224,,,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,
1918,,,BAO_0000224,,,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,
1919,,,BAO_0000224,,,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,
1920,,,BAO_0000224,,,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,
1921,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,
1922,,,BAO_0000019,,,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,
1923,,,BAO_0000224,,,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,
1924,,,BAO_0000224,,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,
1925,,,BAO_0000224,,,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,
1926,,,BAO_0000224,,,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,
1927,Membranes,,BAO_0000249,,,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,
1928,Membranes,,BAO_0000249,,,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,
1929,,,BAO_0000224,,,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,
1930,,,BAO_0000019,,,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,
1931,,,BAO_0000224,,,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
1932,,,BAO_0000224,,,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,
1933,,,BAO_0000224,,,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,
1934,,,BAO_0000019,,,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,
1935,,,BAO_0000019,,,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,
1936,,,BAO_0000019,,,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,
1937,,,BAO_0000219,,485.0,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,10116.0,,
1938,Membranes,,BAO_0000249,,,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,
1939,,,BAO_0000224,,,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,
1940,Brain membranes,,BAO_0000249,,,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,
1941,,In vitro,BAO_0000219,,,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,
1942,,,BAO_0000224,,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
1943,,,BAO_0000224,,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,
1944,,,BAO_0000224,,,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,
1945,Membranes,,BAO_0000249,,,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,
1946,Membranes,,BAO_0000249,,,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,
1947,,,BAO_0000019,1515.0,,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,Thoracic aorta
1948,,,BAO_0000019,,,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,
1949,,,BAO_0000224,,,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,
1950,,,BAO_0000357,,,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,
1951,,,BAO_0000357,,,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,
1952,,,BAO_0000357,,,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,
1953,,,BAO_0000357,,,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,
1954,,,BAO_0000249,,,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,
1955,,,BAO_0000249,,,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,
1956,,,BAO_0000357,2435.0,,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,Striatum
1957,,,BAO_0000019,,,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,
1958,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,
1959,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
1960,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,
1961,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
1962,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,
1963,,,BAO_0000249,,,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,
1964,,,BAO_0000019,,,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,
1965,,,BAO_0000249,,,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,
1966,,,BAO_0000357,,,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,
1967,,,BAO_0000357,,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,Sus scrofa,9823.0,,
1968,,,BAO_0000357,,,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,Oryctolagus cuniculus,9986.0,,
1969,,,BAO_0000019,,,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
1970,,,BAO_0000357,,,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,Oryctolagus cuniculus,9986.0,,
1971,,,BAO_0000357,,,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,
1972,,,BAO_0000019,,,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,
1973,,,BAO_0000019,,,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,
1974,,,BAO_0000357,,,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,
1975,,,BAO_0000019,,,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,
1976,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,
1977,,,BAO_0000357,,,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,
1978,,,BAO_0000019,,,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,
1979,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,
1980,,,BAO_0000357,,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1981,,,BAO_0000357,,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,
1982,,,BAO_0000357,,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,
1983,,,BAO_0000357,,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,
1984,,,BAO_0000357,,,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,
1985,,,BAO_0000357,,,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,
1986,,,BAO_0000357,,,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,
1987,,,BAO_0000357,,,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,
1988,,,BAO_0000219,,722.0,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,
1989,,,BAO_0000357,,,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,Homo sapiens,9606.0,,
1990,,,BAO_0000357,,,15250,,B,,,,,
1991,,,BAO_0000219,,485.0,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,
1992,,,BAO_0000219,,485.0,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,
1993,,,BAO_0000219,,722.0,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,
1994,,,BAO_0000219,,722.0,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,
1995,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,
1996,,,BAO_0000357,,,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,
1997,,,BAO_0000357,,,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,
1998,,,BAO_0000357,,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,
1999,,,BAO_0000219,,485.0,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,
2000,,,BAO_0000219,,485.0,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,
2001,,,BAO_0000019,,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2002,,,BAO_0000019,,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2003,,,BAO_0000019,,,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,
2004,,,BAO_0000019,,,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,
2005,,,BAO_0000019,,,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,
2006,,,BAO_0000357,,,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,
2007,,,BAO_0000357,,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,
2008,,,BAO_0000357,,,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2009,,,BAO_0000357,,,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2010,,,BAO_0000219,,449.0,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,
2011,,,BAO_0000219,,,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,Homo sapiens,9606.0,,
2012,,,BAO_0000357,,,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,
2013,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
2014,,,BAO_0000357,,,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2015,,,BAO_0000357,,,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2016,,,BAO_0000357,,,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2017,,,BAO_0000357,,,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,
2018,,,BAO_0000357,,,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2019,,,BAO_0000357,,,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,
2020,,,BAO_0000019,,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2021,,,BAO_0000219,,722.0,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,
2022,,,BAO_0000219,,722.0,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,
2023,,,BAO_0000219,,449.0,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,
2024,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,
2025,,,BAO_0000357,,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2026,,,BAO_0000357,,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2027,,,BAO_0000357,,,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2028,,,BAO_0000357,,,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
2029,,,BAO_0000357,,,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,
2030,,,BAO_0000219,,449.0,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,
2031,,,BAO_0000219,,485.0,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,
2032,,,BAO_0000219,,485.0,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,
2033,,,BAO_0000019,,,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,
2034,,,BAO_0000219,,485.0,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,
2035,,,BAO_0000357,,,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,
2036,,,BAO_0000219,,449.0,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,
2037,,,BAO_0000219,,485.0,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,
2038,,,BAO_0000219,,485.0,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,
2039,,,BAO_0000219,,485.0,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,
2040,,,BAO_0000219,,485.0,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,
2041,,,BAO_0000357,,,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,
2042,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
2043,,,BAO_0000357,,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,
2044,,,BAO_0000357,,,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,
2045,,,BAO_0000357,,,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,
2046,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,
2047,,,BAO_0000357,,,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,Homo sapiens,9606.0,,
2048,,,BAO_0000357,,,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,
2049,,,BAO_0000357,,,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,Homo sapiens,9606.0,,
2050,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,
2051,,,BAO_0000019,,,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,
2052,,,BAO_0000357,,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,
2053,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,
2054,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,
2055,,,BAO_0000219,,449.0,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
2056,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,
2057,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
2058,,,BAO_0000219,,449.0,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,
2059,,,BAO_0000219,,449.0,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,
2060,,,BAO_0000357,,,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,
2061,,,BAO_0000219,,449.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,
2062,,,BAO_0000357,,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,
2063,,,BAO_0000219,,449.0,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,
2064,,,BAO_0000357,,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
2065,,,BAO_0000357,,,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,
2066,,,BAO_0000219,,449.0,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,
2067,,,BAO_0000219,,449.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,
2068,,,BAO_0000219,,449.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
2069,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,
2070,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,
2071,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,
2072,,,BAO_0000357,,,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,
2073,,,BAO_0000019,,,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,
2074,,,BAO_0000019,,,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,
2075,,,BAO_0000019,,,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,
2076,,,BAO_0000019,,,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,
2077,,,BAO_0000019,,,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,
2078,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,
2079,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,
2080,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,
2081,,,BAO_0000219,,449.0,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,
2082,,,BAO_0000357,,,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,
2083,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,
2084,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2085,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,
2086,,,BAO_0000357,,,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,
2087,,,BAO_0000019,,,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,
2088,,,BAO_0000357,,,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,
2089,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2090,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,
2091,,,BAO_0000219,,449.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,
2092,,,BAO_0000357,,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,
2093,,,BAO_0000219,,449.0,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,
2094,,,BAO_0000357,,,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,
2095,,,BAO_0000219,,449.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,
2096,,,BAO_0000219,,449.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
2097,,,BAO_0000219,,449.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,
2098,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2099,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,
2100,,,BAO_0000357,,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,
2101,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,
2102,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,
2103,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,
2104,,,BAO_0000019,,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,
2105,,In vivo,BAO_0000218,,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,,,,,
2106,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2107,,,BAO_0000019,,,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,
2108,,,BAO_0000019,,,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,Bos taurus,9913.0,,
2109,,,BAO_0000019,,,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,Bos taurus,9913.0,,
2110,,,BAO_0000019,,,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,Bos taurus,9913.0,,
2111,,,BAO_0000019,,,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,
2112,,,BAO_0000019,,,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,Cavia porcellus,10141.0,,
2113,,,BAO_0000019,,,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,Cavia porcellus,10141.0,,
2114,,,BAO_0000019,,,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,Cavia porcellus,10141.0,,
2115,,,BAO_0000224,,,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2116,,,BAO_0000224,,,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2117,,,BAO_0000224,,,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,
2118,,,BAO_0000357,,,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,
2119,,In vivo,BAO_0000218,,,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,,,,,
2120,,,BAO_0000019,,,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,
2121,,,BAO_0000224,,,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,
2122,,,BAO_0000019,,,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,Mus musculus,10090.0,,
2123,,In vivo,BAO_0000218,,,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,,,,,
2124,,,BAO_0000019,,,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,Mus musculus,10090.0,,
2125,,,BAO_0000224,,,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2126,,,BAO_0000224,,,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,
2127,,,BAO_0000224,,,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,
2128,,,BAO_0000019,,,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,Mus musculus,10090.0,,
2129,,,BAO_0000224,,,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,Sus scrofa,9823.0,,
2130,,,BAO_0000224,,,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,Sus scrofa,9823.0,,
2131,,,BAO_0000221,,,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,
2132,,,BAO_0000221,,,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,
2133,,,BAO_0000357,,,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,Sus scrofa,9823.0,,
2134,,,BAO_0000019,,,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,
2135,,,BAO_0000019,,,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,
2136,,,BAO_0000019,,,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,
2137,,,BAO_0000224,,,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,
2138,,,BAO_0000019,,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,Rattus norvegicus,10116.0,,
2139,,,BAO_0000019,,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,
2140,,,BAO_0000019,,,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,
2141,,,BAO_0000019,,,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,
2142,,,BAO_0000019,,,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,
2143,,,BAO_0000224,,,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,
2144,,,BAO_0000224,,,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,Rattus norvegicus,10116.0,,
2145,,,BAO_0000224,,,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,
2146,,,BAO_0000224,,,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,
2147,,,BAO_0000224,,,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,
2148,,,BAO_0000224,,,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,
2149,,,BAO_0000224,,,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,
2150,,,BAO_0000224,,,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,
2151,,,BAO_0000224,,,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,
2152,,,BAO_0000224,,,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,
2153,,,BAO_0000224,,,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,
2154,,,BAO_0000019,,,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,
2155,,,BAO_0000019,,,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,
2156,,,BAO_0000221,10000000.0,,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,Hippocampus
2157,,,BAO_0000221,10000000.0,,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,Hippocampus
2158,,,BAO_0000221,955.0,,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,Rattus norvegicus,10116.0,,Brain
2159,,,BAO_0000019,,,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,
2160,Membranes,,BAO_0000249,,,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,
2161,Membranes,,BAO_0000249,,,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,
2162,,,BAO_0000019,,,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,
2163,,,BAO_0000019,,,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,
2164,,,BAO_0000221,955.0,,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,Rattus norvegicus,10116.0,,Brain
2165,Membranes,,BAO_0000249,,,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,Rattus norvegicus,10116.0,,
2166,,,BAO_0000221,955.0,,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,Brain
2167,,,BAO_0000019,,,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,
2168,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,
2169,,,BAO_0000019,,,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2170,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,
2171,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,
2172,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2173,,,BAO_0000220,955.0,,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,Brain
2174,,,BAO_0000019,,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,
2175,,,BAO_0000249,955.0,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,Brain
2176,,,BAO_0000019,,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,
2177,,,BAO_0000019,,,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,
2178,,,BAO_0000019,,,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2179,,,BAO_0000019,,,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,
2180,,,BAO_0000019,,,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,
2181,,,BAO_0000019,,,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,
2182,,,BAO_0000019,,,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,
2183,,,BAO_0000224,,,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,Rattus norvegicus,10116.0,,
2184,,,BAO_0000019,,,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2185,,,BAO_0000019,,,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2186,,,BAO_0000019,,,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,Rattus norvegicus,10116.0,,
2187,,,BAO_0000224,,,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,
2188,,,BAO_0000249,,,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,
2189,,,BAO_0000019,,,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,
2190,,,BAO_0000019,,,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,
2191,,,BAO_0000224,,,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,
2192,,,BAO_0000221,955.0,,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,Brain
2193,,,BAO_0000019,,,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,
2194,,,BAO_0000019,,,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2195,,,BAO_0000019,,,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2196,,,BAO_0000019,,,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2197,,,BAO_0000019,,,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2198,,,BAO_0000019,,,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2199,,,BAO_0000019,,,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,
2200,,,BAO_0000224,,,9523,Hill coefficient of compound was determined,B,,,,,
2201,,,BAO_0000019,,,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,
2202,,,BAO_0000019,,,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,Rattus norvegicus,10116.0,,
2203,,,BAO_0000019,,,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,
2204,,,BAO_0000019,,,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,
2205,,,BAO_0000357,,,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,
2206,,,BAO_0000019,,,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,
2207,,,BAO_0000019,,,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,
2208,,,BAO_0000224,,,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2209,,,BAO_0000224,,,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,
2210,,,BAO_0000224,,,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,
2211,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,
2212,,,BAO_0000224,,,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,
2213,,,BAO_0000219,,,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,
2214,,,BAO_0000219,,,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,
2215,,,BAO_0000224,,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,
2216,,,BAO_0000224,,,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,
2217,,,BAO_0000224,,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2218,,,BAO_0000224,,,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2219,Brain membranes,,BAO_0000249,,,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,
2220,,,BAO_0000224,,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,
2221,,,BAO_0000224,,,17066,Binding affinity towards 5-HT2 receptor,B,,,,,
2222,,,BAO_0000224,,,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,
2223,,,BAO_0000224,,,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,
2224,,,BAO_0000224,,,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,
2225,,,BAO_0000224,,,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2226,,,BAO_0000224,,,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,
2227,,,BAO_0000224,,,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2228,,,BAO_0000224,,,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2229,,,BAO_0000019,,,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2230,,,BAO_0000224,,,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,
2231,,,BAO_0000357,,,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,
2232,,,BAO_0000357,,,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,
2233,,,BAO_0000224,,,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,
2234,,,BAO_0000224,,,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,
2235,,,BAO_0000224,,,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,
2236,,,BAO_0000357,,,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,
2237,,,BAO_0000357,,,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,
2238,,,BAO_0000357,,,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,
2239,,,BAO_0000357,,,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,
2240,,,BAO_0000357,,,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,
2241,,,BAO_0000357,,,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,
2242,,,BAO_0000357,,,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,
2243,,,BAO_0000357,,,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,
2244,,,BAO_0000218,,,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,
2245,,,BAO_0000224,,,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,Homo sapiens,9606.0,,
2246,,,BAO_0000219,,449.0,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,Homo sapiens,9606.0,,
2247,,,BAO_0000219,,449.0,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,Homo sapiens,9606.0,,
2248,,,BAO_0000219,,449.0,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,Homo sapiens,9606.0,,
2249,,,BAO_0000219,,449.0,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,Homo sapiens,9606.0,,
2250,,,BAO_0000224,,,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2251,,,BAO_0000224,,,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,
2252,,,BAO_0000357,,,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2253,,,BAO_0000224,,,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,
2254,,,BAO_0000357,,,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,
2255,,,BAO_0000357,,,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2256,,,BAO_0000019,,,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,
2257,,,BAO_0000357,,,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,Cavia porcellus,10141.0,,
2258,,,BAO_0000357,,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2259,,,BAO_0000357,,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2260,,,BAO_0000357,,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2261,,,BAO_0000357,,,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,
2262,,,BAO_0000219,,449.0,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,
2263,,,BAO_0000219,,449.0,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,Homo sapiens,9606.0,,
2264,,,BAO_0000219,,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,
2265,,,BAO_0000219,,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,
2266,,,BAO_0000219,,,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,
2267,,,BAO_0000219,,449.0,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,
2268,,,BAO_0000219,,449.0,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,
2269,,,BAO_0000357,,,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,
2270,,,BAO_0000357,,,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2271,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2272,,,BAO_0000219,,,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,
2273,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,
2274,,,BAO_0000219,,449.0,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2275,,,BAO_0000219,,449.0,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,
2276,,,BAO_0000219,,307.0,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,
2277,,,BAO_0000219,,449.0,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2278,,,BAO_0000019,,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,
2279,,,BAO_0000019,,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,
2280,,,BAO_0000219,,449.0,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,
2281,,,BAO_0000219,,449.0,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,
2282,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,
2283,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,
2284,,,BAO_0000019,,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,
2285,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,
2286,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2287,,,BAO_0000357,,,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,
2288,,,BAO_0000357,,,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,
2289,,,BAO_0000357,,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,
2290,,,BAO_0000219,,449.0,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2291,,,BAO_0000357,,,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,
2292,,,BAO_0000019,,,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,Homo sapiens,9606.0,,
2293,,,BAO_0000357,,,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,
2294,,,BAO_0000357,,,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2295,,,BAO_0000357,,,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,
2296,,,BAO_0000219,,449.0,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,
2297,,,BAO_0000219,,,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,
2298,,,BAO_0000357,,,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2299,,,BAO_0000357,,,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,
2300,,,BAO_0000357,,,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2301,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,
2302,,,BAO_0000219,,,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,
2303,,,BAO_0000357,,,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,
2304,,,BAO_0000357,,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,
2305,,,BAO_0000019,,,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,
2306,,,BAO_0000357,,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,
2307,,,BAO_0000219,,722.0,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,
2308,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,
2309,,,BAO_0000357,,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,
2310,,,BAO_0000357,,,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,Homo sapiens,9606.0,,
2311,,,BAO_0000219,,449.0,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,Homo sapiens,9606.0,,
2312,,,BAO_0000357,,,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2313,,,BAO_0000357,,,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2314,,,BAO_0000357,,,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,
2315,,,BAO_0000357,,,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2316,,,BAO_0000357,,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,
2317,,,BAO_0000357,,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2318,,,BAO_0000019,,,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,
2319,,,BAO_0000019,,,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,Rattus norvegicus,10116.0,,
2320,,,BAO_0000224,,,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,
2321,,,BAO_0000019,,,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,
2322,,,BAO_0000019,,,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,
2323,,,BAO_0000224,,,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,
2324,,,BAO_0000019,,,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,
2325,,,BAO_0000019,,,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,
2326,,,BAO_0000019,,,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,
2327,,,BAO_0000019,,,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,
2328,,,BAO_0000224,,,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,
2329,,,BAO_0000224,,,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,
2330,,,BAO_0000224,,,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,
2331,,,BAO_0000224,,,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,
2332,,In vitro,BAO_0000219,,,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,,,,,
2333,,,BAO_0000224,,,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2334,,,BAO_0000224,,,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2335,,,BAO_0000224,,,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,
2336,,,BAO_0000224,,,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,
2337,,,BAO_0000219,,485.0,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,10116.0,,
2338,,,BAO_0000219,,485.0,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,Rattus norvegicus,10116.0,,
2339,,,BAO_0000019,,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,Rattus norvegicus,10116.0,,
2340,,,BAO_0000019,,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,
2341,,,BAO_0000019,,,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,Rattus norvegicus,10116.0,,
2342,,,BAO_0000224,,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,
2343,,,BAO_0000224,,,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,
2344,,,BAO_0000019,,,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,
2345,,,BAO_0000019,,,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,
2346,,,BAO_0000224,,,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,
2347,,,BAO_0000224,,,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2348,,,BAO_0000224,,,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,
2349,,,BAO_0000019,,,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,
2350,,,BAO_0000019,,,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,
2351,,,BAO_0000019,,,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,
2352,,,BAO_0000224,,,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,
2353,,In vivo,BAO_0000218,,,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,,,,,
2354,,,BAO_0000221,955.0,,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,Brain
2355,,,BAO_0000224,,,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,
2356,,,BAO_0000019,,,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,
2357,,,BAO_0000019,,,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,
2358,,,BAO_0000019,1870.0,,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,Frontal cortex
2359,,,BAO_0000224,,,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,
2360,,,BAO_0000224,,,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,
2361,,,BAO_0000224,,,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,Rattus norvegicus,10116.0,,
2362,,,BAO_0000019,,,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,
2363,,,BAO_0000019,2435.0,,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,Rattus norvegicus,10116.0,,Striatum
2364,,,BAO_0000019,,,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,
2365,,,BAO_0000019,,,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,
2366,,,BAO_0000224,,,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,
2367,,,BAO_0000224,,,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,
2368,,,BAO_0000019,,,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,Rattus norvegicus,10116.0,,
2369,,,BAO_0000019,,,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,Rattus norvegicus,10116.0,,
2370,,,BAO_0000019,,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,
2371,,,BAO_0000019,,,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,
2372,,,BAO_0000019,,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,
2373,,,BAO_0000019,,,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,
2374,,,BAO_0000249,,,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,
2375,,,BAO_0000019,,,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,
2376,,,BAO_0000019,,,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,
2377,,,BAO_0000019,,,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,
2378,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,
2379,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,
2380,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,
2381,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,
2382,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,
2383,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,
2384,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,
2385,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,
2386,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,
2387,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,
2388,,,BAO_0000019,,,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,
2389,,,BAO_0000019,,,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,
2390,,,BAO_0000249,,,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,
2391,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,
2392,,,BAO_0000224,,,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,
2393,,,BAO_0000224,,,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2394,,,BAO_0000224,,,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,
2395,,,BAO_0000019,,,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,
2396,,,BAO_0000224,,,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,
2397,,,BAO_0000019,,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,
2398,,,BAO_0000019,,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,
2399,,,BAO_0000019,,,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,
2400,,,BAO_0000019,,,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,
2401,,,BAO_0000224,,,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,
2402,,,BAO_0000224,,,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,
2403,,,BAO_0000019,,,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,
2404,,,BAO_0000221,955.0,,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,Brain
2405,,,BAO_0000224,,,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,
2406,,,BAO_0000224,,,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,
2407,,,BAO_0000224,,,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,Rattus norvegicus,10116.0,,
2408,,,BAO_0000019,,,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,
2409,,,BAO_0000224,,,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,
2410,,,BAO_0000224,,,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,
2411,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2412,,,BAO_0000019,,,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,
2413,,In vivo,BAO_0000218,,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,,,,,
2414,,In vivo,BAO_0000218,,,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,,,,,
2415,,In vivo,BAO_0000218,,,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,,,,,
2416,,In vivo,BAO_0000218,,,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,,,,,
2417,,,BAO_0000221,955.0,,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,Brain
2418,,,BAO_0000019,,,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2419,,,BAO_0000019,,,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,
2420,,,BAO_0000357,,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2421,,,BAO_0000019,,,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,Rattus norvegicus,10116.0,,
2422,,,BAO_0000357,,,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2423,,,BAO_0000019,,,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,
2424,,,BAO_0000357,,,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,
2425,,,BAO_0000357,,,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2426,,,BAO_0000019,,,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,
2427,,,BAO_0000019,,,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,
2428,,,BAO_0000019,,,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,
2429,,,BAO_0000019,,,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2430,Membranes,,BAO_0000249,,,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,
2431,,,BAO_0000019,,,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,
2432,,,BAO_0000019,,,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,
2433,,,BAO_0000219,,449.0,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,
2434,,,BAO_0000357,,,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,
2435,,,BAO_0000357,,,15577,Serotonergic activity of the compound.,B,,,,,
2436,,,BAO_0000249,,,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,
2437,,,BAO_0000019,,,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,Rattus norvegicus,10116.0,,
2438,,,BAO_0000249,,,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,
2439,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,Rattus norvegicus,10116.0,,
2440,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,Rattus norvegicus,10116.0,,
2441,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,Rattus norvegicus,10116.0,,
2442,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2443,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,
2444,,,BAO_0000357,,,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2445,,,BAO_0000357,,,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,
2446,,,BAO_0000357,,,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,
2447,,,BAO_0000357,,,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,
2448,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,
2449,,,BAO_0000357,,,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,Homo sapiens,9606.0,,
2450,,,BAO_0000357,,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,
2451,,,BAO_0000357,,,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2452,,,BAO_0000357,,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,
2453,,,BAO_0000357,,,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2454,,,BAO_0000357,,,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,
2455,,,BAO_0000219,,723.0,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,
2456,,,BAO_0000357,,,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,
2457,,,BAO_0000357,,,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,
2458,,,BAO_0000357,,,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,
2459,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2460,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2461,,,BAO_0000019,,,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,
2462,,,BAO_0000357,,,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,
2463,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2464,,,BAO_0000357,,,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2465,,,BAO_0000357,,,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2466,,,BAO_0000357,,,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,
2467,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,
2468,,,BAO_0000219,,449.0,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,Mus musculus,10090.0,,
2469,,,BAO_0000357,,,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,
2470,,,BAO_0000357,,,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,
2471,,,BAO_0000357,,,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2472,,,BAO_0000357,,,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,
2473,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,
2474,,,BAO_0000357,,,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2475,,,BAO_0000357,,,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2476,,,BAO_0000357,,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,
2477,,,BAO_0000357,,,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,
2478,,,BAO_0000224,,,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,
2479,,,BAO_0000224,,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,
2480,,,BAO_0000224,,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,
2481,,,BAO_0000224,,,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,
2482,,,BAO_0000357,,,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,
2483,,,BAO_0000219,,722.0,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,Homo sapiens,9606.0,,
2484,,,BAO_0000219,,449.0,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,Homo sapiens,9606.0,,
2485,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,
2486,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,Homo sapiens,9606.0,,
2487,,,BAO_0000019,,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,
2488,,,BAO_0000019,,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,
2489,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,
2490,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,
2491,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,
2492,,,BAO_0000019,,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,
2493,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,
2494,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,
2495,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,
2496,,,BAO_0000357,,,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2497,,,BAO_0000357,,,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,
2498,,,BAO_0000357,,,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,
2499,,,BAO_0000019,,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,
2500,,,BAO_0000019,,,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,
2501,,,BAO_0000219,,723.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2502,,,BAO_0000219,,449.0,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,
2503,,,BAO_0000219,,449.0,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,9606.0,,
2504,,,BAO_0000224,,,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,
2505,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
2506,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,
2507,,,BAO_0000219,,307.0,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,
2508,,,BAO_0000219,,307.0,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,
2509,,,BAO_0000219,,307.0,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,
2510,,,BAO_0000219,,307.0,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,
2511,,,BAO_0000357,,,5254,Binding affinity against 5-HT2A receptor,B,,,,,
2512,,,BAO_0000357,,,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2513,,,BAO_0000219,,722.0,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,
2514,,,BAO_0000219,,722.0,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,
2515,,,BAO_0000219,,722.0,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,Homo sapiens,9606.0,,
2516,,,BAO_0000219,,722.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,9606.0,,
2517,,,BAO_0000357,,,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,
2518,,,BAO_0000219,,722.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,9606.0,,
2519,,,BAO_0000219,,722.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,9606.0,,
2520,,,BAO_0000219,,722.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,Homo sapiens,9606.0,,
2521,,,BAO_0000357,,,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,
2522,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2523,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2524,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2525,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,Homo sapiens,9606.0,,
2526,,,BAO_0000219,,722.0,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,
2527,,,BAO_0000219,,722.0,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,
2528,,,BAO_0000219,,722.0,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,Homo sapiens,9606.0,,
2529,,,BAO_0000219,,722.0,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,
2530,,,BAO_0000219,,722.0,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,
2531,,,BAO_0000219,,722.0,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,Homo sapiens,9606.0,,
2532,,,BAO_0000219,,723.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,
2533,,,BAO_0000219,,723.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2534,,,BAO_0000219,,723.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2535,,,BAO_0000219,,722.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,
2536,,,BAO_0000219,,485.0,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,
2537,,,BAO_0000219,,485.0,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,
2538,,,BAO_0000357,,,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,Homo sapiens,9606.0,,
2539,,,BAO_0000219,,722.0,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,
2540,,,BAO_0000219,,722.0,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,
2541,,,BAO_0000219,,449.0,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,Homo sapiens,9606.0,,
2542,,,BAO_0000219,,722.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,
2543,,,BAO_0000219,,722.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,
2544,,,BAO_0000219,,723.0,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,
2545,,,BAO_0000219,,723.0,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,
2546,,,BAO_0000019,,,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,
2547,,,BAO_0000357,,,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,
2548,,,BAO_0000357,,,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,
2549,,,BAO_0000357,,,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,Oryctolagus cuniculus,9986.0,,
2550,,,BAO_0000357,,,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,Oryctolagus cuniculus,9986.0,,
2551,,,BAO_0000357,,,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,Oryctolagus cuniculus,9986.0,,
2552,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
2553,,,BAO_0000357,,,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,Oryctolagus cuniculus,9986.0,,
2554,,,BAO_0000219,,485.0,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,
2555,,,BAO_0000019,,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,
2556,,,BAO_0000019,,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,
2557,,,BAO_0000019,945.0,,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,Stomach
2558,,,BAO_0000019,945.0,,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,Rattus norvegicus,10116.0,,Stomach
2559,,,BAO_0000019,,,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,
2560,,,BAO_0000219,,723.0,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,
2561,,,BAO_0000019,,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,
2562,,,BAO_0000019,,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,
2563,,,BAO_0000357,,,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,
2564,,,BAO_0000357,,,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,
2565,,,BAO_0000019,,,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,Rattus norvegicus,10116.0,,
2566,,,BAO_0000357,,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2567,,,BAO_0000357,,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2568,,,BAO_0000357,,,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2569,,,BAO_0000219,,,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,
2570,,,BAO_0000019,,,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,
2571,,,BAO_0000357,,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,
2572,,,BAO_0000357,,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,Rattus norvegicus,10116.0,,
2573,,,BAO_0000357,,,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,Rattus norvegicus,10116.0,,
2574,,,BAO_0000219,,,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,Rattus norvegicus,10116.0,,
2575,,,BAO_0000219,,,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,
2576,,,BAO_0000019,,,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,
2577,,,BAO_0000019,,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,
2578,,,BAO_0000249,,,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,
2579,,,BAO_0000357,,,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,
2580,,,BAO_0000019,,,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,
2581,,,BAO_0000357,,,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2582,,,BAO_0000019,,,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,
2583,,,BAO_0000357,,,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,
2584,,,BAO_0000019,,,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,
2585,,,BAO_0000019,,,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,
2586,,,BAO_0000019,,,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2587,,,BAO_0000249,,,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2588,,,BAO_0000019,,,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,Rattus norvegicus,10116.0,,
2589,,,BAO_0000357,,,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,
2590,,,BAO_0000357,,,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2591,,,BAO_0000019,,,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,Rattus norvegicus,10116.0,,
2592,,,BAO_0000357,,,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,
2593,,,BAO_0000357,,,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,
2594,,,BAO_0000019,,,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,Rattus norvegicus,10116.0,,
2595,,,BAO_0000357,,,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,
2596,,,BAO_0000019,,,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,
2597,,,BAO_0000019,,,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,
2598,,,BAO_0000019,,,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,
2599,,,BAO_0000019,,,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,
2600,,,BAO_0000019,,,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,
2601,,,BAO_0000019,,,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,
2602,,,BAO_0000019,,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,
2603,,,BAO_0000019,,,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,
2604,,,BAO_0000219,,723.0,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,
2605,,,BAO_0000357,,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,
2606,,,BAO_0000019,,,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2607,,,BAO_0000019,,,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2608,,,BAO_0000221,955.0,,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,Brain
2609,,,BAO_0000357,,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,
2610,,,BAO_0000219,,723.0,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,
2611,,,BAO_0000221,,,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,
2612,,,BAO_0000357,,,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,
2613,,,BAO_0000357,,,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2614,,,BAO_0000019,,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,
2615,,,BAO_0000019,,,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,
2616,,,BAO_0000357,,,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,
2617,,,BAO_0000219,,723.0,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2618,,,BAO_0000357,,,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2619,,,BAO_0000357,,,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2620,,,BAO_0000019,,,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2621,,,BAO_0000357,,,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2622,,,BAO_0000219,,449.0,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,
2623,,,BAO_0000019,,,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,
2624,,,BAO_0000357,,,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,
2625,,,BAO_0000357,,,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,
2626,,,BAO_0000357,,,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2627,,,BAO_0000019,,,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,
2628,,,BAO_0000019,,,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,
2629,,,BAO_0000019,,,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,
2630,,,BAO_0000019,,,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,
2631,,,BAO_0000357,,,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,
2632,,,BAO_0000357,,,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,
2633,,,BAO_0000357,,,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,Rattus norvegicus,10116.0,,
2634,,,BAO_0000357,,,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2635,,,BAO_0000357,,,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,
2636,,,BAO_0000219,,723.0,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,
2637,,,BAO_0000357,,,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,
2638,,,BAO_0000357,,,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,
2639,,,BAO_0000357,,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,
2640,,,BAO_0000357,,,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,Rattus norvegicus,10116.0,,
2641,,,BAO_0000357,,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,
2642,,,BAO_0000357,,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,
2643,,,BAO_0000357,,,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,
2644,,,BAO_0000357,,,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,
2645,,,BAO_0000357,,,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,
2646,,,BAO_0000219,,723.0,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,
2647,,,BAO_0000357,,,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,Rattus norvegicus,10116.0,,
2648,,,BAO_0000019,5383.0,,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,Caudate-putamen
2649,,,BAO_0000357,,,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,
2650,,,BAO_0000357,,,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,
2651,,,BAO_0000357,,,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,
2652,,,BAO_0000019,,,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,
2653,,,BAO_0000357,,,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,
2654,,,BAO_0000221,10000000.0,,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,Hippocampus
2655,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,
2656,,,BAO_0000357,,,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,
2657,,,BAO_0000357,,,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,
2658,,,BAO_0000219,,723.0,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,
2659,,,BAO_0000019,,,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,
2660,,,BAO_0000357,,,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,
2661,,,BAO_0000019,,,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,
2662,,,BAO_0000221,955.0,,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,Brain
2663,,,BAO_0000249,,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2664,,,BAO_0000249,,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2665,,,BAO_0000019,,,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,Rattus norvegicus,10116.0,,
2666,,,BAO_0000249,,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2667,,,BAO_0000249,,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2668,,,BAO_0000249,,,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,
2669,,,BAO_0000019,,,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,Rattus norvegicus,10116.0,,
2670,,,BAO_0000019,,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,
2671,,,BAO_0000019,,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,
2672,,,BAO_0000019,,,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,Rattus norvegicus,10116.0,,
2673,,,BAO_0000019,,,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,Rattus norvegicus,10116.0,,
2674,,,BAO_0000224,,,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,Rattus norvegicus,10116.0,,
2675,,,BAO_0000357,,,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,
2676,,,BAO_0000357,,,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,
2677,,,BAO_0000357,,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,
2678,,,BAO_0000357,,,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,Rattus norvegicus,10116.0,,
2679,,,BAO_0000357,,,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,
2680,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,
2681,,,BAO_0000019,,,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,Rattus norvegicus,10116.0,,
2682,,,BAO_0000019,,,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,
2683,,,BAO_0000019,,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,
2684,,,BAO_0000019,,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,
2685,,,BAO_0000219,,449.0,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,
2686,,,BAO_0000019,,,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,
2687,,,BAO_0000019,,,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,
2688,,,BAO_0000357,,,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,
2689,,,BAO_0000019,,,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,
2690,,,BAO_0000019,,,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,
2691,,,BAO_0000218,,,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,
2692,,,BAO_0000218,,,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,
2693,,,BAO_0000218,,,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,
2694,,,BAO_0000357,,,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,
2695,,,BAO_0000357,,,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,
2696,,,BAO_0000224,,,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,
2697,,,BAO_0000224,,,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,
2698,,,BAO_0000224,,,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,
2699,,,BAO_0000357,,,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,
2700,,,BAO_0000357,,,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,
2701,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,
2702,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,
2703,,,BAO_0000019,,,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,
2704,,,BAO_0000019,1515.0,,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,Thoracic aorta
2705,,,BAO_0000019,1515.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,Thoracic aorta
2706,,,BAO_0000019,1515.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,Thoracic aorta
2707,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
2708,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,
2709,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,
2710,,,BAO_0000019,,,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,
2711,,,BAO_0000219,,339.0,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,
2712,,,BAO_0000219,,339.0,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,
2713,,,BAO_0000019,,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,
2714,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,Rattus norvegicus,10116.0,,
2715,,,BAO_0000357,,,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,
2716,,,BAO_0000357,,,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2717,,,BAO_0000357,,,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,
2718,,,BAO_0000019,,,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,
2719,,,BAO_0000019,,,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,
2720,,,BAO_0000019,,,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,
2721,,,BAO_0000357,,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,
2722,,,BAO_0000357,,,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,
2723,,,BAO_0000019,,,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,
2724,,,BAO_0000019,,,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,
2725,,,BAO_0000219,,722.0,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,
2726,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,
2727,,,BAO_0000357,,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,Homo sapiens,9606.0,,
2728,,,BAO_0000357,,,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,
2729,,,BAO_0000357,,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,
2730,,,BAO_0000357,,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
2731,,,BAO_0000357,,,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,
2732,,,BAO_0000219,,449.0,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,
2733,,,BAO_0000219,,449.0,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,
2734,,,BAO_0000219,,723.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,
2735,,,BAO_0000219,,449.0,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,9606.0,,
2736,,,BAO_0000019,,,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,
2737,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
2738,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,
2739,,,BAO_0000219,,449.0,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,
2740,,,BAO_0000219,,449.0,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,
2741,,,BAO_0000219,,449.0,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,
2742,,,BAO_0000357,,,5254,Binding affinity against 5-HT2C receptor,B,,,,,
2743,,,BAO_0000219,,722.0,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,
2744,,,BAO_0000219,,722.0,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,Homo sapiens,9606.0,,
2745,,,BAO_0000219,,722.0,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,Homo sapiens,9606.0,,
2746,,,BAO_0000357,,,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,
2747,,,BAO_0000219,,722.0,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,Homo sapiens,9606.0,,
2748,,,BAO_0000219,,722.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,Homo sapiens,9606.0,,
2749,,,BAO_0000219,,722.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,Homo sapiens,9606.0,,
2750,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,
2751,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,
2752,,,BAO_0000219,,722.0,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,
2753,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
2754,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
2755,,,BAO_0000219,,722.0,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,
2756,,,BAO_0000219,,722.0,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,
2757,,,BAO_0000219,,722.0,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,
2758,,,BAO_0000219,,722.0,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,Homo sapiens,9606.0,,
2759,,,BAO_0000219,,722.0,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,
2760,,,BAO_0000219,,722.0,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,
2761,,,BAO_0000219,,722.0,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,
2762,,,BAO_0000219,,723.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,
2763,,,BAO_0000219,,722.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,
2764,,,BAO_0000219,,485.0,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,
2765,,,BAO_0000357,,,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,9606.0,,
2766,,,BAO_0000357,,,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,
2767,,,BAO_0000219,,722.0,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,
2768,,,BAO_0000219,,722.0,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,
2769,,,BAO_0000219,,308.0,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,
2770,,,BAO_0000019,,,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,
2771,,,BAO_0000221,10000000.0,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,Hippocampus
2772,,,BAO_0000219,,722.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,
2773,,,BAO_0000219,,722.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,
2774,,,BAO_0000357,,,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,
2775,,,BAO_0000019,945.0,,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,Stomach
2776,,,BAO_0000019,945.0,,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,Stomach
2777,,,BAO_0000219,,625.0,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,
2778,,,BAO_0000219,,723.0,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,
2779,,,BAO_0000219,,723.0,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,
2780,,,BAO_0000219,,723.0,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,
2781,,,BAO_0000019,,,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,
2782,,,BAO_0000019,945.0,,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,Mus musculus,10090.0,,Stomach
2783,,,BAO_0000019,945.0,,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,Rattus norvegicus,10116.0,,Stomach
2784,,,BAO_0000357,,,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,
2785,,,BAO_0000357,,,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,Sus scrofa,9823.0,,
2786,,,BAO_0000357,,,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2787,,,BAO_0000019,,,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,
2788,,,BAO_0000019,,,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,
2789,,,BAO_0000249,,,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,
2790,,,BAO_0000357,,,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,
2791,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2792,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,,,,
2793,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,
2794,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,
2795,,,BAO_0000249,,,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,
2796,,,BAO_0000249,,,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,
2797,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,Sus scrofa,9823.0,,
2798,,,BAO_0000019,,,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,Sus scrofa,9823.0,,
2799,,,BAO_0000357,,,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,Sus scrofa,9823.0,,
2800,,,BAO_0000019,,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,Sus scrofa,9823.0,,
2801,,,BAO_0000357,,,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,Sus scrofa,9823.0,,
2802,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,
2803,,,BAO_0000019,,,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,
2804,,,BAO_0000357,,,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,
2805,,,BAO_0000357,,,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,
2806,,,BAO_0000357,,,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,
2807,,,BAO_0000357,,,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,Rattus norvegicus,10116.0,,
2808,,,BAO_0000357,,,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,Rattus norvegicus,10116.0,,
2809,Brain membranes,,BAO_0000249,,,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,Rattus norvegicus,10116.0,,
2810,,,BAO_0000357,,,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,
2811,,,BAO_0000019,,,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,
2812,,,BAO_0000019,,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,
2813,,In vitro,BAO_0000219,,,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,,,,,
2814,,,BAO_0000219,,723.0,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,
2815,,,BAO_0000357,,,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,
2816,,,BAO_0000357,,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,
2817,,,BAO_0000219,,723.0,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,
2818,,,BAO_0000357,,,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,
2819,,,BAO_0000357,,,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2820,,,BAO_0000357,,,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,
2821,,,BAO_0000357,,,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
2822,,,BAO_0000357,,,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,
2823,,,BAO_0000019,,,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,
2824,,,BAO_0000019,,,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,
2825,,,BAO_0000019,,,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,
2826,,,BAO_0000219,,625.0,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,
2827,,,BAO_0000357,,,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,
2828,,,BAO_0000357,,,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,
2829,,In vitro,BAO_0000219,,,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,,,,,
2830,,,BAO_0000219,,,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,
2831,,,BAO_0000019,5383.0,,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,Caudate-putamen
2832,,,BAO_0000357,,,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,
2833,,,BAO_0000019,,,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,
2834,,,BAO_0000357,,,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,
2835,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,
2836,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,
2837,,,BAO_0000219,,,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,
2838,,,BAO_0000357,,,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,
2839,,,BAO_0000357,,,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,Rattus norvegicus,10116.0,,
2840,,,BAO_0000357,,,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,
2841,,,BAO_0000357,,,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2842,,,BAO_0000219,,,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,
2843,,,BAO_0000019,,,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,Rattus norvegicus,10116.0,,
2844,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2845,,,BAO_0000019,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,
2846,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,
2847,,,BAO_0000357,,,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,
2848,,,BAO_0000357,,,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,
2849,,,BAO_0000019,,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,
2850,,,BAO_0000019,,,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,
2851,,,BAO_0000019,,,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,
2852,,,BAO_0000019,,,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,
2853,,,BAO_0000357,,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,
2854,,,BAO_0000019,,,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,Rattus norvegicus,10116.0,,
2855,,,BAO_0000357,,,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,
2856,,,BAO_0000219,,485.0,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,
2857,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
2858,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,
2859,,,BAO_0000019,,,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,
2860,,,BAO_0000357,,,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
2861,,,BAO_0000357,,,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,
2862,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,
2863,,,BAO_0000357,,,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,
2864,,,BAO_0000357,,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,
2865,,,BAO_0000019,,,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,Homo sapiens,9606.0,,
2866,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,
2867,,,BAO_0000357,,,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,
2868,,,BAO_0000357,,,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,
2869,,,BAO_0000357,,,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,
2870,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,
2871,,,BAO_0000357,,,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,Homo sapiens,9606.0,,
2872,,,BAO_0000219,,722.0,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,Homo sapiens,9606.0,,
2873,,,BAO_0000219,,722.0,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,Homo sapiens,9606.0,,
2874,,,BAO_0000219,,449.0,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,9606.0,,
2875,,,BAO_0000219,,449.0,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,Homo sapiens,9606.0,,
2876,,,BAO_0000219,,722.0,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,
2877,,,BAO_0000219,,722.0,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,
2878,,,BAO_0000219,,722.0,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,
2879,,,BAO_0000219,,722.0,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,Homo sapiens,9606.0,,
2880,,,BAO_0000219,,722.0,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,Homo sapiens,9606.0,,
2881,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,
2882,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,
2883,,,BAO_0000219,,722.0,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,
2884,,,BAO_0000219,,722.0,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,
2885,,,BAO_0000219,,722.0,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,
2886,,,BAO_0000219,,722.0,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,Homo sapiens,9606.0,,
2887,,,BAO_0000219,,722.0,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,Homo sapiens,9606.0,,
2888,,,BAO_0000219,,722.0,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,
2889,,,BAO_0000219,,485.0,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,
2890,,,BAO_0000357,,,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,
2891,,,BAO_0000219,,722.0,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,
2892,,,BAO_0000219,,722.0,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,
2893,,,BAO_0000219,,722.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,
2894,,,BAO_0000219,,722.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,
2895,,,BAO_0000219,,722.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,
2896,,,BAO_0000019,,,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,Oryctolagus cuniculus,9986.0,,
2897,,,BAO_0000019,945.0,,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,Stomach
2898,,,BAO_0000357,945.0,,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,Stomach
2899,,,BAO_0000357,945.0,,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,Stomach
2900,,,BAO_0000019,945.0,,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,Rattus norvegicus,10116.0,,Stomach
2901,,,BAO_0000019,,,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,Rattus norvegicus,10116.0,,
2902,,,BAO_0000019,945.0,,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,Stomach
2903,,,BAO_0000357,945.0,,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,Rattus norvegicus,10116.0,,Stomach
2904,,,BAO_0000019,,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,
2905,,,BAO_0000019,,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,
2906,,,BAO_0000019,,,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,
2907,,,BAO_0000357,945.0,,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,10116.0,,Stomach
2908,,,BAO_0000357,945.0,,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,10116.0,,Stomach
2909,,,BAO_0000357,945.0,,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,10116.0,,Stomach
2910,,,BAO_0000357,945.0,,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,Rattus norvegicus,10116.0,,Stomach
2911,,,BAO_0000019,945.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,Stomach
2912,,,BAO_0000019,945.0,,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,Stomach
2913,,,BAO_0000019,945.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,Stomach
2914,,,BAO_0000019,945.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,Stomach
2915,,,BAO_0000019,945.0,,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,Rattus norvegicus,10116.0,,Stomach
2916,,,BAO_0000019,1515.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,Thoracic aorta
2917,,,BAO_0000357,,,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,
2918,,,BAO_0000357,,,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,
2919,,,BAO_0000357,,,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,
2920,,,BAO_0000357,,,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,
2922,,,BAO_0000019,945.0,,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,Rattus norvegicus,10116.0,,Stomach
2923,,,BAO_0000357,,,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,
2924,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,
2925,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,
2926,,,BAO_0000357,,,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,
2927,,,BAO_0000357,,,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,
2928,,,BAO_0000357,,,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,
2929,,,BAO_0000357,,,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,
2930,,,BAO_0000357,,,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,
2931,,,BAO_0000357,,,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,
2932,,,BAO_0000357,,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,Bos taurus,9913.0,,
2933,,,BAO_0000357,,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,Bos taurus,9913.0,,
2934,,,BAO_0000357,,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,Bos taurus,9913.0,,
2935,,,BAO_0000357,,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,Bos taurus,9913.0,,
2936,,,BAO_0000357,,,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,Bos taurus,9913.0,,
2937,,,BAO_0000357,,,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,Bos taurus,9913.0,,
2938,,,BAO_0000357,,,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,Bos taurus,9913.0,,
2939,,,BAO_0000019,,,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,Cavia porcellus,10141.0,,
2940,,,BAO_0000357,2435.0,,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,Cavia porcellus,10141.0,,Striatum
2941,,,BAO_0000357,,,5254,Binding affinity against 5-HT1A receptor,B,,,,,
2942,,,BAO_0000219,,449.0,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,
2943,,,BAO_0000219,,449.0,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,Homo sapiens,9606.0,,
2944,,,BAO_0000219,,,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,
2945,,,BAO_0000219,,449.0,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,
2946,,,BAO_0000219,,449.0,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,
2947,,,BAO_0000357,,,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,9606.0,,
2948,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,
2949,,,BAO_0000019,,,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,
2950,,,BAO_0000357,,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,
2951,,,BAO_0000357,,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,
2952,,,BAO_0000357,,,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,
2953,,,BAO_0000219,,449.0,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,
2954,,,BAO_0000219,,449.0,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,
2955,,,BAO_0000219,,449.0,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,
2956,,,BAO_0000219,,449.0,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,
2957,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,Homo sapiens,9606.0,,
2958,,,BAO_0000019,,,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,
2959,,,BAO_0000019,,,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,
2960,,,BAO_0000219,,449.0,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,Rattus norvegicus,10116.0,,
2961,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,
2962,,,BAO_0000019,,,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,
2963,,,BAO_0000019,,,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,
2964,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,
2965,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,
2966,,,BAO_0000357,,,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,
2967,,,BAO_0000357,,,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,
2968,,,BAO_0000357,,,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,
2969,,,BAO_0000219,,449.0,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,
2970,,,BAO_0000019,,,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,Homo sapiens,9606.0,,
2971,,,BAO_0000357,,,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,
2972,,,BAO_0000357,,,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,9606.0,,
2973,,,BAO_0000357,,,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,
2974,Membranes,,BAO_0000249,,,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,Rattus norvegicus,10116.0,,
2975,,,BAO_0000223,,,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,
2976,,,BAO_0000019,,,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,Rattus norvegicus,10116.0,,
2977,,,BAO_0000019,,,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,
2978,,,BAO_0000019,,,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,
2979,,,BAO_0000219,,,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,
2980,,,BAO_0000019,,,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,
2981,,,BAO_0000019,,,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,
2982,,,BAO_0000223,,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,
2983,,,BAO_0000223,,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,
2984,,,BAO_0000223,,,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,
2985,,,BAO_0000249,,,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,
2986,,,BAO_0000249,,,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,
2987,Membranes,,BAO_0000249,,,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,
2988,,,BAO_0000223,,,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,
2989,,,BAO_0000019,,,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,
2990,,,BAO_0000223,,,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,
2991,,,BAO_0000223,,,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,
2992,,,BAO_0000019,,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,
2993,,,BAO_0000019,,,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,Rattus norvegicus,10116.0,,
2994,,,BAO_0000249,,,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,
2995,,,BAO_0000223,,,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,
2996,,,BAO_0000019,,,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,
2997,,,BAO_0000019,,,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,
2998,,,BAO_0000019,,,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,
2999,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,
3000,,,BAO_0000249,,,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,
3001,,,BAO_0000019,,,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,
3002,,,BAO_0000019,,,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,
3003,Membranes,,BAO_0000249,,,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,
3004,,,BAO_0000223,,,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3005,,,BAO_0000221,955.0,,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,Brain
3006,,,BAO_0000019,,,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,
3007,,,BAO_0000223,,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,
3008,,,BAO_0000223,,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,
3009,,,BAO_0000223,,,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,
3010,,,BAO_0000223,,,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,
3011,,,BAO_0000223,,,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,
3012,,,BAO_0000019,,,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,
3013,,,BAO_0000019,,,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,
3014,,,BAO_0000223,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,
3015,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,
3016,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,
3017,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,
3018,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,
3019,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,
3020,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,
3021,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,
3022,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,,,,,
3023,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,
3024,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,
3025,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,
3026,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,
3027,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,
3028,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,,,,,
3029,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,,,,,
3030,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,
3031,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,
3032,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,,,,,
3033,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,,,,,
3034,,,BAO_0000019,,,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,
3035,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,
3036,,,BAO_0000019,,,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3037,,,BAO_0000223,,,12861,Binding activity radioligand.,B,,,,,
3038,Brain membranes,,BAO_0000249,,,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,
3039,Brain membranes,,BAO_0000249,,,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,
3040,,,BAO_0000357,,,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,
3041,,,BAO_0000357,,,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,
3042,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,
3043,,,BAO_0000357,,,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,
3044,,,BAO_0000357,,,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,
3045,,,BAO_0000357,,,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,
3046,,,BAO_0000357,,,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,
3047,,,BAO_0000357,,,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,
3048,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,
3049,,,BAO_0000357,,,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,
3050,,,BAO_0000357,,,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,
3051,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,
3052,,,BAO_0000357,,,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,
3053,,,BAO_0000357,,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,
3054,,,BAO_0000357,,,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,
3055,,,BAO_0000357,,,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,
3056,,,BAO_0000357,,,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,
3057,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,
3058,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,
3059,,,BAO_0000357,,,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,
3060,,,BAO_0000357,,,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,Homo sapiens,9606.0,,
3061,,,BAO_0000357,,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,
3062,,,BAO_0000357,,,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,Bos taurus,9913.0,,
3063,,,BAO_0000357,,,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,Bos taurus,9913.0,,
3064,,,BAO_0000019,,,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,Cavia porcellus,10141.0,,
3065,,,BAO_0000221,2116.0,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3066,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,Cavia porcellus,10141.0,,
3067,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,Cavia porcellus,10141.0,,
3068,,,BAO_0000221,2116.0,,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3069,,,BAO_0000221,2116.0,,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,Cavia porcellus,10141.0,,Ileum
3070,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,Cavia porcellus,10141.0,,
3071,,,BAO_0000019,,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,Cavia porcellus,10141.0,,
3072,,,BAO_0000019,,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,Cavia porcellus,10141.0,,
3073,,,BAO_0000019,,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,Cavia porcellus,10141.0,,
3074,,,BAO_0000019,,,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,Cavia porcellus,10141.0,,
3075,,,BAO_0000019,,,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,Cavia porcellus,10141.0,,
3076,,,BAO_0000221,2116.0,,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,Cavia porcellus,10141.0,,Ileum
3077,,,BAO_0000221,2116.0,,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,Cavia porcellus,10141.0,,Ileum
3078,,,BAO_0000221,2116.0,,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,Cavia porcellus,10141.0,,Ileum
3079,,,BAO_0000221,2116.0,,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3080,,,BAO_0000221,2116.0,,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,Cavia porcellus,10141.0,,Ileum
3081,,,BAO_0000223,,,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,Cavia porcellus,10141.0,,
3082,,,BAO_0000221,2116.0,,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3083,,,BAO_0000221,2116.0,,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,Cavia porcellus,10141.0,,Ileum
3084,,,BAO_0000221,2116.0,,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,Cavia porcellus,10141.0,,Ileum
3085,,,BAO_0000221,2116.0,,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,Cavia porcellus,10141.0,,Ileum
3086,,,BAO_0000221,2116.0,,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,Cavia porcellus,10141.0,,Ileum
3087,,,BAO_0000221,2116.0,,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,Cavia porcellus,10141.0,,Ileum
3088,,,BAO_0000221,2116.0,,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3089,,,BAO_0000221,2116.0,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,Cavia porcellus,10141.0,,Ileum
3090,,,BAO_0000221,2116.0,,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3091,,,BAO_0000221,2116.0,,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,Cavia porcellus,10141.0,,Ileum
3092,,,BAO_0000221,2116.0,,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,Cavia porcellus,10141.0,,Ileum
3093,,,BAO_0000221,2116.0,,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,Cavia porcellus,10141.0,,Ileum
3094,,,BAO_0000019,,,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,Cavia porcellus,10141.0,,
3095,,,BAO_0000357,,,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,
3096,,,BAO_0000223,,,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,Homo sapiens,9606.0,,
3097,,,BAO_0000223,,,6013,Binding affinity towards 5-HT3 receptor,B,,,,,
3098,,,BAO_0000223,,,12861,Binding activity radioligand.,B,,,,,
3099,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,
3100,,,BAO_0000223,,,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,
3101,,,BAO_0000223,,,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,
3102,,,BAO_0000223,,,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,
3103,,,BAO_0000019,,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,
3104,,,BAO_0000219,,433.0,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,
3105,,In vivo,BAO_0000218,,,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,,,,,
3106,,,BAO_0000019,,,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,
3107,,,BAO_0000224,,,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,
3108,,,BAO_0000224,,,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,
3109,,,BAO_0000019,,,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,
3110,,,BAO_0000019,,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,
3111,,,BAO_0000218,,,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,
3112,,,BAO_0000219,,,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,
3113,,,BAO_0000019,,,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,
3114,,,BAO_0000019,,,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,
3115,,,BAO_0000224,,,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,
3116,,,BAO_0000219,,,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,
3117,,,BAO_0000219,,,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,
3118,,,BAO_0000224,,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,
3119,,In vitro,BAO_0000219,,,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,,,,,
3120,,,BAO_0000219,,339.0,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,
3121,,,BAO_0000019,,,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,
3122,,,BAO_0000219,,,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,
3123,,,BAO_0000357,,,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,Mus musculus,10090.0,,
3124,,,BAO_0000019,,,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,
3125,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,Sus scrofa,9823.0,,
3126,,,BAO_0000357,,,12861,Binding activity radioligand.,B,,Sus scrofa,9823.0,,
3127,,,BAO_0000223,,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,Oryctolagus cuniculus,9986.0,,
3128,,,BAO_0000223,,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,Oryctolagus cuniculus,9986.0,,
3129,,,BAO_0000223,,,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,Oryctolagus cuniculus,9986.0,,
3130,,,BAO_0000019,,,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,Oryctolagus cuniculus,9986.0,,
3131,,,BAO_0000019,,,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,Oryctolagus cuniculus,9986.0,,
3132,,,BAO_0000019,,,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,Oryctolagus cuniculus,9986.0,,
3133,,,BAO_0000221,2116.0,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,Oryctolagus cuniculus,9986.0,,Ileum
3134,,,BAO_0000019,,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,Oryctolagus cuniculus,9986.0,,
3135,,,BAO_0000019,,,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,Oryctolagus cuniculus,9986.0,,
3136,,,BAO_0000019,,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,Oryctolagus cuniculus,9986.0,,
3137,,,BAO_0000019,,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,Oryctolagus cuniculus,9986.0,,
3138,,,BAO_0000219,,449.0,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,Oryctolagus cuniculus,9986.0,,
3139,,,BAO_0000019,,,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3140,,,BAO_0000019,,,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,
3141,,,BAO_0000357,,,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,
3142,,,BAO_0000019,,,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,Rattus norvegicus,10116.0,,
3143,,,BAO_0000019,,,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,
3144,,In vivo,BAO_0000218,948.0,,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,Heart
3145,,,BAO_0000019,948.0,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,Heart
3146,,,BAO_0000019,948.0,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,Heart
3147,,,BAO_0000019,948.0,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,Heart
3148,,,BAO_0000019,948.0,,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,Heart
3149,,,BAO_0000019,,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3150,,,BAO_0000019,,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3151,,,BAO_0000019,,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3152,,,BAO_0000019,,,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,
3153,,In vivo,BAO_0000218,,,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,,Rattus norvegicus,10116.0,,
3154,,In vivo,BAO_0000218,,,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,,,,,
3155,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,Rattus norvegicus,10116.0,,
3156,,,BAO_0000019,,,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,Rattus norvegicus,10116.0,,
3157,,In vivo,BAO_0000218,,,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,,Rattus norvegicus,10116.0,,
3158,,,BAO_0000019,,,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,Rattus norvegicus,10116.0,,
3159,,,BAO_0000019,,,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,
3160,,,BAO_0000019,,,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3161,,,BAO_0000223,,,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,
3162,,,BAO_0000019,,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,
3163,,,BAO_0000019,,,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,
3164,,,BAO_0000249,,,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,
3165,,,BAO_0000019,,,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,
3166,,,BAO_0000249,955.0,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,Brain
3167,,,BAO_0000221,955.0,,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,Brain
3168,,,BAO_0000249,,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,
3169,,,BAO_0000249,,,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,
3170,,,BAO_0000019,,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,
3171,,,BAO_0000019,,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,Rattus norvegicus,10116.0,,
3172,,,BAO_0000019,,,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,Rattus norvegicus,10116.0,,
3173,,,BAO_0000223,,,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3174,,,BAO_0000019,,,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,
3175,Membranes,,BAO_0000249,,,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,
3176,,,BAO_0000019,,,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,Rattus norvegicus,10116.0,,
3177,,,BAO_0000223,,,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,
3178,,,BAO_0000223,,,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3179,,,BAO_0000219,,433.0,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,
3180,,,BAO_0000219,,433.0,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,
3181,,,BAO_0000019,,,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,
3182,,,BAO_0000019,,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,
3183,,,BAO_0000019,,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,
3184,,,BAO_0000019,,,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,
3185,,,BAO_0000019,,,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,
3186,,,BAO_0000019,,,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,Rattus norvegicus,10116.0,,
3187,,,BAO_0000019,,,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,
3188,,,BAO_0000218,,,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,
3189,,In vivo,BAO_0000218,,,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,,,,,
3190,,,BAO_0000218,,,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,
3191,,In vivo,BAO_0000218,,,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,
3192,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,,,,,
3193,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,,,,,
3194,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,,Rattus norvegicus,10116.0,,
3195,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,
3196,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,,,,,
3197,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,,,,,
3198,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,
3199,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,,,,,
3200,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,
3201,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,
3202,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,,,,,
3203,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,,,,,
3204,,In vivo,BAO_0000218,,,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,
3205,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,,,,,
3206,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,,,,,
3207,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,
3208,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,,,,,
3209,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,,,,,
3210,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,,,,,
3211,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,,,,,
3212,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,,,,,
3213,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,
3214,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,,,,,
3215,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,,,,,
3216,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,,,,,
3217,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,,,,,
3218,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,,,,,
3219,,In vivo,BAO_0000218,,,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,,,,,
3220,,,BAO_0000218,,,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,
3221,,,BAO_0000218,,,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,
3222,,In vivo,BAO_0000218,,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,,,,,
3223,,In vivo,BAO_0000218,,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,,,,,
3224,,In vivo,BAO_0000218,,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,,,,,
3225,,In vivo,BAO_0000218,,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,,,,,
3226,,In vivo,BAO_0000218,,,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,,,,,
3227,,In vivo,BAO_0000218,,,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,,,,,
3228,,,BAO_0000019,,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,
3229,,,BAO_0000019,,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,
3230,,,BAO_0000223,,,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3231,,,BAO_0000019,,,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,
3232,,,BAO_0000221,10000000.0,,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,Hippocampus
3233,,,BAO_0000019,,,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,Rattus norvegicus,10116.0,,
3234,,,BAO_0000019,,,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3235,,,BAO_0000223,,,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,
3236,,,BAO_0000019,,,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,
3237,,,BAO_0000019,,,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,
3238,,,BAO_0000019,,,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,
3239,,,BAO_0000019,,,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,
3240,,,BAO_0000019,,,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,
3241,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,Cavia porcellus,10141.0,,Ileum
3242,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,Cavia porcellus,10141.0,,Ileum
3243,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,Cavia porcellus,10141.0,,Ileum
3244,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,Cavia porcellus,10141.0,,Ileum
3245,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,Cavia porcellus,10141.0,,Ileum
3246,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,Cavia porcellus,10141.0,,Ileum
3247,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,Cavia porcellus,10141.0,,Ileum
3248,,,BAO_0000221,2116.0,,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,Cavia porcellus,10141.0,,Ileum
3249,,,BAO_0000221,2116.0,,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,Cavia porcellus,10141.0,,Ileum
3250,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,Cavia porcellus,10141.0,,Ileum
3251,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,Cavia porcellus,10141.0,,Ileum
3252,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,Cavia porcellus,10141.0,,Ileum
3253,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,Cavia porcellus,10141.0,,Ileum
3254,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,Cavia porcellus,10141.0,,Ileum
3255,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,Cavia porcellus,10141.0,,Ileum
3256,,,BAO_0000221,2116.0,,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,Cavia porcellus,10141.0,,Ileum
3257,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,Cavia porcellus,10141.0,,Ileum
3258,,,BAO_0000221,2116.0,,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,Cavia porcellus,10141.0,,Ileum
3259,,,BAO_0000357,,,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,Cavia porcellus,10141.0,,
3260,,,BAO_0000249,2435.0,,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,10141.0,,Striatum
3261,,,BAO_0000249,2435.0,,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,10141.0,,Striatum
3262,,,BAO_0000357,2435.0,,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,Cavia porcellus,10141.0,,Striatum
3263,,,BAO_0000357,2435.0,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,Cavia porcellus,10141.0,,Striatum
3264,,,BAO_0000357,2435.0,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,Cavia porcellus,10141.0,,Striatum
3265,,,BAO_0000357,2435.0,,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,Cavia porcellus,10141.0,,Striatum
3266,,,BAO_0000221,2116.0,,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,Cavia porcellus,10141.0,,Ileum
3267,,,BAO_0000221,2116.0,,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,Cavia porcellus,10141.0,,Ileum
3268,,,BAO_0000221,2116.0,,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,Cavia porcellus,10141.0,,Ileum
3269,,,BAO_0000357,,,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,Cavia porcellus,10141.0,,
3270,,,BAO_0000357,,,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,Cavia porcellus,10141.0,,
3271,,,BAO_0000019,,,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,Cavia porcellus,10141.0,,
3272,,,BAO_0000019,,,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,Cavia porcellus,10141.0,,
3273,,,BAO_0000019,,,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,Cavia porcellus,10141.0,,
3274,,,BAO_0000357,,,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,Cavia porcellus,10141.0,,
3275,,,BAO_0000357,2435.0,,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,Cavia porcellus,10141.0,,Striatum
3276,,,BAO_0000357,2435.0,,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,Cavia porcellus,10141.0,,Striatum
3277,,,BAO_0000249,2435.0,,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,10141.0,,Striatum
3278,,,BAO_0000249,2435.0,,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,Cavia porcellus,10141.0,,Striatum
3279,,,BAO_0000221,2116.0,,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,Cavia porcellus,10141.0,,Ileum
3280,,,BAO_0000357,,,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,Cavia porcellus,10141.0,,
3281,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,Cavia porcellus,10141.0,,
3282,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,Cavia porcellus,10141.0,,
3283,,,BAO_0000357,,,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,Cavia porcellus,10141.0,,
3284,,,BAO_0000221,2116.0,,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,10141.0,,Ileum
3285,,,BAO_0000221,2116.0,,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,Cavia porcellus,10141.0,,Ileum
3286,,,BAO_0000221,2116.0,,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,Cavia porcellus,10141.0,,Ileum
3287,,,BAO_0000221,2116.0,,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,Cavia porcellus,10141.0,,Ileum
3288,,,BAO_0000221,2116.0,,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,Cavia porcellus,10141.0,,Ileum
3289,,,BAO_0000357,,,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,Cavia porcellus,10141.0,,
3290,,,BAO_0000357,,,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,Cavia porcellus,10141.0,,
3291,,,BAO_0000019,,,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,Cavia porcellus,10141.0,,
3292,,,BAO_0000357,,,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,Cavia porcellus,10141.0,,
3293,,,BAO_0000019,,,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,Cavia porcellus,10141.0,,
3294,,,BAO_0000219,,722.0,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,Cavia porcellus,10141.0,,
3295,,,BAO_0000019,,,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,Cavia porcellus,10141.0,,
3296,,,BAO_0000357,,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,Cavia porcellus,10141.0,,
3297,,,BAO_0000357,,,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,Cavia porcellus,10141.0,,
3298,,,BAO_0000357,2435.0,,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,Cavia porcellus,10141.0,,Striatum
3299,,,BAO_0000221,10000000.0,,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,Cavia porcellus,10141.0,,Hippocampus
3300,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,Cavia porcellus,10141.0,,
3301,,,BAO_0000357,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,Cavia porcellus,10141.0,,
3302,,,BAO_0000221,2116.0,,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,Cavia porcellus,10141.0,,Ileum
3303,,,BAO_0000357,,,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,
3304,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,
3305,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,
3306,,,BAO_0000219,,308.0,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,
3307,,,BAO_0000357,,,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
3308,,,BAO_0000357,,,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,
3309,,,BAO_0000219,,308.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,
3310,,,BAO_0000357,,,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,
3311,,,BAO_0000357,,,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,
3312,,,BAO_0000219,,,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,
3313,,,BAO_0000357,,,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,
3314,,,BAO_0000019,2081.0,,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,Cardiac atrium
3315,,,BAO_0000019,2081.0,,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,Cardiac atrium
3316,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
3317,,,BAO_0000221,10000000.0,,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,Hippocampus
3318,,,BAO_0000221,10000000.0,,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,Sus scrofa,9823.0,,Hippocampus
3319,,,BAO_0000019,,,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,Oryctolagus cuniculus,9986.0,,
3320,,,BAO_0000357,,,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,Rattus norvegicus,10116.0,,
3321,,,BAO_0000019,,,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,
3322,,,BAO_0000357,,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,
3323,,,BAO_0000357,,,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,
3324,,,BAO_0000019,,,670,lntrinsic activity relative to 5-HT receptor,F,,,,,
3325,,,BAO_0000019,,,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,
3326,,,BAO_0000019,,,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,
3327,,,BAO_0000019,,,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,
3328,,,BAO_0000019,,,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,
3329,,,BAO_0000019,,,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,
3330,,,BAO_0000019,,,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,
3331,,,BAO_0000357,,,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,
3332,,,BAO_0000019,,,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,
3333,,,BAO_0000357,,,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,Rattus norvegicus,10116.0,,
3334,,,BAO_0000357,,,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,
3335,,,BAO_0000357,,,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,
3336,,,BAO_0000357,,,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,
3337,,,BAO_0000019,,,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,Rattus norvegicus,10116.0,,
3338,,,BAO_0000249,2435.0,,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,Striatum
3339,,,BAO_0000249,,,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,
3340,,,BAO_0000249,,,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,
3341,,,BAO_0000019,2435.0,,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,Rattus norvegicus,10116.0,,Striatum
3342,,,BAO_0000019,2435.0,,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,Striatum
3343,,,BAO_0000249,2435.0,,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,Striatum
3344,,,BAO_0000019,2435.0,,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,Striatum
3345,,,BAO_0000249,2435.0,,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,Striatum
3346,,,BAO_0000249,2435.0,,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,Striatum
3347,,,BAO_0000249,,,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,
3348,,,BAO_0000221,955.0,,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,Brain
3349,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,
3350,,,BAO_0000019,,,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,
3351,,,BAO_0000019,,,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,
3352,,,BAO_0000019,,,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,
3353,,,BAO_0000019,,,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,
3354,,,BAO_0000357,,,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,Rattus norvegicus,10116.0,,
3355,,,BAO_0000249,2435.0,,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,Striatum
3356,,,BAO_0000019,,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,Rattus norvegicus,10116.0,,
3357,,,BAO_0000019,,,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,
3358,,,BAO_0000019,,,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,
3359,,,BAO_0000019,,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,Rattus norvegicus,10116.0,,
3360,,,BAO_0000019,,,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,
3361,,,BAO_0000019,,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,
3362,,,BAO_0000218,,,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,
3363,,,BAO_0000019,,,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,
3364,,,BAO_0000019,,,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,Rattus norvegicus,10116.0,,
3365,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,
3366,,,BAO_0000357,,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,
3367,,,BAO_0000357,,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,
3368,,,BAO_0000357,,,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,
3369,,,BAO_0000357,,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,
3370,,,BAO_0000019,,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,
3371,,,BAO_0000357,,,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,
3372,,,BAO_0000019,,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,
3373,,,BAO_0000019,,,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,
3374,,,BAO_0000357,,,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,
3375,,,BAO_0000357,,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,
3376,,,BAO_0000357,,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,
3377,,,BAO_0000357,,,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,
3378,,,BAO_0000357,,,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,
3379,Brain membranes,,BAO_0000249,,,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,
3380,Brain membranes,,BAO_0000249,,,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,
3381,Brain membranes,,BAO_0000249,,,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,
3382,,,BAO_0000019,,,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,
3383,,,BAO_0000019,,,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3384,,,BAO_0000221,10000000.0,,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,Hippocampus
3385,,,BAO_0000019,,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,
3386,,,BAO_0000019,,,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,
3387,,,BAO_0000019,,,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,
3388,,,BAO_0000223,,,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3389,,,BAO_0000223,,,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3390,,,BAO_0000019,,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,
3391,,,BAO_0000249,,,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,
3392,,,BAO_0000019,,,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,Rattus norvegicus,10116.0,,
3393,,,BAO_0000019,,,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,
3394,,,BAO_0000019,,,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,
3395,,,BAO_0000019,,,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,
3396,,,BAO_0000249,,,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,
3397,,,BAO_0000223,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,
3398,,,BAO_0000223,,,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,
3399,,,BAO_0000223,,,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,Rattus norvegicus,10116.0,,
3400,,,BAO_0000249,,,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,
3401,,,BAO_0000221,955.0,,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,Brain
3402,,,BAO_0000019,,,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,
3403,,,BAO_0000019,,,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,
3404,,In vivo,BAO_0000218,,,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,,,,,
3405,,,BAO_0000019,,,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,
3406,,,BAO_0000357,,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3407,,,BAO_0000019,,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,
3408,,,BAO_0000019,,,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,
3409,,,BAO_0000019,,,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,
3410,,,BAO_0000019,,,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,
3411,,,BAO_0000249,,,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,
3412,,,BAO_0000019,,,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,Rattus norvegicus,10116.0,,
3413,,,BAO_0000357,,,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3414,,,BAO_0000223,,,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,
3415,,,BAO_0000019,,,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,
3416,,,BAO_0000019,,,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,
3417,,,BAO_0000223,,,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3418,,,BAO_0000223,,,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3419,,,BAO_0000019,,,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,Cavia porcellus,10141.0,,
3420,,,BAO_0000019,,,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,Cavia porcellus,10141.0,,
3421,,,BAO_0000019,,,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,Cavia porcellus,10141.0,,
3422,,,BAO_0000223,,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3423,,,BAO_0000019,,,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,
3424,,,BAO_0000223,,,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,
3425,,,BAO_0000019,,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,
3426,,,BAO_0000019,,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,
3427,,,BAO_0000019,,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,
3428,,,BAO_0000223,,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,
3429,,,BAO_0000019,,,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,
3430,,,BAO_0000019,,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,
3431,,,BAO_0000019,,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,
3432,,,BAO_0000223,,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,
3433,,,BAO_0000223,,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,
3434,,,BAO_0000019,,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,
3435,,,BAO_0000223,,,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,
3436,,,BAO_0000223,,,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3437,,,BAO_0000219,,,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,
3438,,,BAO_0000223,,,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,
3439,,,BAO_0000219,,433.0,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,
3440,,,BAO_0000019,,,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,
3441,,,BAO_0000219,,433.0,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,
3442,,,BAO_0000223,,,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,
3443,,,BAO_0000223,,,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,
3444,,In vitro,BAO_0000219,,,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,,,,,
3445,,,BAO_0000223,,,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,
3446,,,BAO_0000019,,,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,
3447,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,Cavia porcellus,10141.0,,
3448,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,Cavia porcellus,10141.0,,
3449,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,Cavia porcellus,10141.0,,
3450,,,BAO_0000019,,,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,Cavia porcellus,10141.0,,
3451,,,BAO_0000223,,,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,
3452,,,BAO_0000223,,,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3453,,,BAO_0000223,,,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,
3454,,,BAO_0000223,,,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,
3455,,,BAO_0000223,,,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,
3456,,,BAO_0000223,,,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,
3457,,,BAO_0000357,,,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,
3458,,,BAO_0000223,,,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3459,,,BAO_0000357,,,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,
3460,,,BAO_0000357,,,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3461,,,BAO_0000357,,,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,
3462,,,BAO_0000223,,,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,
3463,,,BAO_0000223,,,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,
3464,,,BAO_0000223,,,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,
3465,,,BAO_0000019,,,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,
3466,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3467,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,
3468,,,BAO_0000357,,,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,
3469,,,BAO_0000357,,,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,
3470,,,BAO_0000019,,,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,
3471,,,BAO_0000357,,,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,
3472,,,BAO_0000357,,,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,
3473,,,BAO_0000019,,,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,
3474,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,
3475,,,BAO_0000019,,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,
3476,,,BAO_0000019,,,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,
3477,,,BAO_0000223,,,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,
3478,,,BAO_0000357,,,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,
3479,,,BAO_0000019,,,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,
3480,,,BAO_0000357,,,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,
3481,,,BAO_0000219,,,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,Rattus norvegicus,10116.0,,
3482,,,BAO_0000219,,,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,Rattus norvegicus,10116.0,,
3483,,,BAO_0000219,,,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,Rattus norvegicus,10116.0,,
3484,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,Cavia porcellus,10141.0,,Ileum
3485,,,BAO_0000221,2116.0,,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,Cavia porcellus,10141.0,,Ileum
3486,,,BAO_0000019,,,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,Cavia porcellus,10141.0,,
3487,,,BAO_0000221,2116.0,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,Cavia porcellus,10141.0,,Ileum
3488,,,BAO_0000357,,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,Cavia porcellus,10141.0,,
3489,,,BAO_0000221,2116.0,,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,Cavia porcellus,10141.0,,Ileum
3490,,,BAO_0000221,2116.0,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,Ileum
3491,,,BAO_0000357,,,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,
3492,,,BAO_0000224,,,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,Cavia porcellus,10141.0,,
3493,,,BAO_0000224,,,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,Cavia porcellus,10141.0,,
3494,,,BAO_0000221,2116.0,,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,Cavia porcellus,10141.0,,Ileum
3495,,,BAO_0000224,,,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,Cavia porcellus,10141.0,,
3496,,,BAO_0000224,,,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,Cavia porcellus,10141.0,,
3497,,,BAO_0000019,,,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,Cavia porcellus,10141.0,,
3498,,,BAO_0000019,,,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,Cavia porcellus,10141.0,,
3499,,,BAO_0000219,2081.0,,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,Homo sapiens,9606.0,,Cardiac atrium
3500,,,BAO_0000219,2081.0,,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,Homo sapiens,9606.0,,Cardiac atrium
3501,,,BAO_0000019,,,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,Homo sapiens,9606.0,,
3502,,,BAO_0000219,2081.0,,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,Homo sapiens,9606.0,,Cardiac atrium
3503,,,BAO_0000019,,,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,Mus musculus,10090.0,,
3504,,,BAO_0000019,,,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,Mus musculus,10090.0,,
3505,,,BAO_0000019,,,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,
3506,,,BAO_0000224,,,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,
3507,,,BAO_0000019,,,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,
3508,,,BAO_0000224,,,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,
3509,,,BAO_0000224,,,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,
3510,,,BAO_0000019,945.0,,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,Stomach
3511,,,BAO_0000019,945.0,,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,Stomach
3512,,,BAO_0000019,,,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,
3513,,,BAO_0000224,,,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,
3514,,,BAO_0000224,,,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,
3515,,,BAO_0000221,10000000.0,,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,Hippocampus
3516,,,BAO_0000357,,,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,
3517,,,BAO_0000019,,,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,
3518,,,BAO_0000019,,,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,Rattus norvegicus,10116.0,,
3519,,,BAO_0000224,,,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,Rattus norvegicus,10116.0,,
3520,,,BAO_0000019,955.0,,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,Rattus norvegicus,10116.0,,Brain
3521,,,BAO_0000221,2037.0,,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,Rattus norvegicus,10116.0,,Cerebellum
3522,,,BAO_0000019,,,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,Rattus norvegicus,10116.0,,
3523,,,BAO_0000224,,,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,Rattus norvegicus,10116.0,,
3524,,,BAO_0000019,,,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,
3525,,,BAO_0000224,,,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,Rattus norvegicus,10116.0,,
3526,,,BAO_0000224,,,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,Rattus norvegicus,10116.0,,
3527,,,BAO_0000019,945.0,,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,Rattus norvegicus,10116.0,,Stomach
3528,,In vitro,BAO_0000219,,,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,,Homo sapiens,9606.0,,
3529,,In vitro,BAO_0000219,,,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,,Homo sapiens,9606.0,,
3530,,,BAO_0000357,,,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,
3531,,,BAO_0000357,,,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,
3532,,,BAO_0000019,,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,
3533,,,BAO_0000019,,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,
3534,,,BAO_0000019,,,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,
3535,,,BAO_0000019,,,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,
3536,,,BAO_0000219,,449.0,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,Homo sapiens,9606.0,,
3537,,,BAO_0000019,,,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,Homo sapiens,9606.0,,
3538,,,BAO_0000249,,,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,Homo sapiens,9606.0,,
3539,,,BAO_0000357,,,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,
3540,,,BAO_0000249,,,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,
3541,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,Striatum
3542,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,Striatum
3543,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,Striatum
3544,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,Striatum
3545,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,Striatum
3546,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,Striatum
3547,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,Striatum
3548,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,Striatum
3549,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,Striatum
3550,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,Striatum
3551,,,BAO_0000019,2435.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,Striatum
3552,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,Limbic system
3553,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,Limbic system
3554,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,Limbic system
3555,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,Limbic system
3556,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,Limbic system
3557,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,Limbic system
3558,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,Limbic system
3559,,,BAO_0000357,,,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,
3560,,,BAO_0000019,,,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,
3561,,,BAO_0000357,,,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,
3562,,,BAO_0000357,,,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,
3563,,,BAO_0000357,,,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,
3564,,,BAO_0000357,,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,
3565,,,BAO_0000357,,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,
3566,,,BAO_0000357,,,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,
3567,,,BAO_0000219,,643.0,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,
3568,,,BAO_0000219,,643.0,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,
3569,,,BAO_0000219,,643.0,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,
3570,,,BAO_0000219,,643.0,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,
3571,,,BAO_0000219,,673.0,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,
3572,,,BAO_0000219,,673.0,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,
3573,,,BAO_0000219,,673.0,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,
3574,,,BAO_0000219,,673.0,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,
3575,,,BAO_0000357,,,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,
3576,,,BAO_0000357,,,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,
3577,,,BAO_0000357,,,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,9606.0,,
3578,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,
3579,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,Homo sapiens,9606.0,,
3580,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,9606.0,,
3581,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,Homo sapiens,9606.0,,
3582,,,BAO_0000357,,,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,9606.0,,
3583,,,BAO_0000357,,,6013,Binding affinity towards 5-HT5A receptor,B,,,,,
3584,,,BAO_0000357,,,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,
3585,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,
3586,,,BAO_0000357,,,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,
3587,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
3588,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,
3589,,,BAO_0000219,,722.0,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,
3590,,,BAO_0000357,,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,Mus musculus,10090.0,,
3591,,,BAO_0000357,,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,Mus musculus,10090.0,,
3592,,,BAO_0000357,,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,Mus musculus,10090.0,,
3593,,,BAO_0000357,,,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,Mus musculus,10090.0,,
3594,,,BAO_0000357,,,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,Mus musculus,10090.0,,
3595,,,BAO_0000357,,,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,
3596,,,BAO_0000219,,722.0,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,
3597,,,BAO_0000219,,722.0,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,
3598,,,BAO_0000357,,,4820,Binding affinity towards 5-HT5a receptor,B,,,,,
3599,,,BAO_0000357,,,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,Homo sapiens,9606.0,,
3600,,,BAO_0000357,,,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,
3601,,,BAO_0000357,,,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,
3602,,,BAO_0000357,,,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,
3603,,,BAO_0000357,,,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,
3604,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,
3605,,,BAO_0000019,,,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,Cavia porcellus,10141.0,,
3606,,,BAO_0000223,,,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,
3607,,,BAO_0000357,,,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,9606.0,,
3608,,,BAO_0000357,,,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,Homo sapiens,9606.0,,
3609,,,BAO_0000357,,,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,
3610,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,Homo sapiens,9606.0,,
3611,,,BAO_0000219,,308.0,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,
3612,,,BAO_0000357,,,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,9606.0,,
3613,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,9606.0,,
3614,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,Homo sapiens,9606.0,,
3615,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,Homo sapiens,9606.0,,
3616,,,BAO_0000357,,,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,9606.0,,
3617,,,BAO_0000357,,,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3618,,,BAO_0000357,,,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3619,,,BAO_0000219,,722.0,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,
3620,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,
3621,,,BAO_0000219,,722.0,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,
3622,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3623,,,BAO_0000219,,722.0,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,Homo sapiens,9606.0,,
3624,,,BAO_0000019,,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,
3625,,,BAO_0000019,,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,
3626,,,BAO_0000219,,643.0,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,
3627,,,BAO_0000357,,,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,9606.0,,
3628,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,
3629,,,BAO_0000357,,,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,
3630,,,BAO_0000219,,722.0,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,
3631,,,BAO_0000019,,,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,
3632,,,BAO_0000357,,,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,
3633,,,BAO_0000357,,,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,
3634,,,BAO_0000219,,308.0,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,Homo sapiens,9606.0,,
3635,,,BAO_0000219,,308.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,Homo sapiens,9606.0,,
3636,,,BAO_0000219,,308.0,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,
3637,,,BAO_0000219,,308.0,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,
3638,,,BAO_0000219,,308.0,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,
3639,,,BAO_0000219,,449.0,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,
3640,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,
3641,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,
3642,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,
3643,,,BAO_0000219,,308.0,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,
3644,,,BAO_0000357,,,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3645,,,BAO_0000219,,308.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,
3646,,,BAO_0000357,,,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,
3647,,,BAO_0000357,,,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,
3648,,,BAO_0000219,,308.0,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,
3649,,,BAO_0000357,,,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,
3650,,,BAO_0000219,,,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,
3651,,,BAO_0000219,,308.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,
3652,,,BAO_0000219,,308.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,
3653,,,BAO_0000219,,308.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,
3654,,,BAO_0000219,,308.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,
3655,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,
3656,,,BAO_0000019,,,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,
3657,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,
3658,,,BAO_0000357,,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,
3659,,,BAO_0000219,,308.0,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,Homo sapiens,9606.0,,
3660,,,BAO_0000357,,,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3661,,,BAO_0000357,,,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,
3662,,,BAO_0000019,,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,Homo sapiens,9606.0,,
3663,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,
3664,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,
3665,,,BAO_0000357,,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,
3666,,,BAO_0000357,,,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,
3667,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,
3668,,,BAO_0000019,,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,
3669,,,BAO_0000019,,,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,
3670,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,
3671,,,BAO_0000357,,,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,
3672,,,BAO_0000357,,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,
3673,,,BAO_0000357,,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,
3674,,,BAO_0000357,,,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,
3675,,,BAO_0000357,,,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,
3676,,,BAO_0000357,,,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,Homo sapiens,9606.0,,
3677,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,
3678,,,BAO_0000357,,,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,
3679,,,BAO_0000357,,,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,
3680,,,BAO_0000357,,,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,9606.0,,
3681,,,BAO_0000219,,722.0,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,
3682,,,BAO_0000357,,,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,
3683,,,BAO_0000357,,,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,
3684,,,BAO_0000219,,722.0,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,
3685,,,BAO_0000357,,,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,Homo sapiens,9606.0,,
3686,,,BAO_0000219,,449.0,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,
3687,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,9606.0,,
3688,,,BAO_0000357,,,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,9606.0,,
3689,,,BAO_0000357,,,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,9606.0,,
3690,,,BAO_0000219,,449.0,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,
3691,,,BAO_0000357,,,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,
3692,,,BAO_0000357,,,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,
3693,,,BAO_0000357,,,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,
3694,,,BAO_0000357,,,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,
3695,,,BAO_0000357,,,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,
3696,,,BAO_0000219,,722.0,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,
3697,,,BAO_0000019,,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,
3698,,,BAO_0000019,,,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,
3699,,,BAO_0000357,,,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,9606.0,,
3700,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,
3701,,,BAO_0000357,,,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,
3702,,,BAO_0000219,,449.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,
3703,,,BAO_0000019,,,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,
3704,,,BAO_0000357,,,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,
3705,,,BAO_0000357,,,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,
3706,,,BAO_0000219,,643.0,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,Homo sapiens,9606.0,,
3707,,,BAO_0000219,,643.0,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,
3708,,,BAO_0000219,,722.0,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,Homo sapiens,9606.0,,
3709,,,BAO_0000357,,,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,
3710,,,BAO_0000219,,722.0,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,
3711,,,BAO_0000357,,,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,
3712,,,BAO_0000357,,,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,
3713,,,BAO_0000219,,,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,
3714,,,BAO_0000219,,722.0,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,
3715,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3716,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3717,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3718,,,BAO_0000219,,722.0,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,
3719,,,BAO_0000219,,449.0,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,
3720,,,BAO_0000219,,722.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,
3721,,,BAO_0000219,,722.0,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,
3722,,,BAO_0000219,,722.0,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,
3723,,,BAO_0000219,,722.0,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,
3724,,,BAO_0000357,,,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,
3725,,,BAO_0000219,,643.0,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,
3726,,,BAO_0000219,,722.0,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,
3727,,,BAO_0000219,,722.0,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,
3728,,,BAO_0000219,,722.0,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,
3729,,,BAO_0000219,,722.0,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,Homo sapiens,9606.0,,
3730,,,BAO_0000219,,722.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,
3731,,,BAO_0000219,,722.0,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,
3732,,,BAO_0000219,,722.0,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,
3733,,,BAO_0000357,,,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,Homo sapiens,9606.0,,
3734,,,BAO_0000357,,,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,Mus musculus,10090.0,,
3735,,,BAO_0000019,,,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,Oryctolagus cuniculus,9986.0,,
3736,,,BAO_0000219,,449.0,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,
3737,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,
3738,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,
3739,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,
3740,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,
3741,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,
3742,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,
3743,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,
3744,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,
3745,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,
3746,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,
3747,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,
3748,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,
3749,,,BAO_0000357,,,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,
3750,,,BAO_0000357,,,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,Rattus norvegicus,10116.0,,
3751,,,BAO_0000357,,,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,
3752,,,BAO_0000019,,,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,
3753,,,BAO_0000357,,,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,Rattus norvegicus,10116.0,,
3754,,,BAO_0000357,,,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,Rattus norvegicus,10116.0,,
3755,,,BAO_0000219,,449.0,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,Rattus norvegicus,10116.0,,
3756,,,BAO_0000357,,,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,
3757,,,BAO_0000357,,,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,
3758,,,BAO_0000219,,449.0,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,
3759,,,BAO_0000219,,449.0,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,
3760,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,
3761,,,BAO_0000219,,449.0,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,
3762,,,BAO_0000221,2116.0,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,Ileum
3763,,,BAO_0000221,2116.0,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,Ileum
3764,,,BAO_0000221,2116.0,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,Ileum
3765,Membranes,,BAO_0000249,,,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,Rattus norvegicus,10116.0,,
3766,,,BAO_0000357,,,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3767,,,BAO_0000357,,,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,
3768,,,BAO_0000019,1898.0,,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,Hypothalamus
3769,,,BAO_0000357,,,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,
3770,,,BAO_0000249,1898.0,,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,Hypothalamus
3771,,,BAO_0000357,,,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,
3772,,,BAO_0000219,,722.0,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,Rattus norvegicus,10116.0,,
3773,,,BAO_0000219,,722.0,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,Rattus norvegicus,10116.0,,
3774,,,BAO_0000219,,722.0,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,Rattus norvegicus,10116.0,,
3775,,,BAO_0000357,,,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,
3776,,,BAO_0000357,,,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,
3777,,,BAO_0000357,,,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,
3778,,,BAO_0000357,,,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,Homo sapiens,9606.0,,
3779,,,BAO_0000357,,,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,
3780,,,BAO_0000357,,,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,
3781,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3782,,,BAO_0000019,,,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,
3783,,,BAO_0000357,,,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3784,,,BAO_0000357,,,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,
3785,,,BAO_0000357,,,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,
3786,,,BAO_0000357,,,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,
3787,,,BAO_0000357,,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,
3788,,,BAO_0000357,,,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,
3789,,,BAO_0000357,,,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,
3790,,,BAO_0000357,,,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,
3791,,,BAO_0000357,,,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,
3792,,,BAO_0000357,,,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,
3793,,,BAO_0000221,2116.0,,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,Ileum
3794,,,BAO_0000019,,,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,
3795,,,BAO_0000019,,,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,Homo sapiens,9606.0,,
3796,,,BAO_0000357,,,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,
3797,,,BAO_0000357,,,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,
3798,,,BAO_0000357,,,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,
3799,,,BAO_0000357,178.0,,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,Blood
3800,,,BAO_0000357,178.0,,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,Blood
3801,,,BAO_0000357,,,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,
3802,,,BAO_0000357,,,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,
3803,,,BAO_0000219,,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,
3804,,,BAO_0000019,178.0,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,Blood
3805,,,BAO_0000357,,,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,
3806,,,BAO_0000357,,,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,
3807,,,BAO_0000357,,,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,
3808,,,BAO_0000357,,,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,
3809,,,BAO_0000357,178.0,,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,Homo sapiens,9606.0,,Blood
3810,,,BAO_0000357,,,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,
3811,,,BAO_0000019,,,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,Homo sapiens,9606.0,,
3812,,,BAO_0000019,178.0,,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,Blood
3813,,,BAO_0000019,,,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,
3814,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,
3815,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,
3816,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,
3817,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,
3818,,,BAO_0000219,,,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,
3819,,,BAO_0000357,,,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,
3820,,,BAO_0000019,,,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,
3821,,,BAO_0000357,178.0,,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,Blood
3822,,,BAO_0000357,,,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,
3823,,,BAO_0000219,,,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,
3824,,,BAO_0000357,,,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,
3825,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,
3826,,,BAO_0000357,,,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,
3827,,,BAO_0000357,,,12780,Tested against 5-lipoxygenase,B,,,,,
3828,,,BAO_0000357,,,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,
3829,,,BAO_0000357,,,12780,Tested for activity against 5-lipoxygenase,B,,,,,
3830,,,BAO_0000357,,,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,
3831,,,BAO_0000019,,,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,
3832,,,BAO_0000357,,,13165,Inhibition of Human 5-lipoxygenase,B,,,,,
3833,,,BAO_0000019,,,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,
3834,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,
3835,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,
3836,,,BAO_0000019,,,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,
3837,,,BAO_0000019,,,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,
3838,,,BAO_0000357,178.0,,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,Blood
3839,,,BAO_0000357,,,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,
3840,,,BAO_0000357,,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,
3841,,,BAO_0000019,,,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,
3842,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,
3843,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,
3844,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,
3845,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,
3846,,,BAO_0000219,,,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,
3847,,,BAO_0000357,,,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,
3848,,,BAO_0000357,,,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,
3849,,,BAO_0000357,,,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,
3850,,,BAO_0000357,,,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,
3851,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,
3852,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,
3853,,,BAO_0000019,,,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,
3854,,,BAO_0000019,,,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,
3855,,,BAO_0000357,,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,
3856,,,BAO_0000357,,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,
3857,,,BAO_0000019,,,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,
3858,,,BAO_0000357,,,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,
3859,,,BAO_0000357,,,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,
3860,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,
3861,,,BAO_0000357,,,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,Homo sapiens,9606.0,,
3862,,,BAO_0000357,,,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,
3863,,,BAO_0000357,,,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,
3864,,,BAO_0000357,,,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,
3865,,,BAO_0000357,,,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,
3866,,,BAO_0000357,,,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,Mus musculus,10090.0,,
3867,,,BAO_0000357,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,
3868,,,BAO_0000019,,,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,Sus scrofa,9823.0,,
3869,,,BAO_0000019,,,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,Sus scrofa,9823.0,,
3870,,,BAO_0000019,,,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,Oryctolagus cuniculus,9986.0,,
3871,,,BAO_0000019,,,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,Rattus norvegicus,10116.0,,
3872,,,BAO_0000019,,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,
3873,,,BAO_0000019,,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,
3874,,,BAO_0000019,,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,
3875,,,BAO_0000019,,,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,
3876,,,BAO_0000019,,,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,
3877,,,BAO_0000019,,,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,
3878,,,BAO_0000019,,,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,
3879,,,BAO_0000019,,,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,
3880,,,BAO_0000219,,702.0,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,
3881,,,BAO_0000219,,702.0,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,
3882,,,BAO_0000357,,,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,
3883,,,BAO_0000357,,,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,
3884,,,BAO_0000357,,,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,
3885,,,BAO_0000357,,,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,
3886,,,BAO_0000019,,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,
3887,,,BAO_0000019,,,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,
3888,,,BAO_0000219,,663.0,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,Rattus norvegicus,10116.0,,
3889,,,BAO_0000357,,,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,
3890,,,BAO_0000357,,,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,
3891,,,BAO_0000219,,702.0,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,
3892,,,BAO_0000219,,702.0,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,Rattus norvegicus,10116.0,,
3893,,,BAO_0000357,,,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,
3894,,,BAO_0000219,,702.0,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,
3895,,,BAO_0000219,,702.0,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,
3896,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,
3897,,,BAO_0000219,,702.0,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,
3898,,,BAO_0000357,,,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,
3899,,,BAO_0000357,,,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,
3900,,,BAO_0000357,,,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,
3901,,,BAO_0000019,,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,
3902,,,BAO_0000019,,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,
3903,,,BAO_0000019,,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,
3904,,,BAO_0000019,,,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,
3905,,,BAO_0000219,,702.0,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,
3906,,,BAO_0000219,,702.0,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,
3907,,,BAO_0000219,,702.0,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,
3908,,,BAO_0000019,,,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,
3909,,,BAO_0000357,,,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,Rattus norvegicus,10116.0,,
3910,,,BAO_0000219,,702.0,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,
3911,,,BAO_0000219,,702.0,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,
3912,,,BAO_0000219,,702.0,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,
3913,,,BAO_0000218,,,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,
3914,,,BAO_0000357,,,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,
3915,,,BAO_0000218,,,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,
3916,,,BAO_0000219,,702.0,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,
3917,,,BAO_0000019,178.0,,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,Blood
3918,,,BAO_0000357,,,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,
3919,,,BAO_0000019,,,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,
3920,,,BAO_0000219,,,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,
3921,,,BAO_0000219,,702.0,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,
3922,,,BAO_0000357,,,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,
3923,,,BAO_0000219,,702.0,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,
3924,,,BAO_0000219,,702.0,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,
3925,,,BAO_0000219,,702.0,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,
3926,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,
3927,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,
3928,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,
3929,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,
3930,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,
3931,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,
3932,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,
3933,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,
3934,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,
3935,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,
3936,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,
3937,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,
3938,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,
3939,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,
3940,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,
3941,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,
3942,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,
3943,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,
3944,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,
3945,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,
3946,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,
3947,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,
3948,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,
3949,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,
3950,,,BAO_0000019,,,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,
3951,,,BAO_0000019,,,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,
3952,,,BAO_0000219,,663.0,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,
3953,,,BAO_0000219,,663.0,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,
3954,,,BAO_0000219,,702.0,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,Rattus norvegicus,10116.0,,
3955,,,BAO_0000019,,,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,
3956,,,BAO_0000019,,,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,
3957,,,BAO_0000219,,702.0,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,Rattus norvegicus,10116.0,,
3958,,,BAO_0000219,,702.0,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,
3959,,,BAO_0000357,,,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,
3960,,,BAO_0000219,,702.0,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,
3961,,,BAO_0000219,,702.0,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,
3962,,,BAO_0000019,,,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,Rattus norvegicus,10116.0,,
3963,,,BAO_0000219,,702.0,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,
3964,,,BAO_0000019,,,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,
3965,,,BAO_0000219,,702.0,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,
3966,,,BAO_0000357,,,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,
3967,,,BAO_0000219,,702.0,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,Rattus norvegicus,10116.0,,
3968,,,BAO_0000219,,702.0,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,Rattus norvegicus,10116.0,,
3969,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,
3970,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,
3971,,,BAO_0000219,,702.0,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,Rattus norvegicus,10116.0,,
3972,,,BAO_0000219,,702.0,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
3973,,,BAO_0000019,349.0,,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,Limbic system
3974,,,BAO_0000019,349.0,,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,Limbic system
3975,,,BAO_0000019,,,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,
3976,,,BAO_0000221,10000000.0,,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,Hippocampus
3977,,,BAO_0000221,10000000.0,,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,Hippocampus
3978,,,BAO_0000019,,,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,
3979,,,BAO_0000019,178.0,,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,Canis lupus familiaris,9615.0,,Blood
3980,,,BAO_0000019,178.0,,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,Blood
3981,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,
3982,,,BAO_0000219,,,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,
3983,,,BAO_0000219,,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,
3984,,,BAO_0000219,,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,
3985,,,BAO_0000219,,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,
3986,,,BAO_0000219,,,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,
3987,,,BAO_0000357,,,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,
3988,,,BAO_0000357,,,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,
3989,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3990,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3991,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3992,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3993,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3994,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3995,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3996,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3997,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3998,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
3999,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4000,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4001,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4002,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4003,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4004,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4005,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4006,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4007,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4008,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4009,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4010,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4011,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4012,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4013,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4014,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4015,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4016,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4017,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4018,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4019,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4020,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4021,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4022,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4023,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4024,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4025,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4026,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4027,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4028,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4029,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4030,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4031,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4032,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4033,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4034,,In vivo,BAO_0000218,178.0,,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,,Canis lupus familiaris,9615.0,,Blood
4035,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,Canis lupus familiaris,9615.0,,
4036,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,Canis lupus familiaris,9615.0,,
4037,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,Canis lupus familiaris,9615.0,,
4038,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,Canis lupus familiaris,9615.0,,
4039,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,Canis lupus familiaris,9615.0,,
4040,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,Canis lupus familiaris,9615.0,,
4041,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,Canis lupus familiaris,9615.0,,
4042,,,BAO_0000218,,,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,Canis lupus familiaris,9615.0,,
4043,,,BAO_0000357,,,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,Cavia porcellus,10141.0,,
4044,,,BAO_0000357,,,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,Cavia porcellus,10141.0,,
4045,,,BAO_0000357,,,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,Cavia porcellus,10141.0,,
4046,,,BAO_0000218,178.0,,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,Cavia porcellus,10141.0,,Blood
4047,,,BAO_0000357,,,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,Cavia porcellus,10141.0,,
4048,,,BAO_0000357,,,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,Cavia porcellus,10141.0,,
4049,,,BAO_0000019,,,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,Cavia porcellus,10141.0,,
4050,,,BAO_0000019,,,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,Cavia porcellus,10141.0,,
4051,,,BAO_0000019,,,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,Cavia porcellus,10141.0,,
4052,,,BAO_0000019,,,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,Cavia porcellus,10141.0,,
4053,,,BAO_0000357,,,7788,Inhibitory activity against 5-lipoxygenase,B,,Cavia porcellus,10141.0,,
4054,,,BAO_0000357,,,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,Cavia porcellus,10141.0,,
4055,,,BAO_0000357,,,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,Cavia porcellus,10141.0,,
4056,,,BAO_0000357,,,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,Cavia porcellus,10141.0,,
4057,,,BAO_0000357,,,13243,Inhibitory activity uM,B,,Cavia porcellus,10141.0,,
4058,,,BAO_0000219,,,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,Cavia porcellus,10141.0,,
4059,,,BAO_0000357,,,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,Cavia porcellus,10141.0,,
4060,,,BAO_0000357,,,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,Cavia porcellus,10141.0,,
4061,,,BAO_0000357,,,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,Cavia porcellus,10141.0,,
4062,,,BAO_0000357,,,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,Cavia porcellus,10141.0,,
4063,,,BAO_0000357,,,13243,Inhibitory activity uM,B,,Cavia porcellus,10141.0,,
4064,,,BAO_0000357,,,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,Cavia porcellus,10141.0,,
4065,,,BAO_0000357,,,13243,Inhibitory activity uM,B,,Cavia porcellus,10141.0,,
4066,,,BAO_0000019,,,13243,Inhibitory activity uM,F,,Cavia porcellus,10141.0,,
4067,,,BAO_0000019,,,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,Cavia porcellus,10141.0,,
4068,,,BAO_0000357,,,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,Cavia porcellus,10141.0,,
4069,,,BAO_0000221,2116.0,,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,Cavia porcellus,10141.0,,Ileum
4070,,,BAO_0000357,,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,
4071,,,BAO_0000357,,,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,
4072,,,BAO_0000357,,,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,
4073,,,BAO_0000357,,,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,
4074,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,Rattus norvegicus,10116.0,,Liver
4075,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,Rattus norvegicus,10116.0,,Liver
4076,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,Rattus norvegicus,10116.0,,Liver
4077,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,Rattus norvegicus,10116.0,,Liver
4078,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,Rattus norvegicus,10116.0,,Liver
4079,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,Rattus norvegicus,10116.0,,Liver
4080,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,Rattus norvegicus,10116.0,,Liver
4081,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,Rattus norvegicus,10116.0,,Liver
4082,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,Rattus norvegicus,10116.0,,Liver
4083,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,Rattus norvegicus,10116.0,,Liver
4084,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,Rattus norvegicus,10116.0,,Liver
4085,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,Rattus norvegicus,10116.0,,Liver
4086,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,Rattus norvegicus,10116.0,,Liver
4087,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4088,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,Rattus norvegicus,10116.0,,Liver
4089,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,10116.0,,Liver
4090,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,Rattus norvegicus,10116.0,,Liver
4091,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,Rattus norvegicus,10116.0,,Liver
4092,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,Rattus norvegicus,10116.0,,Liver
4093,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,10116.0,,Liver
4094,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4095,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,Rattus norvegicus,10116.0,,Liver
4096,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4097,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,Rattus norvegicus,10116.0,,Liver
4098,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,Rattus norvegicus,10116.0,,Liver
4099,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,Rattus norvegicus,10116.0,,Liver
4100,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,Rattus norvegicus,10116.0,,Liver
4101,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,10116.0,,Liver
4102,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,Rattus norvegicus,10116.0,,Liver
4103,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4104,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,Rattus norvegicus,10116.0,,Liver
4105,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,Rattus norvegicus,10116.0,,Liver
4106,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,Rattus norvegicus,10116.0,,Liver
4107,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,Rattus norvegicus,10116.0,,Liver
4108,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,Rattus norvegicus,10116.0,,Liver
4109,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,Rattus norvegicus,10116.0,,Liver
4110,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,Rattus norvegicus,10116.0,,Liver
4111,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,Rattus norvegicus,10116.0,,Liver
4112,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,Rattus norvegicus,10116.0,,Liver
4113,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,Rattus norvegicus,10116.0,,Liver
4114,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4115,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,Rattus norvegicus,10116.0,,Liver
4116,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,Rattus norvegicus,10116.0,,Liver
4117,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,Rattus norvegicus,10116.0,,Liver
4118,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,Rattus norvegicus,10116.0,,Liver
4119,Microsomes,,BAO_0000251,2107.0,,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,Rattus norvegicus,10116.0,,Liver
4120,Microsomes,,BAO_0000251,2107.0,,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4121,Microsomes,,BAO_0000251,,,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,Rattus norvegicus,10116.0,,
4122,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,Rattus norvegicus,10116.0,,Liver
4123,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,Rattus norvegicus,10116.0,,Liver
4124,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,Rattus norvegicus,10116.0,,Liver
4125,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,Rattus norvegicus,10116.0,,Liver
4126,Microsomes,,BAO_0000251,2107.0,,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,Rattus norvegicus,10116.0,,Liver
4127,,,BAO_0000219,,741.0,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,Homo sapiens,9606.0,,
4128,,,BAO_0000219,,993.0,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,Homo sapiens,9606.0,,
4129,,,BAO_0000219,,391.0,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,Homo sapiens,9606.0,,
4130,,,BAO_0000219,,391.0,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,Homo sapiens,9606.0,,
4131,,,BAO_0000219,,505.0,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,Cricetulus griseus,10029.0,,
4132,,,BAO_0000219,,505.0,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,Cricetulus griseus,10029.0,,
4133,,,BAO_0000219,,1119.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,Rattus norvegicus,10116.0,,
4134,,,BAO_0000219,,1119.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,Rattus norvegicus,10116.0,,
4135,,,BAO_0000219,,1119.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,Rattus norvegicus,10116.0,,
4136,,,BAO_0000219,,1119.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,Rattus norvegicus,10116.0,,
4137,,,BAO_0000219,,1119.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,Rattus norvegicus,10116.0,,
4138,,,BAO_0000219,,1119.0,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,Rattus norvegicus,10116.0,,
4139,,,BAO_0000219,,391.0,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,Homo sapiens,9606.0,,
4140,,,BAO_0000219,,391.0,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,Homo sapiens,9606.0,,
4141,,,BAO_0000219,,391.0,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,Homo sapiens,9606.0,,
4142,,,BAO_0000219,,391.0,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,Homo sapiens,9606.0,,
4143,,,BAO_0000219,,391.0,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,Homo sapiens,9606.0,,
4144,,,BAO_0000219,,391.0,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,Homo sapiens,9606.0,,
4145,,,BAO_0000219,,391.0,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,Homo sapiens,9606.0,,
4146,,,BAO_0000219,,391.0,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,Homo sapiens,9606.0,,
4147,,,BAO_0000219,,391.0,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,Homo sapiens,9606.0,,
4148,,,BAO_0000219,,391.0,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
4149,,,BAO_0000219,,391.0,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,Homo sapiens,9606.0,,
4150,,,BAO_0000219,,391.0,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,Homo sapiens,9606.0,,
4151,,,BAO_0000219,,391.0,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,Homo sapiens,9606.0,,
4152,,,BAO_0000219,,391.0,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,Homo sapiens,9606.0,,
4153,,,BAO_0000219,,391.0,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,Homo sapiens,9606.0,,
4154,,,BAO_0000219,,391.0,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,Homo sapiens,9606.0,,
4155,,,BAO_0000219,,391.0,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,Homo sapiens,9606.0,,
4156,,,BAO_0000219,,702.0,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,
4157,,,BAO_0000219,,702.0,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,
4158,,,BAO_0000019,,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,
4159,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,
4160,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,
4161,,,BAO_0000357,,,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,
4162,,,BAO_0000219,,,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,
4163,,,BAO_0000219,,702.0,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,
4164,,,BAO_0000357,,,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,
4165,,,BAO_0000357,,,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,
4166,,,BAO_0000357,,,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,
4167,,,BAO_0000357,,,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,
4168,,,BAO_0000357,,,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,
4169,,,BAO_0000019,,,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,Rattus norvegicus,10116.0,,
4170,,,BAO_0000219,,702.0,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,
4171,,,BAO_0000357,,,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,
4172,,,BAO_0000357,,,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,
4173,,,BAO_0000357,,,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,
4174,,,BAO_0000019,,,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,
4175,,,BAO_0000219,,702.0,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,
4176,,,BAO_0000019,,,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,
4177,,,BAO_0000219,,702.0,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,
4178,,,BAO_0000357,,,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,
4179,,,BAO_0000357,,,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,
4180,,,BAO_0000019,,,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,
4181,,,BAO_0000019,,,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,
4182,,,BAO_0000219,,702.0,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,
4183,,,BAO_0000219,,702.0,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,
4184,,,BAO_0000219,,702.0,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,
4185,,,BAO_0000219,,702.0,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,
4186,,,BAO_0000218,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,
4187,,,BAO_0000219,,702.0,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,
4188,,,BAO_0000219,,702.0,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,
4189,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,
4190,,,BAO_0000219,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,
4191,,In vivo,BAO_0000218,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,,,,,
4192,,,BAO_0000219,,663.0,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,
4193,,,BAO_0000219,,663.0,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,
4194,,,BAO_0000019,,,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,
4195,,,BAO_0000019,,,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,
4196,,,BAO_0000019,,,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,
4197,,,BAO_0000019,,,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,
4198,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,
4199,,,BAO_0000219,,702.0,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,
4200,,,BAO_0000357,,,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,Rattus norvegicus,10116.0,,
4201,,,BAO_0000219,,702.0,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,
4202,,,BAO_0000219,,702.0,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,
4203,,,BAO_0000357,,,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,
4204,,,BAO_0000219,,702.0,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,
4205,,,BAO_0000219,,702.0,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,
4206,,,BAO_0000219,,702.0,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,
4207,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,
4208,,,BAO_0000219,,702.0,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,Rattus norvegicus,10116.0,,
4209,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,
4210,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,
4211,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,
4212,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,
4213,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,
4214,,,BAO_0000219,,702.0,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,
4215,,,BAO_0000357,,,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,Rattus norvegicus,10116.0,,
4216,,,BAO_0000357,,,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,
4217,,,BAO_0000357,,,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,
4218,,,BAO_0000219,,702.0,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,
4219,,,BAO_0000219,,702.0,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,
4220,,,BAO_0000219,,702.0,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,
4221,,,BAO_0000219,,702.0,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,
4222,,,BAO_0000219,,702.0,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,
4223,,,BAO_0000019,,,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,
4224,,,BAO_0000357,,,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,
4225,,,BAO_0000357,,,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,
4226,,,BAO_0000219,,702.0,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,
4227,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,
4228,,,BAO_0000219,,702.0,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,
4229,,,BAO_0000219,,702.0,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,
4230,,,BAO_0000219,,702.0,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,
4231,,,BAO_0000219,,702.0,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
4232,,,BAO_0000219,,702.0,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,Rattus norvegicus,10116.0,,
4233,,,BAO_0000019,,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,
4234,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,
4235,,,BAO_0000219,,702.0,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,
4236,,,BAO_0000219,,702.0,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
4237,,,BAO_0000219,,702.0,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,
4238,,,BAO_0000019,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,
4239,,,BAO_0000019,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,
4240,,,BAO_0000019,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,
4241,,,BAO_0000019,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,
4242,,,BAO_0000357,,,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,
4243,,,BAO_0000357,,,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,
4244,,,BAO_0000019,,,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,
4245,,,BAO_0000219,,702.0,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,
4246,,,BAO_0000219,,702.0,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,
4247,,,BAO_0000219,,663.0,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,
4248,,,BAO_0000219,,663.0,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,
4249,,,BAO_0000219,,663.0,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,
4250,,,BAO_0000019,,,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,
4251,,,BAO_0000357,,,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,
4252,,,BAO_0000219,,663.0,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,
4253,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,
4254,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,
4255,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,
4256,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,
4257,,,BAO_0000019,,,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,
4258,,,BAO_0000219,,702.0,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,
4259,,,BAO_0000219,,702.0,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,
4260,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,
4261,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,
4262,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,
4263,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,
4264,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,
4265,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,
4266,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,
4267,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,
4268,,,BAO_0000219,,702.0,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,
4269,,,BAO_0000019,,,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,Rattus norvegicus,10116.0,,
4270,,,BAO_0000357,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,
4271,,,BAO_0000357,,,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,
4272,,,BAO_0000219,,702.0,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,
4273,,,BAO_0000219,,702.0,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,
4274,,,BAO_0000219,,702.0,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,
4275,,,BAO_0000219,,702.0,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,
4276,,,BAO_0000219,,702.0,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,
4277,,,BAO_0000019,,,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,
4278,,,BAO_0000219,,702.0,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,
4279,,,BAO_0000219,,702.0,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,
4280,,,BAO_0000219,,702.0,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,
4281,,,BAO_0000219,,702.0,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,
4282,,,BAO_0000219,,702.0,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,
4283,,,BAO_0000219,,,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,
4284,,,BAO_0000219,,702.0,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,Homo sapiens,9606.0,,
4285,,,BAO_0000219,,702.0,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,Rattus norvegicus,10116.0,,
4286,,,BAO_0000219,,702.0,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,Rattus norvegicus,10116.0,,
4287,,,BAO_0000019,,,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,Rattus norvegicus,10116.0,,
4288,,,BAO_0000357,,,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,Glycine max,3847.0,,
4289,,,BAO_0000019,,,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,
4290,,,BAO_0000357,,,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,
4291,,,BAO_0000357,,,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,
4292,,,BAO_0000357,,,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,
4293,,,BAO_0000219,,702.0,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,
4294,,,BAO_0000357,,,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,
4295,,,BAO_0000357,,,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,
4296,,,BAO_0000357,,,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,
4297,,,BAO_0000357,,,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,
4298,,,BAO_0000019,,,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,
4299,,,BAO_0000357,,,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,
4300,,,BAO_0000357,,,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,
4301,,,BAO_0000357,,,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,
4302,,,BAO_0000357,,,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,
4303,,,BAO_0000357,,,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,
4304,,,BAO_0000219,,702.0,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,
4305,,,BAO_0000357,,,11089,,B,,,,,
4306,,,BAO_0000357,,,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,
4307,,,BAO_0000019,,,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,
4308,,,BAO_0000357,,,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,
4309,,,BAO_0000357,,,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,
4310,,,BAO_0000357,,,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,
4311,,,BAO_0000357,,,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,
4312,,,BAO_0000357,,,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,
4313,,,BAO_0000357,,,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,
4314,,,BAO_0000019,,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,
4315,,,BAO_0000019,,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,
4316,,,BAO_0000019,,,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,
4317,,,BAO_0000220,,,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,
4318,,,BAO_0000019,,,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,Homo sapiens,9606.0,,
4319,,,BAO_0000219,,390.0,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,Homo sapiens,9606.0,,
4320,,,BAO_0000219,,345.0,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,Homo sapiens,9606.0,,
4321,,,BAO_0000219,,345.0,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,Homo sapiens,9606.0,,
4322,,,BAO_0000219,,345.0,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,Homo sapiens,9606.0,,
4323,,,BAO_0000219,,345.0,17589,Growth inhibition against human 5637 cell lines,F,,Homo sapiens,9606.0,,
4324,,,BAO_0000219,,345.0,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,Homo sapiens,9606.0,,
4325,,,BAO_0000219,,345.0,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,Homo sapiens,9606.0,,
4326,,,BAO_0000219,,345.0,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,Homo sapiens,9606.0,,
4327,,,BAO_0000357,,,15285,In vitro inhibition of bovine trypsin(Trp).,B,,Bos taurus,9913.0,,
4328,,,BAO_0000219,,407.0,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,Cercopithecidae,9527.0,,
4329,,,BAO_0000357,,,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,
4330,,,BAO_0000019,,,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,
4331,,In vivo,BAO_0000218,,,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,,,,,
4332,,,BAO_0000357,,,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,Cavia porcellus,10141.0,,
4333,Microsomes,,BAO_0000251,,,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,Rattus norvegicus,10116.0,,
4334,Microsomes,,BAO_0000251,,,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,Rattus norvegicus,10116.0,,
4335,,,BAO_0000019,,,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,
4336,,,BAO_0000019,,,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,
4337,,,BAO_0000019,,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,Trypanosoma brucei,5691.0,,
4338,,,BAO_0000019,,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,Trypanosoma brucei,5691.0,,
4339,,,BAO_0000019,,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,Ovis aries,9940.0,,
4340,,,BAO_0000019,,,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,Ovis aries,9940.0,,
4341,,,BAO_0000357,,,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,
4342,,,BAO_0000019,,,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,Homo sapiens,9606.0,,
4343,,,BAO_0000019,,,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,Homo sapiens,9606.0,,
4344,,,BAO_0000219,,542.0,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,Homo sapiens,9606.0,,
4345,,,BAO_0000219,,542.0,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,Homo sapiens,9606.0,,
4346,,,BAO_0000219,,542.0,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,
4347,,,BAO_0000219,,542.0,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,
4348,,,BAO_0000219,,542.0,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,
4349,,,BAO_0000219,,542.0,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,
4350,,,BAO_0000019,,,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,
4351,,,BAO_0000019,,,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,
4352,,,BAO_0000357,,,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,
4353,,,BAO_0000218,,,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,Plasmodium falciparum,5833.0,,
4354,,,BAO_0000218,,,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,Plasmodium falciparum,5833.0,,
4355,,,BAO_0000218,,,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,Plasmodium falciparum,5833.0,,
4356,,,BAO_0000218,,,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,Plasmodium falciparum,5833.0,,
4357,,,BAO_0000218,,,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,Plasmodium falciparum,5833.0,,
4358,,,BAO_0000218,,850.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4359,,,BAO_0000218,,850.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4360,,,BAO_0000218,,850.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4361,,,BAO_0000218,,850.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4362,,,BAO_0000218,,850.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4363,,,BAO_0000218,,850.0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4364,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,,Mus musculus,10090.0,,
4365,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,,Mus musculus,10090.0,,
4366,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,,Mus musculus,10090.0,,
4367,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,,Mus musculus,10090.0,,
4368,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,,Mus musculus,10090.0,,
4369,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,,Mus musculus,10090.0,,
4370,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,,Mus musculus,10090.0,,
4371,,In vivo,BAO_0000218,,,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,,Mus musculus,10090.0,,
4372,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,,Mus musculus,10090.0,,
4373,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,,Mus musculus,10090.0,,
4374,,In vivo,BAO_0000218,,,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,,Mus musculus,10090.0,,
4375,,,BAO_0000218,,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4376,,,BAO_0000218,,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4377,,,BAO_0000218,,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4378,,,BAO_0000218,,,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,Mus musculus,10090.0,,
4379,,,BAO_0000218,,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,Mus musculus,10090.0,,
4380,,,BAO_0000218,,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,Mus musculus,10090.0,,
4381,,,BAO_0000218,,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,Mus musculus,10090.0,,
4382,,,BAO_0000218,,,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,Mus musculus,10090.0,,
4383,,,BAO_0000218,,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,Mus musculus,10090.0,,
4384,,,BAO_0000218,,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,Mus musculus,10090.0,,
4385,,,BAO_0000218,,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,Mus musculus,10090.0,,
4386,,,BAO_0000218,,,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,Mus musculus,10090.0,,
4387,,,BAO_0000218,,850.0,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,Mus musculus,10090.0,,
4388,,In vivo,BAO_0000218,,,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,,,,,
4389,,,BAO_0000218,,,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,Mus musculus,10090.0,,
4390,,In vivo,BAO_0000218,,850.0,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,,Mus musculus,10090.0,,
4391,,In vivo,BAO_0000218,,850.0,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,,Mus musculus,10090.0,,
4392,,,BAO_0000218,,850.0,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,Mus musculus,10090.0,,
4393,,,BAO_0000218,,850.0,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,Mus musculus,10090.0,,
4394,,,BAO_0000218,,850.0,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,Mus musculus,10090.0,,
4395,,,BAO_0000019,,,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,Staphylococcus aureus,1280.0,,
4396,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,Rattus norvegicus,10116.0,,Liver
4397,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,Rattus norvegicus,10116.0,,Liver
4398,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,Rattus norvegicus,10116.0,,Liver
4399,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,Rattus norvegicus,10116.0,,Liver
4400,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,Rattus norvegicus,10116.0,,Liver
4401,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4402,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,Rattus norvegicus,10116.0,,Liver
4403,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,Rattus norvegicus,10116.0,,Liver
4404,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,Rattus norvegicus,10116.0,,Liver
4405,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,Rattus norvegicus,10116.0,,Liver
4406,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,Rattus norvegicus,10116.0,,Liver
4407,Microsomes,,BAO_0000251,2107.0,,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,Rattus norvegicus,10116.0,,Liver
4408,,In vivo,BAO_0000218,1969.0,,347,The apparent total plasma clearance in monkey,A,,Cercopithecidae,9527.0,,Plasma
4409,,In vivo,BAO_0000218,,,3341,Compound was evaluated for Hepatic clearance in monkey,A,,Cercopithecidae,9527.0,,
4410,,In vivo,BAO_0000218,,,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,,Cercopithecidae,9527.0,,
4411,,In vivo,BAO_0000218,,,4514,Plasma clearance in rhesus monkey,A,,Cercopithecidae,9527.0,,
4412,,In vivo,BAO_0000218,,,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,,Cercopithecidae,9527.0,,
4413,,In vivo,BAO_0000218,,,6821,Plasma clearance of compound was determined in monkey,A,,Cercopithecidae,9527.0,,
4414,,In vivo,BAO_0000218,,,6057,Plasma clearance was calculated in rhesus monkey,A,,Cercopithecidae,9527.0,,
4415,,In vivo,BAO_0000218,,,5145,Plasma clearance in rhesus monkey,A,,Cercopithecidae,9527.0,,
4416,,In vivo,BAO_0000218,,,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Cercopithecidae,9527.0,,
4417,,In vivo,BAO_0000218,,,5472,Plasma clearance was evaluated in rhesus,A,,Cercopithecidae,9527.0,,
4418,,In vivo,BAO_0000218,,,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,,Cercopithecidae,9527.0,,
4419,,In vivo,BAO_0000218,,,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,Cercopithecidae,9527.0,,
4420,,In vivo,BAO_0000218,,,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,,Cercopithecidae,9527.0,,
4421,,In vivo,BAO_0000218,,,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,,Cercopithecidae,9527.0,,
4422,,In vivo,BAO_0000218,,,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,,Cercopithecidae,9527.0,,
4423,,In vivo,BAO_0000218,,,6535,Cmax in monkey after administration of 1 mg/kg iv,A,,Cercopithecidae,9527.0,,
4424,,In vivo,BAO_0000218,,,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,,Cercopithecidae,9527.0,,
4425,,In vivo,BAO_0000218,,,5922,Cmax in cynomolgus monkey by iv administration,A,,Cercopithecidae,9527.0,,
4426,,In vivo,BAO_0000218,,,5922,Cmax in cynomolgus monkey by po administration,A,,Cercopithecidae,9527.0,,
4427,,In vivo,BAO_0000218,,,6078,Cmax value evaluated in monkey,A,,Cercopithecidae,9527.0,,
4428,,In vivo,BAO_0000218,,,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
4429,,In vivo,BAO_0000218,1969.0,,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,Plasma
4430,,In vivo,BAO_0000218,1969.0,,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,Plasma
4431,,In vivo,BAO_0000218,1969.0,,5553,Maximal plasma concentration in squirrel monkeys,A,,Cercopithecidae,9527.0,,Plasma
4432,,In vivo,BAO_0000218,,,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,Cercopithecidae,9527.0,,
4433,,In vivo,BAO_0000218,1969.0,,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,Plasma
4434,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,,Cercopithecidae,9527.0,,
4435,,In vivo,BAO_0000218,,,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,,Cercopithecidae,9527.0,,
4436,,In vivo,BAO_0000218,,,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,,Cercopithecidae,9527.0,,
4437,,In vivo,BAO_0000218,,,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,,Cercopithecidae,9527.0,,
4438,,In vivo,BAO_0000218,,,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
4439,,In vivo,BAO_0000218,1969.0,,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,,Cercopithecidae,9527.0,,Plasma
4440,,,BAO_0000218,,,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,Cercopithecidae,9527.0,,
4441,,,BAO_0000218,,,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,Cercopithecidae,9527.0,,
4442,,In vivo,BAO_0000218,,,4257,Absolute bioavailability was evaluated in monkey,A,,monkey,9443.0,,
4443,,In vivo,BAO_0000218,,,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,,monkey,9443.0,,
4444,,In vivo,BAO_0000218,,,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,,monkey,9443.0,,
4445,,In vivo,BAO_0000218,,,17267,Bioavailability of compound was determined in rhesus monkey,A,,Macaca mulatta,9544.0,,
4446,,In vivo,BAO_0000218,,,4256,Bioavailability determined after oral administration in marmoset,A,,marmosets,38020.0,,
4447,,In vivo,BAO_0000218,,,4256,Oral bioavailability in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
4448,,In vivo,BAO_0000218,,,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,,monkey,9443.0,,
4449,,In vivo,BAO_0000218,,,16365,Bioavailability was evaluated after oral administration in monkey,A,,monkey,9443.0,,
4450,,In vivo,BAO_0000218,,,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,Macaca fascicularis,9541.0,,
4451,,In vivo,BAO_0000218,,,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,,Macaca mulatta,9544.0,,
4452,,In vivo,BAO_0000218,,,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,,Macaca mulatta,9544.0,,
4453,,In vivo,BAO_0000218,,,17592,Bioavailability of the compound was determined in monkey,A,,monkey,9443.0,,
4454,,In vivo,BAO_0000218,,,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,,Saimiri sciureus,9521.0,,
4455,,In vivo,BAO_0000218,,,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,,monkey,9443.0,,
4456,,In vivo,BAO_0000218,,,3341,Oral bioavailability in monkey,A,,monkey,9443.0,,
4457,,In vivo,BAO_0000218,,,64,Compound was tested for bioavailability in squirrel monkey,A,,Saimiri sciureus,9521.0,,
4458,,In vivo,BAO_0000218,,,5005,Oral bioavailability in Rhesus monkey,A,,Macaca mulatta,9544.0,,
4459,,In vivo,BAO_0000218,,,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,,Macaca mulatta,9544.0,,
4460,,In vivo,BAO_0000218,,,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,,Macaca fascicularis,9541.0,,
4461,,In vivo,BAO_0000218,,,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,,Macaca fascicularis,9541.0,,
4462,,In vivo,BAO_0000218,,,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,,monkey,9443.0,,
4463,,In vivo,BAO_0000218,,,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,,monkey,9443.0,,
4464,,In vivo,BAO_0000218,,,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,,Canis lupus familiaris,9615.0,,
4465,,In vivo,BAO_0000218,,,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,,Canis lupus familiaris,9615.0,,
4466,,,BAO_0000218,1969.0,,3854,Plasma half life determined,A,,Canis lupus familiaris,9615.0,,Plasma
4467,,,BAO_0000218,1969.0,,993,Plasma half life in dog,A,,Canis lupus familiaris,9615.0,,Plasma
4468,,,BAO_0000218,1969.0,,4514,Plasma half-life in Beagle dogs,A,,Canis lupus familiaris,9615.0,,Plasma
4469,,In vivo,BAO_0000218,1969.0,,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,,Canis lupus familiaris,9615.0,,Plasma
4470,,In vivo,BAO_0000218,1969.0,,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,,Canis lupus familiaris,9615.0,,Plasma
4471,,In vivo,BAO_0000218,,,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,,Canis lupus familiaris,9615.0,,
4472,,In vivo,BAO_0000218,,,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,,Canis lupus familiaris,9615.0,,
4473,,,BAO_0000218,,,5313,Tested for the half life period in dog,A,,Canis lupus familiaris,9615.0,,
4474,,In vivo,BAO_0000218,,,5313,Tested for the half life period in dog at dosage of 10 mpk,A,,Canis lupus familiaris,9615.0,,
4475,,,BAO_0000218,,,3880,The compound was tested for half life in dog,A,,Canis lupus familiaris,9615.0,,
4476,,,BAO_0000218,1969.0,,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,Canis lupus familiaris,9615.0,,Plasma
4477,,,BAO_0000218,,,3880,The half life was determined,A,,Canis lupus familiaris,9615.0,,
4478,,,BAO_0000218,1969.0,,3918,The plasma half-life in dogs,A,,Canis lupus familiaris,9615.0,,Plasma
4479,,,BAO_0000218,1969.0,,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,Canis lupus familiaris,9615.0,,Plasma
4480,,,BAO_0000218,,,17796,Half life in dog,A,,Canis lupus familiaris,9615.0,,
4481,,In vivo,BAO_0000218,,,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,,Canis lupus familiaris,9615.0,,
4482,,In vivo,BAO_0000218,,,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,,Canis lupus familiaris,9615.0,,
4483,,In vivo,BAO_0000218,,,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
4484,,In vivo,BAO_0000218,,,6113,Cmax in ferrets after 30 mg/kg oral dose,A,,Mustela putorius furo,9669.0,,
4485,,In vivo,BAO_0000218,,,6113,Emesis in ferrets at 30 mg/kg oral dose,F,,Mustela putorius furo,9669.0,,
4486,,In vivo,BAO_0000218,,,17796,Bioavailability in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
4487,,In vivo,BAO_0000218,,,17796,Volume of distribution in cynomolgus,A,,Macaca fascicularis,9541.0,,
4488,,,BAO_0000218,1969.0,,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,Cavia porcellus,10141.0,,Plasma
4489,,,BAO_0000218,,,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,Cavia porcellus,10141.0,,
4490,,,BAO_0000218,,,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,Cavia porcellus,10141.0,,
4491,,In vivo,BAO_0000218,1969.0,,4878,AUC in guinea pig after 3mg/kg oral dose,A,,Cavia porcellus,10141.0,,Plasma
4492,,In vivo,BAO_0000218,,,5308,Bioavailability in guinea pig was tested,A,,Cavia porcellus,10141.0,,
4493,,In vivo,BAO_0000218,,,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,,Cavia porcellus,10141.0,,
4494,,In vivo,BAO_0000218,,,4876,Tested for the oral bioavailability of the compound,A,,Cavia porcellus,10141.0,,
4495,,In vivo,BAO_0000218,,,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,,Cavia porcellus,10141.0,,
4496,,In vivo,BAO_0000218,,,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,,Cavia porcellus,10141.0,,
4497,,In vivo,BAO_0000218,2048.0,,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,Cavia porcellus,10141.0,,Lung
4498,,In vivo,BAO_0000218,,,4878,Cmax in guinea pig after 3mg/kg oral dose,A,,Cavia porcellus,10141.0,,
4499,,,BAO_0000019,178.0,,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,Blood
4500,,,BAO_0000019,955.0,,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,Brain
4501,,,BAO_0000019,,,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,
4502,,,BAO_0000019,160.0,,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,Intestine
4503,,,BAO_0000019,2113.0,,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,Kidney
4504,,,BAO_0000019,2107.0,,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,Liver
4505,,,BAO_0000019,,,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,
4506,,,BAO_0000019,2106.0,,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,Cavia porcellus,10141.0,,Spleen
4507,,In vivo,BAO_0000218,,,14465,Elimination T1/2 in Guinea pig (PO dose),A,,Cavia porcellus,10141.0,,
4508,,,BAO_0000019,,,5689,Partition coefficient was measured as -log (counts per min ),A,,Cavia porcellus,10141.0,,
4509,,In vivo,BAO_0000218,,,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,,Cavia porcellus,10141.0,,
4510,,In vivo,BAO_0000218,,,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,,Cavia porcellus,10141.0,,
4511,,In vivo,BAO_0000218,,,14465,Elimination T1/2 in Guinea pig (PO dose),A,,Cavia porcellus,10141.0,,
4512,,In vivo,BAO_0000218,,,4876,"Tested for the half life period of the compound, intravenously",A,,Cavia porcellus,10141.0,,
4513,,,BAO_0000019,,,5689,Half-life was measured,A,,Cavia porcellus,10141.0,,
4514,,,BAO_0000019,,,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,Cavia porcellus,10141.0,,
4515,,In vivo,BAO_0000218,,,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,,Cavia porcellus,10141.0,,
4516,,In vivo,BAO_0000218,,,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,,Cavia porcellus,10141.0,,
4517,,In vivo,BAO_0000218,,,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,,Cricetulus griseus,10029.0,,
4518,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,
4519,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,
4520,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,
4521,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,
4522,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,,Mus musculus,10090.0,,
4523,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,
4524,,In vivo,BAO_0000218,,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,
4525,,In vivo,BAO_0000218,178.0,,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Blood
4526,,In vivo,BAO_0000218,178.0,,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Blood
4527,,In vivo,BAO_0000218,178.0,,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Blood
4528,,In vivo,BAO_0000218,10000001.0,,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Bone
4529,,In vivo,BAO_0000218,10000001.0,,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Bone
4530,,In vivo,BAO_0000218,10000001.0,,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Bone
4531,,In vivo,BAO_0000218,955.0,,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Brain
4532,,In vivo,BAO_0000218,955.0,,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Brain
4533,,In vivo,BAO_0000218,955.0,,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Brain
4534,,In vivo,BAO_0000218,948.0,,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Heart
4535,,In vivo,BAO_0000218,948.0,,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Heart
4536,,In vivo,BAO_0000218,948.0,,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Heart
4537,,In vivo,BAO_0000218,160.0,,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Intestine
4538,,In vivo,BAO_0000218,160.0,,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Intestine
4539,,In vivo,BAO_0000218,160.0,,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Intestine
4540,,In vivo,BAO_0000218,2113.0,,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Kidney
4541,,In vivo,BAO_0000218,2113.0,,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Kidney
4542,,In vivo,BAO_0000218,2113.0,,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Kidney
4543,,In vivo,BAO_0000218,2107.0,,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Liver
4544,,In vivo,BAO_0000218,2107.0,,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Liver
4545,,In vivo,BAO_0000218,2107.0,,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Liver
4546,,In vivo,BAO_0000218,2048.0,,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Lung
4547,,In vivo,BAO_0000218,2048.0,,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Lung
4548,,In vivo,BAO_0000218,2048.0,,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Lung
4549,,In vivo,BAO_0000218,2385.0,,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Muscle tissue
4550,,In vivo,BAO_0000218,2385.0,,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Muscle tissue
4551,,In vivo,BAO_0000218,2385.0,,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Muscle tissue
4552,,In vivo,BAO_0000218,2106.0,,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Spleen
4553,,In vivo,BAO_0000218,2106.0,,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Spleen
4554,,In vivo,BAO_0000218,2106.0,,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Spleen
4555,,In vivo,BAO_0000218,945.0,,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,,Mus musculus,10090.0,,Stomach
4556,,In vivo,BAO_0000218,945.0,,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,,Mus musculus,10090.0,,Stomach
4557,,In vivo,BAO_0000218,945.0,,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,,Mus musculus,10090.0,,Stomach
4558,,In vivo,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,,Mus musculus,10090.0,,
4559,,In vivo,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,,Mus musculus,10090.0,,
4560,,In vivo,BAO_0000218,,,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,
4561,,In vivo,BAO_0000218,,,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,10090.0,,
4562,,In vivo,BAO_0000218,,,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,10090.0,,
4563,,In vivo,BAO_0000218,,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,Mus musculus,10090.0,,
4564,,,BAO_0000219,,478.0,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,Homo sapiens,9606.0,,
4565,,,BAO_0000219,,478.0,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,Homo sapiens,9606.0,,
4566,,,BAO_0000219,,478.0,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,Homo sapiens,9606.0,,
4567,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,Homo sapiens,9606.0,,
4568,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,Homo sapiens,9606.0,,
4569,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,Homo sapiens,9606.0,,
4570,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,Homo sapiens,9606.0,,
4571,,,BAO_0000219,,478.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,Homo sapiens,9606.0,,
4572,,,BAO_0000219,,478.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,Homo sapiens,9606.0,,
4573,,,BAO_0000219,,478.0,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,Homo sapiens,9606.0,,
4574,,,BAO_0000219,,478.0,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,Homo sapiens,9606.0,,
4575,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,Homo sapiens,9606.0,,
4576,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,Homo sapiens,9606.0,,
4577,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,Homo sapiens,9606.0,,
4578,,,BAO_0000219,,478.0,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,Homo sapiens,9606.0,,
4579,,,BAO_0000219,,478.0,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,Homo sapiens,9606.0,,
4580,,,BAO_0000219,,478.0,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,Homo sapiens,9606.0,,
4581,,,BAO_0000219,,478.0,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,Homo sapiens,9606.0,,
4582,,,BAO_0000218,,478.0,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,Homo sapiens,9606.0,,
4583,,,BAO_0000219,,478.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,Homo sapiens,9606.0,,
4584,,,BAO_0000219,,478.0,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,Homo sapiens,9606.0,,
4585,,,BAO_0000219,,478.0,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,Homo sapiens,9606.0,,
4586,,,BAO_0000219,,478.0,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,Homo sapiens,9606.0,,
4587,,,BAO_0000219,,478.0,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,Homo sapiens,9606.0,,
4588,,,BAO_0000219,,478.0,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,Homo sapiens,9606.0,,
4589,,,BAO_0000218,,478.0,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,Homo sapiens,9606.0,,
4590,,,BAO_0000218,,478.0,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,Homo sapiens,9606.0,,
4591,,,BAO_0000219,,478.0,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,Homo sapiens,9606.0,,
4592,,,BAO_0000219,,478.0,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,Homo sapiens,9606.0,,
4593,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,Homo sapiens,9606.0,,
4594,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,Homo sapiens,9606.0,,
4595,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,Homo sapiens,9606.0,,
4596,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,Homo sapiens,9606.0,,
4597,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,Homo sapiens,9606.0,,
4598,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,Homo sapiens,9606.0,,
4599,,,BAO_0000219,,478.0,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,Homo sapiens,9606.0,,
4600,,,BAO_0000219,,478.0,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,Homo sapiens,9606.0,,
4601,,,BAO_0000219,,478.0,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,Homo sapiens,9606.0,,
4602,,,BAO_0000219,,478.0,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,Homo sapiens,9606.0,,
4603,,,BAO_0000219,,478.0,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,Homo sapiens,9606.0,,
4604,,,BAO_0000219,,478.0,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,Homo sapiens,9606.0,,
4605,,,BAO_0000219,,478.0,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,Homo sapiens,9606.0,,
4606,,,BAO_0000219,,478.0,17270,In vitro cytotoxicity against A2780ADR cell line,F,,Homo sapiens,9606.0,,
4607,,,BAO_0000219,,478.0,17270,In vitro cytotoxicity against A2780CIS cell line,F,,Homo sapiens,9606.0,,
4608,,,BAO_0000219,,478.0,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,Homo sapiens,9606.0,,
4609,,,BAO_0000219,,478.0,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,Homo sapiens,9606.0,,
4610,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,9606.0,,
4611,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,9606.0,,
4612,,In vivo,BAO_0000218,,,17839,Oral bioavailability of compound in rhesus macaques,A,,Macaca mulatta,9544.0,,
4613,,In vivo,BAO_0000218,,,6821,Oral bioavailability in monkey,A,,monkey,9443.0,,
4614,,In vivo,BAO_0000218,,,6078,Oral bioavailability evaluated in monkey,A,,monkey,9443.0,,
4615,,In vivo,BAO_0000218,,,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,,monkey,9443.0,,
4616,,In vivo,BAO_0000218,,,4449,Oral bioavailability in Rhesus monkey,A,,Macaca mulatta,9544.0,,
4617,,In vivo,BAO_0000218,,,6057,Oral bioavailability was calculated in rhesus monkey,A,,Macaca mulatta,9544.0,,
4618,,In vivo,BAO_0000218,,,5922,Oral bioavailability in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
4619,,In vivo,BAO_0000218,,,5940,Oral bioavailability in monkey,A,,monkey,9443.0,,
4620,,In vivo,BAO_0000218,,,6265,Oral bioavailability in monkey,A,,monkey,9443.0,,
4621,,In vivo,BAO_0000218,,,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,,monkey,9443.0,,
4622,,In vivo,BAO_0000218,,,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,,monkey,9443.0,,
4623,,In vivo,BAO_0000218,,,5940,Oral bioavailability in monkey,A,,monkey,9443.0,,
4624,,In vivo,BAO_0000218,,,5940,Oral bioavailability in monkey,A,,monkey,9443.0,,
4625,,In vivo,BAO_0000218,,,4514,Oral bioavailability in rhesus monkey,A,,Macaca mulatta,9544.0,,
4626,,In vivo,BAO_0000218,,,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,,Macaca mulatta,9544.0,,
4627,,In vivo,BAO_0000218,,,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,,Saimiri sciureus,9521.0,,
4628,,In vivo,BAO_0000218,,,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,monkey,9443.0,,
4629,,In vivo,BAO_0000218,,,5472,Oral bioavailability in Rhesus monkey,A,,Macaca mulatta,9544.0,,
4630,,In vivo,BAO_0000218,,,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,,Macaca mulatta,9544.0,,
4631,,In vivo,BAO_0000218,,,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,,monkey,9443.0,,
4632,,In vivo,BAO_0000218,,,5145,Bioavailability in Rhesus monkey,A,,Macaca mulatta,9544.0,,
4633,,,BAO_0000218,,,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4634,,,BAO_0000218,,,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4635,,In vivo,BAO_0000218,,,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,
4636,,In vivo,BAO_0000218,,,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,
4637,,In vivo,BAO_0000218,,,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
4638,,In vivo,BAO_0000218,,,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,,Cercopithecidae,9527.0,,
4639,,In vivo,BAO_0000218,,,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,,Cercopithecidae,9527.0,,
4640,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,,Cercopithecidae,9527.0,,
4641,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,,Cercopithecidae,9527.0,,
4642,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,Cercopithecidae,9527.0,,
4643,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,Cercopithecidae,9527.0,,
4644,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,Cercopithecidae,9527.0,,
4645,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,Cercopithecidae,9527.0,,
4646,,In vivo,BAO_0000218,,,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4647,,In vivo,BAO_0000218,,,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4648,,,BAO_0000019,,,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,Cercopithecidae,9527.0,,
4649,,,BAO_0000218,,,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4650,,,BAO_0000218,,,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4651,,,BAO_0000019,,,6821,Elimination Half-life of compound was determined in monkey,A,,Cercopithecidae,9527.0,,
4652,,,BAO_0000019,,,17267,Half life of compound was determined in rhesus monkey,A,,Cercopithecidae,9527.0,,
4653,,,BAO_0000366,1969.0,,5819,Half life in monkey plasma,A,,Cercopithecidae,9527.0,,Plasma
4654,,,BAO_0000366,1969.0,,5819,Half life in monkey plasma; Not detected,A,,Cercopithecidae,9527.0,,Plasma
4655,,In vivo,BAO_0000218,,,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,Cercopithecidae,9527.0,,
4656,,In vivo,BAO_0000218,,,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,,Cercopithecidae,9527.0,,
4657,,,BAO_0000019,,,1399,Terminal half life of the compound.,A,,Cercopithecidae,9527.0,,
4658,,In vivo,BAO_0000218,,,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,Cercopithecidae,9527.0,,
4659,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,,Cercopithecidae,9527.0,,
4660,,,BAO_0000218,,,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,Cercopithecidae,9527.0,,
4661,,,BAO_0000218,1088.0,,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,Urine
4662,,,BAO_0000218,1088.0,,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,Urine
4663,,In vivo,BAO_0000218,,,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,,Cercopithecidae,9527.0,,
4664,,In vivo,BAO_0000218,,,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,,Cercopithecidae,9527.0,,
4665,,In vivo,BAO_0000218,,,5472,Volume of distribution was evaluated in rhesus,A,,Cercopithecidae,9527.0,,
4666,,In vivo,BAO_0000218,,,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,,Cricetulus griseus,10029.0,,
4667,,In vivo,BAO_0000218,,,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,,Cricetulus griseus,10029.0,,
4668,,In vivo,BAO_0000218,,,4727,Bioavailability in hamster was determined,A,,Cricetulus griseus,10029.0,,
4669,,In vivo,BAO_0000218,,,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,,Cricetulus griseus,10029.0,,
4670,,In vivo,BAO_0000218,,,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,,Cricetulus griseus,10029.0,,
4671,,,BAO_0000221,178.0,,4727,Half life of compound was determined in hamster blood,A,,Cricetulus griseus,10029.0,,Blood
4672,,,BAO_0000019,,,1452,Michaelis-Menten constant of the compound.,A,,Sus scrofa,9823.0,,
4673,,,BAO_0000019,,,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,Sus scrofa,9823.0,,
4674,,,BAO_0000019,,,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,Sus scrofa,9823.0,,
4675,,,BAO_0000019,,,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,Sus scrofa,9823.0,,
4676,,,BAO_0000357,,,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,Homo sapiens,9606.0,,
4677,,,BAO_0000218,,,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,Homo sapiens,9606.0,,
4678,,,BAO_0000019,,,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,Homo sapiens,9606.0,,
4679,,,BAO_0000019,,,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,Homo sapiens,9606.0,,
4680,,,BAO_0000019,,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,Homo sapiens,9606.0,,
4681,,,BAO_0000019,,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,Homo sapiens,9606.0,,
4682,,,BAO_0000019,,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,Homo sapiens,9606.0,,
4683,,,BAO_0000019,,,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,Homo sapiens,9606.0,,
4684,,,BAO_0000218,,,17791,Compound was evaluated for oral bioavailability in human,A,,Homo sapiens,9606.0,,
4685,,,BAO_0000019,1088.0,,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,Homo sapiens,9606.0,,Urine
4686,,,BAO_0000019,,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,Homo sapiens,9606.0,,
4687,,,BAO_0000019,,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,Homo sapiens,9606.0,,
4688,,,BAO_0000019,,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,Homo sapiens,9606.0,,
4689,,,BAO_0000019,,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,Homo sapiens,9606.0,,
4690,,,BAO_0000019,,,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,Homo sapiens,9606.0,,
4691,,,BAO_0000019,,,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,Homo sapiens,9606.0,,
4692,,,BAO_0000019,,,6852,Percent of compound in healthy individuals (Group D),A,,Homo sapiens,9606.0,,
4693,Microsomes,,BAO_0000251,2107.0,,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,Homo sapiens,9606.0,,Liver
4694,,,BAO_0000019,,,17409,Binding towards human plasma protein at 10 uM,A,,Homo sapiens,9606.0,,
4695,,,BAO_0000019,,,17409,Binding towards human plasma protein at 100 uM,A,,Homo sapiens,9606.0,,
4696,,,BAO_0000019,,,17176,Human plasma protein binding activity was determined,A,,Homo sapiens,9606.0,,
4697,,,BAO_0000019,,,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,Homo sapiens,9606.0,,
4698,,,BAO_0000019,,,17267,Percent binding of compound towards human plasma protein was determined,A,,Homo sapiens,9606.0,,
4699,Microsomes,In vitro,BAO_0000251,2107.0,,5944,Plasma clearance in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
4700,Microsomes,In vitro,BAO_0000251,2107.0,,5668,In vitro intrinsic clearance in human liver microsome,A,,Homo sapiens,9606.0,,Liver
4701,Microsomes,In vitro,BAO_0000251,2107.0,,5669,In vitro intrinsic clearance in human liver microsome,A,,Homo sapiens,9606.0,,Liver
4702,Microsomes,In vitro,BAO_0000251,,,5041,In vitro microsome metabolism clearance in human was determined,A,,Homo sapiens,9606.0,,
4703,Microsomes,In vitro,BAO_0000251,,,5041,In vitro microsome metabolism clearance in human was determined; High,A,,Homo sapiens,9606.0,,
4704,Microsomes,In vitro,BAO_0000251,,,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,,Homo sapiens,9606.0,,
4705,Microsomes,In vitro,BAO_0000251,2107.0,,5676,Pharmacokinetic property (clearance) in human liver microsome,A,,Homo sapiens,9606.0,,Liver
4706,Microsomes,In vitro,BAO_0000251,2107.0,,5944,Plasma clearance in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
4707,Microsomes,In vitro,BAO_0000251,2107.0,,17538,In vitro clearance in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
4708,Microsomes,In vitro,BAO_0000251,2107.0,,6331,Intrinsic clearance in human liver microsomes was determined,A,,Homo sapiens,9606.0,,Liver
4709,Microsomes,In vitro,BAO_0000251,2107.0,,5948,Intrinsic clearance in human liver microsomes was determined,A,,Homo sapiens,9606.0,,Liver
4710,,In vivo,BAO_0000218,,,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,,Homo sapiens,9606.0,,
4711,,In vivo,BAO_0000218,,,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,,Homo sapiens,9606.0,,
4712,,,BAO_0000218,,,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,Homo sapiens,9606.0,,
4713,,,BAO_0000019,,,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,Homo sapiens,9606.0,,
4714,,,BAO_0000019,,,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,Homo sapiens,9606.0,,
4715,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4716,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4717,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4718,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4719,,In vivo,BAO_0000218,,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,Mus musculus,10090.0,,
4720,,In vivo,BAO_0000218,,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,Mus musculus,10090.0,,
4721,,In vivo,BAO_0000218,,,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,Mus musculus,10090.0,,
4722,,In vivo,BAO_0000218,,,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,,Mus musculus,10090.0,,
4723,,,BAO_0000218,,,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,Mus musculus,10090.0,,
4724,,,BAO_0000218,,,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,Mus musculus,10090.0,,
4725,,,BAO_0000218,,,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,Mus musculus,10090.0,,
4726,,,BAO_0000218,2107.0,,6251,In vitro metabolic potential in mouse liver microsomes,A,,Mus musculus,10090.0,,Liver
4727,,,BAO_0000218,,,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,Mus musculus,10090.0,,
4728,,,BAO_0000218,2369.0,,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,Mus musculus,10090.0,,Adrenal gland
4729,,,BAO_0000218,955.0,,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,Mus musculus,10090.0,,Brain
4730,,,BAO_0000218,955.0,,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,Mus musculus,10090.0,,Brain
4731,,,BAO_0000218,,,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,Mus musculus,10090.0,,
4732,,,BAO_0000218,2113.0,,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,Mus musculus,10090.0,,Kidney
4733,,,BAO_0000218,,,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,Mus musculus,10090.0,,
4734,,,BAO_0000218,,,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,Mus musculus,10090.0,,
4735,,,BAO_0000218,1977.0,,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,Mus musculus,10090.0,,Serum
4736,,,BAO_0000218,1977.0,,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,Mus musculus,10090.0,,Serum
4737,,,BAO_0000218,1977.0,,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,Mus musculus,10090.0,,Serum
4738,,In vivo,BAO_0000218,1969.0,,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,,Mus musculus,10090.0,,Plasma
4739,,In vivo,BAO_0000218,1969.0,,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,,Mus musculus,10090.0,,Plasma
4740,,In vivo,BAO_0000218,1969.0,,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,,Mus musculus,10090.0,,Plasma
4741,,In vivo,BAO_0000218,,,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,,Mus musculus,10090.0,,
4742,,In vivo,BAO_0000218,,,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,,Mus musculus,10090.0,,
4743,,In vivo,BAO_0000218,,,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,,Mus musculus,10090.0,,
4744,,In vivo,BAO_0000218,,,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,,Mus musculus,10090.0,,
4745,,In vivo,BAO_0000218,,,17764,Half life after intravenous administration in mice at 23 uM/kg,F,,Mus musculus,10090.0,,
4746,,In vivo,BAO_0000218,,,17764,Half life after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,10090.0,,
4747,,In vivo,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,,Mus musculus,10090.0,,
4748,,In vivo,BAO_0000218,,,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,,Mus musculus,10090.0,,
4749,,In vivo,BAO_0000218,,,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,,Mus musculus,10090.0,,
4750,,In vivo,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,,Mus musculus,10090.0,,
4751,,In vivo,BAO_0000218,,,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,,Mus musculus,10090.0,,
4752,,In vivo,BAO_0000218,,,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,,Mus musculus,10090.0,,
4753,,In vivo,BAO_0000218,178.0,,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,,Mus musculus,10090.0,,Blood
4754,,In vivo,BAO_0000218,,,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,
4755,,In vivo,BAO_0000218,,,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,10090.0,,
4756,,,BAO_0000218,,,6619,Half life in ob/ob mice,A,,Mus musculus,10090.0,,
4757,,In vivo,BAO_0000218,,,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,,Mus musculus,10090.0,,
4758,,,BAO_0000218,,,4239,Half-life was measured in mouse,A,,Mus musculus,10090.0,,
4759,,In vivo,BAO_0000218,,,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,,Mus musculus,10090.0,,
4760,,,BAO_0000218,,,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,Mus musculus,10090.0,,
4761,,,BAO_0000218,,,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,Mus musculus,10090.0,,
4762,,,BAO_0000218,955.0,,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Brain
4763,,,BAO_0000218,2113.0,,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Kidney
4764,,,BAO_0000218,2107.0,,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Liver
4765,,,BAO_0000218,2048.0,,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Lung
4766,,,BAO_0000218,2106.0,,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Spleen
4767,,In vivo,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,,Mus musculus,10090.0,,
4768,,In vivo,BAO_0000218,,,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,,Mus musculus,10090.0,,
4769,,In vivo,BAO_0000218,,,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,,Mus musculus,10090.0,,
4770,,In vivo,BAO_0000218,,,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,,Mus musculus,10090.0,,
4771,,In vivo,BAO_0000218,,,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,,Mus musculus,10090.0,,
4772,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,9606.0,,
4773,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,Homo sapiens,9606.0,,
4774,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,9606.0,,
4775,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,9606.0,,
4776,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,9606.0,,
4777,,,BAO_0000219,,478.0,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,Homo sapiens,9606.0,,
4778,,,BAO_0000219,,478.0,17270,In vitro cytotoxicity against A2780TAX cell line,F,,Homo sapiens,9606.0,,
4779,,,BAO_0000219,,481.0,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,Homo sapiens,9606.0,,
4780,,,BAO_0000219,,478.0,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,Homo sapiens,9606.0,,
4781,,,BAO_0000219,,481.0,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,Homo sapiens,9606.0,,
4782,,,BAO_0000219,,481.0,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,Homo sapiens,9606.0,,
4783,,,BAO_0000219,,478.0,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,Homo sapiens,9606.0,,
4784,,,BAO_0000219,,478.0,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,Homo sapiens,9606.0,,
4785,,,BAO_0000219,,478.0,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,Homo sapiens,9606.0,,
4786,,,BAO_0000219,,478.0,12989,In vitro antitumor activity against A2780cisR cell line.,F,,Homo sapiens,9606.0,,
4787,,,BAO_0000219,,478.0,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,Homo sapiens,9606.0,,
4788,,,BAO_0000219,,478.0,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,Homo sapiens,9606.0,,
4789,,,BAO_0000219,,481.0,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,Homo sapiens,9606.0,,
4790,,,BAO_0000219,,478.0,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
4791,,,BAO_0000019,,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,Rattus norvegicus,10116.0,,
4792,,,BAO_0000019,,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,
4793,,,BAO_0000019,,,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,Rattus norvegicus,10116.0,,
4794,,,BAO_0000219,,722.0,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,Homo sapiens,9606.0,,
4795,,,BAO_0000219,,722.0,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,Homo sapiens,9606.0,,
4796,,,BAO_0000019,,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,Mus musculus,10090.0,,
4797,,,BAO_0000019,,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,
4798,,,BAO_0000019,,,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,Mus musculus,10090.0,,
4799,,,BAO_0000357,,,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,
4800,,,BAO_0000219,,574.0,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,Homo sapiens,9606.0,,
4801,,,BAO_0000219,,574.0,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,Homo sapiens,9606.0,,
4802,,,BAO_0000219,,455.0,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,Homo sapiens,9606.0,,
4803,,,BAO_0000219,,455.0,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,Homo sapiens,9606.0,,
4804,,,BAO_0000219,,455.0,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,Homo sapiens,9606.0,,
4805,,,BAO_0000219,,455.0,15313,Inhibition of cell growth in (A375) melan cell line,F,,Homo sapiens,9606.0,,
4806,,,BAO_0000219,,455.0,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,Homo sapiens,9606.0,,
4807,,,BAO_0000219,,455.0,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,Homo sapiens,9606.0,,
4808,,,BAO_0000219,,455.0,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,Homo sapiens,9606.0,,
4809,,,BAO_0000219,,797.0,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,Homo sapiens,9606.0,,
4810,,,BAO_0000219,,797.0,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,Homo sapiens,9606.0,,
4811,,,BAO_0000219,,797.0,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,Homo sapiens,9606.0,,
4812,,,BAO_0000219,,797.0,14368,Inhibition of large cell lung carcinoma (A427),F,,Homo sapiens,9606.0,,
4813,,,BAO_0000219,,797.0,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,Homo sapiens,9606.0,,
4814,,,BAO_0000219,,797.0,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,Homo sapiens,9606.0,,
4815,,,BAO_0000219,,797.0,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,Homo sapiens,9606.0,,
4816,,,BAO_0000219,,797.0,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,Homo sapiens,9606.0,,
4817,,In vivo,BAO_0000218,,,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,,Cercopithecidae,9527.0,,
4818,,In vivo,BAO_0000218,,,4578,Tested for volume of distribution upon iv administration to african green monkey,A,,Cercopithecidae,9527.0,,
4819,,In vivo,BAO_0000218,,,17592,Volume of distribution in monkey,A,,Cercopithecidae,9527.0,,
4820,,In vivo,BAO_0000218,,,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,,Macaca mulatta,9544.0,,
4821,,In vivo,BAO_0000218,,,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,,Macaca mulatta,9544.0,,
4822,,In vivo,BAO_0000218,,,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,,Cercopithecidae,9527.0,,
4823,,In vivo,BAO_0000218,,,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
4824,,In vivo,BAO_0000218,,,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,,Cercopithecidae,9527.0,,
4825,,In vivo,BAO_0000218,,,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,,Cercopithecidae,9527.0,,
4826,,In vivo,BAO_0000218,,,6057,Volume displacement was calculated in rhesus monkey,A,,Cercopithecidae,9527.0,,
4827,,In vivo,BAO_0000218,,,5145,Volume of distribution in steady state was determined in rhesus monkey,A,,Cercopithecidae,9527.0,,
4828,,In vivo,BAO_0000218,,,6821,Volume of distribution of compound was determined in monkey,A,,Cercopithecidae,9527.0,,
4829,,In vivo,BAO_0000218,,,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,,Cercopithecidae,9527.0,,
4830,,In vivo,BAO_0000218,,,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,,Cercopithecidae,9527.0,,
4831,,In vivo,BAO_0000218,,,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Cercopithecidae,9527.0,,
4832,,In vivo,BAO_0000218,,,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
4833,,In vivo,BAO_0000218,,,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,,Cercopithecidae,9527.0,,
4834,,In vivo,BAO_0000218,,,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,,Cercopithecidae,9527.0,,
4835,,In vivo,BAO_0000218,,,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,,Cercopithecidae,9527.0,,
4836,,In vivo,BAO_0000218,,,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
4837,,In vivo,BAO_0000218,,,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,,Cercopithecidae,9527.0,,
4838,,In vivo,BAO_0000218,,,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,,Cercopithecidae,9527.0,,
4839,,,BAO_0000019,,,11271,Baboon plasma free fraction. ,A,,Cercopithecidae,9527.0,,
4840,,,BAO_0000218,,,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,Cercopithecidae,9527.0,,
4841,,,BAO_0000019,,,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,Cercopithecidae,9527.0,,
4842,,,BAO_0000019,,,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,Cercopithecidae,9527.0,,
4843,,In vivo,BAO_0000218,,,5302,Half life period in monkey after 5 mg/kg dose,A,,Cercopithecidae,9527.0,,
4844,,In vivo,BAO_0000218,,,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,,Cercopithecidae,9527.0,,
4845,,In vivo,BAO_0000218,,,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,,Cercopithecidae,9527.0,,
4846,,In vivo,BAO_0000218,1969.0,,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,,Cercopithecidae,9527.0,,Plasma
4847,,In vivo,BAO_0000218,,,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,,Cercopithecidae,9527.0,,
4848,,In vivo,BAO_0000218,,,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
4849,,,BAO_0000019,,,3341,Compound was evaluated for terminal half life in monkey,A,,Cercopithecidae,9527.0,,
4850,,In vivo,BAO_0000218,,,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,,Cercopithecidae,9527.0,,
4851,,In vivo,BAO_0000218,1969.0,,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,,Macaca mulatta,9544.0,,Plasma
4852,,,BAO_0000019,,,4847,Half life of compound was determined in squirrel monkey,A,,Cercopithecidae,9527.0,,
4853,,In vivo,BAO_0000218,,,4256,Half life after iv administration in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
4854,,In vivo,BAO_0000218,1969.0,,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,,Cercopithecidae,9527.0,,Plasma
4855,,,BAO_0000019,,,6057,Half life was calculated in rhesus monkey,A,,Cercopithecidae,9527.0,,
4856,,,BAO_0000019,,,17592,Half life in monkey,A,,Cercopithecidae,9527.0,,
4857,,In vivo,BAO_0000218,,,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Cercopithecidae,9527.0,,
4858,,,BAO_0000019,,,5472,Half life was evaluated in rhesus,A,,Cercopithecidae,9527.0,,
4859,,In vivo,BAO_0000218,,,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,,Cercopithecidae,9527.0,,
4860,,In vivo,BAO_0000218,,,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,,Cercopithecidae,9527.0,,
4861,,In vivo,BAO_0000218,,,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,,Cercopithecidae,9527.0,,
4862,,In vivo,BAO_0000218,,,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,Cercopithecidae,9527.0,,
4863,,In vivo,BAO_0000218,,,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,
4864,,,BAO_0000019,,,6078,Half-life was calculated in monkey,A,,Cercopithecidae,9527.0,,
4865,,,BAO_0000019,,,5147,Half-life in Squirrel monkey,A,,Cercopithecidae,9527.0,,
4866,,,BAO_0000019,,,5145,Half-life in rhesus monkey,A,,Cercopithecidae,9527.0,,
4867,,In vivo,BAO_0000218,,,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,,Cercopithecidae,9527.0,,
4868,,In vivo,BAO_0000218,,,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
4869,,In vivo,BAO_0000218,,,5355,Half-life period after oral administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
4870,,In vivo,BAO_0000218,,,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,,Cercopithecidae,9527.0,,
4871,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4872,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4873,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4874,,,BAO_0000019,1088.0,,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,Homo sapiens,9606.0,,Urine
4875,,,BAO_0000019,1088.0,,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,Homo sapiens,9606.0,,Urine
4876,,,BAO_0000019,1088.0,,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,Homo sapiens,9606.0,,Urine
4877,,,BAO_0000019,1088.0,,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,Homo sapiens,9606.0,,Urine
4878,,,BAO_0000019,1088.0,,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,Homo sapiens,9606.0,,Urine
4879,,In vivo,BAO_0000218,,,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,,Homo sapiens,9606.0,,
4880,,In vivo,BAO_0000218,,,16643,Oral bioavailability in human,A,,Homo sapiens,9606.0,,
4881,,,BAO_0000019,,,17248,Compound was tested for human plasma protein binding,A,,Homo sapiens,9606.0,,
4882,,,BAO_0000019,,,17248,Compound was tested for human plasma protein binding; Not determined,A,,Homo sapiens,9606.0,,
4883,,,BAO_0000019,,,6241,Protein binding activity of compound in human plasma; % Free,A,,Homo sapiens,9606.0,,
4884,,,BAO_0000019,,,17716,Unbound fraction (plasma),A,,Homo sapiens,9606.0,,
4885,,,BAO_0000366,1969.0,,17605,Half life for the hydrolysis of compound in human blood serum,A,,Homo sapiens,9606.0,,Plasma
4886,,,BAO_0000366,1969.0,,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,Homo sapiens,9606.0,,Plasma
4887,,,BAO_0000366,1969.0,,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,Homo sapiens,9606.0,,Plasma
4888,,,BAO_0000366,1969.0,,17747,Half-life in human plasma was determined,A,,Homo sapiens,9606.0,,Plasma
4889,,,BAO_0000019,,,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,Homo sapiens,9606.0,,
4890,,,BAO_0000019,,,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,Homo sapiens,9606.0,,
4891,,,BAO_0000019,,,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,Homo sapiens,9606.0,,
4892,,,BAO_0000019,,,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,Homo sapiens,9606.0,,
4893,,,BAO_0000019,,,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,Homo sapiens,9606.0,,
4894,,,BAO_0000019,,,17599,Partition coefficient (logP),A,,Homo sapiens,9606.0,,
4895,,,BAO_0000019,,,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,Homo sapiens,9606.0,,
4896,Microsomes,,BAO_0000251,,,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,Homo sapiens,9606.0,,
4897,,,BAO_0000019,,,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,Homo sapiens,9606.0,,
4898,,,BAO_0000019,,,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,Homo sapiens,9606.0,,
4899,,,BAO_0000019,,,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,Homo sapiens,9606.0,,
4900,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,Homo sapiens,9606.0,,
4901,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,Homo sapiens,9606.0,,
4902,Microsomes,,BAO_0000251,,,14294,Metabolism of compound in human microsomes; Trace,A,,Homo sapiens,9606.0,,
4903,Microsomes,,BAO_0000251,2107.0,,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,Homo sapiens,9606.0,,Liver
4904,Microsomes,,BAO_0000251,,,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,Homo sapiens,9606.0,,
4905,Microsomes,,BAO_0000251,2107.0,,6251,In vitro metabolic potential in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
4906,,,BAO_0000019,,,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,Homo sapiens,9606.0,,
4907,,,BAO_0000019,,,17313,Tested for human plasma protein binding of the compound; Not tested,A,,Homo sapiens,9606.0,,
4908,,,BAO_0000019,,,6227,Compound was tested for percent protein binding (PB) in human,A,,Homo sapiens,9606.0,,
4909,,,BAO_0000019,1969.0,,5530,Protein binding in human plasma,A,,Homo sapiens,9606.0,,Plasma
4910,,,BAO_0000019,,,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,Homo sapiens,9606.0,,
4911,,,BAO_0000019,,,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,Homo sapiens,9606.0,,
4912,,,BAO_0000019,,,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,Homo sapiens,9606.0,,
4913,,,BAO_0000019,,,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,Homo sapiens,9606.0,,
4914,,,BAO_0000219,,495.0,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,Homo sapiens,9606.0,,
4915,,,BAO_0000219,,495.0,6838,Permeability in Caco-2 cells of compound,A,,Homo sapiens,9606.0,,
4916,,,BAO_0000019,,,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,Homo sapiens,9606.0,,
4917,,,BAO_0000019,,,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,Homo sapiens,9606.0,,
4918,,,BAO_0000019,,,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,Homo sapiens,9606.0,,
4919,,,BAO_0000019,,,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,Homo sapiens,9606.0,,
4920,,,BAO_0000019,,,4514,Compound was tested for protein binding in human plasma,A,,Homo sapiens,9606.0,,
4921,,,BAO_0000019,,,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,Homo sapiens,9606.0,,
4922,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,Homo sapiens,9606.0,,Urine
4923,,In vivo,BAO_0000218,,,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,,Mus musculus,10090.0,,
4924,,In vivo,BAO_0000218,,,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,Mus musculus,10090.0,,
4925,,In vivo,BAO_0000218,,,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,,Mus musculus,10090.0,,
4926,,In vivo,BAO_0000218,1969.0,,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,,Mus musculus,10090.0,,Plasma
4927,,In vivo,BAO_0000218,1969.0,,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,,Mus musculus,10090.0,,Plasma
4928,,In vivo,BAO_0000218,,,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,,Mus musculus,10090.0,,
4929,,In vivo,BAO_0000218,,,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,,Mus musculus,10090.0,,
4930,,In vivo,BAO_0000218,,,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,,Mus musculus,10090.0,,
4931,,In vivo,BAO_0000218,,,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,,Mus musculus,10090.0,,
4932,,In vivo,BAO_0000218,955.0,,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Brain
4933,,In vivo,BAO_0000218,2113.0,,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Kidney
4934,,In vivo,BAO_0000218,2107.0,,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Liver
4935,,In vivo,BAO_0000218,2048.0,,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Lung
4936,,In vivo,BAO_0000218,,,17764,Tmax in mice at 18 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
4937,,In vivo,BAO_0000218,,,17764,Tmax in mice at 23 uM/kg i.v. administration,F,,Mus musculus,10090.0,,
4938,,In vivo,BAO_0000218,,,17764,Tmax in mice at 25 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
4939,,In vivo,BAO_0000218,,,17764,Tmax in mice at 26 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
4940,,In vivo,BAO_0000218,2106.0,,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Spleen
4941,,In vivo,BAO_0000218,,,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,
4942,,In vivo,BAO_0000218,,,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,10090.0,,
4943,,,BAO_0000218,,,5951,Tmax value in IRC mice,A,,Mus musculus,10090.0,,
4944,,In vivo,BAO_0000218,,,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,Mus musculus,10090.0,,
4945,,In vivo,BAO_0000218,,,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,Mus musculus,10090.0,,
4946,,,BAO_0000218,1088.0,,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,Mus musculus,10090.0,,Urine
4947,,,BAO_0000218,1088.0,,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,Mus musculus,10090.0,,Urine
4948,,,BAO_0000218,1088.0,,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,Mus musculus,10090.0,,Urine
4949,,,BAO_0000218,,,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,
4950,,,BAO_0000218,,,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,
4951,,In vivo,BAO_0000218,,,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,,Mus musculus,10090.0,,
4952,,In vivo,BAO_0000218,,,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,,Mus musculus,10090.0,,
4953,,In vivo,BAO_0000218,,,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,,Mus musculus,10090.0,,
4954,,In vivo,BAO_0000218,,,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,Mus musculus,10090.0,,
4955,,In vivo,BAO_0000218,,,5980,Vd in mice,A,,Mus musculus,10090.0,,
4956,,In vivo,BAO_0000218,,,17592,Volume of distribution in mouse,A,,Mus musculus,10090.0,,
4957,,In vivo,BAO_0000218,,,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,,Mus musculus,10090.0,,
4958,,In vivo,BAO_0000218,,,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,,Mus musculus,10090.0,,
4959,,In vivo,BAO_0000218,,,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,,Mus musculus,10090.0,,
4960,,In vivo,BAO_0000218,,,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,,Mus musculus,10090.0,,
4961,,In vivo,BAO_0000218,,,4239,Pharmacokinetic property (vdss) was measured in mouse,A,,Mus musculus,10090.0,,
4962,,In vivo,BAO_0000218,,,2862,Value distribution upon iv administration in mouse,A,,Mus musculus,10090.0,,
4963,,In vivo,BAO_0000218,,,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,
4964,,In vivo,BAO_0000218,,,2675,Volume of distribution was evaluated in mice after intravenous administration,A,,Mus musculus,10090.0,,
4965,,In vivo,BAO_0000218,,,2675,Volume of distribution was evaluated in mice after oral administration,A,,Mus musculus,10090.0,,
4966,,In vivo,BAO_0000218,,,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,,Mus musculus,10090.0,,
4967,,In vivo,BAO_0000218,,,5727,Steady state volume of distribution was determined in mice,A,,Mus musculus,10090.0,,
4968,,In vivo,BAO_0000218,,,17852,Volume distribution (steady state) of compound was determined in mouse,A,,Mus musculus,10090.0,,
4969,,In vivo,BAO_0000218,,,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,10090.0,,
4970,,In vivo,BAO_0000218,,,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,
4971,,In vivo,BAO_0000218,,,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,,Mus musculus,10090.0,,
4972,,In vivo,BAO_0000218,2113.0,,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,,Mus musculus,10090.0,,Kidney
4973,,In vivo,BAO_0000218,178.0,,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,,Mus musculus,10090.0,,Blood
4974,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,,Mus musculus,10090.0,,Blood
4975,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Blood
4976,,,BAO_0000219,,797.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,Homo sapiens,9606.0,,
4977,,,BAO_0000219,,500.0,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
4978,,,BAO_0000219,,500.0,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,Homo sapiens,9606.0,,
4979,,,BAO_0000219,,500.0,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,Homo sapiens,9606.0,,
4980,,,BAO_0000219,,500.0,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,Homo sapiens,9606.0,,
4981,,,BAO_0000219,,500.0,6700,Inhibition of A431 human carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
4982,,,BAO_0000219,,500.0,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,Homo sapiens,9606.0,,
4983,,,BAO_0000219,,500.0,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,Homo sapiens,9606.0,,
4984,,,BAO_0000219,,500.0,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,Homo sapiens,9606.0,,
4985,,,BAO_0000218,,500.0,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,Homo sapiens,9606.0,,
4986,,,BAO_0000219,,500.0,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,Homo sapiens,9606.0,,
4987,,,BAO_0000219,,500.0,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,Homo sapiens,9606.0,,
4988,,,BAO_0000219,,500.0,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,Homo sapiens,9606.0,,
4989,,,BAO_0000219,,500.0,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,
4990,,,BAO_0000219,,500.0,6333,Tested for antiproliferative activity against human A431 cells,F,,Homo sapiens,9606.0,,
4991,,,BAO_0000219,,500.0,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,Homo sapiens,9606.0,,
4992,,,BAO_0000219,,500.0,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,Homo sapiens,9606.0,,
4993,,,BAO_0000219,,500.0,5126,Inhibition of A431 cell proliferation,F,,Homo sapiens,9606.0,,
4994,,,BAO_0000219,,500.0,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,Homo sapiens,9606.0,,
4995,,,BAO_0000219,,500.0,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,Homo sapiens,9606.0,,
4996,,,BAO_0000219,,500.0,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,Homo sapiens,9606.0,,
4997,,,BAO_0000219,,500.0,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,Homo sapiens,9606.0,,
4998,,,BAO_0000219,,500.0,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,Homo sapiens,9606.0,,
4999,,,BAO_0000219,,500.0,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,Homo sapiens,9606.0,,
5000,,,BAO_0000219,,500.0,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,
5001,,,BAO_0000218,,500.0,17824,In vivo antiproliferative activity against A431 cell line,F,,Homo sapiens,9606.0,,
5002,,,BAO_0000219,,500.0,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,Homo sapiens,9606.0,,
5003,,,BAO_0000219,,500.0,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
5004,,,BAO_0000219,,500.0,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,Homo sapiens,9606.0,,
5005,,,BAO_0000219,,500.0,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,Homo sapiens,9606.0,,
5006,,,BAO_0000219,,500.0,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,Homo sapiens,9606.0,,
5007,,,BAO_0000219,,500.0,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,Homo sapiens,9606.0,,
5008,,,BAO_0000019,,,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,Homo sapiens,9606.0,,
5009,,,BAO_0000219,,500.0,12624,Inhibition of A431 cell proliferation,F,,Homo sapiens,9606.0,,
5010,,,BAO_0000219,,500.0,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,Homo sapiens,9606.0,,
5011,,,BAO_0000219,,500.0,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,Homo sapiens,9606.0,,
5012,,,BAO_0000219,,500.0,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,
5013,,,BAO_0000219,,500.0,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,Homo sapiens,9606.0,,
5014,,,BAO_0000219,,500.0,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,Homo sapiens,9606.0,,
5015,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,Homo sapiens,9606.0,,
5016,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,Homo sapiens,9606.0,,
5017,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,Homo sapiens,9606.0,,
5018,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,Homo sapiens,9606.0,,
5019,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,Homo sapiens,9606.0,,
5020,,,BAO_0000019,,,5922,Half-life period in cynomolgus monkey,A,,Cercopithecidae,9527.0,,
5021,,In vitro,BAO_0000366,1969.0,,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,,Cercopithecidae,9527.0,,Plasma
5022,,In vivo,BAO_0000218,,,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,,Cercopithecidae,9527.0,,
5023,,,BAO_0000366,1969.0,,993,Plasma half life in monkey,A,,Cercopithecidae,9527.0,,Plasma
5024,,,BAO_0000366,1969.0,,4514,Plasma half-life in rhesus monkey,A,,Cercopithecidae,9527.0,,Plasma
5025,,In vivo,BAO_0000218,1969.0,,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,,Cercopithecidae,9527.0,,Plasma
5026,,In vivo,BAO_0000218,1969.0,,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,,Cercopithecidae,9527.0,,Plasma
5027,,In vivo,BAO_0000218,,,4578,Tested for half life upon iv administration to african green monkey,A,,Cercopithecidae,9527.0,,
5028,,In vivo,BAO_0000218,,,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
5029,,In vivo,BAO_0000218,,,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,,Cercopithecidae,9527.0,,
5030,,In vivo,BAO_0000218,,,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,,Cercopithecidae,9527.0,,
5031,,In vivo,BAO_0000218,,,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
5032,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5033,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5034,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5035,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5036,,,BAO_0000019,,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5037,,,BAO_0000019,,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5038,,,BAO_0000019,,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5039,,,BAO_0000019,,,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5040,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5041,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5042,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5043,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5044,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5045,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5046,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5047,,,BAO_0000019,,,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,Cercopithecidae,9527.0,,
5048,,In vivo,BAO_0000218,,,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,,Rattus norvegicus,10116.0,,
5049,,In vivo,BAO_0000218,1969.0,,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,,Rattus norvegicus,10116.0,,Plasma
5050,,,BAO_0000218,1969.0,,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,Plasma
5051,,,BAO_0000218,1969.0,,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,Plasma
5052,,In vivo,BAO_0000218,,,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,
5053,,In vivo,BAO_0000218,,,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,
5054,,In vivo,BAO_0000218,,,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,
5055,,,BAO_0000218,,,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,
5056,,In vivo,BAO_0000218,,,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,
5057,,,BAO_0000019,,,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,Papio hamadryas,9557.0,,
5058,,,BAO_0000019,,,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,Papio hamadryas,9557.0,,
5059,,,BAO_0000019,,,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,Papio hamadryas,9557.0,,
5060,,,BAO_0000019,,,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,9557.0,,
5061,,,BAO_0000019,,,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,9557.0,,
5062,,,BAO_0000019,,,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,9557.0,,
5063,,,BAO_0000019,,,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,Papio hamadryas,9557.0,,
5064,,,BAO_0000019,,,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,Papio hamadryas,9557.0,,
5065,,,BAO_0000019,,,3510,Area under curve after 1 mpk peroral administration to beagles,A,,beagle,9615.0,,
5066,,,BAO_0000019,,,3510,Area under curve after 2 mpk peroral administration to beagles,A,,beagle,9615.0,,
5067,,In vivo,BAO_0000218,,,3510,Cmax value after 1 mpk peroral administration to beagles,A,,beagle,9615.0,,
5068,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,Homo sapiens,9606.0,,Urine
5069,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,Homo sapiens,9606.0,,Urine
5070,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,Homo sapiens,9606.0,,Urine
5071,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,Homo sapiens,9606.0,,Urine
5072,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,Homo sapiens,9606.0,,Urine
5073,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,Homo sapiens,9606.0,,Urine
5074,,,BAO_0000019,1088.0,,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,Homo sapiens,9606.0,,Urine
5075,Microsomes,,BAO_0000251,2107.0,,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5076,,,BAO_0000019,,,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,Homo sapiens,9606.0,,
5077,,,BAO_0000019,,,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,Homo sapiens,9606.0,,
5078,,,BAO_0000019,,,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,Homo sapiens,9606.0,,
5079,Microsomes,,BAO_0000251,2107.0,,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,Homo sapiens,9606.0,,Liver
5080,,,BAO_0000019,,,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,Homo sapiens,9606.0,,
5081,,,BAO_0000019,,,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,Homo sapiens,9606.0,,
5082,Microsomes,,BAO_0000251,2107.0,,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5083,Microsomes,,BAO_0000251,2107.0,,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,Homo sapiens,9606.0,,Liver
5084,Microsomes,,BAO_0000251,2107.0,,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,Homo sapiens,9606.0,,Liver
5085,,,BAO_0000218,,,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,Homo sapiens,9606.0,,
5086,,,BAO_0000019,,,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,Homo sapiens,9606.0,,
5087,,,BAO_0000019,,,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,Homo sapiens,9606.0,,
5088,,,BAO_0000019,,,3956,The percent remaining in human plasma after 30 min was determined,A,,Homo sapiens,9606.0,,
5089,,,BAO_0000366,1969.0,,5074,Conversion rate of the prodrug in human plasma,A,,Homo sapiens,9606.0,,Plasma
5090,,,BAO_0000366,1969.0,,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,Homo sapiens,9606.0,,Plasma
5091,,,BAO_0000221,178.0,,4727,Half life of compound was determined in human blood,A,,Homo sapiens,9606.0,,Blood
5092,,,BAO_0000019,,,5965,Half life of compound was determined in man with once daily dosing,A,,Homo sapiens,9606.0,,
5093,Microsomes,In vitro,BAO_0000251,,,5732,Half life in human microsomes,A,,Homo sapiens,9606.0,,
5094,,,BAO_0000366,1969.0,,5819,Half life in human plasma,A,,Homo sapiens,9606.0,,Plasma
5095,,,BAO_0000366,1969.0,,5819,Half life in human plasma; Not detected,A,,Homo sapiens,9606.0,,Plasma
5096,,In vivo,BAO_0000218,,,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,,Homo sapiens,9606.0,,
5097,Microsomes,In vitro,BAO_0000251,2107.0,,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,,Homo sapiens,9606.0,,Liver
5098,,,BAO_0000366,1969.0,,5229,Half-life in human plasma,A,,Homo sapiens,9606.0,,Plasma
5099,,,BAO_0000366,1969.0,,5229,Half-life of the parent prodrug in plasma,A,,Homo sapiens,9606.0,,Plasma
5100,,In vitro,BAO_0000366,1969.0,,2192,In vitro half life in human plasma was determined,A,,Homo sapiens,9606.0,,Plasma
5101,Microsomes,In vitro,BAO_0000251,2107.0,,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,,Homo sapiens,9606.0,,Liver
5102,,In vivo,BAO_0000218,,,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,,Homo sapiens,9606.0,,
5103,,In vivo,BAO_0000218,,,17716,Observed volume of distribution,A,,Homo sapiens,9606.0,,
5104,,In vivo,BAO_0000218,,,15778,Oral bioavailability in human,A,,Homo sapiens,9606.0,,
5105,,,BAO_0000019,,,17313,Tested for human plasma protein binding of the compound,A,,Homo sapiens,9606.0,,
5106,,,BAO_0000019,,,4231,"First order rate constant, k was determined in human plasma",A,,Homo sapiens,9606.0,,
5107,,,BAO_0000019,,,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,Homo sapiens,9606.0,,
5108,,,BAO_0000019,,,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,Homo sapiens,9606.0,,
5109,Microsomes,,BAO_0000251,2107.0,,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5110,,,BAO_0000019,,,10839,The compound was tested for the plasma binding in human,A,,Homo sapiens,9606.0,,
5111,,,BAO_0000019,,,10839,Plasma protein binding (human),A,,Homo sapiens,9606.0,,
5112,Microsomes,In vitro,BAO_0000251,2107.0,,3199,Compound was evaluated for half-life in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5113,,In vitro,BAO_0000221,178.0,,1345,Half life measured in vitro for its stability in human blood,A,,Homo sapiens,9606.0,,Blood
5114,,,BAO_0000019,1977.0,,4297,Half life in human serum,A,,Homo sapiens,9606.0,,Serum
5115,,,BAO_0000019,1977.0,,4297,Half life in human serum; ND=not determined,A,,Homo sapiens,9606.0,,Serum
5116,,,BAO_0000019,,,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,Homo sapiens,9606.0,,
5117,,,BAO_0000019,,,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,Homo sapiens,9606.0,,
5118,,,BAO_0000366,1969.0,,4231,Half life of the in human plasma,A,,Homo sapiens,9606.0,,Plasma
5119,S9,In vitro,BAO_0000220,,,5633,Half life period in human hepatic S9 fraction was determined,A,,Homo sapiens,9606.0,,
5120,Microsomes,In vitro,BAO_0000251,2107.0,,5633,Half life period in human liver microsome was determined,A,,Homo sapiens,9606.0,,Liver
5121,,,BAO_0000019,,,17791,Half life period was determined; 6-7,A,,Homo sapiens,9606.0,,
5122,,,BAO_0000019,,,17791,Half life period was evaluated in human,A,,Homo sapiens,9606.0,,
5123,,,BAO_0000366,1969.0,,3160,Half life time in human plasma,A,,Homo sapiens,9606.0,,Plasma
5124,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Brain
5125,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Heart
5126,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Heart
5127,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Kidney
5128,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,,Mus musculus,10090.0,,Kidney
5129,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Kidney
5130,,In vivo,BAO_0000218,2107.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Liver
5131,,In vivo,BAO_0000218,2107.0,,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,,Mus musculus,10090.0,,Liver
5132,,In vivo,BAO_0000218,2107.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Liver
5133,,In vivo,BAO_0000218,2106.0,,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,,Mus musculus,10090.0,,Spleen
5134,,In vivo,BAO_0000218,2106.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,,Mus musculus,10090.0,,Spleen
5135,,In vivo,BAO_0000218,2106.0,,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Spleen
5136,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,,Mus musculus,10090.0,,Brain
5137,,In vivo,BAO_0000218,178.0,,16438,Biodistribution of compound (oxidized form) in blood tissue,A,,Mus musculus,10090.0,,Blood
5138,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Blood
5139,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Blood
5140,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,,Mus musculus,10090.0,,Blood
5141,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Blood
5142,,In vivo,BAO_0000218,178.0,,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Blood
5143,,In vivo,BAO_0000218,955.0,,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,,Mus musculus,10090.0,,Brain
5144,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Brain
5145,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,,Mus musculus,10090.0,,Brain
5146,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Brain
5147,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Brain
5148,,In vivo,BAO_0000218,955.0,,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Brain
5149,,In vivo,BAO_0000218,948.0,,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,,Mus musculus,10090.0,,Heart
5150,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Heart
5151,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Heart
5152,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,,Mus musculus,10090.0,,Heart
5153,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Heart
5154,,In vivo,BAO_0000218,948.0,,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Heart
5155,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Kidney
5156,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Kidney
5157,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,,Mus musculus,10090.0,,Kidney
5158,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Kidney
5159,,In vivo,BAO_0000218,2113.0,,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,,Mus musculus,10090.0,,Kidney
5160,,In vivo,BAO_0000218,2107.0,,16438,Biodistribution of compound (oxidized form) in liver tissue,A,,Mus musculus,10090.0,,Liver
5161,,In vivo,BAO_0000218,2107.0,,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,,Mus musculus,10090.0,,Liver
5162,,In vivo,BAO_0000218,2107.0,,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,,Mus musculus,10090.0,,Liver
5163,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,Homo sapiens,9606.0,,
5164,,,BAO_0000219,,500.0,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,Homo sapiens,9606.0,,
5165,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,
5166,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,
5167,,,BAO_0000219,,500.0,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,Homo sapiens,9606.0,,
5168,,,BAO_0000219,,500.0,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,Homo sapiens,9606.0,,
5169,,,BAO_0000219,,500.0,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,Homo sapiens,9606.0,,
5170,,,BAO_0000219,,500.0,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,Homo sapiens,9606.0,,
5171,,,BAO_0000219,,500.0,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,Homo sapiens,9606.0,,
5172,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,
5173,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,
5174,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,
5175,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,
5176,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,
5177,,,BAO_0000219,,500.0,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,Homo sapiens,9606.0,,
5178,,,BAO_0000219,,500.0,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,
5179,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,
5180,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,
5181,,,BAO_0000218,,500.0,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,
5182,,,BAO_0000218,,500.0,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,10090.0,,
5183,,,BAO_0000218,,500.0,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,10090.0,,
5184,,,BAO_0000218,,500.0,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,10090.0,,
5185,,,BAO_0000218,,500.0,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,Mus musculus,10090.0,,
5186,,,BAO_0000219,,500.0,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,Homo sapiens,9606.0,,
5187,,,BAO_0000219,,500.0,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,Homo sapiens,9606.0,,
5188,,,BAO_0000219,,500.0,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,Homo sapiens,9606.0,,
5189,,,BAO_0000219,,500.0,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,Homo sapiens,9606.0,,
5190,,,BAO_0000219,,646.0,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,Homo sapiens,9606.0,,
5191,,,BAO_0000219,,646.0,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,Homo sapiens,9606.0,,
5192,,,BAO_0000219,,646.0,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,Homo sapiens,9606.0,,
5193,,,BAO_0000219,,624.0,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,Homo sapiens,9606.0,,
5194,,,BAO_0000219,,624.0,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,Homo sapiens,9606.0,,
5195,,,BAO_0000219,,624.0,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,Homo sapiens,9606.0,,
5196,,,BAO_0000219,,624.0,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,Homo sapiens,9606.0,,
5197,,,BAO_0000219,,624.0,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,Homo sapiens,9606.0,,
5198,,,BAO_0000219,,624.0,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,Homo sapiens,9606.0,,
5199,,,BAO_0000219,,624.0,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,Homo sapiens,9606.0,,
5200,,,BAO_0000219,,624.0,15403,Compound was evaluated against Human cell line renal A498,F,,Homo sapiens,9606.0,,
5201,,,BAO_0000219,,624.0,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,Homo sapiens,9606.0,,
5202,,,BAO_0000219,,624.0,1043,Growth inhibitory activity against A498 human cancer cell line,F,,Homo sapiens,9606.0,,
5203,,,BAO_0000219,,624.0,5858,In vitro antitumor activity against human renal A498 cell line,F,,Homo sapiens,9606.0,,
5204,,,BAO_0000219,,624.0,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,Homo sapiens,9606.0,,
5205,,,BAO_0000219,,624.0,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,Homo sapiens,9606.0,,
5206,,,BAO_0000219,,624.0,12781,Tested for cytostatic activity against renal A498 cell line,F,,Homo sapiens,9606.0,,
5207,,,BAO_0000219,,624.0,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,Homo sapiens,9606.0,,
5208,,,BAO_0000219,,624.0,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,Homo sapiens,9606.0,,
5209,,In vivo,BAO_0000218,,,3510,Cmax value after 2 mpk peroral administration to beagles,A,,beagle,9615.0,,
5210,,In vivo,BAO_0000218,,,3510,Bioavailability,A,,Canis lupus familiaris,9615.0,beagle,
5211,,In vivo,BAO_0000218,,,3510,Bioavailability after 1 mpk peroral administration to beagles,A,,Canis lupus familiaris,9615.0,beagle,
5212,,In vivo,BAO_0000218,,,3510,Bioavailability after 2 mpk peroral administration to beagles,A,,Canis lupus familiaris,9615.0,beagle,
5213,,,BAO_0000019,,,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,Bos taurus,9913.0,,
5214,,,BAO_0000019,,,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,Bos taurus,9913.0,,
5215,,,BAO_0000019,,,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,Bos taurus,9913.0,,
5216,,,BAO_0000019,,,9372,Solubility against bovine alpha-chymotrypsin,A,,Bos taurus,9913.0,,
5217,,,BAO_0000019,,,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,Bos taurus,9913.0,,
5218,,,BAO_0000019,,,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,Bos taurus,9913.0,,
5219,,,BAO_0000221,2106.0,,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,Bos taurus,9913.0,,Spleen
5220,,,BAO_0000019,,,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,Bos taurus,9913.0,,
5221,,,BAO_0000019,,,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,Bos taurus,9913.0,,
5222,,,BAO_0000019,,,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,Bos taurus,9913.0,,
5223,,,BAO_0000221,2106.0,,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,Bos taurus,9913.0,,Spleen
5224,,,BAO_0000019,,,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,Bos taurus,9913.0,,
5225,,,BAO_0000019,,,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,Bos taurus,9913.0,,
5226,,,BAO_0000019,,,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,Bos taurus,9913.0,,
5227,,,BAO_0000019,,,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,Bos taurus,9913.0,,
5228,,,BAO_0000019,,,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,Bos taurus,9913.0,,
5229,,,BAO_0000218,1969.0,,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
5230,,,BAO_0000218,1969.0,,17594,AUC after administration at 100 mg/kg/day in dogs,A,,Canis lupus familiaris,9615.0,,Plasma
5231,,,BAO_0000218,1969.0,,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,Canis lupus familiaris,9615.0,,Plasma
5232,,,BAO_0000218,1969.0,,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,9615.0,,Plasma
5233,,,BAO_0000218,1969.0,,16907,AUC value after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,Plasma
5234,,,BAO_0000218,1969.0,,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,Canis lupus familiaris,9615.0,,Plasma
5235,,,BAO_0000218,1969.0,,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,Plasma
5236,,,BAO_0000218,,,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,Canis lupus familiaris,9615.0,,
5237,,,BAO_0000218,,,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,Canis lupus familiaris,9615.0,,
5238,,,BAO_0000218,,,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
5239,,,BAO_0000218,,,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
5240,,,BAO_0000218,,,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,Canis lupus familiaris,9615.0,,
5241,,,BAO_0000218,,,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
5242,,,BAO_0000218,,,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,Canis lupus familiaris,9615.0,,
5243,,,BAO_0000218,,,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
5244,,,BAO_0000218,,,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
5245,,,BAO_0000218,,,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,Canis lupus familiaris,9615.0,,
5246,,,BAO_0000218,,,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,Canis lupus familiaris,9615.0,,
5247,,,BAO_0000218,,,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,Canis lupus familiaris,9615.0,,
5248,,,BAO_0000218,,,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,Canis lupus familiaris,9615.0,,
5249,,,BAO_0000218,,,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,Canis lupus familiaris,9615.0,,
5250,,,BAO_0000218,,,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,Canis lupus familiaris,9615.0,,
5251,,,BAO_0000218,,,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,Canis lupus familiaris,9615.0,,
5252,,,BAO_0000218,,,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,Canis lupus familiaris,9615.0,,
5253,,,BAO_0000218,,,5006,Area under curve was determined,A,,Canis lupus familiaris,9615.0,,
5254,,,BAO_0000218,,,5006,Area under curve in dogs,A,,Canis lupus familiaris,9615.0,,
5255,,,BAO_0000218,,,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,Canis lupus familiaris,9615.0,,
5256,,,BAO_0000218,,,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,Canis lupus familiaris,9615.0,,
5257,,,BAO_0000218,,,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,Canis lupus familiaris,9615.0,,
5258,,,BAO_0000218,,,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,Canis lupus familiaris,9615.0,,
5259,,,BAO_0000218,,,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
5260,,,BAO_0000218,,,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,Canis lupus familiaris,9615.0,,
5261,,,BAO_0000218,,,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,Canis lupus familiaris,9615.0,,
5262,,,BAO_0000218,,,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,9615.0,,
5263,,,BAO_0000218,,,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5264,,,BAO_0000019,,,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,Homo sapiens,9606.0,,
5265,,,BAO_0000019,,,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,Homo sapiens,9606.0,,
5266,,,BAO_0000019,,,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,Homo sapiens,9606.0,,
5267,,,BAO_0000019,,,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,Homo sapiens,9606.0,,
5268,,,BAO_0000221,178.0,,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,Homo sapiens,9606.0,,Blood
5269,,,BAO_0000366,1969.0,,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,Homo sapiens,9606.0,,Plasma
5270,,,BAO_0000366,1969.0,,6787,Half life in human plasma,A,,Homo sapiens,9606.0,,Plasma
5271,,,BAO_0000366,1969.0,,4898,Half life in human plasma was reported,A,,Homo sapiens,9606.0,,Plasma
5272,,,BAO_0000019,1977.0,,6072,Half life in human serum,A,,Homo sapiens,9606.0,,Serum
5273,,,BAO_0000366,1969.0,,16907,Half life upon exposure to human plasma,A,,Homo sapiens,9606.0,,Plasma
5274,Microsomes,In vitro,BAO_0000251,,,5656,t1/2 in human microsomes,A,,Homo sapiens,9606.0,,
5275,,,BAO_0000366,1969.0,,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,Homo sapiens,9606.0,,Plasma
5276,,,BAO_0000221,14.0,,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,Homo sapiens,9606.0,,Zone of skin
5277,,In vitro,BAO_0000366,1969.0,,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,,Homo sapiens,9606.0,,Plasma
5278,,,BAO_0000019,,,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,Homo sapiens,9606.0,,
5279,Microsomes,In vitro,BAO_0000251,2107.0,,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,,Homo sapiens,9606.0,,Liver
5280,,,BAO_0000366,1969.0,,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,Homo sapiens,9606.0,,Plasma
5281,,,BAO_0000366,1969.0,,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,Homo sapiens,9606.0,,Plasma
5282,,,BAO_0000366,1969.0,,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,Homo sapiens,9606.0,,Plasma
5283,,,BAO_0000019,,,1540,Half-life in the CEM cell extracts,A,,Homo sapiens,9606.0,,
5284,,,BAO_0000366,1969.0,,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,Homo sapiens,9606.0,,Plasma
5285,,,BAO_0000366,1969.0,,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,Homo sapiens,9606.0,,Plasma
5286,,,BAO_0000019,,,5523,Half-life was determined,A,,Homo sapiens,9606.0,,
5287,,,BAO_0000221,178.0,,1499,Half-life (human blood stability),A,,Homo sapiens,9606.0,,Blood
5288,,,BAO_0000221,178.0,,1499,Half-life (human blood stability); no data,A,,Homo sapiens,9606.0,,Blood
5289,,,BAO_0000366,1969.0,,17065,Half-life in human plasma,A,,Homo sapiens,9606.0,,Plasma
5290,,,BAO_0000019,,,6861,CYP3A4 metabolism half-life (t1/2),A,,Homo sapiens,9606.0,,
5291,,,BAO_0000221,178.0,,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,Homo sapiens,9606.0,,Blood
5292,,In vitro,BAO_0000366,1969.0,,530,In vitro half life in human plasma,A,,Homo sapiens,9606.0,,Plasma
5293,,In vitro,BAO_0000366,1969.0,,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,,Homo sapiens,9606.0,,Plasma
5294,,In vitro,BAO_0000366,1969.0,,6695,In vitro hydrolysis in human plasma,A,,Homo sapiens,9606.0,,Plasma
5295,,In vitro,BAO_0000366,1969.0,,6695,In vitro hydrolysis in human plasma; no data,A,,Homo sapiens,9606.0,,Plasma
5296,Microsomes,In vitro,BAO_0000251,2107.0,,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,,Homo sapiens,9606.0,,Liver
5297,,,BAO_0000366,1969.0,,993,Plasma half life in human,A,,Homo sapiens,9606.0,,Plasma
5298,,,BAO_0000366,1969.0,,15429,Stability after incubation with human plasma (at 37 degree C),A,,Homo sapiens,9606.0,,Plasma
5299,,,BAO_0000366,1969.0,,1675,T1/2 was evaluated in human plasma,A,,Homo sapiens,9606.0,,Plasma
5300,,,BAO_0000366,1969.0,,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,Homo sapiens,9606.0,,Plasma
5301,,,BAO_0000366,1969.0,,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,Homo sapiens,9606.0,,Plasma
5302,,,BAO_0000019,,,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,Homo sapiens,9606.0,,
5303,,In vitro,BAO_0000019,,,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,,Homo sapiens,9606.0,,
5304,,In vitro,BAO_0000019,,,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,,Homo sapiens,9606.0,,
5305,,,BAO_0000366,1969.0,,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,Homo sapiens,9606.0,,Plasma
5306,,,BAO_0000366,1969.0,,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,Homo sapiens,9606.0,,Plasma
5307,,,BAO_0000019,,,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,Homo sapiens,9606.0,,
5308,,,BAO_0000019,,,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,Homo sapiens,9606.0,,
5309,Microsomes,,BAO_0000251,2107.0,,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5310,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,
5311,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,
5312,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,
5313,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,
5314,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,
5315,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,10095.0,,
5316,,,BAO_0000219,,391.0,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,Homo sapiens,9606.0,,
5317,,,BAO_0000219,,391.0,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,Homo sapiens,9606.0,,
5318,,,BAO_0000219,,391.0,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,Homo sapiens,9606.0,,
5319,,,BAO_0000219,,391.0,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,Homo sapiens,9606.0,,
5320,,,BAO_0000219,,391.0,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,Homo sapiens,9606.0,,
5321,,,BAO_0000219,,391.0,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,Homo sapiens,9606.0,,
5322,,,BAO_0000219,,391.0,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,Homo sapiens,9606.0,,
5323,,,BAO_0000219,,391.0,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,Homo sapiens,9606.0,,
5324,,,BAO_0000219,,391.0,12888,Cytotoxic effect on renal cancer line 786-0,F,,Homo sapiens,9606.0,,
5325,,,BAO_0000219,,391.0,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,Homo sapiens,9606.0,,
5326,,,BAO_0000219,,391.0,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
5327,,,BAO_0000219,,391.0,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,Homo sapiens,9606.0,,
5328,,,BAO_0000219,,391.0,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,Homo sapiens,9606.0,,
5329,,,BAO_0000219,,391.0,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,Homo sapiens,9606.0,,
5330,,,BAO_0000219,,391.0,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,Homo sapiens,9606.0,,
5331,,,BAO_0000219,,391.0,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,9606.0,,
5332,,,BAO_0000219,,391.0,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,Homo sapiens,9606.0,,
5333,,,BAO_0000219,,391.0,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,Homo sapiens,9606.0,,
5334,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,Homo sapiens,9606.0,,
5335,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,Homo sapiens,9606.0,,
5336,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,Homo sapiens,9606.0,,
5337,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,Homo sapiens,9606.0,,
5338,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,Homo sapiens,9606.0,,
5339,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,Homo sapiens,9606.0,,
5340,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,Homo sapiens,9606.0,,
5341,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,Homo sapiens,9606.0,,
5342,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,Homo sapiens,9606.0,,
5343,,,BAO_0000219,,972.0,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,Homo sapiens,9606.0,,
5344,,,BAO_0000219,,391.0,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,Homo sapiens,9606.0,,
5345,,,BAO_0000019,,,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,
5346,,,BAO_0000219,,741.0,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,Homo sapiens,9606.0,,
5347,,,BAO_0000219,,741.0,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,Homo sapiens,9606.0,,
5348,,,BAO_0000219,,741.0,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,Homo sapiens,9606.0,,
5349,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,Homo sapiens,9606.0,,
5350,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,Homo sapiens,9606.0,,
5351,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5352,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5353,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5354,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5355,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5356,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5357,,,BAO_0000219,,741.0,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5358,,,BAO_0000219,,624.0,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
5359,,,BAO_0000219,,624.0,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,Homo sapiens,9606.0,,
5360,,,BAO_0000219,,624.0,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,Homo sapiens,9606.0,,
5361,,,BAO_0000219,,624.0,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,Homo sapiens,9606.0,,
5362,,,BAO_0000219,,624.0,15277,Cytotoxicity against A 498 tumor cell line,F,,Homo sapiens,9606.0,,
5363,,,BAO_0000219,,624.0,4812,In vitro antitumor activity against A498 human cancer cell line,F,,Homo sapiens,9606.0,,
5364,,,BAO_0000219,,624.0,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,Homo sapiens,9606.0,,
5365,,,BAO_0000219,,624.0,4995,Inhibitory dose required against A498 human tumor cell lines,F,,Homo sapiens,9606.0,,
5366,,,BAO_0000219,,624.0,5847,Anticancer activity against one renal cancer (A498 cell line),F,,Homo sapiens,9606.0,,
5367,,,BAO_0000219,,624.0,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,Homo sapiens,9606.0,,
5368,,,BAO_0000219,,624.0,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,Homo sapiens,9606.0,,
5369,,,BAO_0000219,,624.0,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,Homo sapiens,9606.0,,
5370,,,BAO_0000219,,624.0,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,Homo sapiens,9606.0,,
5371,,,BAO_0000219,,624.0,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,9606.0,,
5372,,,BAO_0000219,,624.0,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,Homo sapiens,9606.0,,
5373,,,BAO_0000219,,624.0,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,Homo sapiens,9606.0,,
5374,,,BAO_0000219,,624.0,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,Homo sapiens,9606.0,,
5375,,,BAO_0000219,,624.0,12888,Cytotoxic effect on renal cancer lines A498,F,,Homo sapiens,9606.0,,
5376,,,BAO_0000219,,624.0,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,Homo sapiens,9606.0,,
5377,,,BAO_0000219,,624.0,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
5378,,,BAO_0000219,,624.0,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,Homo sapiens,9606.0,,
5379,,,BAO_0000219,,624.0,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,Homo sapiens,9606.0,,
5380,,,BAO_0000219,,624.0,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,Homo sapiens,9606.0,,
5381,,,BAO_0000219,,624.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,Homo sapiens,9606.0,,
5382,,,BAO_0000219,,646.0,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
5383,,,BAO_0000219,,646.0,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,Homo sapiens,9606.0,,
5384,,,BAO_0000219,,646.0,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,Homo sapiens,9606.0,,
5385,,,BAO_0000219,,646.0,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,Homo sapiens,9606.0,,
5386,,,BAO_0000219,,646.0,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,Homo sapiens,9606.0,,
5387,,,BAO_0000219,,646.0,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,Homo sapiens,9606.0,,
5388,,,BAO_0000219,,646.0,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,9606.0,,
5389,,,BAO_0000219,,646.0,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,Homo sapiens,9606.0,,
5390,,,BAO_0000219,,646.0,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,Homo sapiens,9606.0,,
5391,,,BAO_0000219,,646.0,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,Homo sapiens,9606.0,,
5392,,,BAO_0000219,,646.0,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,Homo sapiens,9606.0,,
5393,,,BAO_0000219,,646.0,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,Homo sapiens,9606.0,,
5394,,,BAO_0000219,,646.0,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,Homo sapiens,9606.0,,
5395,,,BAO_0000219,,646.0,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,Homo sapiens,9606.0,,
5396,,,BAO_0000219,,646.0,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
5397,,,BAO_0000219,,646.0,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,Homo sapiens,9606.0,,
5398,,,BAO_0000219,,646.0,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,Homo sapiens,9606.0,,
5399,,,BAO_0000219,,646.0,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,Homo sapiens,9606.0,,
5400,,,BAO_0000219,,646.0,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,Homo sapiens,9606.0,,
5401,,,BAO_0000219,,646.0,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,9606.0,,
5402,,,BAO_0000219,,646.0,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,Homo sapiens,9606.0,,
5403,,,BAO_0000219,,646.0,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,Homo sapiens,9606.0,,
5404,,,BAO_0000219,,646.0,4090,Inhibition of A549 cancer cell proliferation,F,,Homo sapiens,9606.0,,
5405,,,BAO_0000219,,646.0,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,Homo sapiens,9606.0,,
5406,,,BAO_0000219,,646.0,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,Homo sapiens,9606.0,,
5407,,,BAO_0000219,,646.0,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,Homo sapiens,9606.0,,
5408,,,BAO_0000219,,646.0,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,Homo sapiens,9606.0,,
5409,,,BAO_0000219,,646.0,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,Homo sapiens,9606.0,,
5410,,,BAO_0000219,,646.0,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,Homo sapiens,9606.0,,
5411,,,BAO_0000218,,,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,Canis lupus familiaris,9615.0,,
5412,,,BAO_0000218,,,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5413,,,BAO_0000218,,,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,
5414,,,BAO_0000218,,,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,
5415,,,BAO_0000218,,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,Canis lupus familiaris,9615.0,,
5416,,,BAO_0000218,,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,Canis lupus familiaris,9615.0,,
5417,,,BAO_0000218,,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,Canis lupus familiaris,9615.0,,
5418,,,BAO_0000218,,,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,Canis lupus familiaris,9615.0,,
5419,,,BAO_0000218,1969.0,,17657,Area under plasma concentration time curve in dog upon oral administration,A,,Canis lupus familiaris,9615.0,,Plasma
5420,,,BAO_0000218,1969.0,,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,Canis lupus familiaris,9615.0,,Plasma
5421,,,BAO_0000218,,,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,Canis lupus familiaris,9615.0,,
5422,,,BAO_0000218,,,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,Canis lupus familiaris,9615.0,,
5423,,,BAO_0000218,,,3132,Area under the curve for the compound was obtained when tested in dog,A,,Canis lupus familiaris,9615.0,,
5424,,,BAO_0000218,,,5473,Area under the curve at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5425,,,BAO_0000218,,,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,Canis lupus familiaris,9615.0,,
5426,,,BAO_0000218,,,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,Canis lupus familiaris,9615.0,,
5427,,,BAO_0000218,,,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5428,,,BAO_0000218,,,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5429,,,BAO_0000218,,,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,Canis lupus familiaris,9615.0,,
5430,,,BAO_0000218,,,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,Canis lupus familiaris,9615.0,,
5431,,,BAO_0000218,,,2877,Compound was evaluated for area under the curve in dog blood.,A,,Canis lupus familiaris,9615.0,,
5432,,,BAO_0000218,,,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,Canis lupus familiaris,9615.0,,
5433,,,BAO_0000218,1969.0,,5130,AUC in dog after oral dose (1 mg/kg),A,,Canis lupus familiaris,9615.0,,Plasma
5434,,,BAO_0000218,,,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5435,,,BAO_0000218,,,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,Canis lupus familiaris,9615.0,,
5436,,,BAO_0000218,,,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,Canis lupus familiaris,9615.0,,
5437,,,BAO_0000218,,,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,Canis lupus familiaris,9615.0,,
5438,,,BAO_0000218,,,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,Canis lupus familiaris,9615.0,,
5439,,,BAO_0000218,,,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,Canis lupus familiaris,9615.0,,
5440,,,BAO_0000218,,,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,Canis lupus familiaris,9615.0,,
5441,,,BAO_0000218,,,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5442,,,BAO_0000218,,,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,Canis lupus familiaris,9615.0,,
5443,,,BAO_0000218,,,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,Canis lupus familiaris,9615.0,,
5444,,,BAO_0000218,,,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,9615.0,,
5445,,,BAO_0000218,,,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,9615.0,,
5446,,,BAO_0000218,,,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,Canis lupus familiaris,9615.0,,
5447,,,BAO_0000218,,,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,Canis lupus familiaris,9615.0,,
5448,,,BAO_0000218,,,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,Canis lupus familiaris,9615.0,,
5449,,,BAO_0000218,,,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,Canis lupus familiaris,9615.0,,
5450,,,BAO_0000218,,,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,Canis lupus familiaris,9615.0,,
5451,,,BAO_0000218,,,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,Canis lupus familiaris,9615.0,,
5452,,,BAO_0000218,,,3880,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5453,,,BAO_0000218,,,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,Canis lupus familiaris,9615.0,,
5454,,,BAO_0000218,1969.0,,17409,Plasma protein binding towards dog plasma at 10 uM,A,,Canis lupus familiaris,9615.0,,Plasma
5455,,,BAO_0000218,1969.0,,17409,Plasma protein binding towards dog plasma at 100 uM,A,,Canis lupus familiaris,9615.0,,Plasma
5456,,In vivo,BAO_0000218,,,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,,Canis lupus familiaris,9615.0,,
5457,,In vivo,BAO_0000218,,,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,,Canis lupus familiaris,9615.0,,
5458,,In vivo,BAO_0000218,,,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
5459,,In vivo,BAO_0000218,,,15145,Bioavailability in dogs,A,,Canis lupus familiaris,9615.0,,
5460,,In vivo,BAO_0000218,,,4219,Bioavailability,A,,Canis lupus familiaris,9615.0,,
5461,,In vivo,BAO_0000218,,,17538,Oral bioavailability in dog (dose 10 mg/kg),A,,Canis lupus familiaris,9615.0,,
5462,,In vivo,BAO_0000218,,,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,,Canis lupus familiaris,9615.0,,
5463,,In vivo,BAO_0000218,,,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,,Canis lupus familiaris,9615.0,,
5464,,In vivo,BAO_0000218,,,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,,Canis lupus familiaris,9615.0,,
5465,,In vivo,BAO_0000218,,,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,,Canis lupus familiaris,9615.0,,
5466,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,
5467,,,BAO_0000218,2107.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,Liver
5468,,,BAO_0000218,2107.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,10095.0,,Liver
5469,,,BAO_0000218,2107.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,Liver
5470,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,
5471,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,
5472,,,BAO_0000218,2385.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,Muscle tissue
5473,,,BAO_0000218,2385.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,10095.0,,Muscle tissue
5474,,,BAO_0000218,2385.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,Muscle tissue
5475,,,BAO_0000218,2106.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,Spleen
5476,,,BAO_0000218,2106.0,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,Spleen
5477,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,Mus sp.,10095.0,,
5478,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,10095.0,,
5479,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,
5480,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,Mus sp.,10095.0,,
5481,,,BAO_0000218,,,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,Mus sp.,10095.0,,
5482,,,BAO_0000019,,,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,9527.0,,
5483,,,BAO_0000019,2037.0,,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,9527.0,,Cerebellum
5484,,,BAO_0000019,1870.0,,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,9527.0,,Frontal cortex
5485,,,BAO_0000019,,,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,Cercopithecidae,9527.0,,
5486,,,BAO_0000019,2435.0,,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,9527.0,,Striatum
5487,,,BAO_0000019,,,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,9527.0,,
5488,,,BAO_0000019,2037.0,,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,9527.0,,Cerebellum
5489,,,BAO_0000019,1870.0,,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,9527.0,,Frontal cortex
5490,,,BAO_0000019,,,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,Cercopithecidae,9527.0,,
5491,,,BAO_0000019,2435.0,,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,Cercopithecidae,9527.0,,Striatum
5492,,,BAO_0000218,,,17791,Compound was evaluated for oral bioavailability in rats,A,,Cercopithecidae,9527.0,,
5493,,In vivo,BAO_0000218,1969.0,,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,,Cercopithecidae,9527.0,,Plasma
5494,,,BAO_0000019,,,17791,Half life period was evaluated in monkey,A,,Cercopithecidae,9527.0,,
5495,,In vivo,BAO_0000218,,,110,Half-life in rhesus monkeys by intravenous administration of dose,A,,Cercopithecidae,9527.0,,
5496,,,BAO_0000218,1969.0,,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,Mus musculus,10090.0,,Plasma
5497,,,BAO_0000218,1969.0,,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,Plasma
5498,,,BAO_0000218,1969.0,,17718,AUC value was determined after oral administration,A,,Mus musculus,10090.0,,Plasma
5499,,,BAO_0000218,,,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,Mus musculus,10090.0,,
5500,,,BAO_0000218,,,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,Mus musculus,10090.0,,
5501,,,BAO_0000218,,,2862,Area under curve by ioral administration in mouse,A,,Mus musculus,10090.0,,
5502,,,BAO_0000218,,,2862,Area under curve by iv administration in mouse,A,,Mus musculus,10090.0,,
5503,,,BAO_0000218,,,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,Mus musculus,10090.0,,
5504,,,BAO_0000218,,,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,Mus musculus,10090.0,,
5505,,,BAO_0000218,,,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,Mus musculus,10090.0,,
5506,,,BAO_0000218,,,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,Mus musculus,10090.0,,
5507,,,BAO_0000218,,,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,Mus musculus,10090.0,,
5508,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,Homo sapiens,9606.0,,
5509,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,Homo sapiens,9606.0,,
5510,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5511,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5512,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5513,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5514,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5515,,,BAO_0000219,,741.0,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5516,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,Homo sapiens,9606.0,,
5517,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,Homo sapiens,9606.0,,
5518,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5519,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5520,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5521,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5522,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,Homo sapiens,9606.0,,
5523,,,BAO_0000219,,741.0,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,Homo sapiens,9606.0,,
5524,,,BAO_0000219,,741.0,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,Homo sapiens,9606.0,,
5525,,,BAO_0000219,,741.0,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,Homo sapiens,9606.0,,
5526,,,BAO_0000219,,741.0,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,Homo sapiens,9606.0,,
5527,,,BAO_0000219,,741.0,17378,Cytotoxicity of compound against 8226/S cells,F,,Homo sapiens,9606.0,,
5528,,,BAO_0000219,,741.0,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,Homo sapiens,9606.0,,
5529,,,BAO_0000219,,741.0,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,Homo sapiens,9606.0,,
5530,,,BAO_0000219,,854.0,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,Homo sapiens,9606.0,,
5531,,,BAO_0000219,,854.0,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,Homo sapiens,9606.0,,
5532,,,BAO_0000219,,854.0,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,Homo sapiens,9606.0,,
5533,,,BAO_0000219,,854.0,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,Homo sapiens,9606.0,,
5534,,,BAO_0000019,,,6608,Inhibitory activity against caspase-1,B,,,,,
5535,,,BAO_0000357,,,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,Enterococcus faecalis,1351.0,,
5536,,,BAO_0000219,,705.0,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,Homo sapiens,9606.0,,
5537,,,BAO_0000219,,705.0,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,Homo sapiens,9606.0,,
5538,,,BAO_0000019,,,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,
5539,,,BAO_0000019,,,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,
5540,,,BAO_0000019,,,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,
5541,,,BAO_0000019,,,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,
5542,,,BAO_0000019,,,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,Streptococcus pyogenes,1314.0,,
5543,,,BAO_0000019,,,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,Streptococcus pyogenes,1314.0,,
5544,,,BAO_0000357,,,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,
5545,,,BAO_0000219,,324.0,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,Homo sapiens,9606.0,,
5546,,,BAO_0000219,,324.0,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,Homo sapiens,9606.0,,
5547,,,BAO_0000219,,,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,Homo sapiens,9606.0,,
5548,,,BAO_0000219,,392.0,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,Rattus norvegicus,10116.0,,
5549,,,BAO_0000219,,392.0,15345,Tested in vitro for anticancer activity against 9L cells,F,,Rattus norvegicus,10116.0,,
5550,,,BAO_0000219,,392.0,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,Rattus norvegicus,10116.0,,
5551,,,BAO_0000219,,646.0,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,Homo sapiens,9606.0,,
5552,,,BAO_0000219,,646.0,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,Homo sapiens,9606.0,,
5553,,,BAO_0000219,,646.0,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,Homo sapiens,9606.0,,
5554,,,BAO_0000219,,646.0,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,Homo sapiens,9606.0,,
5555,,,BAO_0000219,,646.0,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,Homo sapiens,9606.0,,
5556,,,BAO_0000219,,646.0,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,Homo sapiens,9606.0,,
5557,,,BAO_0000219,,646.0,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,Homo sapiens,9606.0,,
5558,,,BAO_0000219,,646.0,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,Homo sapiens,9606.0,,
5559,,,BAO_0000219,,646.0,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,Homo sapiens,9606.0,,
5560,,,BAO_0000219,,646.0,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
5561,,,BAO_0000219,,646.0,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,Homo sapiens,9606.0,,
5562,,,BAO_0000219,,646.0,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,Homo sapiens,9606.0,,
5563,,,BAO_0000219,,646.0,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,Homo sapiens,9606.0,,
5564,,,BAO_0000219,,646.0,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,Homo sapiens,9606.0,,
5565,,,BAO_0000219,,646.0,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,Homo sapiens,9606.0,,
5566,,,BAO_0000219,,646.0,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,Homo sapiens,9606.0,,
5567,,,BAO_0000219,,646.0,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,Homo sapiens,9606.0,,
5568,,,BAO_0000219,,646.0,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,Homo sapiens,9606.0,,
5569,,,BAO_0000219,,646.0,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,Homo sapiens,9606.0,,
5570,,,BAO_0000219,,646.0,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,Homo sapiens,9606.0,,
5571,,,BAO_0000219,,646.0,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,Homo sapiens,9606.0,,
5572,,,BAO_0000219,,646.0,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,Homo sapiens,9606.0,,
5573,,,BAO_0000219,,646.0,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,Homo sapiens,9606.0,,
5574,,,BAO_0000219,,646.0,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,Homo sapiens,9606.0,,
5575,,,BAO_0000219,,646.0,6776,Growth inhibition against A549 cell line was evaluated,F,,Homo sapiens,9606.0,,
5576,,,BAO_0000219,,646.0,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,Homo sapiens,9606.0,,
5577,,,BAO_0000219,,646.0,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,Homo sapiens,9606.0,,
5578,,,BAO_0000219,,646.0,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,Homo sapiens,9606.0,,
5579,,,BAO_0000219,,646.0,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,Homo sapiens,9606.0,,
5580,,,BAO_0000219,,646.0,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,Homo sapiens,9606.0,,
5581,,,BAO_0000219,,646.0,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,Homo sapiens,9606.0,,
5582,,,BAO_0000219,,646.0,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,Homo sapiens,9606.0,,
5583,,,BAO_0000219,,646.0,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,Homo sapiens,9606.0,,
5584,,,BAO_0000219,,646.0,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,Homo sapiens,9606.0,,
5585,,,BAO_0000219,,646.0,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,Homo sapiens,9606.0,,
5586,,,BAO_0000219,,646.0,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,Homo sapiens,9606.0,,
5587,,,BAO_0000219,,646.0,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,Homo sapiens,9606.0,,
5588,,,BAO_0000219,,646.0,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,Homo sapiens,9606.0,,
5589,,,BAO_0000219,,646.0,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,Homo sapiens,9606.0,,
5590,,,BAO_0000219,,646.0,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,Homo sapiens,9606.0,,
5591,,,BAO_0000219,,646.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,Homo sapiens,9606.0,,
5592,,,BAO_0000219,,646.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,Homo sapiens,9606.0,,
5593,,,BAO_0000219,,646.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,Homo sapiens,9606.0,,
5594,,,BAO_0000219,,646.0,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,Homo sapiens,9606.0,,
5595,,,BAO_0000219,,646.0,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,Homo sapiens,9606.0,,
5596,,,BAO_0000219,,646.0,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,Homo sapiens,9606.0,,
5597,,,BAO_0000219,,646.0,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,Homo sapiens,9606.0,,
5598,,,BAO_0000219,,646.0,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,Homo sapiens,9606.0,,
5599,,In vivo,BAO_0000218,,,3043,Oral bioavailability in dog (conscious),A,,Canis lupus familiaris,9615.0,,
5600,,In vivo,BAO_0000218,,,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,,Canis lupus familiaris,9615.0,,
5601,,In vivo,BAO_0000218,,,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,,Canis lupus familiaris,9615.0,,
5602,,In vivo,BAO_0000218,,,4453,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5603,,In vivo,BAO_0000218,,,1696,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5604,,In vivo,BAO_0000218,,,5045,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5605,,In vivo,BAO_0000218,,,5356,Oral bioavailability in dog (fasted),A,,Canis lupus familiaris,9615.0,,
5606,,In vivo,BAO_0000218,,,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,9615.0,,
5607,,In vivo,BAO_0000218,,,6448,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5608,,In vivo,BAO_0000218,,,1475,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5609,,In vivo,BAO_0000218,,,3788,Percent bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5610,,In vivo,BAO_0000218,,,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,,Canis lupus familiaris,9615.0,,
5611,,In vivo,BAO_0000218,,,13397,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5612,,In vivo,BAO_0000218,,,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,,Canis lupus familiaris,9615.0,,
5613,,In vivo,BAO_0000218,,,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,,Canis lupus familiaris,9615.0,,
5614,,In vivo,BAO_0000218,,,6448,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
5615,,,BAO_0000218,,,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,Canis lupus familiaris,9615.0,,
5616,,In vivo,BAO_0000218,1969.0,,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,,Canis lupus familiaris,9615.0,,Plasma
5617,,,BAO_0000218,,,6316,C24 after oral administration at 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
5618,,,BAO_0000218,,,5238,Clearance after oral and iv dosing in dogs,A,,Canis lupus familiaris,9615.0,,
5619,,,BAO_0000218,1969.0,,17796,Clearance of the drug was measured in the plasma of dog,A,,Canis lupus familiaris,9615.0,,Plasma
5620,,,BAO_0000218,,,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,Canis lupus familiaris,9615.0,,
5621,,In vivo,BAO_0000218,,,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5622,,In vivo,BAO_0000218,,,6621,Clearance of compound was determined in dogs,A,,Canis lupus familiaris,9615.0,,
5623,,In vivo,BAO_0000218,,,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,,Canis lupus familiaris,9615.0,,
5624,,In vivo,BAO_0000218,,,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,Canis lupus familiaris,9615.0,,
5625,,In vivo,BAO_0000218,,,17267,Plasma clearance in dog was determined,A,,Canis lupus familiaris,9615.0,,
5626,,In vivo,BAO_0000218,,,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,,Canis lupus familiaris,9615.0,,
5627,,In vivo,BAO_0000218,,,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,,Canis lupus familiaris,9615.0,,
5628,,In vivo,BAO_0000218,,,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,,Canis lupus familiaris,9615.0,,
5629,,In vivo,BAO_0000218,,,6535,Plasma clearance in dogs,A,,Canis lupus familiaris,9615.0,,
5630,,In vivo,BAO_0000218,,,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,,Canis lupus familiaris,9615.0,,
5631,,In vivo,BAO_0000218,,,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,,Canis lupus familiaris,9615.0,,
5632,,In vivo,BAO_0000218,,,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,9615.0,,
5633,,In vivo,BAO_0000218,,,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,
5634,,In vivo,BAO_0000218,,,16367,Plasma administration to dogs,A,,Canis lupus familiaris,9615.0,,
5635,,In vivo,BAO_0000218,,,5505,Plasma clearance was determined,A,,Canis lupus familiaris,9615.0,,
5636,,In vivo,BAO_0000218,,,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
5637,,In vivo,BAO_0000218,,,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,,Canis lupus familiaris,9615.0,,
5638,Microsomes,In vitro,BAO_0000251,2107.0,,5007,Intrinsic clearance in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5639,Microsomes,In vitro,BAO_0000251,2107.0,,5007,Intrinsic clearance in human liver microsomes,A,,Homo sapiens,9606.0,,Liver
5640,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,,Canis lupus familiaris,9615.0,,
5641,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,,Canis lupus familiaris,9615.0,,
5642,,In vivo,BAO_0000218,,,16452,Clearance in dog (dose 1 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
5643,,In vivo,BAO_0000218,,,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,,Canis lupus familiaris,9615.0,,
5644,,In vivo,BAO_0000218,,,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,Canis lupus familiaris,9615.0,,
5645,,In vivo,BAO_0000218,,,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,,Canis lupus familiaris,9615.0,,
5646,,In vivo,BAO_0000218,,,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,,Canis lupus familiaris,9615.0,,
5647,,In vivo,BAO_0000218,,,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5648,,In vivo,BAO_0000218,,,15660,Plasma clearance was measured in dog,A,,Canis lupus familiaris,9615.0,,
5649,,In vivo,BAO_0000218,,,15660,Plasma clearance was measured in dog,A,,Canis lupus familiaris,9615.0,,
5650,,In vivo,BAO_0000218,,,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,,Canis lupus familiaris,9615.0,,
5651,,In vivo,BAO_0000218,,,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,,Canis lupus familiaris,9615.0,,
5652,,In vivo,BAO_0000218,,,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,9615.0,,
5653,,In vivo,BAO_0000218,,,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
5654,,In vivo,BAO_0000218,,,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
5655,,In vivo,BAO_0000218,,,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
5656,,In vivo,BAO_0000218,,,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5657,,In vivo,BAO_0000218,,,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5658,,In vivo,BAO_0000218,1969.0,,1918,Clearance value was evaluated in dog plasma,A,,Canis lupus familiaris,9615.0,,Plasma
5659,,In vivo,BAO_0000218,,,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5660,,In vivo,BAO_0000218,1969.0,,4839,Compound was tested for plasma clearance in dog,A,,Canis lupus familiaris,9615.0,,Plasma
5661,,In vivo,BAO_0000218,,,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,,Canis lupus familiaris,9615.0,,
5662,,,BAO_0000218,,,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,Mus musculus,10090.0,,
5663,,,BAO_0000218,,,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,Mus musculus,10090.0,,
5664,,,BAO_0000218,,,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,Mus musculus,10090.0,,
5665,,,BAO_0000218,,,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,Mus musculus,10090.0,,
5666,,,BAO_0000218,,,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,Mus musculus,10090.0,,
5667,,,BAO_0000218,,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,Mus musculus,10090.0,,
5668,,,BAO_0000218,,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,Mus musculus,10090.0,,
5669,,,BAO_0000218,,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,Mus musculus,10090.0,,
5670,,,BAO_0000218,,,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,Mus musculus,10090.0,,
5671,,,BAO_0000218,,,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,10090.0,,
5672,,,BAO_0000218,,,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,Mus musculus,10090.0,,
5673,,,BAO_0000218,,,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,Mus musculus,10090.0,,
5674,,,BAO_0000218,,,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,Mus musculus,10090.0,,
5675,,,BAO_0000218,,,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,Mus musculus,10090.0,,
5676,,,BAO_0000218,,,3132,Area under the curve for the compound was obtained when tested in mouse,A,,Mus musculus,10090.0,,
5677,,,BAO_0000218,,,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,Mus musculus,10090.0,,
5678,,,BAO_0000218,,,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,Mus musculus,10090.0,,
5679,,,BAO_0000218,,,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,Mus musculus,10090.0,,
5680,,,BAO_0000218,,,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,Mus musculus,10090.0,,
5681,,,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,Mus musculus,10090.0,,
5682,,,BAO_0000218,,,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,Mus musculus,10090.0,,
5683,,,BAO_0000218,,,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,Mus musculus,10090.0,,
5684,,,BAO_0000218,,,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,Mus musculus,10090.0,,
5685,,,BAO_0000218,,,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,Mus musculus,10090.0,,
5686,,,BAO_0000218,,,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,Mus musculus,10090.0,,
5687,,,BAO_0000218,,,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,Mus musculus,10090.0,,
5688,,,BAO_0000218,,,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,Mus musculus,10090.0,,
5689,,,BAO_0000218,,,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,Mus musculus,10090.0,,
5690,,,BAO_0000218,,,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,Mus musculus,10090.0,,
5691,,,BAO_0000218,,,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,Mus musculus,10090.0,,
5692,,,BAO_0000218,,,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,Mus musculus,10090.0,,
5693,,,BAO_0000218,,,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,Mus musculus,10090.0,,
5694,,,BAO_0000218,,,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,Mus musculus,10090.0,,
5695,,,BAO_0000218,,,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,Mus musculus,10090.0,,
5696,,,BAO_0000218,,,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,Mus musculus,10090.0,,
5697,,,BAO_0000218,,,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,Mus musculus,10090.0,,
5698,,,BAO_0000218,,,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,Mus musculus,10090.0,,
5699,,,BAO_0000218,,,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,Mus musculus,10090.0,,
5700,,,BAO_0000218,,,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,Mus musculus,10090.0,,
5701,,,BAO_0000218,,,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,Mus musculus,10090.0,,
5702,,,BAO_0000218,,,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,Mus musculus,10090.0,,
5703,,,BAO_0000218,,,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,Mus musculus,10090.0,,
5704,,,BAO_0000218,,,2675,Area under the curve was evaluated in mice after intravenous administration,A,,Mus musculus,10090.0,,
5705,,,BAO_0000218,,,2675,Area under the curve was evaluated in mice after oral administration,A,,Mus musculus,10090.0,,
5706,,,BAO_0000218,1969.0,,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,Plasma
5707,,,BAO_0000218,1969.0,,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,10090.0,,Plasma
5708,,,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,Mus musculus,10090.0,,
5709,,,BAO_0000218,,,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,
5710,,In vivo,BAO_0000218,178.0,,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Blood
5711,,,BAO_0000219,,392.0,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,
5712,,,BAO_0000019,,,2181,Anti proliferation activity determined; Weak effect,F,,Rattus norvegicus,10116.0,,
5713,,,BAO_0000219,,,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,Rattus norvegicus,10116.0,,
5714,,,BAO_0000219,,,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,Rattus norvegicus,10116.0,,
5715,,,BAO_0000219,,,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,Rattus norvegicus,10116.0,,
5716,,,BAO_0000019,,,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,Mus musculus,10090.0,,
5717,,,BAO_0000019,,,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,Mus musculus,10090.0,,
5718,,,BAO_0000019,,,15508,Partition coefficient (logD6.5),A,,,,,
5719,,,BAO_0000219,,478.0,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,Homo sapiens,9606.0,,
5720,,,BAO_0000219,,455.0,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,Homo sapiens,9606.0,,
5721,,,BAO_0000219,,500.0,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,Homo sapiens,9606.0,,
5722,,,BAO_0000219,,500.0,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,Homo sapiens,9606.0,,
5723,,,BAO_0000219,,624.0,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,Homo sapiens,9606.0,,
5724,,,BAO_0000219,,624.0,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,Homo sapiens,9606.0,,
5725,,,BAO_0000219,,624.0,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,Homo sapiens,9606.0,,
5726,,,BAO_0000219,,624.0,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,Homo sapiens,9606.0,,
5727,,,BAO_0000219,,624.0,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,Homo sapiens,9606.0,,
5728,,,BAO_0000019,,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,Staphylococcus aureus,1280.0,,
5729,,,BAO_0000019,,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,Staphylococcus aureus,1280.0,,
5730,,,BAO_0000019,,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,Staphylococcus aureus,1280.0,,
5731,,,BAO_0000019,,,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,Staphylococcus aureus,1280.0,,
5732,,,BAO_0000219,,646.0,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,Homo sapiens,9606.0,,
5733,,,BAO_0000219,,646.0,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,Homo sapiens,9606.0,,
5734,,,BAO_0000219,,646.0,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,Homo sapiens,9606.0,,
5735,,,BAO_0000219,,646.0,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,Homo sapiens,9606.0,,
5736,,,BAO_0000219,,646.0,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,Homo sapiens,9606.0,,
5737,,,BAO_0000219,,646.0,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,Homo sapiens,9606.0,,
5738,,,BAO_0000219,,646.0,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,Homo sapiens,9606.0,,
5739,,,BAO_0000219,,646.0,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,Homo sapiens,9606.0,,
5740,,,BAO_0000219,,646.0,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,Homo sapiens,9606.0,,
5741,,,BAO_0000219,,646.0,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,Homo sapiens,9606.0,,
5742,,,BAO_0000219,,646.0,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,Homo sapiens,9606.0,,
5743,,,BAO_0000219,,646.0,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,Homo sapiens,9606.0,,
5744,,,BAO_0000219,,646.0,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,Homo sapiens,9606.0,,
5745,,,BAO_0000218,,,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,
5746,,In vivo,BAO_0000218,,,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,,,,,
5747,,In vivo,BAO_0000218,,,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,,,,,
5748,,In vivo,BAO_0000218,,,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,,,,,
5749,,In vivo,BAO_0000218,,,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,,,,,
5750,,In vivo,BAO_0000218,,,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,,,,,
5751,,,BAO_0000219,,624.0,3600,Inhibition of A-498 human Renal cell proliferation,F,,Homo sapiens,9606.0,,
5752,,,BAO_0000019,,,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,Rattus norvegicus,10116.0,,
5753,,,BAO_0000019,,,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,Rattus norvegicus,10116.0,,
5754,,,BAO_0000019,,,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,Rattus norvegicus,10116.0,,
5755,,,BAO_0000219,,622.0,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,Homo sapiens,9606.0,,
5756,,,BAO_0000219,,622.0,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,9606.0,,
5757,,,BAO_0000219,,622.0,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,9606.0,,
5758,,,BAO_0000219,,646.0,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,Homo sapiens,9606.0,,
5759,,,BAO_0000219,,646.0,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,Homo sapiens,9606.0,,
5760,,,BAO_0000219,,646.0,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,Homo sapiens,9606.0,,
5761,,,BAO_0000219,,646.0,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,Homo sapiens,9606.0,,
5762,,,BAO_0000219,,646.0,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,Homo sapiens,9606.0,,
5763,,,BAO_0000219,,646.0,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,Homo sapiens,9606.0,,
5764,,,BAO_0000219,,646.0,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,Homo sapiens,9606.0,,
5765,,,BAO_0000219,,646.0,6851,Cytotoxicity of compound against A549 cell line,F,,Homo sapiens,9606.0,,
5766,,,BAO_0000219,,646.0,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,Homo sapiens,9606.0,,
5767,,,BAO_0000219,,646.0,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,Homo sapiens,9606.0,,
5768,,,BAO_0000219,,646.0,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,Homo sapiens,9606.0,,
5769,,,BAO_0000219,,646.0,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,Homo sapiens,9606.0,,
5770,,,BAO_0000219,,646.0,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,Homo sapiens,9606.0,,
5771,,,BAO_0000219,,646.0,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,Homo sapiens,9606.0,,
5772,,,BAO_0000219,,646.0,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,Homo sapiens,9606.0,,
5773,,,BAO_0000219,,646.0,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
5774,,,BAO_0000219,,646.0,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,Homo sapiens,9606.0,,
5775,,,BAO_0000219,,646.0,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,Homo sapiens,9606.0,,
5776,,,BAO_0000219,,646.0,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,Homo sapiens,9606.0,,
5777,,,BAO_0000219,,646.0,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
5778,,,BAO_0000218,,646.0,17824,In vivo antiproliferative activity against A549 cell line,F,,Homo sapiens,9606.0,,
5779,,,BAO_0000219,,646.0,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,Homo sapiens,9606.0,,
5780,,,BAO_0000219,,646.0,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,Homo sapiens,9606.0,,
5781,,,BAO_0000219,,646.0,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,Homo sapiens,9606.0,,
5782,,,BAO_0000219,,646.0,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,Homo sapiens,9606.0,,
5783,,,BAO_0000219,,646.0,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,Homo sapiens,9606.0,,
5784,,,BAO_0000219,,646.0,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,Homo sapiens,9606.0,,
5785,,,BAO_0000219,,646.0,4862,Inhibitory activity against A549 lung cancer cell line,F,,Homo sapiens,9606.0,,
5786,,,BAO_0000219,,646.0,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,Homo sapiens,9606.0,,
5787,,,BAO_0000219,,646.0,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,Homo sapiens,9606.0,,
5788,,,BAO_0000219,,646.0,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,Homo sapiens,9606.0,,
5789,,,BAO_0000219,,646.0,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
5790,,,BAO_0000219,,646.0,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,Homo sapiens,9606.0,,
5791,,,BAO_0000219,,646.0,13736,Activity against A549 cancer cell line.,F,,Homo sapiens,9606.0,,
5792,,,BAO_0000219,,646.0,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,Homo sapiens,9606.0,,
5793,,,BAO_0000219,,646.0,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,Homo sapiens,9606.0,,
5794,,,BAO_0000219,,646.0,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,Homo sapiens,9606.0,,
5795,,,BAO_0000219,,646.0,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,Homo sapiens,9606.0,,
5796,,,BAO_0000219,,646.0,4634,Inhibitory activity against A549 lung cancer cell line,F,,Homo sapiens,9606.0,,
5797,,,BAO_0000219,,646.0,1149,Inhibitory activity against A549 cell line; inactive,F,,Homo sapiens,9606.0,,
5798,,,BAO_0000219,,646.0,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,Homo sapiens,9606.0,,
5799,,,BAO_0000219,,646.0,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,Homo sapiens,9606.0,,
5800,,,BAO_0000219,,646.0,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,Homo sapiens,9606.0,,
5801,,,BAO_0000219,,646.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,Homo sapiens,9606.0,,
5802,,,BAO_0000219,,646.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,Homo sapiens,9606.0,,
5803,,,BAO_0000219,,646.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,Homo sapiens,9606.0,,
5804,,,BAO_0000219,,646.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,Homo sapiens,9606.0,,
5805,,,BAO_0000219,,646.0,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,Homo sapiens,9606.0,,
5806,,,BAO_0000219,,646.0,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,Homo sapiens,9606.0,,
5807,,In vivo,BAO_0000218,,,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,,Canis lupus familiaris,9615.0,,
5808,,In vivo,BAO_0000218,,,5985,Plasma clearance was measured in dog,A,,Canis lupus familiaris,9615.0,,
5809,,In vivo,BAO_0000218,,,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,,Canis lupus familiaris,9615.0,,
5810,,In vivo,BAO_0000218,,,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5811,,In vivo,BAO_0000218,1969.0,,4839,Tested for plasma clearance in dog,A,,Canis lupus familiaris,9615.0,,Plasma
5812,,In vivo,BAO_0000218,,,3639,The compound was tested for clearance in dog plasma.,A,,Canis lupus familiaris,9615.0,,
5813,,In vivo,BAO_0000218,,,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,,Canis lupus familiaris,9615.0,,
5814,,In vivo,BAO_0000218,,,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,,Canis lupus familiaris,9615.0,,
5815,,In vivo,BAO_0000218,1969.0,,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,,Canis lupus familiaris,9615.0,,Plasma
5816,Microsomes,In vitro,BAO_0000218,2107.0,,17538,In vitro clearance in dog liver microsomes,A,,Canis lupus familiaris,9615.0,,Liver
5817,,In vivo,BAO_0000218,,,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,,Canis lupus familiaris,9615.0,,
5818,,In vivo,BAO_0000218,,,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,,Canis lupus familiaris,9615.0,,
5819,,In vivo,BAO_0000218,,,1696,Plasma clearance in dog,A,,Canis lupus familiaris,9615.0,,
5820,,In vivo,BAO_0000218,,,6762,Clearance rate in dog,A,,Canis lupus familiaris,9615.0,,
5821,,In vivo,BAO_0000218,1969.0,,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,,Canis lupus familiaris,9615.0,,Plasma
5822,,In vivo,BAO_0000218,,,6305,Clearance in dogs,A,,Canis lupus familiaris,9615.0,,
5823,,In vivo,BAO_0000218,,,4942,Plasma clearance in dogs,A,,Canis lupus familiaris,9615.0,,
5824,,In vivo,BAO_0000218,,,4219,Plasma clearance was determined,A,,Canis lupus familiaris,9615.0,,
5825,,In vivo,BAO_0000218,,,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,,Canis lupus familiaris,9615.0,,
5826,,In vivo,BAO_0000218,,,4514,Plasma clearance in Beagle dogs,A,,Canis lupus familiaris,9615.0,,
5827,,In vivo,BAO_0000218,,,6448,Plasma clearance (Clp) in dog,A,,Canis lupus familiaris,9615.0,,
5828,,In vivo,BAO_0000218,,,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5829,,In vivo,BAO_0000218,,,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,,Canis lupus familiaris,9615.0,,
5830,,In vivo,BAO_0000218,,,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5831,,In vivo,BAO_0000218,,,6821,Plasma clearance of compound was determined in dog,A,,Canis lupus familiaris,9615.0,,
5832,,In vivo,BAO_0000218,,,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5833,,In vivo,BAO_0000218,,,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,,Canis lupus familiaris,9615.0,,
5834,,In vivo,BAO_0000218,,,5374,Plasma clearance in dog was determined,A,,Canis lupus familiaris,9615.0,,
5835,,In vivo,BAO_0000218,,,6057,Plasma clearance was calculated in dog,A,,Canis lupus familiaris,9615.0,,
5836,,In vivo,BAO_0000218,,,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5837,,In vivo,BAO_0000218,,,5145,Plasma clearance in dog,A,,Canis lupus familiaris,9615.0,,
5838,,In vivo,BAO_0000218,,,17657,Plasma clearance in dog,A,,Canis lupus familiaris,9615.0,,
5839,,In vivo,BAO_0000218,,,17657,Plasma clearance in dog; Unable to calculate,A,,Canis lupus familiaris,9615.0,,
5840,,In vivo,BAO_0000218,,,5145,Plasma clearance in rhesus monkey,A,,Canis lupus familiaris,9615.0,,
5841,,In vivo,BAO_0000218,,,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,9615.0,,
5842,,In vivo,BAO_0000218,,,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Canis lupus familiaris,9615.0,,
5843,,In vivo,BAO_0000218,,,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Canis lupus familiaris,9615.0,,
5844,,In vivo,BAO_0000218,,,5472,Plasma clearance was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
5845,,In vivo,BAO_0000218,,,5472,Plasma clearance was evaluated in dog; Not tested,A,,Canis lupus familiaris,9615.0,,
5846,,In vivo,BAO_0000218,,,5472,Plasma clearance was evaluated in rhesus,A,,Canis lupus familiaris,9615.0,,
5847,,In vivo,BAO_0000218,,,5472,Plasma clearance was evaluated in rhesus; Not tested,A,,Canis lupus familiaris,9615.0,,
5848,,In vivo,BAO_0000218,,,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,,Canis lupus familiaris,9615.0,,
5849,,In vivo,BAO_0000218,,,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,,Canis lupus familiaris,9615.0,,
5850,,In vivo,BAO_0000218,,,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,Canis lupus familiaris,9615.0,,
5851,,In vivo,BAO_0000218,,,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,
5852,,In vivo,BAO_0000218,,,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,,Canis lupus familiaris,9615.0,,
5853,,In vivo,BAO_0000218,1969.0,,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
5854,,In vivo,BAO_0000218,,,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,
5855,,In vivo,BAO_0000218,,,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,
5856,,In vivo,BAO_0000218,,,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,Canis lupus familiaris,9615.0,,
5857,,In vivo,BAO_0000218,,,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,,Canis lupus familiaris,9615.0,,
5858,,In vivo,BAO_0000218,,,6535,Cmax in dog after administration of 1 mg/kg iv,A,,Canis lupus familiaris,9615.0,,
5859,,In vivo,BAO_0000218,1969.0,,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,,Canis lupus familiaris,9615.0,,Plasma
5860,,In vivo,BAO_0000218,,,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,,Canis lupus familiaris,9615.0,,
5861,,In vivo,BAO_0000218,,,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,,Canis lupus familiaris,9615.0,,
5862,,In vivo,BAO_0000218,,,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,,Canis lupus familiaris,9615.0,,
5863,,In vivo,BAO_0000218,,,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
5864,,In vivo,BAO_0000218,,,5600,Cmax after 0.3 mg/kg po administration in dog,A,,Canis lupus familiaris,9615.0,,
5865,,In vivo,BAO_0000218,,,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,,Canis lupus familiaris,9615.0,,
5866,,In vivo,BAO_0000218,,,6123,Cmax in dog after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
5867,,In vivo,BAO_0000218,,,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,,Canis lupus familiaris,9615.0,,
5868,,In vivo,BAO_0000218,,,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
5869,,In vivo,BAO_0000218,,,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,9615.0,,
5870,,In vivo,BAO_0000218,178.0,,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Blood
5871,,In vivo,BAO_0000218,178.0,,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Blood
5872,,In vivo,BAO_0000218,10000001.0,,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Bone
5873,,In vivo,BAO_0000218,10000001.0,,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Bone
5874,,In vivo,BAO_0000218,10000001.0,,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Bone
5875,,In vivo,BAO_0000218,,,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,
5876,,In vivo,BAO_0000218,,,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,
5877,,In vivo,BAO_0000218,,,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,
5878,,In vivo,BAO_0000218,948.0,,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Heart
5879,,In vivo,BAO_0000218,948.0,,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Heart
5880,,In vivo,BAO_0000218,948.0,,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Heart
5881,,In vivo,BAO_0000218,2113.0,,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Kidney
5882,,In vivo,BAO_0000218,2113.0,,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Kidney
5883,,In vivo,BAO_0000218,2113.0,,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Kidney
5884,,In vivo,BAO_0000218,160.0,,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Intestine
5885,,In vivo,BAO_0000218,160.0,,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Intestine
5886,,In vivo,BAO_0000218,160.0,,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Intestine
5887,,In vivo,BAO_0000218,2107.0,,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Liver
5888,,In vivo,BAO_0000218,2107.0,,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Liver
5889,,In vivo,BAO_0000218,2107.0,,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Liver
5890,,In vivo,BAO_0000218,2048.0,,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Lung
5891,,In vivo,BAO_0000218,2048.0,,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Lung
5892,,In vivo,BAO_0000218,2048.0,,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Lung
5893,,In vivo,BAO_0000218,2385.0,,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Muscle tissue
5894,,In vivo,BAO_0000218,2385.0,,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Muscle tissue
5895,,In vivo,BAO_0000218,2385.0,,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Muscle tissue
5896,,In vivo,BAO_0000218,,,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,
5897,,In vivo,BAO_0000218,,,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,
5898,,In vivo,BAO_0000218,,,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,
5899,,In vivo,BAO_0000218,160.0,,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Intestine
5900,,In vivo,BAO_0000218,160.0,,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Intestine
5901,,In vivo,BAO_0000218,160.0,,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Intestine
5902,,In vivo,BAO_0000218,2106.0,,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Spleen
5903,,In vivo,BAO_0000218,2106.0,,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Spleen
5904,,In vivo,BAO_0000218,2106.0,,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Spleen
5905,,In vivo,BAO_0000218,945.0,,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Stomach
5906,,In vivo,BAO_0000218,945.0,,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Stomach
5907,,,BAO_0000219,,622.0,2036,Cytotoxicity against A-172 human tumor cell lines,F,,Homo sapiens,9606.0,,
5908,,,BAO_0000219,,622.0,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,Homo sapiens,9606.0,,
5909,,,BAO_0000219,,623.0,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,Homo sapiens,9606.0,,
5910,,,BAO_0000219,,478.0,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,Homo sapiens,9606.0,,
5911,,,BAO_0000219,,455.0,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,Homo sapiens,9606.0,,
5912,,,BAO_0000219,,455.0,12152,Tested in vitro against A-375 cell line human melanoma,F,,Homo sapiens,9606.0,,
5913,,,BAO_0000219,,797.0,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,Homo sapiens,9606.0,,
5914,,,BAO_0000219,,797.0,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,9606.0,,
5915,,,BAO_0000219,,797.0,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,Homo sapiens,9606.0,,
5916,,,BAO_0000219,,797.0,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,Homo sapiens,9606.0,,
5917,,,BAO_0000219,,797.0,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,Homo sapiens,9606.0,,
5918,,,BAO_0000219,,797.0,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,Homo sapiens,9606.0,,
5919,,,BAO_0000219,,797.0,17134,In vitro antitumor effects against human A-427 cell lines.,F,,Homo sapiens,9606.0,,
5920,,,BAO_0000219,,797.0,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,Homo sapiens,9606.0,,
5921,,,BAO_0000219,,797.0,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,Homo sapiens,9606.0,,
5922,,,BAO_0000219,,797.0,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,Homo sapiens,9606.0,,
5923,,,BAO_0000219,,500.0,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,Homo sapiens,9606.0,,
5924,,,BAO_0000219,,624.0,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,Homo sapiens,9606.0,,
5925,,,BAO_0000219,,624.0,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,Homo sapiens,9606.0,,
5926,,,BAO_0000219,,624.0,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,Homo sapiens,9606.0,,
5927,,,BAO_0000219,,624.0,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,Homo sapiens,9606.0,,
5928,,,BAO_0000219,,624.0,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,Homo sapiens,9606.0,,
5929,,,BAO_0000219,,624.0,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,Homo sapiens,9606.0,,
5930,,,BAO_0000219,,624.0,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,Homo sapiens,9606.0,,
5931,,,BAO_0000219,,624.0,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,Homo sapiens,9606.0,,
5932,,,BAO_0000219,,624.0,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,Homo sapiens,9606.0,,
5933,,,BAO_0000219,,624.0,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,Homo sapiens,9606.0,,
5934,,,BAO_0000219,,624.0,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,Homo sapiens,9606.0,,
5935,,,BAO_0000219,,646.0,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,Homo sapiens,9606.0,,
5936,,,BAO_0000219,,646.0,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,Homo sapiens,9606.0,,
5937,,,BAO_0000219,,646.0,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,Homo sapiens,9606.0,,
5938,,,BAO_0000219,,646.0,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,Homo sapiens,9606.0,,
5939,,,BAO_0000219,,646.0,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,Homo sapiens,9606.0,,
5940,,,BAO_0000219,,646.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,Homo sapiens,9606.0,,
5941,,,BAO_0000219,,646.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,Homo sapiens,9606.0,,
5942,,,BAO_0000219,,646.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,Homo sapiens,9606.0,,
5943,,,BAO_0000219,,646.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,Homo sapiens,9606.0,,
5944,,,BAO_0000219,,646.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,Homo sapiens,9606.0,,
5945,,,BAO_0000219,,646.0,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,Homo sapiens,9606.0,,
5946,,,BAO_0000219,,646.0,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,Homo sapiens,9606.0,,
5947,,,BAO_0000219,,646.0,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,Homo sapiens,9606.0,,
5948,,,BAO_0000219,,646.0,6513,Cytotoxic activity against A-549 cell line,F,,Homo sapiens,9606.0,,
5949,,,BAO_0000219,,646.0,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,Homo sapiens,9606.0,,
5950,,,BAO_0000219,,646.0,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,Homo sapiens,9606.0,,
5951,,,BAO_0000219,,646.0,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,Homo sapiens,9606.0,,
5952,,,BAO_0000219,,646.0,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,Homo sapiens,9606.0,,
5953,,,BAO_0000219,,646.0,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,Homo sapiens,9606.0,,
5954,,,BAO_0000219,,646.0,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,Homo sapiens,9606.0,,
5955,,,BAO_0000219,,646.0,5771,Cytotoxic activity towards A-549 cells,F,,Homo sapiens,9606.0,,
5956,,,BAO_0000219,,646.0,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,Homo sapiens,9606.0,,
5957,,,BAO_0000219,,646.0,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,Homo sapiens,9606.0,,
5958,,,BAO_0000219,,646.0,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,Homo sapiens,9606.0,,
5959,,,BAO_0000219,,646.0,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,Homo sapiens,9606.0,,
5960,,,BAO_0000219,,646.0,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,Homo sapiens,9606.0,,
5961,,,BAO_0000219,,646.0,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,9606.0,,
5962,,,BAO_0000219,,646.0,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,Homo sapiens,9606.0,,
5963,,,BAO_0000218,,646.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,9606.0,,
5964,,,BAO_0000218,,646.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,9606.0,,
5965,,,BAO_0000218,,646.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,9606.0,,
5966,,,BAO_0000218,,646.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,9606.0,,
5967,,,BAO_0000218,,646.0,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,Homo sapiens,9606.0,,
5968,,,BAO_0000219,,646.0,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,Homo sapiens,9606.0,,
5969,,,BAO_0000218,,646.0,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,Homo sapiens,9606.0,,
5970,,,BAO_0000219,,646.0,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,Homo sapiens,9606.0,,
5971,,,BAO_0000219,,646.0,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,Homo sapiens,9606.0,,
5972,,,BAO_0000219,,646.0,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,Homo sapiens,9606.0,,
5973,,,BAO_0000219,,646.0,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,Homo sapiens,9606.0,,
5974,,,BAO_0000219,,646.0,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,Homo sapiens,9606.0,,
5975,,,BAO_0000219,,646.0,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,Homo sapiens,9606.0,,
5976,,,BAO_0000219,,646.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,Homo sapiens,9606.0,,
5977,,,BAO_0000219,,646.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,Homo sapiens,9606.0,,
5978,,,BAO_0000219,,646.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,Homo sapiens,9606.0,,
5979,,,BAO_0000219,,646.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,Homo sapiens,9606.0,,
5980,,,BAO_0000219,,646.0,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,Homo sapiens,9606.0,,
5981,,,BAO_0000219,,646.0,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,Homo sapiens,9606.0,,
5982,,,BAO_0000219,,646.0,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,Homo sapiens,9606.0,,
5983,,,BAO_0000219,,646.0,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,Homo sapiens,9606.0,,
5984,,,BAO_0000219,,646.0,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,Homo sapiens,9606.0,,
5985,,,BAO_0000219,,646.0,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,Homo sapiens,9606.0,,
5986,,,BAO_0000219,,646.0,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,Homo sapiens,9606.0,,
5987,,,BAO_0000219,,646.0,17737,In vitro antiproliferative activity against A549 cell line,F,,Mus musculus,10090.0,,
5988,,,BAO_0000219,,646.0,6630,Synergism with indomethacin in A549 cells,F,,,,,
5989,,,BAO_0000219,,646.0,6630,Synergism with tolmetin in A549 cells,F,,,,,
5990,,,BAO_0000219,,646.0,6630,Synergism with sulindac in A549 cells,F,,,,,
5991,,,BAO_0000219,,646.0,6630,Antagonism of indomethacin in A549 cells,F,,,,,
5992,,,BAO_0000219,,646.0,6630,Antagonism of sulindac in A549 cells,F,,,,,
5993,,,BAO_0000219,,646.0,6630,Antagonism of tolmetin in A549 cells,F,,,,,
5994,,,BAO_0000219,,646.0,6630,Synergism with indomethacin in A549 cells,F,,,,,
5995,,,BAO_0000219,,646.0,6630,Synergism with sulindac in A549 cells,F,,,,,
5996,,,BAO_0000219,,646.0,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,
5997,,In vivo,BAO_0000218,,,16907,Cmax value after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,
5998,,In vivo,BAO_0000218,,,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,Canis lupus familiaris,9615.0,,
5999,,In vivo,BAO_0000218,,,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,,Canis lupus familiaris,9615.0,,
6000,,In vivo,BAO_0000218,,,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,Canis lupus familiaris,9615.0,,
6001,,In vivo,BAO_0000218,,,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,,Canis lupus familiaris,9615.0,,
6002,,In vivo,BAO_0000218,,,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,,Canis lupus familiaris,9615.0,,
6003,,In vivo,BAO_0000218,,,6241,Cmax value in dog,A,,Canis lupus familiaris,9615.0,,
6004,,In vivo,BAO_0000218,,,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
6005,,In vivo,BAO_0000218,,,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,,Canis lupus familiaris,9615.0,,
6006,,In vivo,BAO_0000218,1969.0,,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,,Canis lupus familiaris,9615.0,,Plasma
6007,,In vivo,BAO_0000218,1969.0,,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,,Canis lupus familiaris,9615.0,,Plasma
6008,,In vivo,BAO_0000218,,,1021,Concentration maxima after oral dosing in dogs,A,,Canis lupus familiaris,9615.0,,
6009,,In vivo,BAO_0000218,,,1021,Concentration maxima after oral dosing in dogs; not available,A,,Canis lupus familiaris,9615.0,,
6010,,In vivo,BAO_0000218,,,1021,Concentration maxima after oral dosing in dogs; not available,A,,Canis lupus familiaris,9615.0,,
6011,,In vivo,BAO_0000218,,,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,,Canis lupus familiaris,9615.0,,
6012,,In vivo,BAO_0000218,,,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,,Canis lupus familiaris,9615.0,,
6013,,In vivo,BAO_0000218,,,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6014,,In vivo,BAO_0000218,,,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,,Canis lupus familiaris,9615.0,,
6015,,In vivo,BAO_0000218,,,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,,Canis lupus familiaris,9615.0,,
6016,,In vivo,BAO_0000218,1969.0,,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,,Canis lupus familiaris,9615.0,,Plasma
6017,,In vivo,BAO_0000218,1969.0,,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6018,,In vivo,BAO_0000218,1969.0,,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6019,,In vivo,BAO_0000218,1969.0,,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,,Canis lupus familiaris,9615.0,,Plasma
6020,,In vivo,BAO_0000218,1969.0,,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,,Canis lupus familiaris,9615.0,,Plasma
6021,,In vivo,BAO_0000218,,,3031,Maximum concentration of compound in dog was evaluated.,A,,Canis lupus familiaris,9615.0,,
6022,,In vivo,BAO_0000218,,,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
6023,,In vivo,BAO_0000218,,,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,,Canis lupus familiaris,9615.0,,
6024,,In vivo,BAO_0000218,,,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,Canis lupus familiaris,9615.0,,
6025,,In vivo,BAO_0000218,1969.0,,3132,Maximum concentration obtained in dog plasma was determined,A,,Canis lupus familiaris,9615.0,,Plasma
6026,,In vivo,BAO_0000218,,,5006,Maximum concentration was determined,A,,Canis lupus familiaris,9615.0,,
6027,,In vivo,BAO_0000218,,,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6028,,In vivo,BAO_0000218,,,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,Canis lupus familiaris,9615.0,,
6029,,In vivo,BAO_0000218,1969.0,,1918,Maximum concentration was evaluated in dog plasma,A,,Canis lupus familiaris,9615.0,,Plasma
6030,,In vivo,BAO_0000218,,,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,,Canis lupus familiaris,9615.0,,
6031,,In vivo,BAO_0000218,1969.0,,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,,Canis lupus familiaris,9615.0,,Plasma
6032,,In vivo,BAO_0000218,1969.0,,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,,Canis lupus familiaris,9615.0,,Plasma
6033,,In vivo,BAO_0000218,1969.0,,933,Maximum plasma concentration in dog,A,,Canis lupus familiaris,9615.0,,Plasma
6034,,In vivo,BAO_0000218,1969.0,,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6035,,In vivo,BAO_0000218,1969.0,,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6036,,In vivo,BAO_0000218,1969.0,,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6037,,In vivo,BAO_0000218,1969.0,,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6038,,In vivo,BAO_0000218,1969.0,,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,Plasma
6039,,In vivo,BAO_0000218,1969.0,,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6040,,In vivo,BAO_0000218,1969.0,,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,Plasma
6041,,In vivo,BAO_0000218,1969.0,,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,Plasma
6042,,In vivo,BAO_0000218,1969.0,,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,,Canis lupus familiaris,9615.0,,Plasma
6043,,In vivo,BAO_0000218,1969.0,,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6044,,In vivo,BAO_0000218,1969.0,,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,Plasma
6045,,In vivo,BAO_0000218,1969.0,,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,,Canis lupus familiaris,9615.0,,Plasma
6046,,In vivo,BAO_0000218,1969.0,,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,,Canis lupus familiaris,9615.0,,Plasma
6047,,In vivo,BAO_0000218,1969.0,,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6048,,In vivo,BAO_0000218,1969.0,,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6049,,In vivo,BAO_0000218,1969.0,,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6050,,In vivo,BAO_0000218,1969.0,,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6051,,In vivo,BAO_0000218,1969.0,,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6052,,In vivo,BAO_0000218,,,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6053,,In vivo,BAO_0000218,,,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
6054,,In vivo,BAO_0000218,945.0,,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Stomach
6055,,In vivo,BAO_0000218,1088.0,,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,,Mus musculus,10090.0,,Urine
6056,,In vivo,BAO_0000218,1088.0,,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,,Mus musculus,10090.0,,Urine
6057,,In vivo,BAO_0000218,1088.0,,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,,Mus musculus,10090.0,,Urine
6058,,,BAO_0000218,,,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,Mus musculus,10090.0,,
6059,,,BAO_0000218,,,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,Mus musculus,10090.0,,
6060,,,BAO_0000218,,,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,Mus musculus,10090.0,,
6061,,,BAO_0000218,178.0,,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,Mus musculus,10090.0,,Blood
6062,,,BAO_0000218,,,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,Mus musculus,10090.0,,
6063,,,BAO_0000218,,,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,Mus musculus,10090.0,,
6064,,,BAO_0000218,,,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,Mus musculus,10090.0,,
6065,,,BAO_0000218,178.0,,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,Mus musculus,10090.0,,Blood
6066,,,BAO_0000218,178.0,,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,Mus musculus,10090.0,,Blood
6067,,,BAO_0000218,,,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,Mus musculus,10090.0,,
6068,,,BAO_0000218,,,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,Mus musculus,10090.0,,
6069,,,BAO_0000218,,,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,Mus musculus,10090.0,,
6070,,,BAO_0000218,,,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,Mus musculus,10090.0,,
6071,,,BAO_0000218,,,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,Mus musculus,10090.0,,
6072,,,BAO_0000218,,,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,Mus musculus,10090.0,,
6073,,,BAO_0000218,,,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,Mus musculus,10090.0,,
6074,,,BAO_0000218,,,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,Mus musculus,10090.0,,
6075,,,BAO_0000218,,,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,Mus musculus,10090.0,,
6076,,,BAO_0000218,,,17827,Time at maximum activity in mice (Radiolabeled compound),A,,Mus musculus,10090.0,,
6077,,,BAO_0000218,,,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,Mus musculus,10090.0,,
6078,,,BAO_0000218,,,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,Mus musculus,10090.0,,
6079,,,BAO_0000218,,,17409,Binding towards mouse plasma protein at 10 uM,A,,Mus musculus,10090.0,,
6080,,,BAO_0000218,,,17409,Binding towards mouse plasma protein at 100 uM,A,,Mus musculus,10090.0,,
6081,,In vivo,BAO_0000218,,,2675,Bioavailability was evaluated in mice after intravenous administration,A,,Mus musculus,10090.0,,
6082,,In vivo,BAO_0000218,,,2675,Bioavailability was evaluated in mice after oral administration,A,,Mus musculus,10090.0,,
6083,,In vivo,BAO_0000218,,,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,,Mus musculus,10090.0,,
6084,,In vivo,BAO_0000218,,,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,,Mus musculus,10090.0,,
6085,,In vivo,BAO_0000218,,,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,10090.0,,
6086,,In vivo,BAO_0000218,,,2862,Oral bioavailability in mouse,A,,Mus musculus,10090.0,,
6087,,In vivo,BAO_0000218,,,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,10090.0,,
6088,,In vivo,BAO_0000218,955.0,,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Brain
6089,,In vivo,BAO_0000218,955.0,,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Brain
6090,,In vivo,BAO_0000218,955.0,,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Brain
6091,,In vivo,BAO_0000218,955.0,,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Brain
6092,,In vivo,BAO_0000218,955.0,,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Brain
6093,,In vivo,BAO_0000218,955.0,,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Brain
6094,,In vivo,BAO_0000218,948.0,,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Heart
6095,,In vivo,BAO_0000218,948.0,,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Heart
6096,,In vivo,BAO_0000218,948.0,,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Heart
6097,,In vivo,BAO_0000218,948.0,,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Heart
6098,,,BAO_0000219,,646.0,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,Homo sapiens,9606.0,,
6099,,,BAO_0000219,,646.0,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,Homo sapiens,9606.0,,
6100,,,BAO_0000219,,646.0,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,Homo sapiens,9606.0,,
6101,,,BAO_0000219,,646.0,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,Homo sapiens,9606.0,,
6102,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,Homo sapiens,9606.0,,
6103,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,Homo sapiens,9606.0,,
6104,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,Homo sapiens,9606.0,,
6105,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,Homo sapiens,9606.0,,
6106,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,Homo sapiens,9606.0,,
6107,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,Homo sapiens,9606.0,,
6108,,,BAO_0000219,,646.0,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,Homo sapiens,9606.0,,
6109,,,BAO_0000219,,646.0,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,Homo sapiens,9606.0,,
6110,,,BAO_0000219,,646.0,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,Homo sapiens,9606.0,,
6111,,,BAO_0000219,,646.0,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,Homo sapiens,9606.0,,
6112,,,BAO_0000219,,646.0,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,Homo sapiens,9606.0,,
6113,,,BAO_0000219,,646.0,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,Homo sapiens,9606.0,,
6114,,,BAO_0000219,,646.0,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,Homo sapiens,9606.0,,
6115,,,BAO_0000219,,646.0,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,Homo sapiens,9606.0,,
6116,,,BAO_0000219,,646.0,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,Homo sapiens,9606.0,,
6117,,,BAO_0000219,,646.0,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,Homo sapiens,9606.0,,
6118,,,BAO_0000219,,646.0,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,Homo sapiens,9606.0,,
6119,,,BAO_0000219,,646.0,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
6120,,,BAO_0000219,,646.0,3265,Antitumoral activity was assayed against A-549 cell line,F,,Homo sapiens,9606.0,,
6121,,,BAO_0000219,,646.0,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,Homo sapiens,9606.0,,
6122,,,BAO_0000219,,646.0,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,Homo sapiens,9606.0,,
6123,,,BAO_0000219,,646.0,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
6124,,,BAO_0000219,,646.0,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,Homo sapiens,9606.0,,
6125,,,BAO_0000219,,646.0,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,Homo sapiens,9606.0,,
6126,,,BAO_0000219,,646.0,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,Homo sapiens,9606.0,,
6127,,,BAO_0000219,,646.0,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,Homo sapiens,9606.0,,
6128,,,BAO_0000219,,646.0,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,Homo sapiens,9606.0,,
6129,,,BAO_0000219,,646.0,1847,Cytotoxic activity against A-549 cell lines.,F,,Homo sapiens,9606.0,,
6130,,,BAO_0000219,,646.0,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,Homo sapiens,9606.0,,
6131,,,BAO_0000219,,646.0,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,Homo sapiens,9606.0,,
6132,,,BAO_0000219,,646.0,15313,Inhibition of cell growth in (A-549) lung cell line,F,,Homo sapiens,9606.0,,
6133,,,BAO_0000219,,646.0,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,Homo sapiens,9606.0,,
6134,,,BAO_0000219,,646.0,16049,In vitro antitumor activity against A-549 tumor cells.,F,,Homo sapiens,9606.0,,
6135,,,BAO_0000219,,646.0,17134,In vitro antitumor effects against human A-549 cell lines.,F,,Homo sapiens,9606.0,,
6136,,,BAO_0000219,,646.0,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,Homo sapiens,9606.0,,
6137,,,BAO_0000219,,646.0,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,Homo sapiens,9606.0,,
6138,,,BAO_0000219,,646.0,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,Homo sapiens,9606.0,,
6139,,,BAO_0000219,,646.0,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,Homo sapiens,9606.0,,
6140,,,BAO_0000219,,646.0,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,Homo sapiens,9606.0,,
6141,,,BAO_0000219,,646.0,6663,Inhibitory concentration of compound against A-549 cell line,F,,Homo sapiens,9606.0,,
6142,,,BAO_0000219,,646.0,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,Homo sapiens,9606.0,,
6143,,,BAO_0000219,,646.0,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,Homo sapiens,9606.0,,
6144,,,BAO_0000219,,646.0,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,Homo sapiens,9606.0,,
6145,,,BAO_0000219,,646.0,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,Homo sapiens,9606.0,,
6146,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,Homo sapiens,9606.0,,
6147,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,Homo sapiens,9606.0,,
6148,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,Homo sapiens,9606.0,,
6149,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,Homo sapiens,9606.0,,
6150,,,BAO_0000219,,646.0,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,
6151,,,BAO_0000219,,646.0,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,Homo sapiens,9606.0,,
6152,,,BAO_0000219,,646.0,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,Homo sapiens,9606.0,,
6153,,,BAO_0000219,,646.0,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,Homo sapiens,9606.0,,
6154,,,BAO_0000219,,646.0,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,Homo sapiens,9606.0,,
6155,,,BAO_0000219,,646.0,5609,In vitro anticancer activity against human lung (A549) cell line,F,,Homo sapiens,9606.0,,
6156,,,BAO_0000219,,646.0,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,Homo sapiens,9606.0,,
6157,,,BAO_0000219,,646.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6158,,,BAO_0000219,,646.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6159,,,BAO_0000219,,646.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6160,,,BAO_0000219,,646.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6161,,,BAO_0000219,,646.0,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6162,,,BAO_0000219,,646.0,16295,Inhibition of A549 human lung tumor cell proliferation,F,,Homo sapiens,9606.0,,
6163,,,BAO_0000219,,646.0,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,Homo sapiens,9606.0,,
6164,,,BAO_0000219,,646.0,3439,In vitro cytotoxicity against human tumor cell line A549,F,,Homo sapiens,9606.0,,
6165,,,BAO_0000219,,646.0,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,Homo sapiens,9606.0,,
6166,,,BAO_0000219,,646.0,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,Homo sapiens,9606.0,,
6167,,,BAO_0000219,,646.0,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,Homo sapiens,9606.0,,
6168,,,BAO_0000219,,646.0,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,Homo sapiens,9606.0,,
6169,,,BAO_0000219,,646.0,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,Homo sapiens,9606.0,,
6170,,,BAO_0000219,,646.0,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,Homo sapiens,9606.0,,
6171,,,BAO_0000219,,646.0,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,Homo sapiens,9606.0,,
6172,,,BAO_0000219,,646.0,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,Homo sapiens,9606.0,,
6173,,,BAO_0000219,,646.0,5609,In vitro anticancer activity against human lung (A549) cell line,F,,Homo sapiens,9606.0,,
6174,,,BAO_0000219,,646.0,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,Homo sapiens,9606.0,,
6175,,,BAO_0000219,,646.0,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,Homo sapiens,9606.0,,
6176,,,BAO_0000219,,646.0,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,Homo sapiens,9606.0,,
6177,,,BAO_0000219,,646.0,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,Homo sapiens,9606.0,,
6178,,,BAO_0000219,,646.0,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,Homo sapiens,9606.0,,
6179,,,BAO_0000219,,646.0,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,Homo sapiens,9606.0,,
6180,,,BAO_0000219,,646.0,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,Homo sapiens,9606.0,,
6181,,,BAO_0000219,,646.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,Homo sapiens,9606.0,,
6182,,,BAO_0000219,,646.0,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,Homo sapiens,9606.0,,
6183,,,BAO_0000219,,646.0,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,Homo sapiens,9606.0,,
6184,,,BAO_0000219,,646.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,Homo sapiens,9606.0,,
6185,,,BAO_0000219,,646.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,Homo sapiens,9606.0,,
6186,,,BAO_0000219,,646.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,Homo sapiens,9606.0,,
6187,,,BAO_0000219,,646.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,Homo sapiens,9606.0,,
6188,,,BAO_0000219,,646.0,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,Homo sapiens,9606.0,,
6189,,,BAO_0000219,,646.0,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,Homo sapiens,9606.0,,
6190,,,BAO_0000219,,646.0,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,Homo sapiens,9606.0,,
6191,,,BAO_0000219,,646.0,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,Homo sapiens,9606.0,,
6192,,,BAO_0000219,,646.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6193,,,BAO_0000219,,646.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6194,,,BAO_0000219,,646.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6195,,,BAO_0000219,,646.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6196,,In vivo,BAO_0000218,,,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
6197,,In vivo,BAO_0000218,,,6084,Pharmacokinetic activity (Cmax) in dog,A,,Canis lupus familiaris,9615.0,,
6198,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,,Canis lupus familiaris,9615.0,,
6199,,In vivo,BAO_0000218,,,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,,Canis lupus familiaris,9615.0,,
6200,,In vivo,BAO_0000218,,,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,,Canis lupus familiaris,9615.0,,
6201,,In vivo,BAO_0000218,1969.0,,5932,Cmax in dog plasma after 30mg/kg oral dose,A,,Canis lupus familiaris,9615.0,,Plasma
6202,,In vivo,BAO_0000218,178.0,,4273,Tested for the peak blood level in dog,A,,Canis lupus familiaris,9615.0,,Blood
6203,,In vivo,BAO_0000218,,,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,,Canis lupus familiaris,9615.0,,
6204,,In vivo,BAO_0000218,,,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,,Canis lupus familiaris,9615.0,,
6205,,In vivo,BAO_0000218,178.0,,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,,Canis lupus familiaris,9615.0,,Blood
6206,,,BAO_0000218,,,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6207,,,BAO_0000218,,,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,Canis lupus familiaris,9615.0,,
6208,,,BAO_0000218,1969.0,,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6209,,,BAO_0000218,,,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,Canis lupus familiaris,9615.0,,
6210,,,BAO_0000218,,,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,Canis lupus familiaris,9615.0,,
6211,,,BAO_0000218,,,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,Canis lupus familiaris,9615.0,,
6212,,,BAO_0000218,,,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,Canis lupus familiaris,9615.0,,
6213,,,BAO_0000218,1088.0,,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,Canis lupus familiaris,9615.0,,Urine
6214,,,BAO_0000218,1088.0,,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,Canis lupus familiaris,9615.0,,Urine
6215,,,BAO_0000218,1088.0,,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,Canis lupus familiaris,9615.0,,Urine
6216,,In vivo,BAO_0000218,,,4257,Absolute bioavailability was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
6217,,In vivo,BAO_0000218,,,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,,Canis lupus familiaris,9615.0,,
6218,,In vivo,BAO_0000218,,,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
6219,,In vivo,BAO_0000218,,,17267,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6220,,In vivo,BAO_0000218,,,6621,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6221,,In vivo,BAO_0000218,,,3854,Bioavailability after intravenous administration in dogs,A,,Canis lupus familiaris,9615.0,,
6222,,In vivo,BAO_0000218,,,3854,Bioavailability after peroral administration in dogs,A,,Canis lupus familiaris,9615.0,,
6223,,In vivo,BAO_0000218,,,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6224,,In vivo,BAO_0000218,,,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,,Canis lupus familiaris,9615.0,,
6225,,In vivo,BAO_0000218,1969.0,,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,,Canis lupus familiaris,9615.0,,Plasma
6226,,In vivo,BAO_0000218,,,5006,Bioavailability,A,,Canis lupus familiaris,9615.0,,
6227,,In vivo,BAO_0000218,,,5199,Bioavailability,A,,Canis lupus familiaris,9615.0,,
6228,,In vivo,BAO_0000218,,,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6229,,In vivo,BAO_0000218,,,3771,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6230,,In vivo,BAO_0000218,,,4953,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6231,,In vivo,BAO_0000218,,,5064,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6232,,In vivo,BAO_0000218,,,17657,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6233,,In vivo,BAO_0000218,,,17796,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6234,,In vivo,BAO_0000218,,,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,,Canis lupus familiaris,9615.0,,
6235,,In vivo,BAO_0000218,,,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6236,,In vivo,BAO_0000218,,,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,,Canis lupus familiaris,9615.0,,
6237,,In vivo,BAO_0000218,,,5006,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6238,,In vivo,BAO_0000218,,,16365,Bioavailability was evaluated after oral administration in dog,A,,Canis lupus familiaris,9615.0,,
6239,,In vivo,BAO_0000218,,,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,Canis lupus familiaris,9615.0,,
6240,,In vivo,BAO_0000218,,,1918,Bioavailability was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
6241,,In vivo,BAO_0000218,,,4239,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6242,,In vivo,BAO_0000218,,,6505,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6243,,In vivo,BAO_0000218,,,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,,Canis lupus familiaris,9615.0,,
6244,,In vivo,BAO_0000218,,,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,,Canis lupus familiaris,9615.0,,
6245,,In vivo,BAO_0000218,,,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,,Canis lupus familiaris,9615.0,,
6246,,In vivo,BAO_0000218,,,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,
6247,,In vivo,BAO_0000218,,,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
6248,,In vivo,BAO_0000218,,,17804,Bioavailability of compound in dog was determined after peroral administration,A,,Canis lupus familiaris,9615.0,,
6249,,In vivo,BAO_0000218,,,3184,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6250,,In vivo,BAO_0000218,,,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,,Canis lupus familiaris,9615.0,,
6251,,In vivo,BAO_0000218,,,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,,Canis lupus familiaris,9615.0,,
6252,,In vivo,BAO_0000218,,,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,,Canis lupus familiaris,9615.0,,
6253,,In vivo,BAO_0000218,,,4839,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6254,,In vivo,BAO_0000218,,,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6255,,In vivo,BAO_0000218,948.0,,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Heart
6256,,In vivo,BAO_0000218,948.0,,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Heart
6257,,In vivo,BAO_0000218,2113.0,,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Kidney
6258,,In vivo,BAO_0000218,2113.0,,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Kidney
6259,,In vivo,BAO_0000218,2113.0,,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Kidney
6260,,In vivo,BAO_0000218,2113.0,,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Kidney
6261,,In vivo,BAO_0000218,2113.0,,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Kidney
6262,,In vivo,BAO_0000218,2113.0,,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Kidney
6263,,In vivo,BAO_0000218,2107.0,,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Liver
6264,,In vivo,BAO_0000218,2107.0,,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Liver
6265,,In vivo,BAO_0000218,2107.0,,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Liver
6266,,In vivo,BAO_0000218,2107.0,,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Liver
6267,,In vivo,BAO_0000218,2107.0,,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Liver
6268,,In vivo,BAO_0000218,2107.0,,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Liver
6269,,In vivo,BAO_0000218,2048.0,,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Lung
6270,,In vivo,BAO_0000218,2048.0,,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Lung
6271,,In vivo,BAO_0000218,2048.0,,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Lung
6272,,In vivo,BAO_0000218,2048.0,,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Lung
6273,,In vivo,BAO_0000218,2048.0,,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Lung
6274,,In vivo,BAO_0000218,2048.0,,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,,Mus musculus,10090.0,,Lung
6275,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,
6276,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,
6277,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,
6278,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,
6279,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,
6280,,,BAO_0000218,955.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Brain
6281,,,BAO_0000218,955.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Brain
6282,,,BAO_0000218,955.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Brain
6283,,,BAO_0000218,955.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Brain
6284,,,BAO_0000218,955.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Brain
6285,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Heart
6286,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Heart
6287,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Heart
6288,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Heart
6289,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Heart
6290,,,BAO_0000218,2113.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Kidney
6291,,,BAO_0000218,2113.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Kidney
6292,,,BAO_0000218,2113.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Kidney
6293,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,Homo sapiens,9606.0,,
6294,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,Homo sapiens,9606.0,,
6295,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,Homo sapiens,9606.0,,
6296,,,BAO_0000219,,646.0,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,Homo sapiens,9606.0,,
6297,,,BAO_0000219,,646.0,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
6298,,,BAO_0000219,,646.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,Homo sapiens,9606.0,,
6299,,,BAO_0000219,,646.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,Homo sapiens,9606.0,,
6300,,,BAO_0000219,,646.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,Homo sapiens,9606.0,,
6301,,,BAO_0000219,,646.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,Homo sapiens,9606.0,,
6302,,,BAO_0000219,,646.0,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,Homo sapiens,9606.0,,
6303,,,BAO_0000219,,646.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,Homo sapiens,9606.0,,
6304,,,BAO_0000219,,646.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,Homo sapiens,9606.0,,
6305,,,BAO_0000219,,646.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,Homo sapiens,9606.0,,
6306,,,BAO_0000219,,646.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,Homo sapiens,9606.0,,
6307,,,BAO_0000219,,646.0,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,Homo sapiens,9606.0,,
6308,,,BAO_0000219,,646.0,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,Homo sapiens,9606.0,,
6309,,,BAO_0000219,,646.0,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,Homo sapiens,9606.0,,
6310,,,BAO_0000219,,646.0,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,Homo sapiens,9606.0,,
6311,,,BAO_0000219,,646.0,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,Homo sapiens,9606.0,,
6312,,,BAO_0000219,,646.0,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,Homo sapiens,9606.0,,
6313,,,BAO_0000219,,646.0,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,Homo sapiens,9606.0,,
6314,,,BAO_0000219,,646.0,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,Homo sapiens,9606.0,,
6315,,,BAO_0000219,,646.0,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,Homo sapiens,9606.0,,
6316,,,BAO_0000219,,646.0,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,Homo sapiens,9606.0,,
6317,,,BAO_0000219,,646.0,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,Homo sapiens,9606.0,,
6318,,,BAO_0000219,,646.0,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,Homo sapiens,9606.0,,
6319,,,BAO_0000219,,646.0,11333,Cytotoxic concentration against A-549 tumor cells.,F,,Homo sapiens,9606.0,,
6320,,,BAO_0000219,,646.0,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,Homo sapiens,9606.0,,
6321,,,BAO_0000219,,646.0,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,Homo sapiens,9606.0,,
6322,,,BAO_0000218,,,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,Acinetobacter baumannii,470.0,,
6323,,,BAO_0000218,,,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,Acinetobacter calcoaceticus,471.0,,
6324,,,BAO_0000218,,,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,Aspergillus flavus,5059.0,,
6325,,,BAO_0000218,,,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,Aspergillus flavus,5059.0,,
6326,,,BAO_0000218,,,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,Aspergillus fumigatus,746128.0,,
6327,,,BAO_0000218,,,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,Aspergillus fumigatus,746128.0,,
6328,,,BAO_0000218,,,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,Aspergillus fumigatus,746128.0,,
6329,,,BAO_0000218,,,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,Aspergillus fumigatus,746128.0,,
6330,,,BAO_0000218,,,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,Aspergillus fumigatus,746128.0,,
6331,,,BAO_0000218,,,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,Aspergillus fumigatus,746128.0,,
6332,,,BAO_0000218,,,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,Aspergillus fumigatus,746128.0,,
6333,,,BAO_0000218,,,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,Actinomyces naeslundii,1655.0,,
6334,,,BAO_0000218,,,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,Actinomyces viscosus,1656.0,,
6335,,,BAO_0000218,,,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,Acanthocheilonema viteae,6277.0,,
6336,,,BAO_0000218,,,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,Acanthocheilonema viteae,6277.0,,
6337,,,BAO_0000218,,,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,Aggregatibacter actinomycetemcomitans,714.0,,
6338,,,BAO_0000218,,,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,Aggregatibacter actinomycetemcomitans,714.0,,
6339,,,BAO_0000218,,,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,Aggregatibacter actinomycetemcomitans,714.0,,
6340,,,BAO_0000219,,646.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6341,,,BAO_0000219,,646.0,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6342,,,BAO_0000219,,646.0,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,Homo sapiens,9606.0,,
6343,,,BAO_0000219,,646.0,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,Homo sapiens,9606.0,,
6344,,,BAO_0000219,,646.0,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,Homo sapiens,9606.0,,
6345,,,BAO_0000219,,646.0,16381,GI values against A549 cells (lung cancer),F,,Homo sapiens,9606.0,,
6346,,,BAO_0000219,,646.0,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,Homo sapiens,9606.0,,
6347,,,BAO_0000219,,646.0,16325,Inhibitory activity against A549 human adenocarcinoma,F,,Homo sapiens,9606.0,,
6348,,,BAO_0000218,,646.0,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,Homo sapiens,9606.0,,
6349,,,BAO_0000218,,646.0,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,Homo sapiens,9606.0,,
6350,,,BAO_0000219,,646.0,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,Homo sapiens,9606.0,,
6351,,,BAO_0000219,,646.0,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,Homo sapiens,9606.0,,
6352,,,BAO_0000219,,646.0,17488,Cytotoxicity against human A549 lung cells,F,,Homo sapiens,9606.0,,
6353,,,BAO_0000218,,646.0,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,Homo sapiens,9606.0,,
6354,,,BAO_0000219,,646.0,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,Homo sapiens,9606.0,,
6355,,,BAO_0000219,,646.0,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,Homo sapiens,9606.0,,
6356,,,BAO_0000219,,646.0,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,Homo sapiens,9606.0,,
6357,,,BAO_0000219,,646.0,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,Homo sapiens,9606.0,,
6358,,,BAO_0000219,,646.0,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,Homo sapiens,9606.0,,
6359,,,BAO_0000219,,646.0,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,Homo sapiens,9606.0,,
6360,,,BAO_0000219,,646.0,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,Homo sapiens,9606.0,,
6361,,,BAO_0000219,,646.0,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,Homo sapiens,9606.0,,
6362,,,BAO_0000219,,646.0,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,Homo sapiens,9606.0,,
6363,,,BAO_0000219,,646.0,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,Homo sapiens,9606.0,,
6364,,,BAO_0000219,,646.0,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,Homo sapiens,9606.0,,
6365,,,BAO_0000219,,646.0,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,Homo sapiens,9606.0,,
6366,,,BAO_0000219,,646.0,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,Homo sapiens,9606.0,,
6367,,,BAO_0000219,,646.0,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,Homo sapiens,9606.0,,
6368,,,BAO_0000219,,646.0,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,Homo sapiens,9606.0,,
6369,,,BAO_0000219,,646.0,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,Homo sapiens,9606.0,,
6370,,,BAO_0000219,,646.0,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,Homo sapiens,9606.0,,
6371,,,BAO_0000219,,646.0,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,Homo sapiens,9606.0,,
6372,,,BAO_0000219,,646.0,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,Homo sapiens,9606.0,,
6373,,,BAO_0000219,,646.0,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,Homo sapiens,9606.0,,
6374,,,BAO_0000219,,646.0,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,Homo sapiens,9606.0,,
6375,,,BAO_0000219,,646.0,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
6376,,,BAO_0000219,,646.0,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,Homo sapiens,9606.0,,
6377,,,BAO_0000219,,646.0,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,Homo sapiens,9606.0,,
6378,,,BAO_0000219,,646.0,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,Homo sapiens,9606.0,,
6379,,,BAO_0000219,,646.0,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,Homo sapiens,9606.0,,
6380,,,BAO_0000219,,646.0,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,Homo sapiens,9606.0,,
6381,,,BAO_0000219,,646.0,12301,Antitumor activity against A549/ATCC cell line,F,,Homo sapiens,9606.0,,
6382,,,BAO_0000219,,646.0,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,Homo sapiens,9606.0,,
6383,,,BAO_0000219,,646.0,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,Homo sapiens,9606.0,,
6384,,,BAO_0000219,,646.0,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,Homo sapiens,9606.0,,
6385,,,BAO_0000219,,646.0,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,Homo sapiens,9606.0,,
6386,,,BAO_0000219,,646.0,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,Homo sapiens,9606.0,,
6387,,,BAO_0000219,,646.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,Homo sapiens,9606.0,,
6388,,,BAO_0000219,,,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,Homo sapiens,9606.0,,
6389,,In vivo,BAO_0000218,,,5005,Compound was tested for oral bioavailability in dogs,A,,Canis lupus familiaris,9615.0,,
6390,,In vivo,BAO_0000218,,,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,,Canis lupus familiaris,9615.0,,
6391,,In vivo,BAO_0000218,,,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,,Canis lupus familiaris,9615.0,,
6392,,In vivo,BAO_0000218,,,5374,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6393,,In vivo,BAO_0000218,,,5374,Compound was tested for the oral bioavailability in dog; No availability,A,,Canis lupus familiaris,9615.0,,
6394,,In vivo,BAO_0000218,,,6265,Oral bioavailability in dog (dose 5 mg/kg),A,,Canis lupus familiaris,9615.0,,
6395,,In vivo,BAO_0000218,,,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,,Canis lupus familiaris,9615.0,,
6396,,In vivo,BAO_0000218,,,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,,Canis lupus familiaris,9615.0,,
6397,,In vivo,BAO_0000218,,,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,,Canis lupus familiaris,9615.0,,
6398,,In vivo,BAO_0000218,,,5302,Oral bioavailability in dog (dose 5 mg/kg),A,,Canis lupus familiaris,9615.0,,
6399,,In vivo,BAO_0000218,,,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,,Canis lupus familiaris,9615.0,,
6400,,In vivo,BAO_0000218,,,16452,Oral bioavailability of active FTIs in dogs,A,,Canis lupus familiaris,9615.0,,
6401,,In vivo,BAO_0000218,,,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6402,,In vivo,BAO_0000218,,,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
6403,,In vivo,BAO_0000218,,,17839,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6404,,In vivo,BAO_0000218,,,6762,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6405,,In vivo,BAO_0000218,,,6821,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6406,,In vivo,BAO_0000218,,,6821,Oral bioavailability of compound was determined in dog; Not tested,A,,Canis lupus familiaris,9615.0,,
6407,,In vivo,BAO_0000218,,,5210,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6408,,In vivo,BAO_0000218,,,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
6409,,In vivo,BAO_0000218,,,761,Oral bioavailability,A,,Canis lupus familiaris,9615.0,,
6410,,In vivo,BAO_0000218,,,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,,Canis lupus familiaris,9615.0,,
6411,,In vivo,BAO_0000218,,,761,Oral bioavailability administered in solution in rats,A,,Canis lupus familiaris,9615.0,,
6412,,In vivo,BAO_0000218,,,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6413,,In vivo,BAO_0000218,,,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,
6414,,In vivo,BAO_0000218,,,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,,Canis lupus familiaris,9615.0,,
6415,,In vivo,BAO_0000218,,,6535,Oral bioavailability in Dog; ND = not determined,A,,Canis lupus familiaris,9615.0,,
6416,,In vivo,BAO_0000218,,,3352,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6417,,In vivo,BAO_0000218,,,6168,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6418,,In vivo,BAO_0000218,,,5988,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6419,,In vivo,BAO_0000218,,,4942,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6420,,In vivo,BAO_0000218,,,4942,Oral bioavailability in dogs; No data,A,,Canis lupus familiaris,9615.0,,
6421,,In vivo,BAO_0000218,,,14541,Oral bioavailability measured in dogs,A,,Canis lupus familiaris,9615.0,,
6422,,In vivo,BAO_0000218,,,4449,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6423,,In vivo,BAO_0000218,,,6057,Oral bioavailability was calculated in dog,A,,Canis lupus familiaris,9615.0,,
6424,,In vivo,BAO_0000218,,,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,,Canis lupus familiaris,9615.0,,
6425,,In vivo,BAO_0000218,,,5542,Oral bioavailability in dog (i.v. dosing),A,,Canis lupus familiaris,9615.0,,
6426,,In vivo,BAO_0000218,,,5542,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6427,,In vivo,BAO_0000218,,,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,,Canis lupus familiaris,9615.0,,
6428,,In vivo,BAO_0000218,,,4514,Oral bioavailability in Beagle dogs,A,,Canis lupus familiaris,9615.0,,
6429,,In vivo,BAO_0000218,,,3624,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6430,,In vivo,BAO_0000218,,,3854,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6431,,In vivo,BAO_0000218,,,5836,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6432,,In vivo,BAO_0000218,,,5940,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6433,,In vivo,BAO_0000218,,,6168,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6434,,In vivo,BAO_0000218,,,6227,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6435,,In vivo,BAO_0000218,,,6251,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6436,,In vivo,BAO_0000218,,,6448,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6437,,In vivo,BAO_0000218,,,6647,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6438,,In vivo,BAO_0000218,,,5940,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6439,,In vivo,BAO_0000218,,,933,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6440,,In vivo,BAO_0000218,,,5210,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6441,,In vivo,BAO_0000218,,,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,,Canis lupus familiaris,9615.0,,
6442,,In vivo,BAO_0000218,,,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,,Canis lupus familiaris,9615.0,,
6443,,In vivo,BAO_0000218,,,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,,Canis lupus familiaris,9615.0,,
6444,,In vivo,BAO_0000218,,,5472,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6445,,In vivo,BAO_0000218,,,5985,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6446,,In vivo,BAO_0000218,,,15660,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6447,,In vivo,BAO_0000218,,,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6448,,In vivo,BAO_0000218,,,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6449,,In vivo,BAO_0000218,,,6305,Oral bioavailability (F) in dogs,A,,Canis lupus familiaris,9615.0,,
6450,,In vivo,BAO_0000218,,,5210,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6451,,In vivo,BAO_0000218,,,5238,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6452,,In vivo,BAO_0000218,,,5668,Oral bioavailability in dog (dose 10 mg/kg),A,,Canis lupus familiaris,9615.0,,
6453,,In vivo,BAO_0000218,,,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,,Canis lupus familiaris,9615.0,,
6454,,In vivo,BAO_0000218,,,5668,Oral bioavailability in dog (dose 5 mg/kg),A,,Canis lupus familiaris,9615.0,,
6455,,In vivo,BAO_0000218,,,6084,Oral bioavailability in dog (dose 10 mg/kg),A,,Canis lupus familiaris,9615.0,,
6456,,,BAO_0000218,2113.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Kidney
6457,,,BAO_0000218,2113.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Kidney
6458,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Liver
6459,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Liver
6460,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Liver
6461,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Liver
6462,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Liver
6463,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Lung
6464,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Lung
6465,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Lung
6466,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Lung
6467,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Lung
6468,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,
6469,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,
6470,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,
6471,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,
6472,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,
6473,,,BAO_0000218,2106.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Spleen
6474,,,BAO_0000218,2106.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Spleen
6475,,,BAO_0000218,2106.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Spleen
6476,,,BAO_0000218,2106.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Spleen
6477,,,BAO_0000218,2106.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Spleen
6478,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,
6479,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,
6480,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,
6481,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,
6482,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,
6483,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,
6484,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,
6485,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,
6486,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,
6487,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,
6488,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Heart
6489,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Heart
6490,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Heart
6491,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Heart
6492,,,BAO_0000218,948.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Heart
6493,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Liver
6494,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Liver
6495,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Liver
6496,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Liver
6497,,,BAO_0000218,2107.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Liver
6498,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,Lung
6499,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,Lung
6500,,,BAO_0000218,,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,aeinetobacter anitrotap,107673.0,,
6501,,,BAO_0000218,,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,
6502,,,BAO_0000218,,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,
6503,,,BAO_0000218,,,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,aeinetobacter anitrotap,107673.0,,
6504,,,BAO_0000218,,,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,Acinetobacter calcoaceticus,471.0,,
6505,,,BAO_0000218,,,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,Anolis carolinensis,28377.0,,
6506,,,BAO_0000218,,,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,Anolis carolinensis,28377.0,,
6507,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,Actinomyces naeslundii,1655.0,,
6508,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,Actinomyces naeslundii,1655.0,,
6509,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,Actinomyces naeslundii,1655.0,,
6510,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,Actinomyces naeslundii,1655.0,,
6511,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,Actinomyces naeslundii,1655.0,,
6512,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,Actinomyces naeslundii,1655.0,,
6513,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,Actinomyces naeslundii,1655.0,,
6514,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,Actinomyces naeslundii,1655.0,,
6515,,,BAO_0000218,,,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,Artemia salina,85549.0,,
6516,,,BAO_0000218,,,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,Artemia salina,85549.0,,
6517,,,BAO_0000218,,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,Ascaris suum,6253.0,,
6518,,,BAO_0000218,,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,Ascaris suum,6253.0,,
6519,,,BAO_0000218,,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,Ascaris suum,6253.0,,
6520,,,BAO_0000218,,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,Ascaris suum,6253.0,,
6521,,,BAO_0000218,,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,Ascaris suum,6253.0,,
6522,,,BAO_0000218,,,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,Ascaris suum,6253.0,,
6523,,,BAO_0000218,,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,Ascaris suum,6253.0,,
6524,,,BAO_0000218,,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,Ascaris suum,6253.0,,
6525,,,BAO_0000218,,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,Ascaris suum,6253.0,,
6526,,,BAO_0000218,,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,Ascaris suum,6253.0,,
6527,,,BAO_0000218,,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,Ascaris suum,6253.0,,
6528,,,BAO_0000218,,,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,Ascaris suum,6253.0,,
6529,,,BAO_0000218,,,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,Actinomyces viscosus,1656.0,,
6530,,,BAO_0000218,,,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,Actinomyces viscosus,1656.0,,
6531,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,Actinomyces viscosus,1656.0,,
6532,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,Actinomyces viscosus,1656.0,,
6533,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,Actinomyces viscosus,1656.0,,
6534,,,BAO_0000218,,,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,Actinomyces viscosus,1656.0,,
6535,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,Actinomyces viscosus,1656.0,,
6536,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,Actinomyces viscosus,1656.0,,
6537,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,Actinomyces viscosus,1656.0,,
6538,,,BAO_0000218,,,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,Actinomyces viscosus,1656.0,,
6539,,,BAO_0000218,,,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,Actinomyces viscosus,1656.0,,
6540,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,Actinomyces viscosus,1656.0,,
6541,,,BAO_0000218,,,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,Actinomyces viscosus,1656.0,,
6542,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6543,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6544,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6545,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6546,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6547,,,BAO_0000219,,165.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,Homo sapiens,9606.0,,
6548,,,BAO_0000219,,645.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,Homo sapiens,9606.0,,
6549,,,BAO_0000219,,,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,Rattus norvegicus,10116.0,,
6550,,,BAO_0000219,,625.0,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,Mus musculus,10090.0,,
6551,,,BAO_0000219,,625.0,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,Mus musculus,10090.0,,
6552,,,BAO_0000219,,625.0,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,Homo sapiens,9606.0,,
6553,,,BAO_0000219,,625.0,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,Homo sapiens,9606.0,,
6554,,,BAO_0000219,,874.0,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,Homo sapiens,9606.0,,
6555,,,BAO_0000219,,625.0,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,Mus musculus,10090.0,,
6556,,,BAO_0000219,,625.0,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,Mus musculus,10090.0,,
6557,,,BAO_0000219,,625.0,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,Mus musculus,10090.0,,
6558,,,BAO_0000219,,625.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,Mus musculus,10090.0,,
6559,,,BAO_0000219,,625.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,Mus musculus,10090.0,,
6560,,,BAO_0000019,,,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,
6561,,,BAO_0000219,,625.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,Mus musculus,10090.0,,
6562,,,BAO_0000219,,625.0,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,Mus musculus,10090.0,,
6563,,,BAO_0000219,,975.0,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,Cricetulus griseus,10029.0,,
6564,,,BAO_0000219,,,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,Homo sapiens,9606.0,,
6565,,,BAO_0000219,,,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,Homo sapiens,9606.0,,
6566,,,BAO_0000219,,974.0,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,Homo sapiens,9606.0,,
6567,,,BAO_0000219,,974.0,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,Homo sapiens,9606.0,,
6568,,,BAO_0000219,,974.0,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,Homo sapiens,9606.0,,
6569,,,BAO_0000219,,379.0,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,Homo sapiens,9606.0,,
6570,,,BAO_0000219,,274.0,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,Cricetulus griseus,10029.0,,
6571,,,BAO_0000219,,185.0,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,Cricetulus griseus,10029.0,,
6572,,,BAO_0000219,,185.0,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,Cricetulus griseus,10029.0,,
6573,,,BAO_0000219,,185.0,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,Cricetulus griseus,10029.0,,
6574,,,BAO_0000219,,185.0,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,Cricetulus griseus,10029.0,,
6575,,,BAO_0000219,,185.0,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,Cricetulus griseus,10029.0,,
6576,,,BAO_0000219,,185.0,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,Cricetulus griseus,10029.0,,
6577,,,BAO_0000219,,185.0,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,Cricetulus griseus,10029.0,,
6578,,,BAO_0000219,,185.0,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,Cricetulus griseus,10029.0,,
6579,,,BAO_0000219,,185.0,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,Cricetulus griseus,10029.0,,
6580,,,BAO_0000219,,185.0,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,Cricetulus griseus,10029.0,,
6581,,,BAO_0000219,,185.0,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,Cricetulus griseus,10029.0,,
6582,,,BAO_0000219,,185.0,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,Cricetulus griseus,10029.0,,
6583,,,BAO_0000219,,185.0,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,Cricetulus griseus,10029.0,,
6584,,,BAO_0000219,,185.0,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,Cricetulus griseus,10029.0,,
6585,,,BAO_0000219,,185.0,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,Cricetulus griseus,10029.0,,
6586,,,BAO_0000219,,185.0,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,Cricetulus griseus,10029.0,,
6587,,,BAO_0000219,,185.0,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,hampster,36483.0,,
6588,,,BAO_0000219,,185.0,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,Cricetulus griseus,10029.0,,
6589,,,BAO_0000219,,185.0,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,Cricetulus griseus,10029.0,,
6590,,,BAO_0000219,,185.0,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,Cricetulus griseus,10029.0,,
6591,,In vivo,BAO_0000218,,,6084,Oral bioavailability in dog (dose 10 mg/kg),A,,Canis lupus familiaris,9615.0,,
6592,,In vivo,BAO_0000218,,,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,,Canis lupus familiaris,9615.0,,
6593,,In vivo,BAO_0000218,,,4353,Oral bioavailability in dog (dose 5 uM/kg),A,,Canis lupus familiaris,9615.0,,
6594,,In vivo,BAO_0000218,,,4353,Oral bioavailability in dog (dose 5 uM/kg),A,,Canis lupus familiaris,9615.0,,
6595,,In vivo,BAO_0000218,,,17800,Oral bioavailability in dog (mongrel),A,,Canis lupus familiaris,9615.0,,
6596,,In vivo,BAO_0000218,,,3994,Oral bioavailability in dog (dose 10 mg/kg),A,,Canis lupus familiaris,9615.0,,
6597,,In vivo,BAO_0000218,,,3994,Oral bioavailability in dog (dose 10 mg/kg),F,,Canis lupus familiaris,9615.0,,
6598,,In vivo,BAO_0000218,,,5145,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6599,,In vivo,BAO_0000218,,,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
6600,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,,Canis lupus familiaris,9615.0,,
6601,,In vivo,BAO_0000218,,,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,,Canis lupus familiaris,9615.0,,
6602,,In vivo,BAO_0000218,,,4273,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6603,,In vivo,BAO_0000218,,,12500,Bioavailability in dog (dose 3-10 mg/kg),A,,Canis lupus familiaris,9615.0,,
6604,,In vivo,BAO_0000218,1969.0,,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,,Canis lupus familiaris,9615.0,,Plasma
6605,,In vivo,BAO_0000218,,,3639,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6606,,In vivo,BAO_0000218,,,3880,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6607,,In vivo,BAO_0000218,,,4838,Bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6608,,In vivo,BAO_0000218,,,15600,oral bioavailability was measured in dogs,A,,Canis lupus familiaris,9615.0,,
6609,,,BAO_0000218,,,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,Canis lupus familiaris,9615.0,,
6610,,,BAO_0000218,,,17248,Compound was tested for plasma protein binding of dog,A,,Canis lupus familiaris,9615.0,,
6611,,,BAO_0000218,,,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,Canis lupus familiaris,9615.0,,
6612,,,BAO_0000218,,,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,Canis lupus familiaris,9615.0,,
6613,,In vivo,BAO_0000218,,,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,,Canis lupus familiaris,9615.0,,
6614,,,BAO_0000218,,,3749,Half life was determined,A,,Canis lupus familiaris,9615.0,,
6615,,In vivo,BAO_0000218,,,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
6616,,,BAO_0000218,,,3022,Half life was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
6617,,,BAO_0000218,,,3749,Half life was determined,A,,Canis lupus familiaris,9615.0,,
6618,,In vivo,BAO_0000218,,,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,,Canis lupus familiaris,9615.0,,
6619,,In vivo,BAO_0000218,948.0,,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,,Canis lupus familiaris,9615.0,,Heart
6620,,In vivo,BAO_0000218,2113.0,,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,,Canis lupus familiaris,9615.0,,Kidney
6621,,In vivo,BAO_0000218,2107.0,,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,,Canis lupus familiaris,9615.0,,Liver
6622,,In vivo,BAO_0000218,2048.0,,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,,Canis lupus familiaris,9615.0,,Lung
6623,,In vivo,BAO_0000218,2106.0,,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,,Canis lupus familiaris,9615.0,,Spleen
6624,,,BAO_0000218,,,3639,LogP in dog,A,,Canis lupus familiaris,9615.0,,
6625,,,BAO_0000218,,,6227,Partition coefficient (logP),A,,Canis lupus familiaris,9615.0,,
6626,,,BAO_0000218,,,6227,Partition coefficient in dog,A,,Canis lupus familiaris,9615.0,,
6627,,In vivo,BAO_0000218,,,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,9615.0,,
6628,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,,Canis lupus familiaris,9615.0,,
6629,,,BAO_0000218,,,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,Canis lupus familiaris,9615.0,,
6630,,,BAO_0000218,,,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,Canis lupus familiaris,9615.0,,
6631,,,BAO_0000218,,,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,Canis lupus familiaris,9615.0,,
6632,,,BAO_0000218,,,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,Canis lupus familiaris,9615.0,,
6633,,,BAO_0000218,2107.0,,6251,In vitro metabolic potential in dog liver microsomes,A,,Canis lupus familiaris,9615.0,,Liver
6634,,In vivo,BAO_0000218,,,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,,Canis lupus familiaris,9615.0,,
6635,,In vivo,BAO_0000218,,,2713,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6636,,In vivo,BAO_0000218,,,6512,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6637,,In vivo,BAO_0000218,,,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,,Canis lupus familiaris,9615.0,,
6638,,In vivo,BAO_0000218,,,3749,The compound was tested for bioavailability in dogs,A,,Canis lupus familiaris,9615.0,,
6639,,In vivo,BAO_0000218,,,3749,The compound was tested for oral bioavailability in dogs,A,,Canis lupus familiaris,9615.0,,
6640,,In vivo,BAO_0000218,,,6742,Oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
6641,,,BAO_0000218,,,6227,Compound was tested for percent protein binding (PB) in dog,A,,Canis lupus familiaris,9615.0,,
6642,,,BAO_0000218,,,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,Canis lupus familiaris,9615.0,,
6643,,In vivo,BAO_0000218,1969.0,,2877,Compound was evaluated for plasma clearance.,A,,Canis lupus familiaris,9615.0,,Plasma
6644,,In vivo,BAO_0000218,1969.0,,12500,The compound was tested for plasma clearance in dog,A,,Canis lupus familiaris,9615.0,,Plasma
6645,,In vivo,BAO_0000218,1969.0,,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,,Canis lupus familiaris,9615.0,,Plasma
6646,,,BAO_0000218,,,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6647,,,BAO_0000218,2107.0,,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,Canis lupus familiaris,9615.0,,Liver
6648,,In vivo,BAO_0000218,,,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,
6649,,In vivo,BAO_0000218,,,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,,Canis lupus familiaris,9615.0,,
6650,,In vivo,BAO_0000218,,,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,9615.0,,
6651,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,Lung
6652,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,Lung
6653,,,BAO_0000218,2048.0,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,Lung
6654,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,Mus musculus,10090.0,,
6655,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,Mus musculus,10090.0,,
6656,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,Mus musculus,10090.0,,
6657,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,Mus musculus,10090.0,,
6658,,,BAO_0000218,,42.0,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,Mus musculus,10090.0,,
6659,,,BAO_0000218,955.0,,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Brain
6660,,,BAO_0000218,2113.0,,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Kidney
6661,,,BAO_0000218,2107.0,,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Liver
6662,,,BAO_0000218,2048.0,,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Lung
6663,,,BAO_0000218,2106.0,,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Spleen
6664,,In vivo,BAO_0000218,,,17852,Plasma clearance in mouse,A,,Mus musculus,10090.0,,
6665,,In vivo,BAO_0000218,,,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,,Mus musculus,10090.0,,
6666,,In vivo,BAO_0000218,,,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,,Mus musculus,10090.0,,
6667,,In vivo,BAO_0000218,,,2675,Clearance was evaluated in mice after intravenous administration,A,,Mus musculus,10090.0,,
6668,,In vivo,BAO_0000218,,,2675,Clearance was evaluated in mice after oral administration,A,,Mus musculus,10090.0,,
6669,,In vivo,BAO_0000218,,,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,,Mus musculus,10090.0,,
6670,,In vivo,BAO_0000218,,,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,,Mus musculus,10090.0,,
6671,,In vivo,BAO_0000218,,,17753,Plasma clearance of at 24 mg/Kg,A,,Mus musculus,10090.0,,
6672,,In vivo,BAO_0000218,,,17753,Plasma clearance at 24 mg/Kg,A,,Mus musculus,10090.0,,
6673,,In vivo,BAO_0000218,,,17753,Plasma clearance at 5 mg/Kg,A,,Mus musculus,10090.0,,
6674,,In vivo,BAO_0000218,,,5727,Plasma clearance in mice,A,,Mus musculus,10090.0,,
6675,,In vivo,BAO_0000218,,,2862,Plasma clearance value upon iv administration in mouse,A,,Mus musculus,10090.0,,
6676,,In vivo,BAO_0000218,1969.0,,5980,Total plasma clearance in mice,A,,Mus musculus,10090.0,,Plasma
6677,,In vivo,BAO_0000218,,,17592,Clearance in mouse,A,,Mus musculus,10090.0,,
6678,,In vivo,BAO_0000218,,,17718,Clearance value was determined,A,,Mus musculus,10090.0,,
6679,,In vivo,BAO_0000218,,,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,
6680,,,BAO_0000100,,,17384,Calculated partition coefficient (clogP),P,,,,,
6681,,In vivo,BAO_0000218,,,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,,Mus musculus,10090.0,,
6682,,In vivo,BAO_0000218,,,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,
6683,,In vivo,BAO_0000218,,,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,,Mus musculus,10090.0,,
6684,,In vivo,BAO_0000218,,,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,,Mus musculus,10090.0,,
6685,,In vivo,BAO_0000218,,,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,,Mus musculus,10090.0,,
6686,,In vivo,BAO_0000218,,,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,Mus musculus,10090.0,,
6687,,In vivo,BAO_0000218,,,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,,Mus musculus,10090.0,,
6688,,In vivo,BAO_0000218,,,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,,Mus musculus,10090.0,,
6689,,In vivo,BAO_0000218,,,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,,Mus musculus,10090.0,,
6690,,In vivo,BAO_0000218,955.0,,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Brain
6691,,In vivo,BAO_0000218,2113.0,,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Kidney
6692,,In vivo,BAO_0000218,2107.0,,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Liver
6693,,In vivo,BAO_0000218,2048.0,,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Lung
6694,,In vivo,BAO_0000218,,,17764,Cmax in mice at 18 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
6695,,In vivo,BAO_0000218,,,17764,Cmax in mice at 23 uM/kg i.v. administration,F,,Mus musculus,10090.0,,
6696,,In vivo,BAO_0000218,,,17764,Cmax in mice at 24 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
6697,,In vivo,BAO_0000218,,,17764,Cmax in mice at 25 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
6698,,In vivo,BAO_0000218,,,17764,Cmax in mice at 26 uM/kg i.p. administration,F,,Mus musculus,10090.0,,
6699,,In vivo,BAO_0000218,2106.0,,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,,Mus musculus,10090.0,,Spleen
6700,,In vivo,BAO_0000218,,,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,,Mus musculus,10090.0,,
6701,,In vivo,BAO_0000218,,,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,,Mus musculus,10090.0,,
6702,,In vivo,BAO_0000218,,,5727,Cmax value was determined,A,,Mus musculus,10090.0,,
6703,,In vivo,BAO_0000218,,,5951,Cmax value in IRC mice,A,,Mus musculus,10090.0,,
6704,,In vivo,BAO_0000218,,,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,Mus musculus,10090.0,,
6705,,In vivo,BAO_0000218,,,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,Mus musculus,10090.0,,
6706,,In vivo,BAO_0000218,1969.0,,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,,Mus musculus,10090.0,,Plasma
6707,,In vivo,BAO_0000218,1969.0,,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,,Mus musculus,10090.0,,Plasma
6708,,In vivo,BAO_0000218,,,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,,Mus musculus,10090.0,,
6709,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6710,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6711,,,BAO_0000218,,,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,Acanthocheilonema viteae,6277.0,,
6712,,,BAO_0000219,,455.0,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,Homo sapiens,9606.0,,
6713,Brain membranes,,BAO_0000249,,,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,Rattus norvegicus,10116.0,,
6714,,,BAO_0000019,,,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,Homo sapiens,9606.0,,
6715,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,
6716,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,
6717,,,BAO_0000219,,449.0,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,
6718,,,BAO_0000219,,449.0,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,
6719,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,
6720,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,
6721,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,
6722,,,BAO_0000219,,449.0,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,Homo sapiens,9606.0,,
6723,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,
6724,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,
6725,,,BAO_0000219,,449.0,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,
6726,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,
6727,,,BAO_0000219,,449.0,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,
6728,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,
6729,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,
6730,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,
6731,,,BAO_0000219,,449.0,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,
6732,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,
6733,,,BAO_0000219,,449.0,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,
6734,,,BAO_0000219,,449.0,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,
6735,,,BAO_0000219,,164.0,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,Oryctolagus cuniculus,9986.0,,
6736,,,BAO_0000219,,164.0,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,Rattus norvegicus,10116.0,,
6737,,,BAO_0000219,,164.0,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,Rattus norvegicus,10116.0,,
6738,,,BAO_0000219,,164.0,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,Rattus norvegicus,10116.0,,
6739,,,BAO_0000219,,164.0,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,Rattus norvegicus,10116.0,,
6740,,,BAO_0000219,,164.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,Rattus norvegicus,10116.0,,
6741,,,BAO_0000219,,185.0,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,Cricetulus griseus,10029.0,,
6742,,,BAO_0000219,,185.0,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,Cricetulus griseus,10029.0,,
6743,,,BAO_0000219,,185.0,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,Cricetulus griseus,10029.0,,
6744,,,BAO_0000219,,185.0,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,Cricetulus griseus,10029.0,,
6745,,,BAO_0000219,,185.0,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,Cricetulus griseus,10029.0,,
6746,,,BAO_0000219,,185.0,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,Cricetulus griseus,10029.0,,
6747,,,BAO_0000219,,185.0,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,Cricetulus griseus,10029.0,,
6748,,,BAO_0000219,,185.0,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,Cricetulus griseus,10029.0,,
6749,,,BAO_0000219,,185.0,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,Cricetulus griseus,10029.0,,
6750,,,BAO_0000219,,185.0,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,Cricetulus griseus,10029.0,,
6751,,,BAO_0000219,,185.0,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,Cricetulus griseus,10029.0,,
6752,,,BAO_0000219,,185.0,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,Cricetulus griseus,10029.0,,
6753,,,BAO_0000219,,185.0,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,Cricetulus griseus,10029.0,,
6754,,,BAO_0000219,,185.0,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,Cricetulus griseus,10029.0,,
6755,,,BAO_0000219,,185.0,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,Cricetulus griseus,10029.0,,
6756,,,BAO_0000219,,185.0,10368,Cytotoxicity against AA8 cell line,F,,Cricetulus griseus,10029.0,,
6757,,,BAO_0000219,,185.0,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,Cricetulus griseus,10029.0,,
6758,,,BAO_0000219,,185.0,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,Cricetulus griseus,10029.0,,
6759,,,BAO_0000219,,185.0,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,Cricetulus griseus,10029.0,,
6760,,,BAO_0000219,,185.0,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,Cricetulus griseus,10029.0,,
6761,,,BAO_0000219,,185.0,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,Cricetulus griseus,10029.0,,
6762,,,BAO_0000219,,185.0,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,Cricetulus griseus,10029.0,,
6763,,,BAO_0000219,,185.0,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,Cricetulus griseus,10029.0,,
6764,,,BAO_0000218,,,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,Cricetulus griseus,10029.0,,
6765,,,BAO_0000219,,185.0,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,Cricetulus griseus,10029.0,,
6766,,,BAO_0000219,,185.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,Cricetulus griseus,10029.0,,
6767,,,BAO_0000219,,185.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,Cricetulus griseus,10029.0,,
6768,,,BAO_0000219,,185.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,Cricetulus griseus,10029.0,,
6769,,,BAO_0000219,,185.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,Cricetulus griseus,10029.0,,
6770,,,BAO_0000219,,185.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,Cricetulus griseus,10029.0,,
6771,,,BAO_0000219,,185.0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,Cricetulus griseus,10029.0,,
6772,,,BAO_0000219,,185.0,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,Cricetulus griseus,10029.0,,
6773,,,BAO_0000219,,185.0,11616,Concentration required to reduce AA8 cell survival by 10%,F,,Cricetulus griseus,10029.0,,
6774,,,BAO_0000219,,185.0,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,Cricetulus griseus,10029.0,,
6775,,,BAO_0000219,,185.0,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,Cricetulus griseus,10029.0,,
6776,,,BAO_0000219,,185.0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,Cricetulus griseus,10029.0,,
6777,,,BAO_0000219,,185.0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,Cricetulus griseus,10029.0,,
6778,,,BAO_0000219,,185.0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,Cricetulus griseus,10029.0,,
6779,,,BAO_0000219,,185.0,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,Cricetulus griseus,10029.0,,
6780,,,BAO_0000219,,185.0,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,Cricetulus griseus,10029.0,,
6781,,,BAO_0000019,,,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,Cricetulus griseus,10029.0,,
6782,,,BAO_0000219,,185.0,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,Cricetulus griseus,10029.0,,
6783,,,BAO_0000219,,185.0,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,Cricetulus griseus,10029.0,,
6784,,In vivo,BAO_0000218,,,16907,Half life period after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6785,,In vivo,BAO_0000218,,,16907,Half life period after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6786,,In vivo,BAO_0000218,,,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,,Canis lupus familiaris,9615.0,,
6787,,In vivo,BAO_0000218,,,9579,Half life was measured in dog after oral 17b administration,A,,Canis lupus familiaris,9615.0,,
6788,,In vivo,BAO_0000218,,,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,,Canis lupus familiaris,9615.0,,
6789,,In vivo,BAO_0000218,,,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,,Canis lupus familiaris,9615.0,,
6790,,In vivo,BAO_0000218,,,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6791,,In vivo,BAO_0000218,,,16907,Tmax value after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6792,,In vivo,BAO_0000218,,,3184,Compound was evaluated for its half life when administered intravenously in dog,A,,Canis lupus familiaris,9615.0,,
6793,,In vivo,BAO_0000218,1969.0,,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,,Canis lupus familiaris,9615.0,,Plasma
6794,,,BAO_0000218,,,6821,Elimination Half-life of compound was determined in dog,A,,Canis lupus familiaris,9615.0,,
6795,,In vivo,BAO_0000218,,,17839,Half life of compound in dog following oral administration,A,,Canis lupus familiaris,9615.0,,
6796,,,BAO_0000218,,,17267,Half life of compound was determined in dog,A,,Canis lupus familiaris,9615.0,,
6797,,,BAO_0000218,178.0,,4727,Half life of compound was determined in dog blood,A,,Canis lupus familiaris,9615.0,,Blood
6798,,In vivo,BAO_0000218,,,5238,Half life after oral and iv dosing in dogs,A,,Canis lupus familiaris,9615.0,,
6799,,,BAO_0000218,,,4942,Half life in dogs in hours,A,,Canis lupus familiaris,9615.0,,
6800,,In vivo,BAO_0000218,,,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,,Canis lupus familiaris,9615.0,,
6801,,In vivo,BAO_0000218,,,5130,t1/2 in dog after oral dose (1 mg/kg),A,,Canis lupus familiaris,9615.0,,
6802,,,BAO_0000218,,,1475,Half life was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
6803,,In vivo,BAO_0000218,,,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,,Canis lupus familiaris,9615.0,,
6804,,In vivo,BAO_0000218,,,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,,Canis lupus familiaris,9615.0,,
6805,,In vivo,BAO_0000218,,,6084,Half life period (10 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
6806,,In vivo,BAO_0000218,,,6084,Half life period (10 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
6807,,In vivo,BAO_0000218,,,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,,Canis lupus familiaris,9615.0,,
6808,,In vivo,BAO_0000218,,,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,,Canis lupus familiaris,9615.0,,
6809,,,BAO_0000218,,,6084,Half life period in dog,A,,Canis lupus familiaris,9615.0,,
6810,,In vivo,BAO_0000218,,,6241,Half life period in dogs after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
6811,,In vivo,BAO_0000218,,,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,Canis lupus familiaris,9615.0,,
6812,,,BAO_0000218,,,6621,Half-life of compound was determined in dogs,A,,Canis lupus familiaris,9615.0,,
6813,,,BAO_0000218,1969.0,,1696,Half-life in dog plasma,A,,Canis lupus familiaris,9615.0,,Plasma
6814,,,BAO_0000218,,,17800,Half-life in mongrel dogs was determined,A,,Canis lupus familiaris,9615.0,,
6815,,In vivo,BAO_0000218,,,17657,Half-life in dog upon oral administration,A,,Canis lupus familiaris,9615.0,,
6816,,In vivo,BAO_0000218,,,17657,Half-life in dog upon oral administration; Unable to calculate,A,,Canis lupus familiaris,9615.0,,
6817,,,BAO_0000218,,,4239,Half-life was measured in dog,A,,Canis lupus familiaris,9615.0,,
6818,,,BAO_0000218,,,5985,Half-life was measured in dog,A,,Canis lupus familiaris,9615.0,,
6819,,,BAO_0000218,,,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,Canis lupus familiaris,9615.0,,
6820,,In vivo,BAO_0000218,,,5199,Oral half life was determined,A,,Canis lupus familiaris,9615.0,,
6821,,In vivo,BAO_0000218,1969.0,,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,,Canis lupus familiaris,9615.0,,Plasma
6822,,,BAO_0000218,1969.0,,1475,Plasma half life was evaluated,A,,Canis lupus familiaris,9615.0,,Plasma
6823,,,BAO_0000218,1969.0,,1475,Plasma half life was evaluated in Dog,A,,Canis lupus familiaris,9615.0,,Plasma
6824,,,BAO_0000218,1969.0,,1475,Plasma half life was evaluated in dog,A,,Canis lupus familiaris,9615.0,,Plasma
6825,,In vivo,BAO_0000218,,,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
6826,,,BAO_0000218,,,4883,Tested for the half life value in dog,A,,Canis lupus familiaris,9615.0,,
6827,,In vivo,BAO_0000218,,,4727,Maximum time at the dose of 2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
6828,,In vivo,BAO_0000218,,,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,Canis lupus familiaris,9615.0,,
6829,,In vivo,BAO_0000218,178.0,,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,Blood
6830,,In vivo,BAO_0000218,178.0,,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,Blood
6831,,In vivo,BAO_0000218,,,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
6832,,In vivo,BAO_0000218,,,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,,Canis lupus familiaris,9615.0,,
6833,,In vivo,BAO_0000218,,,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,Canis lupus familiaris,9615.0,,
6834,,,BAO_0000218,,,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,Canis lupus familiaris,9615.0,,
6835,,In vivo,BAO_0000218,,,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,,Canis lupus familiaris,9615.0,,
6836,,In vivo,BAO_0000218,1969.0,,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,,Canis lupus familiaris,9615.0,,Plasma
6837,,In vivo,BAO_0000218,1969.0,,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,,Canis lupus familiaris,9615.0,,Plasma
6838,,,BAO_0000218,1969.0,,933,Time taken for maximum plasma concentration in dog,A,,Canis lupus familiaris,9615.0,,Plasma
6839,,In vivo,BAO_0000218,,,16367,Time to reach Cmax after oral administration to dogs,A,,Canis lupus familiaris,9615.0,,
6840,,In vivo,BAO_0000218,1969.0,,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,Plasma
6841,,In vivo,BAO_0000218,,,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
6842,,In vivo,BAO_0000218,,,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
6843,,In vivo,BAO_0000218,,,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
6844,,In vivo,BAO_0000218,,,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
6845,,In vivo,BAO_0000218,,,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,,Canis lupus familiaris,9615.0,,
6846,,In vivo,BAO_0000218,,,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,,Mus musculus,10090.0,,
6847,,In vivo,BAO_0000218,,,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,,Mus musculus,10090.0,,
6848,,In vivo,BAO_0000218,,,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,Mus musculus,10090.0,,
6849,,In vivo,BAO_0000218,1969.0,,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,Mus musculus,10090.0,,Plasma
6850,,In vivo,BAO_0000218,1969.0,,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,,Mus musculus,10090.0,,Plasma
6851,,In vivo,BAO_0000218,1969.0,,3132,Maximum concentration obtained in mouse plasma was determined,A,,Mus musculus,10090.0,,Plasma
6852,,In vivo,BAO_0000218,1969.0,,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,,Mus musculus,10090.0,,Plasma
6853,,In vivo,BAO_0000218,1969.0,,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,,Mus musculus,10090.0,,Plasma
6854,,In vivo,BAO_0000218,1969.0,,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,,Mus musculus,10090.0,,Plasma
6855,,In vivo,BAO_0000218,1969.0,,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,,Mus musculus,10090.0,,Plasma
6856,,In vivo,BAO_0000218,1969.0,,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,,Mus musculus,10090.0,,Plasma
6857,,In vivo,BAO_0000218,1969.0,,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,,Mus musculus,10090.0,,Plasma
6858,,In vivo,BAO_0000218,1969.0,,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,,Mus musculus,10090.0,,Plasma
6859,,In vivo,BAO_0000218,1969.0,,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,,Mus musculus,10090.0,,Plasma
6860,,In vivo,BAO_0000218,,,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,,Mus musculus,10090.0,,
6861,,In vivo,BAO_0000218,,,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,,Mus musculus,10090.0,,
6862,,In vivo,BAO_0000218,,,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,,Mus musculus,10090.0,,
6863,,In vivo,BAO_0000218,,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,,Mus musculus,10090.0,,
6864,,In vivo,BAO_0000218,,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,,Mus musculus,10090.0,,
6865,,In vivo,BAO_0000218,,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,,Mus musculus,10090.0,,
6866,,In vivo,BAO_0000218,,,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,,Mus musculus,10090.0,,
6868,,In vivo,BAO_0000218,,,5961,Cmax in male mice after 2 mg/kg oral dose,A,,Mus musculus,10090.0,,
6869,,In vivo,BAO_0000218,,,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,,Mus musculus,10090.0,,
6870,,In vivo,BAO_0000218,,,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,,Mus musculus,10090.0,,
6871,,,BAO_0000218,,,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,Mus musculus,10090.0,,
6872,,,BAO_0000218,,,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,Mus musculus,10090.0,,
6873,,,BAO_0000218,,,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,Mus musculus,10090.0,,
6874,,,BAO_0000218,,,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,Mus musculus,10090.0,,
6875,,,BAO_0000218,,,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,Mus musculus,10090.0,,
6876,,,BAO_0000218,,,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,Mus musculus,10090.0,,
6877,,,BAO_0000218,1969.0,,2862,Maximum concentration in plasma upon oral administration in mouse,A,,Mus musculus,10090.0,,Plasma
6878,,,BAO_0000218,1969.0,,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,Mus musculus,10090.0,,Plasma
6879,,In vivo,BAO_0000218,1969.0,,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,,Mus musculus,10090.0,,Plasma
6880,,,BAO_0000218,,,5399,Dose at which the compound induced fecal excretion in mice,A,,Mus musculus,10090.0,,
6893,,,BAO_0000219,,164.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,Rattus norvegicus,10116.0,,
6894,,,BAO_0000219,,164.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,Rattus norvegicus,10116.0,,
6895,,,BAO_0000219,,164.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,Rattus norvegicus,10116.0,,
6896,,,BAO_0000219,,164.0,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,Rattus norvegicus,10116.0,,
6897,,,BAO_0000219,,164.0,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,Rattus norvegicus,10116.0,,
6898,,,BAO_0000219,,393.0,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,Homo sapiens,9606.0,,
6899,,,BAO_0000219,,393.0,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,Homo sapiens,9606.0,,
6900,,,BAO_0000219,,393.0,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,Homo sapiens,9606.0,,
6901,,,BAO_0000219,,393.0,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,Homo sapiens,9606.0,,
6902,,,BAO_0000219,,393.0,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,Homo sapiens,9606.0,,
6903,,,BAO_0000219,,393.0,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,Homo sapiens,9606.0,,
6904,,,BAO_0000219,,393.0,1003,Cytotoxicity against human A121 ovarian cells,F,,Homo sapiens,9606.0,,
6905,,,BAO_0000219,,393.0,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,Homo sapiens,9606.0,,
6906,,,BAO_0000219,,393.0,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,Homo sapiens,9606.0,,
6907,,,BAO_0000219,,393.0,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,Homo sapiens,9606.0,,
6908,,,BAO_0000219,,393.0,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,Homo sapiens,9606.0,,
6909,,,BAO_0000219,,393.0,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,Homo sapiens,9606.0,,
6910,,,BAO_0000219,,393.0,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,Homo sapiens,9606.0,,
6911,,,BAO_0000219,,622.0,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,Homo sapiens,9606.0,,
6912,,,BAO_0000219,,622.0,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,Homo sapiens,9606.0,,
6913,,,BAO_0000219,,622.0,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,Homo sapiens,9606.0,,
6914,,,BAO_0000219,,622.0,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,Homo sapiens,9606.0,,
6915,,,BAO_0000219,,622.0,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,Homo sapiens,9606.0,,
6916,,,BAO_0000224,,,8975,Association constant against A2 adenosine receptor,B,,Canis lupus familiaris,9615.0,,
6917,,,BAO_0000219,,1085.0,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,fish,,,
6918,,,BAO_0000224,,,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,Rattus norvegicus,10116.0,,
6919,,,BAO_0000219,,623.0,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,Homo sapiens,9606.0,,
6920,,,BAO_0000219,,623.0,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,Homo sapiens,9606.0,,
6921,,,BAO_0000219,,404.0,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,Homo sapiens,9606.0,,
6922,,,BAO_0000219,,973.0,13160,Growth inhibition against Human squamous cell line(A 253),F,,Homo sapiens,9606.0,,
6923,,,BAO_0000219,,973.0,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,Homo sapiens,9606.0,,
6924,,,BAO_0000219,,973.0,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,Homo sapiens,9606.0,,
6925,,,BAO_0000219,,973.0,15984,Growth inhibition of A253 cell lines.,F,,Homo sapiens,9606.0,,
6926,,,BAO_0000219,,973.0,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,Homo sapiens,9606.0,,
6927,,,BAO_0000219,,973.0,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,Homo sapiens,9606.0,,
6928,,,BAO_0000219,,973.0,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,Homo sapiens,9606.0,,
6929,,,BAO_0000219,,478.0,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,Homo sapiens,9606.0,,
6930,,,BAO_0000219,,478.0,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,Homo sapiens,9606.0,,
6931,,,BAO_0000219,,478.0,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,Homo sapiens,9606.0,,
6932,,,BAO_0000219,,478.0,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,Homo sapiens,9606.0,,
6933,,,BAO_0000219,,478.0,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,Homo sapiens,9606.0,,
6934,,,BAO_0000219,,478.0,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,Homo sapiens,9606.0,,
6935,,,BAO_0000219,,478.0,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,Homo sapiens,9606.0,,
6936,,,BAO_0000219,,478.0,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
6937,,,BAO_0000219,,478.0,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
6938,,,BAO_0000219,,478.0,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,Homo sapiens,9606.0,,
6939,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,Homo sapiens,9606.0,,
6940,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,Homo sapiens,9606.0,,
6941,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,Homo sapiens,9606.0,,
6942,,,BAO_0000019,,,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,Cricetulus griseus,10029.0,,
6943,,,BAO_0000219,,185.0,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,Cricetulus griseus,10029.0,,
6944,,,BAO_0000219,,185.0,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,Cricetulus griseus,10029.0,,
6945,,,BAO_0000219,,185.0,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,Cricetulus griseus,10029.0,,
6946,,,BAO_0000219,,185.0,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,Cricetulus griseus,10029.0,,
6947,,,BAO_0000019,,,11858,Growth inhibition against CHO-derived cell line AA8,F,,Cricetulus griseus,10029.0,,
6948,,,BAO_0000219,,185.0,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,Cricetulus griseus,10029.0,,
6949,,,BAO_0000219,,185.0,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,hampster,36483.0,,
6950,,,BAO_0000219,,185.0,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,Cricetulus griseus,10029.0,,
6951,,,BAO_0000219,,185.0,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,Cricetulus griseus,10029.0,,
6952,,,BAO_0000219,,185.0,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,Cricetulus griseus,10029.0,,
6953,,,BAO_0000219,,185.0,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,Cricetulus griseus,10029.0,,
6954,,,BAO_0000219,,185.0,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,Cricetulus griseus,10029.0,,
6955,,,BAO_0000019,,,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,
6956,,,BAO_0000019,,,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,
6957,,,BAO_0000225,,,16037,Association constant for binding to AATT duplex,B,,,,,
6958,,,BAO_0000219,,416.0,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,Homo sapiens,9606.0,,
6959,,,BAO_0000218,,1064.0,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,Mus musculus,10090.0,,
6960,,,BAO_0000218,,,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,Oryctolagus cuniculus,9986.0,,
6961,,In vivo,BAO_0000218,,,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,,Oryctolagus cuniculus,9986.0,,
6962,,,BAO_0000357,,,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,
6963,,,BAO_0000357,,,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,
6964,,,BAO_0000219,,978.0,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,Homo sapiens,9606.0,,
6965,,,BAO_0000219,,978.0,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,Homo sapiens,9606.0,,
6966,,,BAO_0000219,,998.0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,Human immunodeficiency virus 1,11676.0,,
6967,,,BAO_0000219,,998.0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,Human immunodeficiency virus 1,11676.0,,
6968,,,BAO_0000219,,998.0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,Human immunodeficiency virus 1,11676.0,,
6969,,,BAO_0000219,,626.0,11843,Inhibition of growth of renal cancer ACHN cell line,F,,Homo sapiens,9606.0,,
6970,,,BAO_0000219,,626.0,16939,Inhibition of growth of ACHN renal cancer cell line,F,,Homo sapiens,9606.0,,
6971,,,BAO_0000219,,626.0,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,Homo sapiens,9606.0,,
6972,,,BAO_0000219,,626.0,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,Homo sapiens,9606.0,,
6973,,,BAO_0000219,,626.0,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,Homo sapiens,9606.0,,
6974,,,BAO_0000219,,626.0,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,Homo sapiens,9606.0,,
6975,,,BAO_0000219,,626.0,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,Homo sapiens,9606.0,,
6976,,,BAO_0000219,,626.0,5858,In vitro antitumor activity against human renal ACHN cell line,F,,Homo sapiens,9606.0,,
6977,,,BAO_0000219,,626.0,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,Homo sapiens,9606.0,,
6978,,,BAO_0000219,,626.0,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,Homo sapiens,9606.0,,
6979,,,BAO_0000219,,626.0,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,Homo sapiens,9606.0,,
6980,,,BAO_0000219,,626.0,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,Homo sapiens,9606.0,,
6981,,,BAO_0000219,,626.0,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,Homo sapiens,9606.0,,
6982,,,BAO_0000219,,626.0,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,Homo sapiens,9606.0,,
6983,,,BAO_0000219,,626.0,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,Homo sapiens,9606.0,,
6984,,,BAO_0000219,,626.0,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
6985,,,BAO_0000219,,626.0,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,Homo sapiens,9606.0,,
6986,,,BAO_0000219,,626.0,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,Homo sapiens,9606.0,,
6987,,,BAO_0000219,,626.0,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,Homo sapiens,9606.0,,
6988,,,BAO_0000219,,626.0,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,Homo sapiens,9606.0,,
6989,,,BAO_0000219,,626.0,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,Homo sapiens,9606.0,,
6990,,,BAO_0000219,,626.0,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,Homo sapiens,9606.0,,
6991,,In vivo,BAO_0000218,,,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,,Canis lupus familiaris,9615.0,,
6992,,,BAO_0000218,,,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,Canis lupus familiaris,9615.0,,
6993,,,BAO_0000218,,,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,Canis lupus familiaris,9615.0,,
6994,,In vivo,BAO_0000218,,,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6995,,In vivo,BAO_0000218,,,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,,Canis lupus familiaris,9615.0,,
6996,,In vivo,BAO_0000218,,,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,,Canis lupus familiaris,9615.0,,
6997,,In vivo,BAO_0000218,,,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
6998,,In vivo,BAO_0000218,,,5472,Volume of distribution was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
6999,,In vivo,BAO_0000218,,,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7000,,,BAO_0000218,,,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
7001,,In vivo,BAO_0000218,,,12500,The compound was tested for volume of distribution in dog,A,,Canis lupus familiaris,9615.0,,
7002,,In vivo,BAO_0000218,,,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,,Canis lupus familiaris,9615.0,,
7003,,In vivo,BAO_0000218,,,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,,Canis lupus familiaris,9615.0,,
7004,,In vivo,BAO_0000218,,,6227,Vd in dog,A,,Canis lupus familiaris,9615.0,,
7005,,In vivo,BAO_0000218,,,4219,Volume distribution was determined,A,,Canis lupus familiaris,9615.0,,
7006,,In vivo,BAO_0000218,,,1696,Volume of distribution in dog,A,,Canis lupus familiaris,9615.0,,
7007,,In vivo,BAO_0000218,,,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,,Canis lupus familiaris,9615.0,,
7008,,In vivo,BAO_0000218,,,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,,Canis lupus familiaris,9615.0,,
7009,,In vivo,BAO_0000218,,,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,
7010,,In vivo,BAO_0000218,,,4727,Volume distribution at the dose of 2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
7011,,In vivo,BAO_0000218,,,16367,Steady state volume of distribution was determined,A,,Canis lupus familiaris,9615.0,,
7012,,In vivo,BAO_0000218,,,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,,Canis lupus familiaris,9615.0,,
7013,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,,Canis lupus familiaris,9615.0,,
7014,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,,Canis lupus familiaris,9615.0,,
7015,,In vivo,BAO_0000218,,,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
7016,,In vivo,BAO_0000218,,,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,,Canis lupus familiaris,9615.0,,
7017,,In vivo,BAO_0000218,,,4239,Pharmacokinetic property (vdss) was measured in dog,A,,Canis lupus familiaris,9615.0,,
7018,,In vivo,BAO_0000218,,,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
7019,,In vivo,BAO_0000218,,,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,,Canis lupus familiaris,9615.0,,
7020,,In vivo,BAO_0000218,,,6057,Volume displacement was calculated in dog,A,,Canis lupus familiaris,9615.0,,
7021,,In vivo,BAO_0000218,,,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7022,,In vivo,BAO_0000218,,,5505,Volume distribution constant was determined,A,,Canis lupus familiaris,9615.0,,
7023,,In vivo,BAO_0000218,,,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
7024,,In vivo,BAO_0000218,,,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,,Canis lupus familiaris,9615.0,,
7025,,In vivo,BAO_0000218,,,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,,Canis lupus familiaris,9615.0,,
7026,,In vivo,BAO_0000218,,,15660,Volume distribution (Vdss) was measured in dog,A,,Canis lupus familiaris,9615.0,,
7027,,In vivo,BAO_0000218,,,15660,Volume distribution (Vdss) was measured in dog,A,,Canis lupus familiaris,9615.0,,
7028,,In vivo,BAO_0000218,,,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,,Canis lupus familiaris,9615.0,,
7029,,In vivo,BAO_0000218,,,5145,Volume of distribution in steady state was determined in dog,A,,Canis lupus familiaris,9615.0,,
7030,,In vivo,BAO_0000218,,,6821,Volume of distribution of compound was determined in dog,A,,Canis lupus familiaris,9615.0,,
7031,,In vivo,BAO_0000218,,,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,,Canis lupus familiaris,9615.0,,
7032,,In vivo,BAO_0000218,,,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,,Canis lupus familiaris,9615.0,,
7033,,In vivo,BAO_0000218,,,15660,Volume of distribution (Vdss) was measured in dog,A,,Canis lupus familiaris,9615.0,,
7034,,In vivo,BAO_0000218,,,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,9615.0,,
7035,,In vivo,BAO_0000218,,,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Canis lupus familiaris,9615.0,,
7036,,In vivo,BAO_0000218,,,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Canis lupus familiaris,9615.0,,
7037,,,BAO_0000218,,,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,Canis lupus familiaris,9615.0,,
7038,,In vivo,BAO_0000218,,,6448,Steady state volume distribution in dog,A,,Canis lupus familiaris,9615.0,,
7039,,In vivo,BAO_0000218,,,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,,Canis lupus familiaris,9615.0,,
7040,,In vivo,BAO_0000218,,,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,,Canis lupus familiaris,9615.0,,
7041,,In vivo,BAO_0000218,,,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,,Canis lupus familiaris,9615.0,,
7042,,In vivo,BAO_0000218,,,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,,Canis lupus familiaris,9615.0,,
7043,,In vivo,BAO_0000218,,,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,,Canis lupus familiaris,9615.0,,
7044,,In vivo,BAO_0000218,,,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
7045,,In vivo,BAO_0000218,,,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,,Canis lupus familiaris,9615.0,,
7046,,,BAO_0000218,,,3639,Vss was determined,A,,Canis lupus familiaris,9615.0,,
7047,,,BAO_0000218,,,3639,Vss in dog,A,,Canis lupus familiaris,9615.0,,
7048,,In vivo,BAO_0000218,,,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7049,,In vivo,BAO_0000218,,,4942,Volume distribution in dogs,A,,Canis lupus familiaris,9615.0,,
7050,,In vivo,BAO_0000218,,,17796,Volume of distribution in dog,A,,Canis lupus familiaris,9615.0,,
7051,,In vivo,BAO_0000218,,,4883,Tested for the oral bioavailability in dog,A,,Canis lupus familiaris,9615.0,,
7060,,In vivo,BAO_0000218,,,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,,Mus musculus,10090.0,,
7061,,In vivo,BAO_0000218,,,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,,Mus musculus,10090.0,,
7062,,In vivo,BAO_0000218,,,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,,Mus musculus,10090.0,,
7063,,In vivo,BAO_0000218,,,4239,Bioavailability was measured in mouse,A,,Mus musculus,10090.0,,
7064,,In vivo,BAO_0000218,,,17592,Bioavailability in mouse,A,,Mus musculus,10090.0,,
7065,,In vivo,BAO_0000218,,,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,,Mus musculus,10090.0,,
7066,,In vivo,BAO_0000218,,,2801,Bioavailability in mouse,A,,Mus musculus,10090.0,,
7067,,In vivo,BAO_0000218,,,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,,Mus musculus,10090.0,,
7068,,In vivo,BAO_0000218,,,17718,Oral bioavailability in mouse,A,,Mus musculus,10090.0,,
7069,,In vivo,BAO_0000218,,,5727,Oral availability at 50 mg/kg po in male mice,A,,Mus musculus,10090.0,,
7070,,In vivo,BAO_0000218,,,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,,Mus musculus,10090.0,,
7071,,In vivo,BAO_0000218,,,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,,Mus musculus,10090.0,,
7072,,In vivo,BAO_0000218,,,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,,Mus musculus,10090.0,,
7074,,In vivo,BAO_0000218,,,6091,Oral bioavailability in mouse,A,,Mus musculus,10090.0,,
7075,,In vivo,BAO_0000218,,,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,,Mus musculus,10090.0,,
7076,,In vivo,BAO_0000218,,,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,,Mus musculus,10090.0,,
7077,,In vivo,BAO_0000218,,,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,,Mus musculus,10090.0,,
7078,,In vivo,BAO_0000218,,,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,,Mus musculus,10090.0,,
7079,,In vivo,BAO_0000218,,,3802,Tested for bioavailability of the compound,A,,Mus musculus,10090.0,,
7080,,In vivo,BAO_0000218,,,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,,Mus musculus,10090.0,,
7081,,,BAO_0000218,1969.0,,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,Mus musculus,10090.0,,Plasma
7082,,,BAO_0000218,1969.0,,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,Mus musculus,10090.0,,Plasma
7083,,,BAO_0000218,1969.0,,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,Mus musculus,10090.0,,Plasma
7084,,,BAO_0000218,1969.0,,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,Mus musculus,10090.0,,Plasma
7085,,,BAO_0000218,1969.0,,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,Mus musculus,10090.0,,Plasma
7086,,,BAO_0000218,,,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,Mus musculus,10090.0,,
7087,,,BAO_0000218,,,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,Mus musculus,10090.0,,
7088,,,BAO_0000218,,,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,Mus musculus,10090.0,,
7089,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Blood
7090,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Blood
7091,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Blood
7092,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Blood
7093,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Blood
7094,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Blood
7095,,In vivo,BAO_0000218,178.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Blood
7096,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Bone
7097,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,,Mus musculus,10090.0,,Bone
7098,,,BAO_0000219,,478.0,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,Homo sapiens,9606.0,,
7099,,,BAO_0000219,,478.0,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,Homo sapiens,9606.0,,
7100,,,BAO_0000219,,478.0,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,Homo sapiens,9606.0,,
7101,,,BAO_0000219,,478.0,15688,Inhibition of A2780 cell clonogenic assay,F,,Homo sapiens,9606.0,,
7102,,,BAO_0000219,,478.0,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,Homo sapiens,9606.0,,
7103,,,BAO_0000219,,478.0,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,Homo sapiens,9606.0,,
7104,,,BAO_0000219,,478.0,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,Homo sapiens,9606.0,,
7105,,,BAO_0000219,,478.0,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,Homo sapiens,9606.0,,
7106,,,BAO_0000219,,478.0,17582,Antiproliferative activity against human A2780 cells,F,,Homo sapiens,9606.0,,
7107,,,BAO_0000219,,478.0,17764,Inhibition of human A2780 cell proliferation,F,,Homo sapiens,9606.0,,
7108,,,BAO_0000219,,478.0,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,Homo sapiens,9606.0,,
7109,,,BAO_0000219,,478.0,17764,Inhibition of human A2780 cell proliferation (No data),F,,Homo sapiens,9606.0,,
7110,,,BAO_0000219,,478.0,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,Homo sapiens,9606.0,,
7111,,,BAO_0000219,,478.0,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,Homo sapiens,9606.0,,
7112,,,BAO_0000219,,478.0,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,Homo sapiens,9606.0,,
7113,,,BAO_0000219,,478.0,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,Homo sapiens,9606.0,,
7114,,,BAO_0000019,,,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,Homo sapiens,9606.0,,
7115,,,BAO_0000219,,478.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,Homo sapiens,9606.0,,
7116,,,BAO_0000219,,478.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,Homo sapiens,9606.0,,
7117,,,BAO_0000219,,478.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,Homo sapiens,9606.0,,
7118,,,BAO_0000219,,478.0,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,Homo sapiens,9606.0,,
7119,,,BAO_0000219,,478.0,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,Homo sapiens,9606.0,,
7120,,,BAO_0000219,,478.0,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,Homo sapiens,9606.0,,
7121,,,BAO_0000219,,478.0,15069,In vitro inhibition of human ovarian cell line A2780,F,,Homo sapiens,9606.0,,
7122,,,BAO_0000219,,478.0,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,Homo sapiens,9606.0,,
7123,,,BAO_0000219,,478.0,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,Homo sapiens,9606.0,,
7124,,,BAO_0000219,,478.0,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,Homo sapiens,9606.0,,
7125,,,BAO_0000219,,478.0,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,Homo sapiens,9606.0,,
7126,,,BAO_0000219,,478.0,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,Homo sapiens,9606.0,,
7127,,,BAO_0000219,,478.0,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,Homo sapiens,9606.0,,
7128,,,BAO_0000219,,478.0,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,Homo sapiens,9606.0,,
7129,,,BAO_0000219,,478.0,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,Homo sapiens,9606.0,,
7130,,,BAO_0000219,,478.0,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,Homo sapiens,9606.0,,
7131,,,BAO_0000219,,478.0,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,Homo sapiens,9606.0,,
7132,,,BAO_0000219,,478.0,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,Homo sapiens,9606.0,,
7133,,,BAO_0000219,,478.0,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,Homo sapiens,9606.0,,
7134,,,BAO_0000219,,478.0,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,Homo sapiens,9606.0,,
7135,,,BAO_0000219,,478.0,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,Homo sapiens,9606.0,,
7136,,,BAO_0000219,,478.0,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,Homo sapiens,9606.0,,
7137,,,BAO_0000219,,478.0,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,Homo sapiens,9606.0,,
7138,,,BAO_0000219,,478.0,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,Homo sapiens,9606.0,,
7139,,,BAO_0000219,,478.0,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,Homo sapiens,9606.0,,
7140,,,BAO_0000219,,478.0,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,Homo sapiens,9606.0,,
7141,,,BAO_0000219,,478.0,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,Homo sapiens,9606.0,,
7142,,,BAO_0000219,,478.0,12989,In vitro antitumor activity against A2780 cell line.,F,,Homo sapiens,9606.0,,
7143,,,BAO_0000219,,478.0,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,Homo sapiens,9606.0,,
7144,,,BAO_0000219,,478.0,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,Homo sapiens,9606.0,,
7145,,,BAO_0000219,,626.0,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,Homo sapiens,9606.0,,
7146,,,BAO_0000219,,626.0,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,Homo sapiens,9606.0,,
7147,,,BAO_0000219,,626.0,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,Homo sapiens,9606.0,,
7148,,,BAO_0000219,,626.0,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,Homo sapiens,9606.0,,
7149,,,BAO_0000219,,626.0,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,Homo sapiens,9606.0,,
7150,,,BAO_0000219,,626.0,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,Homo sapiens,9606.0,,
7151,,,BAO_0000219,,626.0,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,Homo sapiens,9606.0,,
7152,,,BAO_0000219,,626.0,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,Homo sapiens,9606.0,,
7153,,,BAO_0000219,,626.0,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,Homo sapiens,9606.0,,
7154,,,BAO_0000219,,626.0,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,Homo sapiens,9606.0,,
7155,,,BAO_0000219,,626.0,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,Homo sapiens,9606.0,,
7156,,,BAO_0000219,,626.0,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,Homo sapiens,9606.0,,
7157,,,BAO_0000219,,626.0,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,Homo sapiens,9606.0,,
7158,,,BAO_0000219,,626.0,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,Homo sapiens,9606.0,,
7159,,,BAO_0000219,,626.0,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,Homo sapiens,9606.0,,
7160,,,BAO_0000219,,626.0,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,Homo sapiens,9606.0,,
7161,,,BAO_0000219,,626.0,12888,Cytotoxic effect on renal cancer line ACHN,F,,Homo sapiens,9606.0,,
7162,,,BAO_0000219,,626.0,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,Homo sapiens,9606.0,,
7163,,,BAO_0000219,,626.0,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,Homo sapiens,9606.0,,
7164,,,BAO_0000219,,626.0,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,Homo sapiens,9606.0,,
7165,,,BAO_0000219,,626.0,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,Homo sapiens,9606.0,,
7166,,,BAO_0000219,,626.0,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,Homo sapiens,9606.0,,
7167,,,BAO_0000219,,626.0,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,Homo sapiens,9606.0,,
7168,,,BAO_0000219,,626.0,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,Homo sapiens,9606.0,,
7169,,,BAO_0000219,,626.0,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,Homo sapiens,9606.0,,
7170,,,BAO_0000219,,626.0,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,Homo sapiens,9606.0,,
7171,,,BAO_0000219,,626.0,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,Homo sapiens,9606.0,,
7172,,,BAO_0000219,,626.0,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,Homo sapiens,9606.0,,
7173,,,BAO_0000019,,,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,
7174,,,BAO_0000019,,,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,
7175,,,BAO_0000218,,468.0,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,Cytomegalovirus,10358.0,,
7176,,,BAO_0000218,,,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,Cytomegalovirus,10358.0,,
7177,,,BAO_0000357,,,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,
7178,,,BAO_0000357,,,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,
7179,,,BAO_0000219,,979.0,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,Bos taurus,9913.0,,
7180,,,BAO_0000219,,980.0,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,Mus musculus,10090.0,,
7181,,,BAO_0000219,,980.0,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,Mus musculus,10090.0,,
7182,,,BAO_0000219,,980.0,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,Mus musculus,10090.0,,
7183,,,BAO_0000219,,980.0,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,Mus musculus,10090.0,,
7184,,,BAO_0000219,,980.0,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,Mus musculus,10090.0,,
7185,,,BAO_0000219,,980.0,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,Mus musculus,10090.0,,
7186,,,BAO_0000019,,,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,Mus musculus,10090.0,,
7187,,,BAO_0000019,,,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,Mus musculus,10090.0,,
7188,,,BAO_0000019,,,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,Mus musculus,10090.0,,
7189,,In vivo,BAO_0000218,,,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,,Bacillus subtilis,1423.0,,
7190,,,BAO_0000218,1969.0,,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
7191,,,BAO_0000218,1969.0,,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
7192,,In vivo,BAO_0000218,,,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
7193,,In vivo,BAO_0000218,,,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
7194,,In vivo,BAO_0000218,,,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
7195,,In vivo,BAO_0000218,,,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,,Canis lupus familiaris,9615.0,,
7196,,In vivo,BAO_0000218,,,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
7197,,In vivo,BAO_0000218,,,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,,Canis lupus familiaris,9615.0,,
7198,,,BAO_0000100,,,4219,Calculated partition coefficient (clogP),P,,,,,
7199,,,BAO_0000218,,,3748,Half life in dog,A,,Canis lupus familiaris,9615.0,,
7200,,,BAO_0000218,,,3132,Time taken for EC90 was determined when tested in dog,A,,Canis lupus familiaris,9615.0,,
7201,,,BAO_0000218,,,4219,Half life (iv) was determined,A,,Canis lupus familiaris,9615.0,,
7202,,,BAO_0000218,2107.0,,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,Canis lupus familiaris,9615.0,,Liver
7203,,,BAO_0000218,,,6057,Area under the curve was calculated in dog after iv administration,A,,Canis lupus familiaris,9615.0,,
7204,,,BAO_0000218,,,6057,Area under the curve was calculated in dog after peroral administration,A,,Canis lupus familiaris,9615.0,,
7205,,,BAO_0000218,,,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,Canis lupus familiaris,9615.0,,
7206,,,BAO_0000218,,,3639,pKa was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
7207,,,BAO_0000218,,,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,Canis lupus familiaris,9615.0,,
7208,,In vivo,BAO_0000218,,,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
7209,,In vivo,BAO_0000218,,,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,,Canis lupus familiaris,9615.0,,
7210,,In vivo,BAO_0000218,,,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,,Canis lupus familiaris,9615.0,,
7211,,,BAO_0000218,,,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,Canis lupus familiaris,9615.0,,
7212,,In vivo,BAO_0000218,178.0,,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,Blood
7213,,In vivo,BAO_0000218,178.0,,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,Canis lupus familiaris,9615.0,,Blood
7214,,In vivo,BAO_0000218,,,4709,Half life after intravenous administration of 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
7215,,,BAO_0000218,,,15660,Half life was measured in dog,A,,Canis lupus familiaris,9615.0,,
7216,,In vivo,BAO_0000218,,,5302,Half life period in dog after 5 mg/kg dose,A,,Canis lupus familiaris,9615.0,,
7217,,,BAO_0000218,,,17791,Half life period was evaluated in dog; 4-4.8,A,,Canis lupus familiaris,9615.0,,
7218,,In vivo,BAO_0000218,,,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,,Canis lupus familiaris,9615.0,,
7219,,In vivo,BAO_0000218,,,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,,Canis lupus familiaris,9615.0,,
7220,,,BAO_0000218,,,3771,Half-life was determined,A,,Canis lupus familiaris,9615.0,,
7221,,,BAO_0000218,,,6305,Half life in dogs,A,,Canis lupus familiaris,9615.0,,
7222,,In vivo,BAO_0000218,1969.0,,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,,Canis lupus familiaris,9615.0,,Plasma
7223,,In vivo,BAO_0000218,,,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,
7224,,In vivo,BAO_0000218,,,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,,Canis lupus familiaris,9615.0,,
7225,,In vivo,BAO_0000218,,,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,,Canis lupus familiaris,9615.0,,
7226,,,BAO_0000218,,,4839,Compound was tested for half life in dog,A,,Canis lupus familiaris,9615.0,,
7227,,,BAO_0000218,,,4839,Compound was tested for its half life in dog,A,,Canis lupus familiaris,9615.0,,
7228,,In vivo,BAO_0000218,,,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,Canis lupus familiaris,9615.0,,
7229,,,BAO_0000218,,,17839,Half life of compound in dog was determined,A,,Canis lupus familiaris,9615.0,,
7230,,In vivo,BAO_0000218,,,4219,Half life (iv) was determined,A,,Canis lupus familiaris,9615.0,,
7231,,,BAO_0000218,178.0,,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,Canis lupus familiaris,9615.0,,Blood
7232,,In vivo,BAO_0000218,1969.0,,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,,Canis lupus familiaris,9615.0,,Plasma
7233,,In vivo,BAO_0000218,1969.0,,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,,Canis lupus familiaris,9615.0,,Plasma
7234,,,BAO_0000218,,,4453,Half life in dog,A,,Canis lupus familiaris,9615.0,,
7235,,,BAO_0000218,1969.0,,6535,Half life in dog plasma,A,,Canis lupus familiaris,9615.0,,Plasma
7236,,In vivo,BAO_0000218,1969.0,,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,,Canis lupus familiaris,9615.0,,Plasma
7237,,In vivo,BAO_0000218,1969.0,,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,,Canis lupus familiaris,9615.0,,Plasma
7238,,In vivo,BAO_0000218,1969.0,,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,,Canis lupus familiaris,9615.0,,Plasma
7239,,,BAO_0000218,,,5374,Half life in dog was determined,A,,Canis lupus familiaris,9615.0,,
7240,,In vivo,BAO_0000218,,,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,Canis lupus familiaris,9615.0,,
7241,,,BAO_0000218,1969.0,,16907,Half life upon exposure to human plasma,A,,Canis lupus familiaris,9615.0,,Plasma
7242,,,BAO_0000218,,,6057,Half life was calculated in dog,A,,Canis lupus familiaris,9615.0,,
7243,,,BAO_0000218,,,5006,Half life was determined,A,,Canis lupus familiaris,9615.0,,
7244,,,BAO_0000218,,,5473,Half life was determined,A,,Canis lupus familiaris,9615.0,,
7245,,In vivo,BAO_0000218,,,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
7246,,,BAO_0000218,,,6448,Half life in dog,A,,Canis lupus familiaris,9615.0,,
7247,,,BAO_0000218,,,4353,Half life in dog after intra venous administration of the compound,A,,Canis lupus familiaris,9615.0,,
7248,,,BAO_0000218,,,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,Canis lupus familiaris,9615.0,,
7249,,In vivo,BAO_0000218,,,4353,Half life in dog after po administration of the compound,A,,Canis lupus familiaris,9615.0,,
7250,,In vivo,BAO_0000218,,,4353,Half life in dog after po administration of the compound; ND means Not determined,A,,Canis lupus familiaris,9615.0,,
7251,,In vivo,BAO_0000218,,,6265,Half life in dog at the single oral dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7252,,,BAO_0000218,,,5006,Half life in dogs,A,,Canis lupus familiaris,9615.0,,
7253,,In vivo,BAO_0000218,,,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,,Canis lupus familiaris,9615.0,,
7254,,,BAO_0000218,,,405,Half life in rat,A,,Canis lupus familiaris,9615.0,,
7255,,In vivo,BAO_0000218,,,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,Canis lupus familiaris,9615.0,,
7256,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Bone
7257,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Bone
7258,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Bone
7259,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Bone
7260,,In vivo,BAO_0000218,10000001.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Bone
7261,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Gut
7262,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Gut
7263,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Gut
7264,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Gut
7265,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Gut
7266,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Gut
7267,,In vivo,BAO_0000218,10000004.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Gut
7268,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Heart
7269,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Heart
7270,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Heart
7271,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Heart
7272,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Heart
7273,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Heart
7274,,In vivo,BAO_0000218,948.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Heart
7275,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Kidney
7276,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,,Mus musculus,10090.0,,Kidney
7277,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Kidney
7278,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Kidney
7279,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Kidney
7280,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Kidney
7281,,In vivo,BAO_0000218,2113.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Kidney
7282,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Liver
7283,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Liver
7284,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Liver
7285,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Liver
7286,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Liver
7287,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Liver
7288,,In vivo,BAO_0000218,2107.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Liver
7289,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Lung
7290,,,BAO_0000219,,478.0,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,Homo sapiens,9606.0,,
7291,,,BAO_0000219,,478.0,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,Homo sapiens,9606.0,,
7292,,,BAO_0000219,,478.0,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,Homo sapiens,9606.0,,
7293,,,BAO_0000219,,478.0,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,Homo sapiens,9606.0,,
7294,,,BAO_0000219,,478.0,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,Homo sapiens,9606.0,,
7295,,,BAO_0000219,,478.0,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,Homo sapiens,9606.0,,
7296,,,BAO_0000219,,478.0,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,Homo sapiens,9606.0,,
7297,,,BAO_0000219,,478.0,17270,In vitro cytotoxicity against A2780 cell line,F,,Homo sapiens,9606.0,,
7298,,,BAO_0000219,,478.0,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,Homo sapiens,9606.0,,
7299,,,BAO_0000219,,478.0,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,Homo sapiens,9606.0,,
7300,,,BAO_0000218,,478.0,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,Homo sapiens,9606.0,,
7301,,,BAO_0000219,,478.0,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,Homo sapiens,9606.0,,
7302,,,BAO_0000219,,478.0,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,Homo sapiens,9606.0,,
7303,,,BAO_0000219,,478.0,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,Homo sapiens,9606.0,,
7304,,,BAO_0000219,,478.0,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,Homo sapiens,9606.0,,
7305,,,BAO_0000219,,478.0,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,Homo sapiens,9606.0,,
7306,,,BAO_0000219,,478.0,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,Homo sapiens,9606.0,,
7307,,,BAO_0000219,,478.0,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,Homo sapiens,9606.0,,
7308,,,BAO_0000219,,478.0,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,Homo sapiens,9606.0,,
7309,,,BAO_0000219,,481.0,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,
7310,,,BAO_0000219,,481.0,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,
7311,,,BAO_0000219,,481.0,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,
7312,,,BAO_0000219,,481.0,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,
7313,,,BAO_0000218,,478.0,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,Homo sapiens,9606.0,,
7314,,In vivo,BAO_0000218,,478.0,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,,Homo sapiens,9606.0,,
7315,,,BAO_0000219,,478.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,Homo sapiens,9606.0,,
7316,,,BAO_0000219,,478.0,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,Homo sapiens,9606.0,,
7317,,,BAO_0000219,,478.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,Homo sapiens,9606.0,,
7318,,,BAO_0000219,,478.0,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,Homo sapiens,9606.0,,
7319,,,BAO_0000218,,478.0,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,Homo sapiens,9606.0,,
7320,,,BAO_0000219,,478.0,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,Homo sapiens,9606.0,,
7321,,,BAO_0000219,,478.0,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,Homo sapiens,9606.0,,
7322,,,BAO_0000219,,478.0,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,Homo sapiens,9606.0,,
7323,,,BAO_0000219,,478.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,Homo sapiens,9606.0,,
7324,,,BAO_0000219,,478.0,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,Homo sapiens,9606.0,,
7325,,,BAO_0000219,,478.0,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,Homo sapiens,9606.0,,
7326,,,BAO_0000219,,478.0,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,Homo sapiens,9606.0,,
7327,,,BAO_0000219,,478.0,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,Homo sapiens,9606.0,,
7328,,,BAO_0000219,,478.0,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,Homo sapiens,9606.0,,
7329,,,BAO_0000219,,478.0,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,Homo sapiens,9606.0,,
7330,,,BAO_0000219,,478.0,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,Homo sapiens,9606.0,,
7331,,,BAO_0000219,,478.0,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,Homo sapiens,9606.0,,
7332,,,BAO_0000219,,478.0,17737,In vitro antiproliferative activity against A2780 cell line,F,,Mus musculus,10090.0,,
7333,,,BAO_0000219,,478.0,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,Mus musculus,10090.0,,
7334,,,BAO_0000219,,478.0,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,Homo sapiens,9606.0,,
7335,,,BAO_0000219,,478.0,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,Homo sapiens,9606.0,,
7336,,,BAO_0000218,,,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
7337,,In vivo,BAO_0000218,,,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,,Canis lupus familiaris,9615.0,,
7338,,,BAO_0000019,,,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,Cercopithecidae,9527.0,,
7339,,,BAO_0000218,1969.0,,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,Plasma
7340,,,BAO_0000218,1969.0,,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,Plasma
7341,,In vivo,BAO_0000218,,,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
7342,,In vivo,BAO_0000218,,,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
7343,,In vivo,BAO_0000218,,,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,,Macaca fascicularis,9541.0,,
7344,,In vivo,BAO_0000218,,,4256,Oral Bioavailability in rat,A,,Rattus norvegicus,10116.0,,
7345,,,BAO_0000218,,,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,Cercopithecidae,9527.0,,
7346,,,BAO_0000218,,,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,Cercopithecidae,9527.0,,
7347,,,BAO_0000218,,,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,Cercopithecidae,9527.0,,
7348,,,BAO_0000019,,,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
7349,,,BAO_0000019,,,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
7350,,,BAO_0000019,,,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,Cercopithecidae,9527.0,,
7351,,,BAO_0000218,,,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,Cercopithecidae,9527.0,,
7352,,,BAO_0000218,,,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,Cercopithecidae,9527.0,,
7353,,,BAO_0000218,,,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,Cercopithecidae,9527.0,,
7354,,,BAO_0000218,,,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
7355,,,BAO_0000019,,,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
7356,,,BAO_0000218,,,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,Cercopithecidae,9527.0,,
7357,,,BAO_0000218,,,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,Cercopithecidae,9527.0,,
7358,,,BAO_0000218,,,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,Cercopithecidae,9527.0,,
7359,,,BAO_0000218,,,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,Cercopithecidae,9527.0,,
7360,,In vivo,BAO_0000218,,,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,,Cercopithecidae,9527.0,,
7361,,,BAO_0000218,,,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,Cercopithecidae,9527.0,,
7362,,In vivo,BAO_0000218,,,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
7363,,In vivo,BAO_0000218,,,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,Cercopithecidae,9527.0,,
7364,,,BAO_0000019,,,17409,Binding towards monkey plasma protein at 10 uM,A,,Cercopithecidae,9527.0,,
7365,,,BAO_0000019,,,17409,Binding towards monkey plasma protein at 100 uM,A,,Cercopithecidae,9527.0,,
7366,,In vivo,BAO_0000218,,,1052,Apparent bioavailability in squirrel monkey was determined,A,,Cercopithecidae,9527.0,,
7367,,In vivo,BAO_0000218,,,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,,Cercopithecidae,9527.0,,
7368,,In vivo,BAO_0000218,,,17509,Bioavailability in monkey (dose 2 mg/kg),A,,monkey,9443.0,,
7369,,In vivo,BAO_0000218,,,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,,Cercopithecidae,9527.0,,
7370,,In vivo,BAO_0000218,,,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
7371,,In vivo,BAO_0000218,,,11219,Bioavailability in monkey (i.d. dosing),A,,monkey,9443.0,,
7372,,In vivo,BAO_0000218,,,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,,Cercopithecidae,9527.0,,
7373,,,BAO_0000019,,,17796,Clearance of the drug was measured in cynomolgus,A,,Cercopithecidae,9527.0,,
7374,,In vivo,BAO_0000218,,,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,,Cercopithecidae,9527.0,,
7375,,In vivo,BAO_0000218,,,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,Cercopithecidae,9527.0,,
7376,,In vivo,BAO_0000218,1969.0,,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,,Macaca mulatta,9544.0,,Plasma
7377,,In vivo,BAO_0000218,,,17267,Plasma clearance in rhesus monkey was determined,A,,Cercopithecidae,9527.0,,
7378,,In vivo,BAO_0000218,,,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,,Cercopithecidae,9527.0,,
7379,,In vivo,BAO_0000218,,,5922,Plasma clearance in cynomolgus monkey,A,,Cercopithecidae,9527.0,,
7380,,In vivo,BAO_0000218,,,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,,Cercopithecidae,9527.0,,
7381,,In vivo,BAO_0000218,,,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,,Cercopithecidae,9527.0,,
7382,,In vivo,BAO_0000218,,,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,,Cercopithecidae,9527.0,,
7383,,In vivo,BAO_0000218,,,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,,Cercopithecidae,9527.0,,
7384,,In vivo,BAO_0000218,,,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,,Cercopithecidae,9527.0,,
7385,,In vivo,BAO_0000218,,,4578,Tested for Clearance upon iv administration to african green monkey,A,,Cercopithecidae,9527.0,,
7386,,In vivo,BAO_0000218,,,17592,Clearance in monkey,A,,Cercopithecidae,9527.0,,
7387,,In vivo,BAO_0000218,,,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Canis lupus familiaris,9615.0,,
7388,,In vivo,BAO_0000218,,,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,,Canis lupus familiaris,9615.0,,
7389,,In vivo,BAO_0000218,,,16367,Half life was evaluated after intravenous administration to dogs,A,,Canis lupus familiaris,9615.0,,
7390,,,BAO_0000218,,,5472,Half life was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
7391,,,BAO_0000218,,,5474,Half life was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
7392,,In vivo,BAO_0000218,,,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7393,,In vivo,BAO_0000218,,,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,,Canis lupus familiaris,9615.0,,
7394,,In vivo,BAO_0000218,,,6227,Half life period after intravenous administration in dog,A,,Canis lupus familiaris,9615.0,,
7395,,In vivo,BAO_0000218,,,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,,Canis lupus familiaris,9615.0,,
7396,,,BAO_0000218,,,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
7397,,In vivo,BAO_0000218,,,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,,Canis lupus familiaris,9615.0,,
7398,,In vivo,BAO_0000218,,,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,,Canis lupus familiaris,9615.0,,
7399,,,BAO_0000218,,,3854,Half life period was determined,A,,Canis lupus familiaris,9615.0,,
7400,,,BAO_0000218,,,5505,Half life period was determined,A,,Canis lupus familiaris,9615.0,,
7401,,In vivo,BAO_0000218,,,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,,Canis lupus familiaris,9615.0,,
7402,,,BAO_0000218,,,1918,Half life period was evaluated in dog,A,,Canis lupus familiaris,9615.0,,
7403,,In vivo,BAO_0000218,,,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,Canis lupus familiaris,9615.0,,
7404,,In vivo,BAO_0000218,,,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,,Canis lupus familiaris,9615.0,,
7405,,In vivo,BAO_0000218,,,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,,Canis lupus familiaris,9615.0,,
7406,,In vivo,BAO_0000218,,,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
7407,,In vivo,BAO_0000218,,,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,,Canis lupus familiaris,9615.0,,
7408,,In vivo,BAO_0000218,,,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,,Canis lupus familiaris,9615.0,,
7409,,In vivo,BAO_0000218,,,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,,Canis lupus familiaris,9615.0,,
7410,,In vivo,BAO_0000218,,,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,,Canis lupus familiaris,9615.0,,
7411,,In vivo,BAO_0000218,,,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7412,,,BAO_0000218,1969.0,,5210,Half-life of compound in plasma of dog was determined,A,,Canis lupus familiaris,9615.0,,Plasma
7413,,,BAO_0000218,,,5210,Half-life of compound was determined in dogs,A,,Canis lupus familiaris,9615.0,,
7414,,In vivo,BAO_0000218,,,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,,Canis lupus familiaris,9615.0,,
7415,,In vivo,BAO_0000218,,,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,,Canis lupus familiaris,9615.0,,
7416,,,BAO_0000218,,,5064,Half-life in Dog,A,,Canis lupus familiaris,9615.0,,
7417,,,BAO_0000218,,,5147,Half-life in Dog,A,,Canis lupus familiaris,9615.0,,
7418,,,BAO_0000218,,,5145,Half-life in dog,A,,Canis lupus familiaris,9615.0,,
7419,,In vivo,BAO_0000218,,,6123,Half-life in dog after oral administration at 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7420,,In vivo,BAO_0000218,,,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,,Canis lupus familiaris,9615.0,,
7421,,,BAO_0000218,,,4333,Half-life in dogs,A,,Canis lupus familiaris,9615.0,,
7422,,,BAO_0000218,,,4333,Half-life in dogs; ND indicates not determined,A,,Canis lupus familiaris,9615.0,,
7423,,,BAO_0000218,1969.0,,12500,Half-life in plasma of dog,A,,Canis lupus familiaris,9615.0,,Plasma
7424,,,BAO_0000218,1969.0,,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,Canis lupus familiaris,9615.0,,Plasma
7425,,In vivo,BAO_0000218,,,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7426,,In vivo,BAO_0000218,,,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7427,,In vivo,BAO_0000218,,,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,,Canis lupus familiaris,9615.0,,
7428,,In vivo,BAO_0000218,,,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,,Canis lupus familiaris,9615.0,,
7429,,In vivo,BAO_0000218,,,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,,Canis lupus familiaris,9615.0,,
7430,,In vivo,BAO_0000218,,,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,,Canis lupus familiaris,9615.0,,
7431,,In vivo,BAO_0000218,,,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
7432,,In vivo,BAO_0000218,,,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
7433,,In vivo,BAO_0000218,,,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,,Canis lupus familiaris,9615.0,,
7434,,,BAO_0000218,,,6227,t1/2 in dog,A,,Canis lupus familiaris,9615.0,,
7435,,,BAO_0000218,,,14541,Half-life period measured in dogs,A,,Canis lupus familiaris,9615.0,,
7436,,In vivo,BAO_0000218,,,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,,Canis lupus familiaris,9615.0,,
7437,,In vivo,BAO_0000218,,,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,,Canis lupus familiaris,9615.0,,
7438,,In vivo,BAO_0000218,,,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,,Canis lupus familiaris,9615.0,,
7439,,In vitro,BAO_0000218,1969.0,,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,,Canis lupus familiaris,9615.0,,Plasma
7440,,In vivo,BAO_0000218,,,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,,Canis lupus familiaris,9615.0,,
7441,,In vivo,BAO_0000218,,,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,,Canis lupus familiaris,9615.0,,
7442,,In vivo,BAO_0000218,,,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,,Canis lupus familiaris,9615.0,,
7443,,In vivo,BAO_0000218,,,4353,Oral bioavailability in dog (dose 5 uM/kg),A,,Canis lupus familiaris,9615.0,,
7444,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,,Canis lupus familiaris,9615.0,,
7445,,In vivo,BAO_0000218,,,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,,Canis lupus familiaris,9615.0,,
7446,,In vivo,BAO_0000218,,,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,,Canis lupus familiaris,9615.0,,
7447,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,,Mus musculus,10090.0,,Lung
7448,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Lung
7449,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Lung
7450,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Lung
7451,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Lung
7452,,In vivo,BAO_0000218,2048.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Lung
7453,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Muscle tissue
7454,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,,Mus musculus,10090.0,,Muscle tissue
7455,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Muscle tissue
7456,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Muscle tissue
7457,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Muscle tissue
7458,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Muscle tissue
7459,,In vivo,BAO_0000218,2385.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Muscle tissue
7460,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Zone of skin
7461,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Zone of skin
7462,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Zone of skin
7463,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Zone of skin
7464,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Zone of skin
7465,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Zone of skin
7466,,In vivo,BAO_0000218,14.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Zone of skin
7467,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Spleen
7468,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Spleen
7469,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Spleen
7470,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Spleen
7471,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Spleen
7472,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Spleen
7473,,In vivo,BAO_0000218,2106.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Spleen
7474,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,,Mus musculus,10090.0,,Stomach
7475,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,,Mus musculus,10090.0,,Stomach
7476,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,,Mus musculus,10090.0,,Stomach
7477,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,,Mus musculus,10090.0,,Stomach
7478,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,,Mus musculus,10090.0,,Stomach
7479,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,,Mus musculus,10090.0,,Stomach
7480,,In vivo,BAO_0000218,945.0,,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,,Mus musculus,10090.0,,Stomach
7481,,In vivo,BAO_0000218,,,4689,Oral bioavailability in rat,A,,Rattus norvegicus,10116.0,,
7482,,In vivo,BAO_0000218,,,4950,Tested for the bioavailability in rat,A,,Rattus norvegicus,10116.0,,
7483,,In vivo,BAO_0000218,,,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,,Rattus norvegicus,10116.0,,
7484,,In vivo,BAO_0000218,,,406,Bioavailability in rat,A,,Rattus norvegicus,10116.0,,
7485,,In vivo,BAO_0000218,,,12500,Bioavailability in rat,A,,Rattus norvegicus,10116.0,,
7486,,In vivo,BAO_0000218,,,12500,Bioavailability in rat (dose 3-10 mg/kg),A,,Rattus norvegicus,10116.0,,
7487,,In vivo,BAO_0000218,,,5247,Bioavailability in rat,A,,Rattus norvegicus,10116.0,,
7488,,In vivo,BAO_0000218,1969.0,,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,,Rattus norvegicus,10116.0,,Plasma
7489,,In vivo,BAO_0000218,1969.0,,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,,Rattus norvegicus,10116.0,,Plasma
7490,,In vivo,BAO_0000218,,,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,,Rattus norvegicus,10116.0,,
7491,,,BAO_0000218,,,6484,Half life was determined,A,,Rattus norvegicus,10116.0,,
7492,,In vivo,BAO_0000218,,,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,,Rattus norvegicus,10116.0,,
7493,,In vivo,BAO_0000218,1969.0,,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,,Rattus norvegicus,10116.0,,Plasma
7494,,,BAO_0000218,,,3307,Half life in rats,A,,Rattus norvegicus,10116.0,,
7495,,In vivo,BAO_0000218,178.0,,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,,Rattus norvegicus,10116.0,,Blood
7496,,,BAO_0000218,,,8833,Hill coefficient of the compound,A,,Rattus norvegicus,10116.0,,
7497,,,BAO_0000218,178.0,,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,Rattus norvegicus,10116.0,,Blood
7498,,,BAO_0000218,178.0,,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,Rattus norvegicus,10116.0,,Blood
7499,,,BAO_0000218,178.0,,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,Rattus norvegicus,10116.0,,Blood
7500,,,BAO_0000218,178.0,,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,Rattus norvegicus,10116.0,,Blood
7501,,,BAO_0000218,178.0,,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,Rattus norvegicus,10116.0,,Blood
7502,,,BAO_0000218,178.0,,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,Rattus norvegicus,10116.0,,Blood
7503,,,BAO_0000218,178.0,,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,Rattus norvegicus,10116.0,,Blood
7504,,,BAO_0000218,,,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,Rattus norvegicus,10116.0,,
7505,,In vivo,BAO_0000218,955.0,,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Brain
7506,,In vivo,BAO_0000218,955.0,,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Brain
7507,,In vivo,BAO_0000218,955.0,,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Brain
7508,,In vivo,BAO_0000218,955.0,,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Brain
7509,,In vivo,BAO_0000218,955.0,,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Brain
7510,,In vivo,BAO_0000218,2046.0,,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Thyroid gland
7511,,In vivo,BAO_0000218,2046.0,,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Thyroid gland
7512,,In vivo,BAO_0000218,2046.0,,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Thyroid gland
7513,,In vivo,BAO_0000218,2046.0,,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Thyroid gland
7514,,In vivo,BAO_0000218,2046.0,,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,,Rattus norvegicus,10116.0,,Thyroid gland
7515,,In vivo,BAO_0000218,178.0,,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,,Rattus norvegicus,10116.0,,Blood
7516,,In vivo,BAO_0000218,178.0,,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,,Rattus norvegicus,10116.0,,Blood
7517,,In vivo,BAO_0000218,178.0,,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,,Rattus norvegicus,10116.0,,Blood
7518,,In vivo,BAO_0000218,10000001.0,,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,,Rattus norvegicus,10116.0,,Bone
7519,,In vivo,BAO_0000218,10000001.0,,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,,Rattus norvegicus,10116.0,,Bone
7520,,In vivo,BAO_0000218,10000001.0,,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,,Rattus norvegicus,10116.0,,Bone
7521,,In vivo,BAO_0000218,948.0,,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,,Rattus norvegicus,10116.0,,Heart
7522,,In vivo,BAO_0000218,948.0,,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,,Rattus norvegicus,10116.0,,Heart
7523,,In vivo,BAO_0000218,948.0,,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,,Rattus norvegicus,10116.0,,Heart
